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Abstract 
This thesis contains six chapters and the research presented within focuses on three 
parts. The first part (chapter one to three) was the isolation of antibacterial and 
antioxidant mushroom metabolites, and the synthesis towards analogues of discovered 
natural products. The following part (chapter four) was to assess antioxidant activities 
of synthetic compounds and investigate their SAR (structure-activity relationship), by 
use of a developed DPPH assay. The last part (chapter five to six) was the discovery of 
an abiotic halogenation reaction among a class of fungal metabolites, azaphilones. A 
series of their synthetic analogues were applied as model compounds to understand the 
mechanism of the discovered unusual and facile non-enzymatic nucleophilic 
halogenation reaction. 
Chapter one is a review of antioxidants in mushrooms. The components with antioxidant 
activities discovered from mushrooms were summarised by their chemical structures 
and representative samples were listed. In addition, the potential mechanisms of those 
antioxidants were described in this chapter. 
In chapter two, extracts of 20 mushrooms from PNG (Papua New Guinea) were screened 
against both Gram-positive and Gram-negative bacteria, six of them were chosen as 
chemical survey candidates for their strong antibacterial activities. Extracts of 37 PNG 
mushrooms were screened for their antioxidant using a modified DPPH assay, 14 of 
them were chosen as chemical survey candidates based on their antioxidant capacities. 
In chemical examination guided by bioactivity, five natural products including two novel 
furan fatty acids (2.1-2.2) and three known compounds, i.e. grifolin (2.3), grifolic acid 
(2.4) and grifolic acid methyl ether (2.5), were isolated from four selected mushroom 
samples. 
Chapter three described the synthetic efforts towards analogues of three isolated 
antioxidant fungal metabolites (2.3-2.5). Inspired by 15 synthetic targets, a short and 
versatile general synthetic route was established to deliver 40 compounds possessing 
structures related to the natural products. Based on these structures, a compound 
library was established for antioxidant assessment in the following SAR research. The 
synthetic work resulted in the preparation of 33 novel structures. 
 V 
In chapter four, various antioxidant assays and their working mechanisms were 
reviewed, as well as their corresponding advantages and drawbacks. A developed DPPH 
assay was optimised to offer an accurate and reproducible antioxidant evaluation for 
SAR research in the achieved compound library. The results indicated that a structure 
with an aromatic ring to be allylated with a carbon chain in addition to the presence of 
phenols, is required to show an antioxidant activity, and the increased length of a carbon 
chain (more prenyl units) enhances the antioxidant activity. 
Chapter five focused on naturally occurring organohalogen compounds with biotic 
origins. The representative halogenated natural products with a variety of bioactivities 
were categorised following a chemical structural classification as well as a bioactive 
classification, to showcase both their structural diversity and bioactive variety. The 
biosynthetic mechanisms of halogenated natural products were reviewed in this chapter. 
Chapter six detailed the investigation of a novel halogenation reaction that was 
discovered to be occurring with some azaphilone fungal metabolites, for example the 
conversion of (+)-deschlorosclerotiorin (6.2) into (+)-sclerotiorin (6.1). Various non-
halogenated model compounds with an azaphilone core structure were created to shed 
light on the authenticity of numerous halogenated azaphilones reported as natural 
products. The ensuing synthetic work resulted in an efficient general procedure 
producing the required targets. The following investigation of the halogenation revealed 
a novel, facile, non-enzymatic nucleophilic reaction and its proposed mechanism is 
discussed. The synthetic efforts resulted in the creation of 22 novel structures. 
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Chapter 1: Antioxidants in Mushrooms 
1.1 Introduction 
The term “mushroom” has had various specific meanings in different regions and at 
different times. While generally speaking, mushroom refers to all larger fungi, so “a 
mushroom is a macrofungus with a distinctive fruiting body which can be either 
epigeous (above ground) or hypogeous (under ground) and large enough to be seen with 
the naked eye and to be picked by hand.”1-4 The typical characteristics of a mushroom 
are an umbrella shape with a cap (pileus), a stem (stipe), sometimes additionally with a 
ring (annulus) or a cup (volva).2-4 
Since their first existence 300 million years ago, mushrooms have evolved to kingdom 
status with a vast number of species. Current knowledge indicates around 15,000 
mushrooms have been described, however, that is only 10% of the 150,000 estimated 
total mushroom species. Mushrooms are ecologically categorised into three groups: 
saprophytes, parasites, and mycorrhiza, the first category compromises the dominant 
grouping.2,4,5 
Mushrooms can also be classified into four types: edible, medicinal, poisonous and 
miscellaneous mushrooms based on their usages.2 Mushrooms have been collected and 
used for dietary and medicinal purposes by humans since the prehistoric era, numerous 
records of mushroom can be found in all the civilizations over the world, namely Europe, 
Africa, Asia and America, such as Romans, Greek, Egyptians, Indian, Chinese and Mayan. 
While thousands of years of historical use are documented, mushroom have only been 
cultivated for hundreds of years, with Auricularia auricula being first farmed in China on 
wood logs around A.D. 600.2 Naturally, knowledge of mushrooms has accumulated from 
generation to generation, thus mushrooms are widely applied in ethnologically diverse 
diets and medicines, such as Shiitake (Lentinula edodes) and Ringzhi (Ganoderma 
lucidum).6-20 In many cases, mushrooms are served as both foods and medicines. 
Poisonous mushrooms are generally divided into five classes: Amanita-type poisoning, 
Muscarine-type poisoning, psychotropic (hallucinogenic) poisoning, Coprinus and 
poisoning from external sources. Some of those mushrooms are used for religious 
ceremonies or used as recreational drugs.2 
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As traditionally used foods and medicines, many known mushrooms have been 
intensively studied. Abundant research shows mushrooms are rich in proteins and 
amino acids, fat, vitamins, carbohydrate, fibre, pigments, minerals and nucleic acids. 
These components among others have contributed to mushrooms’ promising 
bioactivities, such as antioxidant, anti-inflammatory, antimicrobial, antiviral, antitumor, 
antidiabetic, anti-hypercholesterolemia, antihypertensive, hepatoprotective, 
immunomodulatory, cardiovascular and brain protective effects.1-4,6-13,21-25 Among those 
health benefits, antioxidant value is often highlighted and regarded as the most 
important function, so antioxidant bioactive components and their mechanisms are 
attracting increasing attention from scientists.4,6,8,10,12,13,22-25 Since many synthetic 
antioxidants are found to exhibit dose-dependent toxicity restricting their use, 
mushrooms and their extracts, with antioxidant property, are regarded as an important 
source of natural antioxidants, with promising applications in the nutrition, cosmetic 
and pharmaceutical industries.4,6,12,13,22,24,25 
In Australia, mushrooms play a very important role in agriculture, generating the second 
most profitable crop after potatoes in the fresh vegetable market.15 Many Australasian 
mushrooms display significant health benefits including antioxidant effects, thus 
numerous research groups including our group contribute to research on antioxidant 
mushrooms.15,26,27 
This chapter gives a brief introduction to antioxidant components in mushrooms and 
their mechanisms action. For more detail and other bioactivities, several literature 
sources are available and readers can refer to these comprehensive reviews.2,3,22,24,28 
1.2 Antioxidant Components in Mushrooms 
1.2.1 Introduction 
Based on Nawar’s definition, antioxidants are compounds or systems that delay 
autoxidation by inhibiting formation of free radicals or by interrupting propagation of 
the free radical by one (or more) of several mechanisms: (1) scavenging species that 
initiate peroxidation, (2) chelating metal ions such that they are unable to generate 
reactive species or decompose lipid peroxides, (3) quenching O2·- preventing formation 
of peroxides, (4) breaking the autoxidative chain reaction, and/or (5) reducing localised 
O2 concentrations.29,30 However, reactive oxygen species (ROS) are the major reactive 
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species (RS) in aerobic cells, others are reactive nitrogen species (RNS), reactive carbon 
species (RCS) and reactive sulphur species (RSS).22,24 Thus antioxidants in a broader 
sense are compounds which can inhibit or reduce the generations of RS or scavenge the 
existing RS. It is necessary to note that, recent research has found that in many cases, 
antioxidants play reversible roles depending on concentrations. They act as antioxidants 
in low concentration while they work as prooxidants in high concentration.24,25,31 So the 
public should be aware that an antioxidant may be a two-edged sword; in some 
circumstances, a simple overdose of antioxidants will bring negative effects. For 
example, ascorbic acid, vitamin E and vitamin A are widely recognised antioxidants, but 
lots of evidence show long-term frequent intakes of these individual compounds can 
increase the risk of diseases caused by oxidative stress.24 In this chapter, any compound, 
as long as it displays antioxidative effects, regardless of its possible reversible effect, will 
be described as “antioxidant”. 
In an organism, there is an equilibrium between free radical production and antioxidant 
defences to maintain the normal metabolism and keep this process in order. Free 
radicals can either be produced endogenously, as in energy production in mitochondrial 
or inflammatory reactions caused by diseases or drugs, or produced exogenously as 
through the impacts of radiation.22,24 Overproduction of free radicals or weaker 
antioxidant defences results in ≈70% of chronic diseases, in that moment intake of 
antioxidants to rebalance the equilibrium can play a significant role in reducing oxidative 
damages.22 
Synthetic antioxidants like butylated hydroxyanisole (BHA), butylated hydroxytoluene 
(BHT) and tert-butylhydroquinone (TBHQ) have been confirmed to possess many side 
effects which has led to the use of synthetic antioxidants to be more restricted, while 
natural antioxidants are more widely applied.22,24 For example, dairy foods are a rich 
source of natural antioxidants.30 Besides the unique textures and flavours, the 
antioxidant benefit is an important reason for the broad acceptance and increasing 
consumption of mushrooms. 
1.2.2 Chemical Structures and Mechanisms 
Antioxidants in mushrooms are comprised of various chemical structures. In this chapter 
these compounds are classified into four categories; polyphenols, polysaccharides, 
vitamins and minerals. 
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1.2.2.1 Polyphenols 
Polyphenols are the most common antioxidants in the diet and are well represented in 
mushrooms.4,13,22,24,32 Polyphenols can be sub-classified into phenolic compounds and 
flavonoids.  
 
Phenolic compounds are simply aromatic hydroxylated compounds, possessing one or 
more aromatic rings with one or more hydroxy groups. The main phenolic compounds 
found in mushrooms are phenolic acids.13,22 Phenolic acids are represented by two 
major groups, namely hydroxybenzoic acids and hydroxycinnamic acids (Figure 1-1), 
which can be derived from the non-phenolic molecules benzoic acid (1.1) and cinnamic 
acid (1.2), respectively.22,24 Benzoic acid (1.1) has been discovered from the Korean 
mushrooms Sparassis crispa and Agaricus blazei. Protocatechuic acid (1.3) was isolated 
from various mushrooms, like the Finnish mushroom Agaricus bisporus, the Indian 
mushroom Termitomyces heimii, the Portuguese mushroom Lepista nuda, and the 
Korean mushroom Pleurotus ostreatus. Gallic acid (1.4) has also been found in 
mushrooms Termitomyces heimii and Pleurotus ostreatus. Cinnamic acid (1.2), caffeic 
acid (1.5), p-coumaric acid (1.6) and ferulic acid (1.7) are very common in mushrooms, 
Termitomyces heimii was reported to contain all these phenolic compounds. 
Termitomyces heimii is one of the most intensively researched mushroom species, and 
it possesses the highest diversity phenolic compounds.22  
R2 R1
COOHR3
R4
benzoic acid (1.1) R1=R2=R3=R4=H
protocatechuic acid (1.3) R1=R2=H, R3=R4=OH
gallic acid (1.4) R1=H, R2=R3=R4=OH
R2 R1
R3
R4
cinnamic acid (1.2) R1=R2=R3=R4=H
caffeic acid (1.5) R1=R4=H, R2=R3=OH
p-coumaric acid (1.6) R1=R2=R4=H, R3=OH
ferulic acid (1.7) R1=R4=H, R2=CH3O, R3=OH
COOH
 
Figure 1-1 Antioxidant Phenolic Compounds in Mushrooms 
The antioxidant activity of phenolic acids is mainly due to phenolic hydrogens. Firstly, 
the number of hydroxy groups affects antioxidant effects; more hydroxy groups 
generally means better activity. For instance, protocatechuic acid (1.3) is a weaker 
antioxidant than gallic acid (1.4) due to possessing fewer hydroxy groups.22 Similarly 
1.2.2.1.1 Phenolic Compounds 
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caffeic acid (1.5) possesses better antioxidant activity than both p-coumaric acid (1.6) 
and ferulic acid (1.7). Intramolecular hydrogen bonds can enhance antioxidant activity. 
An intramolecular hydrogen bond can be formed between 3-CH3O and 4-OH, which 
enables ferulic acid (1.7) to have better antioxidant activity than p-coumaric acid (1.6). 
Nevertheless, the acid proton contributes little on antioxidant activity, some reports 
suggest the allylic group may enhance the stability of phenolic radical.22 
The main mechanism of phenolic compounds exerting antioxidant effects is to interrupt 
the autoxidative chain reaction (Scheme 1-1).22 
RO2 ArOH ROOH ArO
RO2 R ROOH
RH RH
protected
RH
oxidised
 
Scheme 1-1 Mechanism of Phenolic Compounds Interrupting the Chain Reaction 
The electron in the generated phenolic radical ArO. can be delocalised by the aromatic 
ring, which becomes a less active free radical and slowly reacts with substrate RH while 
RO2· can rapidly be scavenged by a phenolic compound ArOH, so it can protect RH from 
oxidative damage of active free radical RO2·. It is clear that the antioxidant capacity of 
ArOH mainly depends on the stability of the generated radical ArO· which well explains 
the aforementioned involvement of phenolic hydrogens in antioxidant activity.22 Apart 
from direct reaction with free radicals, phenolic compounds currently are also regarded 
to either promote endogenous antioxidant capacity or stimulate synthesis of 
endogenous antioxidants, or they are involved in cell signalling pathways to modify the 
redox status of the cell or modulate certain molecules activities which can repair 
damage caused by free radicals, in order to conduct their antioxidant effects.22,24 
 
The basic structure of flavonoid is a C6-C3-C6 skeleton, which is a flavan nucleus 
consisting of two benzene rings (A and B) joined by an oxygen-containing pyran ring (C) 
(Figure 1-2). 
1.2.2.1.2 Flavonoids 
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Figure 1-2 the Skeleton of Flavonoids 
The various classes of flavonoids derive from the level of oxidation of the C ring of the 
basic 4-oxoflavonoid (2-phenyl-benzo-γ-pyrone) nucleus. The six common subclasses of 
flavonoids (1.8-1.20) in mushrooms are flavonols, flavones, flavanols, flavanones, 
isoflavones and anthocyanidins (Figure 1-3), however, only one example of an 
anthocyanidin in mushrooms has been determined even though anthocyanidins are 
frequently regarded as an antioxidant component in mushrooms and other 
foods.20,22,24,33-39 Flavonols quercetin (1.8), rutin (1.9), kaempferol (1.10) and myricetin 
(1.11) were isolated from Portuguese Suillus luteus, Indian Pleurotus ostreatus, Korean 
Sparassis crispa and Korean Ganoderma lucidum mushrooms, respectively.22 
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HO
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Figure 1-3 Structures of Flavonoids in Mushrooms 
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As phenolic compounds, flavonoids can directly exert antioxidant effects by interrupting 
the chain reaction, following the same mechanism shown in Scheme 1-1, which is 
regarded as the primary mechanism. Additionally, flavonoids can chelate trace metal 
ions involved in RS formation or inhibit enzymes involved in RS production or regenerate 
membrane-bound antioxidants, which also result in antioxidant effects.22,24  
1.2.2.2 Polysaccharides 
Polysaccharides are biomolecules which are comprised of simple sugars in different 
ratios showing diversity in their structure and composition.10 Polysaccharides, as well as 
polysaccharide-protein complexes, are a class of antioxidants found in mushrooms.24 
For instance, Cordyceps sinensis (Dong Chong Xia Cao) is a high value Traditional Chinese 
Medicine, while several polysaccharides, like poly-N-acetylhexosamine (1.21) (Figure 
1-4), Cereus sinensis polysaccharide-1 (CSP-1) and capsular polysaccharide-1 (CPS-1) 
have exhibited significant antioxidant activity.10,40 The structure elucidation of 
polysaccharides is challenging, as they frequently produce complicated, poorly 
dispersed nuclear magnetic resonance (NMR) spectra. As a result only a few 
polysaccharides have had their structures confirmed. Among polysaccharides, β-glucans 
are recognised as the major active components while α-glucans are eukaryotic nutrient 
components and are easily degraded by mammalian enzymes.10 
O
HO
O
NH
O
OH
O
O
O
O
NH
O
OH
O
HO
HO
HO
OH
m
n
[-4-β-D-ManNAc-(1→3)-β-D-GalNAc-1→]n
3
↑
1
(α-D-Gal)m
m=1-2, n=9-13, MW=6 kDa
poly-N-acetylhexosamine (1.21)  
Figure 1-4 Structure of poly-N-acetylhexosamine 
The antioxidant capacity of polysaccharides is attributed to their ability to directly 
scavenge RS, following a similar mechanism to that exhibited in Scheme 1-1 involving 
hydrogen atom transfer reactions involving polysaccharides abundant hydroxy group. 
Also, polysaccharides are thought to chelate trace metal ions involved in RS generation, 
or to modulate enzymes’ activities, either enhancing enzymes using RS as substrates or 
inhibiting enzymes forming RS.10,24 
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1.2.2.3 Vitamins 
 
Vitamin C, also known as L-ascorbic acid (1.22) (Figure 1-5), is an essential nutrient for a 
number of animals, including humans, that are incapable of its de novo synthesis and 
must therefore acquire it from dietary uptake.22,24 Vitamin C is recognised as an 
antioxidant and is abundant in foods. As one of the simplest vitamins, it has been 
detected in diverse mushrooms including chanterelles (Cantharellus cibarius), wood 
ears (Auricularia mesenterica), maitakes (Grifola frondosa) and peppery milk-caps 
(Lactarius piperatus). While the content varies in different mushrooms, in some 
mushrooms vitamin C content is much higher than in some fruits and vegetables which 
are recommended as a good natural source of vitamin C.22,24 
OH
OH
OH
OO
HO
vitamin C (1.22)  
Figure 1-5 Structure of Vitamin C 
Vitamin C is a powerful RS scavenger, it far more effectively inhibits lipid peroxidation 
triggered by a lipid peroxyl radical (LOO·) initiator than other plasma constituents, like 
vitamin E. Vitamin C can protect biomembranes from being damaged by LOO·, where 
the basic mechanism is recognised to involve direct trapping of LOO· before they initiate 
lipid peroxidation.24 Apart from direct reaction with RS, the primary mechanism of 
vitamin C antioxidant function is to recycle vitamin E (tocopherols) via a synergistic 
procedure (also mentioned for vitamin E; section 1.2.2.3.2), which is shown below 
(Scheme 1-2). That is, vitamin E firstly reacts with a RS to generate a vitamin E radical, 
which is rapidly trapped by vitamin C, the vitamin C radical (semidehydroascorbate) 
formed is reduced by nicotinamide adenine dinucleotide (NADH).22,24 
Vitamin C + Vitamin E Vitamin C + Vitamin E
Vitamin C + NAD + Vitamin CNADH
(semidehydroascorbate)
(semidehydroascorbate)  
Scheme 1-2 Primary Mechanism of Vitamin C Antioxidant Effect 
1.2.2.3.1 Vitamin C 
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Like vitamin C, vitamin E is another well recognised antioxidant which also exists 
abundantly in foods such as grains and nuts, vegetables and fruits. Essentially, “vitamin 
E” is a family of chemicals which share a common structure with a chromanol head and 
isoprenic side chain.22,24 Based on the structures, vitamin E can be divided into two 
classifications tocopherols and tocotrienols, which both have four types α, β, γ, δ (Figure 
1-6). Therefore vitamin E does not refer to one single molecules, but is instead 
comprised of eight structures (1.23-1.30). Numerous references have confirmed that 
diverse mushrooms contain vitamin E, however, the detected vitamin E content is only 
limited to tocopherols, so far no tocotrienols have been detected in mushrooms.22,24 For 
instance, α-tocopherol (1.23) was found in Auricularia mesenterica and Grifola frondosa, 
β-tocopherol (1.24) was found in horse mushrooms (Agaricus arvensis) and porcini 
mushrooms (Boletus edulis), γ-tocopherol (1.25) was found in reishi mushrooms 
(Ganoderma lucidum) and shitakes (Lentinula edodes), δ-tocopherol (1.26) was found in 
lion’s mane (Hericium erinaceus) and the white beech mushroom (Hypsizygus 
marmoreus).22 From these eight forms of vitamin E, α-tocopherol (1.23) is regarded as 
the most active one, nevertheless, other vitamin forms are recently emphasised in terms 
of their pro-health functions.22,24 
O
R1
HO
R2
O
R1
HO
R2
Tocopherol
α-tocopherol (1.23) R1=R2=Me
β-tocopherol (1.24) R1=Me, R2=H
γ-tocopherol (1.25) R1=H, R2=Me
δ-tocopherol (1.26) R1=R2=H
Tocotrienol
α-tocotrienol (1.27) R1=R2=Me
β-tocotrienol (1.28) R1=Me, R2=H
γ-tocotrienol (1.29) R1=H, R2=Me
δ-tocotrienol (1.30) R1=R2=H  
Figure 1-6 Chemical Structures of Vitamin E 
1.2.2.3.2 Vitamin E 
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 The mian biological role of vitamin E is to protect cell membranes against oxidative 
damage. The general mechanism is described below (Scheme 1-3). After lipids react with 
the initial RS, a lipid radical L. is generated, which can react with oxygen to form a peroxyl 
radical LOO· with high activities and toxicities, however, LOO· can be rapidly scavenged 
by tocopherol to form neutral hydroperoxide lipids LOOH and a poorly active tocopherol 
radical. Then the tocopherol radical, as mentioned above (section 1.2.2.3.1), can be 
neutralised by vitamin C and consequently tocopherol is recycled through this 
synergistic procedure (Scheme 1-2).22,24 The interactions between vitamin E and vitamin 
C suggests the concentration of each antioxidant alone may not be adequate to 
effectively protect cells, therefore ingestion of vitamin E and vitamin C together may be 
helpful in order to improve the antioxidant effect.22 
L + LOO
LOO + LOOH + TocopherolTocopherol
LH + Oxidant initiator L
O2
 
Scheme 1-3 General Mechanism of Vitamin E Antioxidant Effect 
 
Carotenoids are a class of chemicals possessing a polyisoprenoid skeleton with 40 
carbons. Within that common structure, a conjugated double bond chain forms the 
central part of the molecule which in some instances forms a bilateral symmetry (e.g. 
1.31) located around the trans disubstituted central double bond (Figure 1-7).22,24 
Carotenoids can be synthesised by plants and microorganisms, not by animals. They are 
the most distributed pigments in nature, and dozens of carotenoids are found in foods 
such as fruits and vegetables. The predominant carotenoids, greater than 90%, in the 
human diet are represented by β–carotene (1.31), α-carotene (1.32), lycopene (1.33), 
β–cryptoxanthin (1.34) and lutein (1.35) (Figure 1-7). Among them, β–carotene, α-
carotene and β–cryptoxanthin are able to function as provitamin A and play important 
biological roles as vitamin A dietary sources. Vitamin A represents a group of 
unsaturated nutritional compounds with biological significance including its activity as 
an antioxidant. Apart from the carotenoids, vitamin A exists as other major forms such 
as retinol (1.36) and retinal (1.37) (Figure 1-7) in animals.41 Many carotenoids have been 
discovered in mushrooms species, particularly, β–carotene (1.31) widely distributed in 
1.2.2.3.3 Vitamin A and Carotenoids 
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various species like peppery milk-caps (Lactarius piperatus), the bell morel (Verpa 
conica), Agaricus romagnesii and the white beech mushroom (Hypsizygus 
marmoreus).22,24 
β-carotene (1.31)
α-carotene (1.32)
β-cryptoxanthin (1.34)
lycopene (1.33)
OH
lutein (1.35)
OH
HO
OH
retinol (1.36)
O
retinal (1.37)  
Figure 1-7 Structures of Major Carotenoids and Vitamin A 
The antioxidant property of carotenoids has been the focus of a lot of recent research, 
as carotenoids are believed to directly react with RS and function as a chain-breaking 
antioxidant in a lipid environment to generate inactive and short-lived carotenoid 
radicals (Scheme 1-4).22,24 The peroxyl radical LOO· is produced after the lipid radical 
reacts with oxygen, and is very harmful to cells, can be attacked by a carotenoid and 
consequently forms an inactive product to minimise the oxidative damage. The 
extensive conjugated double bonds enable carotenoids to react with the peroxyl radical 
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LOO·. As such the conjugated double bonds are regarded as essential for antioxidant 
function. Since carotenoid radicals can be stabilised by virtue of the delocalization of the 
unpaired electron over the conjugated polyene and this delocalization also allows 
additional reactions to take place at many sites on the radical, reactivity of the 
scavenging lipid radical depends on the length of the conjugated polyene chain and the 
characteristics of the end groups.22,24 
L + LOO
LOO + Formation of inactive productsCarotenoid
LH + Oxidant initiator L
O2
 
Scheme 1-4 Proposed Mechanism of Carotenoids Antioxidant Activities 
 
Vitamin D (Figure 1-8) is a group of fat-soluble secosteroids which are responsible for 
enhancing intestinal absorption of calcium (Ca), iron (Fe), magnesium (Mg), phosphorus 
(P) and zinc (Zn), so vitamin D is vital for bond function. It is also has other biological 
effects like increase immune system and muscle functions.24 The most important 
compounds of the vitamin D family in humans are vitamin D2 (1.38), or ergocalciferol 
and vitamin D3 (1.39), or cholecalciferol (Figure 1-8). However, both vitamin D2 and D3 
are biologically inactive and must be metabolised in the liver to generate 25-
hydroxyvitamin D (1.40) and further metabolised in the kidney to produce the biological 
active form 1,25-dihydroxyvitamin D (1.41) (Figure 1-8).24 Vitamin D is sourced from 
food, generally, vitamin D3 has animal origins while vitamin D2 is predominantly from 
mushrooms and yeast.24 For instance, white and brown button mushrooms (Agaricus 
bisporus) are a major dietary source of vitamin D2 but it is also found in edible 
chanterelle mushrooms Cantharellus cibarius and Cantharellus tubaeformis.42,43 
Recently vitamin D, including D2, D3 and their bioactive metabolite 1,25-
dihydroxyvitamin D was recognised as a powerful antioxidant,24,44-50 but the mechanism 
of vitamin D antioxidant activity remains unclear. 
1.2.2.3.4 Vitamin D 
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Figure 1-8 Structures of Vitamin D2, D3 and Their Metabolites 
Vitamin D antioxidant property is proposed to associate with its conjugated double 
bonds system, which is similar to vitamin A, in addition, vitamin D is regarded to stabilise 
membrane with reducing membrane fluidity to inhibit iron-dependent liposomal lipid 
peroxidation.44 
1.2.2.4 Ergothioneine 
Ergothioneine (ET) (1.42), is a naturally occurring amino acid and is a thiourea derivative 
of histidine (Figure 1-9). In humans, ET is obtained exclusively through dietary intake. It 
is widely distributed in various species of edible mushrooms including Agaricus bisporus, 
Lentinus edodes, Grifola frondosa, and the oyster mushrooms Pleurotus ostreatus and 
Pleurotus eryngii. ET has also been used as an antioxidant in food storage and 
preservation.24,51-56 
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Figure 1-9 Structure of Ergothioneine 
A deficiency of ET is associated with increased mitochondrial deoxyribonucleic acid (DNA) 
damage and protein oxidation. High mitochondrial concentration suggests that ET is able 
to protect mitochondrial components against oxidative damage from O2·- produced 
within mitochondria.24 The detail of how ET actually works as an antioxidant is not 
known. 
1.2.2.5 Minerals 
Minerals are another important aspect of components attributed to mushroom’s 
antioxidant effects. Mushrooms are able to accumulate trace elements and deliver them 
to our bodies to achieve bio-accumulative effects through the diet.57,58 Wild mushrooms 
are reported to possess a stronger capacity to accumulate minerals than those produced 
in monocultural practices.24 
Many dietary trace elements like selenium, zinc, copper, manganese and iron are 
cofactors of enzymes, which scavenge RS or eliminate oxidative damage caused by 
RS.22,24 Peroxidases are a large family of enzymes that use hydrogen peroxide or organic 
hydroperoxides as substrates. Se is essential for the biosynthesis of glutathione 
peroxidases (GPx), and it can reduce lipid hydroperoxides to their corresponding 
alcohols and reduce free hydrogen peroxide to water. Selenoprotein-P has a similar 
function to GPx in terms of minimising cellular oxidative harm. Those two enzymes are 
the major Se compounds secreted in blood, so they play a vital role in endogenous 
enzymatic antioxidant defences.22,24 Heme peroxidases are another important type of 
peroxidases with metal chelated to enzymes. They utilise hydrogen peroxide as the 
electron acceptor to catalyse a number of oxidative reactions to reduce the cytotoxic 
effects. Mushrooms are also capable of accumulating heavy metals, such as cadmium 
(Cd) and lead (Pb).24 
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1.3 Conclusions 
Around 70% of chronic diseases are associated with imbalance between free radical 
production and antioxidant defences, so research on antioxidant reagents and their 
corresponding mechanisms play a significant role in the prevention and therapy of such 
diseases. Functional foods with antioxidant properties have been receiving increasing 
attention and are perceived to be of high value for this reason. As the traditionally used 
food and medicines in various regions of the world, mushrooms represent a readily 
available resource for the discovery of antioxidants for academia and the 
pharmaceutical industry. Inspired by their tremendous biological diversity and their 
promising bioactivities, our group has an ongoing  interest in mushrooms and one aspect 
of this program focuses on a chemical survey and bioactivity assessment of mushrooms 
traditionally used by communities in the Eastern Highland province of Papua New 
Guinea. 
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Chapter 2: Chemical Forays of Mushrooms Traditionally 
Used in Papua New Guinea 
2.1 Introduction 
Natural products and their derivatives are major sources of drug discovery, and they 
greatly benefit the pharmaceutical industry,1 with the wealth of fungi-derived drugs 
demonstrating the importance of investigation of fungal metabolites.2,3 Not only in 
ancient but also contemporary practice, macrofungi (mushrooms) are used worldwide 
for dietary or medicinal purposes, examples include Oyster mushrooms and Reishi.4 The 
usage of mushrooms in traditional medicines, such as Chinese, Indian and European, 
dates from thousands of years ago and the validation of medicinal mushrooms and their 
various bioactivities have been confirmed by modern researchers.5-12 Nevertheless, out 
of an estimated total 150,000 species of mushrooms, only 10%, or approximately 14,000 
species have been described in the literature.13,14 Such surprisingly limited knowledge 
of mushrooms illustrates lead compounds from mushrooms could be a solution of 
economical and sustainable attraction to challenges in current drug discovery. 
Papua New Guinea (PNG) is located to the north of Australia. It has very close ties with 
Australia with regard to economy, culture or ecology. PNG is one of the world’s 
biologically diverse regions, especially rich in fungi (2390 species), with a large amount 
still undescribed.4,15 Indigenous tribes of PNG widely and traditionally use mushrooms 
as food and/or medicine and abundant firsthand knowledge has been accumulated 
(Figure 2-1). However, such knowledge is poorly documented. Due to the developing 
economic levels and living conditions associated with poor public service and 
infrastructure in many areas of PNG, residents do not have ready easy access to 
established healthcare, and as a result functional foods and medicinal mushrooms play 
a crucial role in the wellbeing and health of a community. Thus the investigation of 
traditionally used mushrooms is very useful for both PNG and the broader scientific 
communities. Searching for bioactive compounds from mushrooms with demonstrated 
efficacy and inherent low toxicity, coupled with traditional knowledge, appears an 
obvious advantage over random screening.16 Additionally, the PNG community will 
benefit from the feedback of this investigation. Firstly, traditional culture and knowledge 
will be preserved and extended. The local community is able to use those mushrooms 
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more safely and efficiently. In the general case, validated medicinal mushrooms seem 
more useful than distant hospitals and unavailable drugs. Also, mushrooms confirmed 
to have functions such as antioxidant, antihyperglycemic and antihypertensive activities 
can be applied as functional food or cosmetic ingredients, and the local economy could 
benefit from production of those mushrooms. Therefore, it is necessary and worthy to 
conduct some chemical studies of mushrooms traditionally used in PNG. 
 
Figure 2-1 Images of PNG and Local Traditionally Used Mushrooms 
1 Photo comes from google map 
2 Photo comes from Wikipedia Eastern Highlands Province. http://en.wikipedia.org/wiki/Eastern_Highlands_Province 
3 Photos are courtesy of colleague Dr Edwin M Castillo Martinez 
Bacterial infections are major causes of illness and death in PNG. As reviewed in chapter 
one, oxidative damage is associated with a number of diseases including cancer, 
diabetes and Alzheimer’s disease.16-20 Thus, chemical survey of mushrooms in my PhD 
program will focus on the chemicals possessing antibacterial and antioxidant activities.  
By means of collaboration with local communities in PNG, our group profiled native 
mushrooms and their common usages and corresponding traditional knowledge. These 
mushrooms were collected and their ethanol extracts were sent back to Australia and 
stored for further investigation. 
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2.2 Screenings of Mushroom Extracts 
In order to rapidly identify bioactive candidates from mushroom extracts for chemical 
survey, crude screenings were conducted, including antibacterial and antioxidant assays. 
2.2.1 Antibacterial Screening 
Ethanol extracts of 20 mushroom samples (MMSP01-MMSP20) were subjected to 
antibacterial screening against bacteria Staphylococcus epidermidis (Gram-positive) and 
Escherichia coli (Gram-negative) by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (Figure 2-2). The evaluation of their antibacterial 
activities was used to choose candidate mushroom samples for further study. 
 
Figure 2-2 Crude Antibacterial Screening of Mushroom Extracts by MTT Assay 
MTT is a tetrazolium dye, it gives a yellowish colour in solution. MTT can be reduced by 
dehydrogenases and reducing agents present in metabolically active cells, yielding a 
water insoluble violet-blue formazan (Figure 2-3).21,22 The minimum inhibitory 
concentration (MIC) of a test sample can be visually determined by solution colour after 
adding MTT to the incubated bacterial inoculum containing the testing sample. A yellow 
colour indicated bacterial inhibition while a blue colour indicates bacterial growth. Also, 
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the amount of formazan generated from MTT has been widely recognised as the 
indicator of cell activity, it is directly proportional to the number of living bacteria. Since 
MTT and its reduced product formazan have the greatest absorption difference around 
580 nm wavelength (Figure 2-4), the antibacterial activity of a test sample can be 
quantified by measuring an individual well’s absorbance. Based on inhibitory ratio of 
testing samples, its half maximum inhibitory concentration (IC50) can be calculated. 
 
Figure 2-3 Reduction from MTT to Formazan in Active Cell 
 
Figure 2-4 Absorption Spectrum of MTT and Its Reduced Product Formazan21 
As a result of testing (Table 2-1), mushroom extracts MMSP 01, 02, 03, 05, 06, 10, 15, 18 
show obvious antibacterial capacities against Escherichia coli. Mushroom extracts 
MMSP 01, 02, 03, 04, 07, 08, 10, 12, 15, 16, 17, 18 show obvious antibacterial capacities 
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against Staphylococcus epidermidis. However, attempts to measure antibacterial 
capacity of mushroom extracts based on absorbance often encountered severe 
interference from either extracts’ background absorbance, or absorbance of complexes 
from reactions between extracts and MTT. So 6 mushroom samples MMSP 01, 02, 03, 
10, 15, 18 were chosen as chemical survey candidates for their strong antibacterial 
activities both against Gram-positive and Gram-negative bacteria. 
Table 2-1 Antibacterial Screening Result of Mushroom Extracts 
Samples 
MIC (mg/mL) 
E. coli S. epidermidis 
Kanamycin sulfate 0.00008 0.00008 
MMSP01 37.6 9.4 
MMSP02 10.2 5.1 
MMSP03 3.5 0.2 
MMSP04 ― 4.9 
MMSP05 37.6 ― 
MMSP06 10.2 ― 
MMSP07 ― 28.3 
MMSP08 ― 4.9 
MMSP09 ― ― 
MMSP10 5.1 2.6 
MMSP11 ― ― 
MMSP12 ― 4.9 
MMSP13 ― ― 
MMSP14 ― ― 
MMSP15 28.3 3.5 
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MMSP16 ― 1.2 
MMSP17 ― 37.6 
MMSP18 10.2 2.6 
MMSP19 ― ― 
MMSP20 ― ― 
 
2.2.2 Antioxidant Screening 
Ethanol extracts of 37 mushroom samples * (MMSP03-MMSP20, KMSP1-KMSP5 and 
KUMSP2-25) were subjected to antioxidant screening via DPPH assay (Figure 2-5). The 
evaluation of their antioxidant activities was used to choose candidate mushroom 
samples for further investigation. 
 
Figure 2-5 Crude Antioxidant Screening of Mushroom Extracts by DPPH Assay 
DPPH is a black crystalline picrylhydrazyl. It is a stable free-radical, with a deep violet 
colour in solution. This radical can be scavenged and generate a neutralised product with 
pale yellow colour in solution after reacting with an antioxidant reagent. DPPH and its 
neutralised product have the largest absorption difference round 520 nm wavelength 
(Figure 2-6), which can be monitored to quantify the scavenging capacity toward DPPH 
                                                     
* Two collections of mushrooms were received from PNG. When the second collection was received the 
focus of my work had changed to be solely on antioxidants. 
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radicals. Based on the DPPH scavenging ratio, its half maximum effective concentration 
(EC50) can be determined. 
 
Figure 2-6 Absorption Spectrum of DPPH and Its Neutralised Product23 
As a result (Table 2-2), 14 mushroom samples MMSP03, MMSP06, MMSP07, MMSP08, 
MMSP15, MMSP16, MMSP19, MMSP20, KMSP3, KMSP5, KUMSP3, KUMSP14, KUMSP15 
and KUMSP19 were regarded to be good antioxidants (EC50 < 0.50 mg/mL), they were 
chosen as chemical survey candidates. However, absorbance data were also found to be 
interfered with through absorbance of either an extract’s background or the generated 
complex’s absorbance from interacting with DPPH. 
Table 2-2 Antioxidant Screening Result of Mushroom Extracts 
Samples EC50 (mg/mL) 
L-ascorbic acid 0.005 
MMSP03 < 0.45 
MMSP04 0.69 
MMSP05 1.05 
MMSP06 < 0.37 
MMSP07 0.46 
MMSP08 < 0.61 
MMSP09 0.87 
Chapter 2: Chemical Forays of Mushrooms Traditionally Used in Papua New Guinea 25 
MMSP11 0.79 
MMSP12 1.43 
MMSP13 0.93 
MMSP14 1.69 
MMSP15 < 0.32 
MMSP16 < 0.18 
MMSP17 0.67 
MMSP18 0.92 
MMSP19 0.16 
MMSP20 0.14 
KMSP1 1.57 
KMSP2 > 1.30 
KMSP3 < 0.25 
KMSP4 0.80 
KMSP5 < 0.89 
KUMSP2 > 1.56 
KUMSP3 < 0.50 
KUMSP4 1.17 
KUMSP5 0.86 
KUMSP9 1.25 
KUMSP12 1.12 
KUMSP14 < 0.30 
KUMSP15 < 0.43 
KUMSP16 1.73 
KUMSP17 1.35 
KUMSP18 2.39 
KUMSP19 < 0.49 
KUMSP20 0.92 
KUMSP22 < 2.10 
KUMSP25 1.29 
 
2.3 Bioactivities Guided Isolation of Mushroom Extracts 
Among the selected candidates, 4 mushroom extracts with code numbers MMSP01, 
MMSP02, MMSP03 and MMSP10 were selected for chemical examination, guided by 
antibacterial screening using paper disc assay or antioxidant screening using the DPPH 
assay. 
The MTT assay has been already reported to afford false results due to its susceptibility 
and many interferences.24,25 On account of the significant interference to absorbance 
values found in the current MTT antibacterial assay, Kirby-Bauer paper disc diffusion 
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assay offers the complementary antibacterial assessment.26 As a rapid procedure, the 
paper disc assay was used to determine antibacterial activities of the mushroom extracts 
subjected to chemical survey and to track the activity in partitioned fractions’ 
antibacterial capacity. In the paper disc assay, the bacterium Escherichia coli was 
cultivated on agar in a petri plate, paper discs soaked with samples were laid on the 
surface of agar plate. After incubation, an inhibition zone around a paper disc will be 
observed if a sample has antibacterial activity (Figure 2-7). The size of the inhibition zone 
is proportional to the strength of the sample’s antibacterial capacity and indicative of its 
ability to diffuse through the aqueous agar medium. 
 
Figure 2-7 Antibacterial Paper Disc Assay Guided in Chemical Survey† 
2.3.1 Chemical Survey of Mushroom MMSP01 Extract 
This mushroom (Figure 2-8) (local name is Nagisavoi sma in PNG) was collected from 
Eastern Highland province. This specimen has not been classified according to Linnaean 
taxonomy. Recollection in the remote PNG highlands is required to allow extraction of 
DNA and this was not achieved in the timeframe of this study.  A voucher sample is kept 
in the University of Goroka and the assignment of taxonomy is to be completed when 
experts travel to PNG. This mushroom is found growing on soil under the trunks of fallen 
trees. 
                                                     
† A-E refer to PE, DCM, EtOAc, n-BuOH and aqueous fractions respectively. 
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Figure 2-8 Mushroom MMSP01 (Nagisavoi sma) 
The crude ethanol extract was subjected to a modified Kupchan solvent partition and 
divided into five fractions, specifically, petroleum ether (PE), dichloromethane (DCM), 
ethyl acetate (EtOAc), n-Butanol (n-BuOH) and aqueous fractions (Figure 2-9).27 PE, DCM, 
EtOAc fractions exhibited significant antibacterial activities, and thin layer 
chromatography (TLC) indicated the same components were predominant in these 
fractions. Two compounds with very similar retention factors (Rf) values and behaviour 
on TLC were isolated from these fractions in the following purification. 1H NMR spectra 
of these two compounds were also very similar, especially two proton resonances, δ 
5.92, 1H, d, J= 3.1 Hz and δ 6.00, 1H, d, J= 3.1 Hz; and δ 5.92, 1H, d, J= 3.2 Hz and δ 6.15, 
1H, d, J= 3.2 Hz respectively which suggested the presence of a 2,5-dialkylated furan 
structure in these two compounds. The two different olefinic proton resonances, δ 6.05, 
1H, dt, J= 15.9, 6.7 Hz and δ 6.13, 1H, dt, J= 15.9, 1.0 Hz; and δ 5.40, 1H, dt, J= 11.7, 7.3 
Hz and δ 6.28, 1H, dt, J= 11.7, 1.7 Hz respectively, indicated they were diastereomers, 
the former structure had a trans configuration while the later had a cis configuration. 
Based on heteronuclear single quantum correlation (HSQC) and heteronuclear multiple 
bond correlation (HMBC) and MS analysis, two furan fatty acid isomers (E)-9-(5-
pentylfuran-2-yl) non-8-enoic acid (2.1) and (Z)-9-(5-pentylfuran-2-yl) non-8-enoic acid 
28 Chapter 2: Chemical Forays of Mushrooms Traditionally Used in Papua New Guinea 
 
 
(2.2) (Figure 2-10) were elucidated as the structures, which represented previously 
unreported compounds simultaneously isolated by group colleague Dr Edwin M Castillo 
Martinez from a PNG mushroom with local name Fulaga dive, identified as a new 
Amanita sp..28 Compounds 2.1 and 2.2 represent novel fatty acids. 
EtOH extract
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concentrated
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extracted by DCM
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Figure 2-9 Modified Kupchan Solvent Partition 
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(E)-9-(5-pentylfuran-2-yl) non-8-enoic acid (2.1)
(Z)-9-(5-pentylfuran-2-yl) non-8-enoic acid (2.2)  
Figure 2-10 Structures of Isolated Mushroom Metabolites Furan Fatty Acids 
2.3.2 Chemical Survey of Mushroom MMSP02 Extract 
This mushroom (Figure 2-11) (local name is Fella Yaluwasa sma, which translates to 
bracket fungus) was collected from the Eastern Highland province and is used 
traditionally, to treat swollen body parts, by the Lohu tribe in Ungga-bena district. This 
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specimen has not been classified according to Linnaean taxonomy. Voucher samples are 
kept in the University of Goroka. This mushroom grows on stems and bark of trees of 
the genus Castanopsis. 
 
Figure 2-11 Mushroom MMSP02 (Fella Yaluwasa sma) 
Following the same modified Kupchan solvent partition protocol used previously, this 
mushroom ethanol extract was also divided into five fractions, with DCM, EtOAc, n-
BuOH fractions displaying significant antibacterial activities. Further purification was 
conducted on these fractions but unfortunately no pure compound was isolated due to 
a lack of material. 
2.3.3 Chemical Survey of Mushroom MMSP03 Extract 
Mushroom MMSP03 (Figure 2-12) (local name is Fella Nagisavoi in PNG) was collected 
from the Eastern Highland province and traditionally used as food by the Lohu tribe in 
Ungga-bena district (section 2 in Figure 2-1). This specimen has not been classified 
according to Linnaean taxonomy. A voucher sample is kept in the University of Goroka 
and is awaiting assessment by taxonomists. Recollection of a fresh sample is planned to 
provide DNA for molecular identification. This mushroom grows on soil and under tree 
trunks. 
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Figure 2-12 Mushroom MMSP03 (Fella Nagisavoi) 
Using the modified Kupchan partition protocol, this mushroom’s ethanol extract was 
divided into five fractions. The PE, DCM and EtOAc fractions showed significant 
antioxidant activities (Figure 2-13 and Table 2-3). All three fractions were found to 
contain the same major components based on TLC and NMR spectra. Subsequently, 
three natural compounds with very similar Rf values and behaviour on TLC were isolated 
from the DCM fraction. These isolated compounds possessed very similar 1H NMR 
spectra including four singlet CH3 signals from δ 1.56 to δ 1.82, two broad olefinic proton 
resonances around δ 5.08, and a triplet olefinic proton resonance around δ 5.20 with 
the coupling constant around 7.0 Hz, which suggests the presence of a farnesyl structure. 
In addition, a singlet CH3 signal with the chemical shift over δ 2.00 and singlet aromatic 
proton resonance around δ 6.25 indicated the presence of a multi-substituted phenyl 
structure. The isolated natural products were identified as known structures grifolin 
(2.3), grifolic acid (2.4) and grifolic acid methyl ether (2.5) (Figure 2-14) after the analysis 
of 2D NMR spectra and MS. Grifolin (2.3) had  also been isolated by a group colleague, 
Dr Edwin M Castillo Martinez from a PNG mushroom with local name Igura hivi 
(Albatrellus sp. Gray).28 
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Figure 2-13 Antioxidant Screening of MMSP03 Fractions by DPPH Assay 
Table 2-3 Antioxidant Screening of MMSP03 Fractions by DPPH Assay 
 PE DCM EtOAc n-BuOH Aqueous 
EC50 
(mg/mL) 
< 0.228 0.088 < < 0.175 0.093 < < 0.185 0.275 < < 0.550 1.470 < < 2.940 
 
grifolic acid methyl ether (2.5)
OH
OH
OH
OH
COOH
OMe
OH
COOH
grifolin (2.3) grifolic acid (2.4)
 
Figure 2-14 Structures of Isolated Mushroom Metabolites Grifolin and Its Derivatives 
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2.3.4 Chemical Survey of Mushroom MMSP10 Extract 
This mushroom (Figure 2-15) (local name is Yalluwasa sma in PNG) was collected from 
the Eastern Highland province. This specimen has not been classified according to 
Linnaean taxonomy. A voucher sample is kept in the University of Goroka. This 
mushroom grows on fallen, dead logs. 
 
Figure 2-15 Mushroom MMSP10 
The ethanol extract of the mushroom was divided into five fractions following the 
modified Kupchan solvent partition protocol employed previously. However, no further 
isolation was conducted because no fraction displayed activity in antibacterial assay. 
This suggests either a false positive result of antibacterial screening via MTT assay or 
more than likely decomposition of the active component. 
2.4 Discussion and Conclusions 
20 Mushroom samples were screened for antibacterial activity against bacteria 
Staphylococcus epidermidis (Gram-positive) and Escherichia coli (ATCC 25922) (Gram-
negative) via MTT assay. Six of these mushroom extracts (see Table 2-1) were chosen as 
chemical survey candidates for their strong antibacterial activities both against Gram-
positive and Gram-negative bacteria. 
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37 Mushroom samples were screened for their antioxidant activities using the modified 
DPPH assay. Out of them, 14 mushroom samples were chosen as chemical survey 
candidates based on their antioxidant capacities (see Table 2-2). 
Among these selected candidates, investigations of four PNG mushroom extracts were 
carried out resulting in the isolation and identification of five natural products. The two 
isolated compounds (E)-9-(5-pentylfuran-2-yl) non-8-enoic acid (2.1) and (Z)-9-(5-
pentylfuran-2-yl) non-8-enoic acid (2.2), isolated from mushroom MMSP01 extract, 
represented previously unreported compounds and are new fatty acids. They show 
strong antibacterial activities against Staphylococcus aureus with IC50 29.63 μg/mL and 
20.01 μg/mL, respectively.28 Grifolin (2.3), grifolic acid (2.4) and grifolic acid methyl 
ether (2.5) were isolated from the edible mushroom MMSP03 extract. These 
meroterpenoid natural products have been identified previously and evidence of their 
antioxidant properties have been demonstrated by many references.29-36 
Crude bioactivity screenings of mushroom extracts, MTT antibacterial assays in 
particular, were found to be interfered with by either extracts’ background absorbance, 
or complexes’ absorbance yielded from reactions between extracts and essential 
working reagents (MTT). It is worthy to note that previous researchers have found that 
antioxidants present in crude extracts and pure compounds can react with MTT and also 
generate the reduced formazan product.25 So the false positive antibacterial outcome 
of mushroom MMSP10 may be the result from such interference. The susceptibility of 
MTT to possibly afford false negative or positive results will also influence the results’ 
accuracy.24 Because of the severe interference in MTT assay, paper disc assay was 
applied in the following mushroom extracts’ chemical survey. Due to the complicated 
components in crude extracts, their interactions with the essential working reagents, 
either MTT or DPPH, are inexplicable and the subsequent influence on absorbance is 
indelible. The influence of an extract’s background absorbance can be eliminated by 
adding a blank group to the 96-well plate. Despite this the bioassay results of mushroom 
extracts give an initial assessment and offer leads to the discovery of bioactive 
compounds. The bioassay guided isolation also enables a more efficient discovery of 
bioactive natural products. The MTT and DPPH based assays are promising methods for 
the assessment of a pure compound’s bioactivity. 
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2.5 Experimental 
2.5.1 Equipment and Chemical Reagents 
2.5.1.1 Bioassays 
Westinghouse WFM0900 bar freezer was set at -30 °C to store frozen bacterial strains. 
Thermoline I60G incubator was set at 37 °C for incubation and set 120 revolutions per 
minute (RPM) for agitation. Labconco Logic A2 biological safety cabinet was used to 
afford sterile operating conditions. Tomy ES-315 vertical autoclave was used to 
autoclave experimental materials. BioTek Epoch microplate spectrophotometer was 
used to read the absorbance of 96-well plates. Shimadzu UVmini-1240 UV-Vis 
spectrophotometer was used to measure the absorbance (optical density) of the 
bacterial cultures. Eppendorf Research® series pipettes were used to transfer solutions. 
Ratek OM6 orbital mixer was used to blend suspensions. Hanna HI1290 pH meter was 
used to adjust culture medium pH. 
Culture media, Mueller Hinton broth (MHB) and Mueller Hinton agar (MHA), were 
supplied by Bacto Laboratories Pty Ltd, Mount Pritchard, NSW 2170, Australia and 
prepared as per the manufacturer’s instruction unless otherwise noted. The pH of the 
medium was adjusted to 7.3 ± 0.1 with ultrapure water before autoclaving. MHA plates 
were prepared following a previously reported method.26 Plastic tissue culture tubes, 
plastic petri dishes, clear flat bottom 96-well culture plates, MTT and L-ascorbic acid 
were suppliered by Thermo Fisher Scientific Australia Pty Ltd, Scoresby, VIC 3179, 
Australia. DPPH, Kanamycin sulfate, methanol and dimethyl sulfoxide (DMSO) were 
supplied by Sigma Aldrich Australia Pty Ltd, Castle Hill, NSW 2154, Australia. Paper discs 
with 6 mm diameter were cut from filter paper supplied by Whatman International Pty Ltd, 
Maidstone, ME14 2LE United Kingdom. All standard drugs were BioReagent grade, all 
chemicals and solvents were AR or A.C.S. grade, unless otherwise stated. 
2.5.1.2 Chemical Survey 
All nuclear magnetic resonance spectra (NMR) were recorded on a Bruker Biospin GmbH 
spectrometer at 300 K with a 5 mm PABBO BB/19F-1H/D Z-GRD Z116098/0258 probe. 
1H and 13C NMR experiments were undertaken at 400 MHz and 100 MHz respectively, 
unless otherwise indicated. 1H and 13C signals were described by chemical shift δ 
(integration, multiplicity, coupling constant J (Hz), assignment) using ppm. The 
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multiplicities were expressed by the abbreviations: s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet). Assignments are supported by 2D NMR data. 
Low resolution electron ionisation mass spectra (LREIMS) were recorded on a Finnigan 
Polaris Q ion trap mass spectrometer using ionisation energy at 70 eV. LREIMS were 
described by the Mass/charge ratios (m/z) followed the format (value, the relative 
abundance), molecular ions were symbolised as M while fragment ions weren’t specified 
unless otherwise stated. The relative abundance is shown as percentage of the base 
peak intensity. High resolution electron ionisation mass spectra (HREIMS) were recorded 
on a Waters VG autospec premier spectrometer using ionisation energy at 70 eV. 
HREIMS were described by (m/z) followed the format (ion actual value, ion calculation 
value). Low resolution electrospray mass spectra (LRESIMS) were recorded on a Waters 
Micromass ZMD single quadrupole mass spectrometer using ionisation electric field at 
3500 V, source temperature 100 °C, desolvation temperature at 150 °C, coupling to a 
Waters Alliance 2995 HPLC system. LRESIMS were described followed the same format 
as LREIMS. High resolution electrospray mass spectra (HRESIMS) were recorded on a 
Waters LCT Premier mass spectrometer using ionisation electric field at 2500 V, source 
temperature 100 °C, desolvation temperature at 150 °C, coupling to a Waters Alliance 
2995 HPLC system. HRESIMS are described following the same format as for HREIMS. All 
MS used positive ionisation mode unless otherwise indicated.  
Gas chromatography-mass spectra (GC-MS) experiments were recorded using an Agilent 
7890A GC and 5975C MS detector. The instrument was equipped with a HP-5 column 
[(cross-linked 5 % phenyl methyl silicone), 30 m x 0.25 mm x 0.25 μm film thickness] and 
flow split 2:1 using Helium as carrier gas (1 mL/min) by using positive ion detection. Oven 
temperature program started at 40 °C for 1 min, increasing 10 °C/min up to 280 °C, 
holding that temperature for 3 min. Inlet temperature was 250 °C unless otherwise 
indicated. In GC-MS, MS were described followed the same format as LREIMS. 
Semi-preparative HPLC was performed on an Agilent 1100 HPLC system, using a 
Phenomenex Luna 5μ Silica column (250 x 10.00 mm). 
Fluorescent active thin layer chromatography (TLC) plates (silica gel 60 F254) and silica 
gel (230-400 mesh) for flash chromatography were supplied by Merck Millipore Pty Ltd, 
Bayswater, VIC 3153, Australia. Sephadex LH-20 was supplied by GE Healthcare Pty Ltd, 
Parramatta, NSW 2150, Australia. Other fine chemicals and solvents were supplied by 
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Thermo Fisher Scientific Australia Pty Ltd, Scoresby, VIC 3179, Australia. HPLC grade 
solvents were only used for HPLC operation, other chemicals and solvents were AR or 
ACS grade, unless otherwise stated. Petroleum ether has its boiling range 60-80 °C 
unless otherwise stated. 
2.5.2 General Procedure of Antibacterial Screening 
2.5.2.1 Preparation of Test Bacteria 
Escherichia coli (ATCC 25922, β-lactamase negative) and Staphylococcus epidermidis 
(clinical isolate) were used for antibacterial assay. E. coli was supplied by our 
collaborators from Macquarie University, Department of Chemistry and Biomolecular 
Sciences, NSW 2109. S. epidermidis was obtained from the Department of Microbiology, 
Canberra Hospital, Garran, ACT 2605. Bacterial strains were sub-cultured in liquid media 
as described below and stored at -30 °C in glycerol/water matrix. 
A small portion of the glycerol/water matrix containing the bacteria was scraped and 
mixed thoroughly into 10 mL sterile Mueller Hinton broth (MHB) in a sterile tissue 
culture tube. After incubation overnight at 37 °C, approximately 5 μL of the bacterial 
suspension was transferred into a sterile MHA plate, spread evenly and incubated at 
37 °C overnight. A single colony was selected from the incubated MHA plate and 
transferred into 10 mL of sterile MHB in a sterile tissue culture tube. After incubation at 
37 °C overnight, the optical density (OD) at 600 nm (0.08-0.1) of the bacterial suspension 
was adjusted to achieve a 0.5 McFarland Standard, then diluted 1:100 in sterile MHB, 
the diluted suspension was used as bacterial inoculum for the assays. 
2.5.2.2 Preparation of Test Samples  
Mushroom extracts were concentrated to dryness, 20-30 mg of which were dissolved in 
50 μL fresh distilled DMSO, then added to 450 μL sterile MHB and mixed thoroughly to 
produce test samples. 
2.5.2.3 Preparation of Positive Controls 
Antibiotic kanamycin sulfate was used as positive control for E. coli and S. epidermidis. 
Kanamycin sulfate (2.5 mg) was dissolved in 5mL sterile MHB, then 50 μL of this solution 
was mixed with 50 μL distilled DMSO and 400 μL sterile MHB to produce the positive 
control solution (50 μg/mL). 
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2.5.2.4 MTT Assay 
This procedure represents a modification based on previously reported methods.28,37-39 
Kanamycin sulfate (80 μL), sample (80 μL) and sterile MHB (80 μL), representing the 
negative control and blank, were dispensed into wells in the first row (A1-A12) of a 96 
well plate (Figure 2-16). Subsequently, 40 μL was removed from each well of the first 
row and added into the next well in the same column (B1-B12), mixed with 40 μL sterile 
MHB. This operation was repeated to serially dilute the positive control (kanamycin 
sulfate) and the samples in duplicate through to the final row (H1-H12). Column 11 (A11-
H11) was used as negative control. Column 12 (A12-H12) was used as blank group, 
containing only MHB. Finally, to each well except those in the blank group (column 12) 
was added 150 μL bacterial inoculum to make total volume 190 μL. To the wells in the 
blank group was added 150 μL sterile MHB. The 96-well plate was incubated for 20 h at 
37 °C. After incubation, 10 μL MTT methanol solution (5 mg/mL) was added to each well 
in the plate. Absorbance of each well was measured at 600 nm wavelength after the 96-
well plate was incubated at 37 °C for 1 h. The average value of blank group’s absorbance 
was applied for autozero, the original absorbance of each well was subtracted and the 
processed value was recorded. The average value of negative controls absorbance was 
used as A negative control. In positive control, the average absorbance value of two wells in 
the first row was used as A positive control. In each test sample, absorbance was taken as the 
average value of two wells with same concentration. 
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Figure 2-16 the Outline of a 96-well Plate on MTT Assay 
The following equation (Equation 2-1) is used to calculate test sample inhibitory ratio. 
Since all test samples were crude mushroom extracts, some of which were highly 
coloured, and/or contained metabolites that could react with MTT, some absorbance 
values had interference around 600 nm and consequently produced unreliable results 
of inhibitory ratio. In order to confirm antibacterial activity of mushroom extracts to 
guide chemical examination, the calculation of inhibitory ratio was used with caution, 
complemented with visual observations of the MIC. 
Equation 2-1 Antibacterial Inhibitory Ratio 
% inhibition
 =
100 ×
A negative control
 − A 
test sample
A negative control
 − A 
positive control  
2.5.3 General Procedure of Antioxidant Screening 
2.5.3.1 Preparation of DPPH Testing Solution 
DPPH (99 mg) was dissolved in 200 mL ethanol, then 4 mL of the solution was diluted 
with ethanol to 50 mL, which was sealed in an amber bottle covered by aluminium foil 
and used as the DPPH testing solution (100 μM). The entire operation was conducted 
under low light conditions (laboratory lighting off).  
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2.5.3.2 Preparation of Test Samples 
Mushroom extracts were concentrated to dryness, 20-30 mg of which were dissolved in 
250 μL distilled DMSO to produce test samples. 
2.5.3.3 Preparation of Positive Controls 
L-ascorbic acid is a widely-recognised antioxidant, it was used as positive control for 
scavenging of the DPPH radical. 177 mg L-ascorbic acid was dissolved in 100mL distilled 
DMSO to produce positive control solution (10 mM). 
2.5.3.4 DPPH Assay 
This procedure represents a modification based on previously reported methods.40-42 L-
ascorbic acid solution (20 μL), test sample solution (20 μL) and distilled DMSO (20 μL), 
representing the negative control and blank, were dispensed into wells in the first row 
(A1-A12) of a 96 well plate (see Figure 2-16). Subsequently, 10 μL was removed from 
each well of the first row and added into the next well in the same column (B1-B12), and 
mixed with 10 μL of distilled DMSO. This operation was repeated to serially dilute the 
positive control (L-ascorbic acid) and the samples in duplicate through to the final row 
(H1-H12). Column 11 (A11-H11) was used as negative control. Column 12 (A12-H12) was 
used as blank group, containing only DMSO. Finally, to each well except those in the 
blank group (column 12) was added 190 μL DPPH solution to make total volume 200 μL. 
To the wells in the blank group was added 190 μL ethanol. The absorbance of each well 
was measured at 515 nm wavelength after the 96-well plate was incubated at 37 °C for 
0.5 h. The whole operation was conducted under dark conditions. The average value of 
blank group’s absorbance was applied for autozero, the original absorbance of each well 
was subtracted and the processed value was recorded. The average values of negative 
controls absorbance were used as A negative control. In positive control, the average 
absorbance value of two wells in the first row was used as A positive control. In each test 
sample, absorbance was taken as the average value of two wells with same 
concentration. 
Equation (Equation 2-1) was used to calculate test sample DPPH radical scavenging 
activity. Subsequently, various test sample concentrations (mg/mL) and their 
corresponding radical scavenging activities were analysed by Origin (OriginLab, 
Northampton, MA) software, followed by sigmoidal fit using category “growth/ 
sigmoidal”, function “dose/ response”. EC50 value of each test sample were determined. 
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2.5.4 General Procedure of Antibacterial Paper Disc Assay 
2.5.4.1 Preparation of Agar Petri Plate 
Escherichia coli (ATCC 25922, β-lactamase negative) was the test bacterium used to track 
activity. The preparation of a bacterial suspension (OD600 = 0.5 McFarland Standard) 
followed the same method described in the MTT assay above (Section 5.2). A suspension 
of bacteria (1 mL) was transferred to a sterile MHA petri plate, spread evenly and 
incubated at 37 °C for 12 h. After that, the incubated petri plates with a thin and even 
layer of bacterial colonies were selected as test petri plates. 
2.5.4.2 Preparation of Test Samples 
Various extracts partitioned fractions were concentrated to dryness, then the same 
mass (around 5 mg) solid materials were dissolved in 1 mL methanol or other soluble 
solvents to produce various fraction solutions. 
2.5.4.3 Paper Disc Assay 
The procedure was slightly modified based on previously reported method.26,43 Sterile 
paper discs with 6 mm diameter were soaked into these prepared test sample solutions, 
allowed to dry, then gently pasted on the surface of test petri plate. After incubation at 
37 °C for 20 h, inhibition zone were measured as diameters of the annulus surrounding 
the disc. 
2.5.5 Characterisation of Natural Products Isolated 
The crude ethanol extract of mushroom MMSP01 was concentrated to dryness, to 
return 3.4 g of material. This was suspended in methanol (80 mL), extracted with 
petroleum ether (260 mL), the methanol layer was concentrated to dryness again and 
suspended in water (80 mL), then extracted with dichloromethane (260 mL), ethyl 
acetate (260 mL) and n-butanol (260 mL) respectively. All partitioned fractions were 
concentrated to dryness to return the following masses: PE (782 mg), DCM (618 mg), 
EtOAc (66 mg), n-BuOH (316 mg) and aqueous (1414 mg). The DCM fraction was 
subjected to flash column chromatography on silica using 70% EtOAc in petroleum ether 
as eluent. Fractions possessing antibiotic activity were further purified by semi-
preparative HPLC using 15% EtOAc in petroleum ether as eluent to give two pure 
compounds, namely (E)-9-(5-pentylfuran-2-yl) non-8-enoic acid (2.1) as a pale yellow 
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solid (11 mg) and (Z)-9-(5-pentylfuran-2-yl) non-8-enoic acid (2.2) as a pale yellow solid 
(8 mg). 
(E)-9‘’-(5-pentylfuran-2-yl) non-8‘’-
enoic acid (2.1). 1H NMR (400 MHz, 
CDCl3): δ 0.90 (3H, t, J= 6.9 Hz, 5’-H), 
1.31-1.68 (14H, m, 2’, 3’, 4’, 3’’, 4’’, 5’’, 6’’-H), 2.12-2.18 (2H, m, 7’’-H), 2.35 (2H, t, J= 7.5 
Hz, 2’’-H), 2.59 (2H, t, J= 7.5 Hz, 1’-H), 5.92 (1H, d, J= 3.1 Hz, 4-H), 6.00 (1H, d, J= 3.1 Hz, 
3-H), 6.05 (1H, dt, J= 15.9, 6.7 Hz, 8’’-H), 6.13 (1H, dt, J= 15.9, 1.0 Hz, 9’’-H). 13C NMR 
(100 MHz, CDCl3): δ 14.2 (5’-C), 22.6 (4’-C), 24.8 (3’’-C), 27.9 (2’-C), 28.3 (1’-C), 28.9 (5’’-
C), 29.1 (4’’-C), 29.3 (6’’-C), 31.6 (3’-C), 32.8 (7’’-C), 34.1 (2’’-C), 106.3 (4-C), 106.9 (3-C), 
119.0 (9’’-C), 128.4 (8’’-C), 151.7 (2-C), 155.8 (5-C), 179.5 (1’’-C). EIMS: m/z [M]·+ 292 
(74), 235 (22), 177 (100), 151 (21), 121 (26), 107 (84), 95 (24), 55 (26). HREIMS: m/z 
292.2033 (calculated for C18H28O3 292.2038). 
(Z)-9‘’-(5-pentylfuran-2-yl) non-8‘’-enoic 
acid (2.2). 1H NMR (800 MHz, C6D6): δ 
0.83 (3H, t, J= 7.1 Hz, 5’-H), 1.11-1.59 
(14H, m, 2’, 3’, 4’, 3’’, 4’’, 5’’, 6’’-H), 2.04 (2H, t, J= 7.5 Hz, 2’’-H), 2.46-2.51 (4H, m, 1’, 7’’-
H), 5.40 (1H, dt, J= 11.7, 7.3 Hz, 8’’-H), 5.92 (1H, d, J= 3.2 Hz, 4-H), 6.15 (1H, d, J= 3.2 Hz, 
3-H), 6.28 (1H, dt, J= 11.7, 1.7 Hz, 9’’-H). 13C NMR (200 MHz, C6D6): δ 14.2 (5’-C), 22.8 (4’-
C), 24.9 (3’’-C), 28.1 (1’-C), 28.5 (2’-C), 29.2 (4’’-C), 29.3 (5’’-C), 29.7 (6’’,7’’-C), 31.7 (3’-
C), 33.9 (2’’-C), 106.9 (4-C), 110.3 (3-C), 118.2 (9’’-C), 129.7 (8’’-C), 152.4 (2-C), 155.8 (5-
C), 178.8 (1’’-C). EIMS: m/z [M]·+ 292 (74), 235 (22), 177 (100), 151 (21), 121 (26), 107 
(84), 95 (24), 55 (26). HREIMS: m/z 292.2033 (calculated for C18H28O3 292.2038). 
The crude ethanol extract of mushroom MMSP03 was concentrated to dryness to return 
3.3 g of material. This was suspended in methanol (80 mL), extracted with petroleum 
ether (260 mL), the methanol layer was concentrated to dryness and suspended in water 
(80 mL), then extracted with dichloromethane (260 mL), ethyl acetate (260 mL) and n-
butanol (260 mL) respectively. All partitioned fractions were concentrated to dryness to 
return; PE (1222 mg), DCM (162 mg), EtOAc (105 mg), n-BuOH (315 mg) and aqueous 
(1616 mg). The DCM fraction was purified by semi-preparative HPLC using 12% EtOAc in 
petroleum ether as eluent to give three pure compounds (Figure 2-17). The peak eluting 
with the shortest retention time (t=17.5 min) was concentrated to give grifolin (2.3) as 
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a colourless solid (1 mg). The peak eluting with the intermediate retention time (t=20.1 
min) was concentrated to give grifolic acid methyl ether (2.5) as a colourless solid (2 mg). 
The peak eluting with the longest retention time (t=29.7 min) was concentrated to give 
grifolic acid (2.4) as a colourless solid (6 mg). 
 
Figure 2-17 HPLC Chromatogram of Mushroom MMSP03 Isolation  
grifolin (2.3). 1H NMR (400 MHz, CDCl3): δ 
1.59 (3H, s, 14’-H), 1.60 (3H, s, 13’-H), 1.68 
(3H, s, 12’-H), 1.82 (3H, s, 15’-H), 1.87-2.10 
(8H, m, 4’, 5’, 8’, 9’-H), 2.21 (3H, s, 7-H), 
3.39 (2H, d, J= 7.1 Hz, 1’-H), 5.09 (2H, brs, 6’, 10’-H), 5.27 (1H, t, J= 7.1 Hz, 2’-H), 6.24 (2H, 
s, 4, 6-H). 13C NMR (100 MHz, CDCl3): δ 16.2 (15’-C), 16.4 (14’-C), 17.8 (13’-C), 21.2 (7-C), 
22.3 (1’-C), 25.8 (12’-C), 26.5 (5’-C), 26.8 (9’-C), 39.8 (4’, 8’-C), 109.2 (4, 6-C), 110.6 (2-C), 
121.8 (2’-C), 123.7 (6’-C), 124.5 (10’-C), 131.4 (11’-C), 135.7 (7’-C), 137.6 (5-C), 139.0 (3’-
C), 154.5 (3-C), 154.9 (1-C). It has the same Rf value and behaviour on TLC as the 
standard reference compound. 
grifolic acid (2.4). 1H NMR (400 MHz, CDCl3): 
δ 1.59 (6H, s, 13’, 14’-H), 1.67 (3H, s, 12’-H), 
1.82 (3H, s, 15’-H), 1.94-2.12 (8H, m, 4’, 5’, 
8’, 9’-H), 2.53 (3H, s, 7-H), 3.43 (2H, d, J= 
7.1 Hz, 1’-H), 5.08 (2H, brs, 6’, 10’-H), 5.27 
(1H, t, J= 7.1 Hz, 2’-H), 6.26 (1H, s, 5-H), 11.89 (1H, s, COOH-H). 13C NMR (100 MHz, CDCl3): 
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δ 16.2 (15’-C), 16.4 (14’-C), 17.8 (13’-C), 21.2 (7-C), 22.2 (1’-C), 25.8 (12’-C), 26.5 (5’-C), 
26.8 (9’-C), 39.8 (4’, 8’-C), 103.9 (1-C), 111.6 (3-C), 111.9 (5-C), 121.4 (2’-C), 123.7 (6’-C), 
124.5 (10’-C), 131.4 (11’-C), 135.8 (7’-C), 139.3 (3’-C), 142.4 (6-C), 160.5 (4-C), 163.7 (2-
C), 175.1 (COOH-C). It has the same Rf value and behaviour on TLC as the standard 
reference compound. 
grifolic acid methyl ether (2.5). 1H NMR (400 
MHz, CDCl3): δ 1.56 (3H, s, 14’-H), 1.58 (3H, s, 
13’-H), 1.67 (3H, s, 12’-H), 1.77 (3H, s, 15’-H), 
1.92-2.06 (8H, m, 4’, 5’, 8’, 9’-H), 2.58 (3H, s, 
7-H), 3.33 (2H, d, J= 6.9 Hz, 1’-H), 3.86 (3H, s, 
OMe-H), 5.07 (2H, brs, 6’, 10’-H), 5.19 (1H, t, J= 7.0 Hz, 2’-H), 6.31 (1H, s, 5-H), 11.63 (1H, 
s, COOH-H). EIMS: m/z [M]·+ 386 (10), 368 (5), 342 (11), 335 (15), 334 (100), 329 (13), 
299 (20). It has the same Rf value and behaviour on TLC as the standard reference 
compound. 
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2.8 Appendix NMR Spectra of Natural Products 
Figure 2-18 1H NMR Spectrum of Furan Fatty Acid (2.1) (400 MHz, CDCl3) 
Figure 2-19 13C NMR Spectrum of Furan Fatty Acid (2.1) (100 MHz, CDCl3) 
Figure 2-20 1H NMR Spectrum of Furan Fatty Acid (2.2) (800 MHz, C6D6) 
Figure 2-21 13C NMR Spectrum of Furan Fatty Acid (2.2) (100 MHz, C6D6) 
Figure 2-22 1H NMR Spectrum of Grifolin (2.3) (400 MHz, CDCl3) 
Figure 2-23 1H NMR Spectrum of Grifolic Acid (2.4) (400 MHz, CDCl3) 
Figure 2-24 1H NMR Spectrum of Grifolic Acid Methyl Ether (2.5) (400 MHz, CDCl3) 
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Figure 2-18 1H NMR Spectrum of Furan Fatty Acid (2.1) (400 MHz, CDCl3) 
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Figure 2-19 13C NMR Spectrum of Furan Fatty Acid (2.1) (100 MHz, CDCl3) 
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Figure 2-20 1H NMR Spectrum of Furan Fatty Acid (2.2) (800 MHz, C6D6) 
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Figure 2-21 13C NMR Spectrum of Furan Fatty Acid (2.2) (100 MHz, C6D6) 
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Figure 2-22 1H NMR Spectrum of Grifolin (2.3) (400 MHz, CDCl3) 
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Figure 2-23 1H NMR Spectrum of Grifolic Acid (2.4) (400 MHz, CDCl3) 
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Figure 2-24 1H NMR Spectrum of Grifolic Acid Methyl Ether (2.5) (400 MHz, CDCl3) 
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Chapter 3: Synthesis of Grifolin Analogues 
3.1 Introduction 
The antioxidant activities of grifolin (2.3), grifolic acid (2.4) and their derivatives have 
been widely reported and our research has also confirmed grifolin’s antioxidant 
activity.1-8 As mentioned in the first chapter, the application of synthetic antioxidants is 
more restricted with increased regulations for their toxicities and side-effects, while 
natural antioxidants are becoming more and more popular for health authorities and 
the public for the perceived wellbeing they offer. These natural antioxidants have 
attracted the attention of organic chemists in academia and pharmaceutical industry, 
with many approaches applied to the synthesis of grifolin and analogues.2,6,9-19 However, 
the common challenges in organic synthesis, high cost, high step count and low yields 
limited their applications in industrial production. The application of biosynthesis offers 
a considerable and promising solution to produce natural antioxidants in an 
environmentally friendly and sustainable manner.20,21 Mushrooms, producing natural 
antioxidants as metabolites, such as grifolin, are able to be utilised for harvesting 
functional foods or to produce semi-synthetic antioxidants. Research correlated to these 
objectives is ongoing within our group with studies focussed on the traditional use of 
mushrooms in PNG.22 PNG has abundant mushroom resources afforded by its climate 
and geography, providing the local communities exceptional advantages to boost their 
mushroom production, with concomitant economic benefits. 
Grifolin and its derivatives comprise two portions (Figure 3-1); an aromatic core like 
orcinol or orsellinic acid and an aliphatic side chain of varying length such as prenyl, 
geranyl or farnesyl. Following the principles of biosynthesis, the aromatic core originates 
from the polyketide pathway, while the aliphatic side chain most likely comes from the 
isoprene pathway, then they are assembled together to generate meroterpene 
metabolites. In order to yield grifolin and its derivatives, it is practicable to add 
components with these two classes of chemical structures to mushroom culture 
medium in anticipation of them being incorporated to increase metabolite yield. 
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Figure 3-1 Some Known Grifolin Derivatives 
The literature reports contradictory results of antioxidant activities among grifolin and 
its derivatives, and different opinions were put forward regarding their structure-activity 
relationships (SAR), specifically the impacts of the position and the length of an aliphatic 
side chain, and the number of free phenols, on the effect of antioxidant capacity.1,4-6,23 
We embarked upon a study to systematically investigate grifolin and its derivatives’ SAR 
for the application of aberrant biosynthesis. In this direction 15 synthetic targets (3.1-
3.15) were designed (Figure 3-2), 10 of which have not been previously synthetically 
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achieved. The targeted compounds belong to two different substitution patterns based 
around grifolin and neogrifolin architectures (see Figure 3-1), with different numbers of 
free phenol. The investigation of relationship between these structures and their 
antioxidant activities should prove useful to identify optimal precursors for cost-efficient 
antioxidant production through aberrant biosynthesis. 
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Figure 3-2 Synthetic Targets for SAR Investigation 
3.2 Synthesis 
3.2.1 Synthetic Efforts 
3.2.1.1 Suzuki Coupling 
Retrosynthetic analysis indicates disconnections that would allow the target framework 
to be assembled through Suzuki coupling of an appropriately substituted boronic acid 
and an allyl halide. Investigation of this route (Scheme 3-1) began with commercially 
available orcinol. After dimethylation under standard Williamson conditions, the 
generated ether (3.16) was then regioselectively brominated by N-bromosuccinimide 
(NBS), providing  bromide (3.17) in 51% yield as the only isolable product.24 With this 
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bromide in hand, the next synthetic step was to generate a boronic acid which can be 
utilised for Suzuki coupling with a prenyl halide.25,26 It was reasoned the aryl bromide 
(3.17) could be employed in a lithium halogen exchange using n-butyl lithium as the 
reagent and subsequently reacted with triisopropyl borate to furnish the corresponding 
boronic acid after work-up. However, all efforts were unsuccessful with a hydroxy 
substituted product 2,4-dimethoxy-6-methylphenol (3.18). When phenylboronic acid 
was used to test the effectiveness of the Suzuki coupling with prenyl bromide, the 
desired compound (3.19) was only ever isolated in 6% yield.27 Based on these results, 
this synthetic pathway was abandoned. 
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Scheme 3-1 Halogen-Metal Exchange and Suzuki Coupling Synthetic Attempt 
3.2.1.2 Friedel-Crafts Acylation and Ketone Reduction 
Friedel-Crafts acylation using acid anhydrides to acylate aromatic rings had been 
successfully utilised by members of our group to produce related compounds so 
exploratory work was conducted in attempts to exploit this chemistry. This route 
(Scheme 3-2) began with commercially available 3-methylcrotonic acid, after 
dehydration to afford the corresponding anhydride (3.20) which was used to acylate the 
compound 3.16, generating three acylation products (3.21-3.23) in a ratio of 50:16:39. 
In order to furnish the prenyl chain, these products required the selective reduction of 
the carbonyl moiety in the presence of an α,β-unsaturated ketone. Various conditions, 
looking for selective 1,2-addition at the carbonyl while suppressing 1,4-addition which 
reduces the carbon-carbon double bond were explored.28-30 Unfortunately all efforts 
proved to be unsuccessful, with carbon-carbon double bond being more susceptible 
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than the carbonyl double bond. For instance, one of the acylation products 3.21 was 
subjected to a multitude of reducing conditions (Scheme 3-2). Compound 3.21 
underwent a retro Friedel-Crafts reaction resulting in a deacylation product 3.16 using 
triethylsilane (TES) in a large excess of trifluoroacetic acid (TFA). Using increased 
equivalents of the silane reducing reagent compound 3.21 underwent a similar 
deacylation albeit along with concomitant double bond reduction (7%), resulting from 
1,4-addition to produce 3.24. Sodium borohydride in methanol solution was found too 
weak to reduce the carbonyl double bond returning starting material. When Luche 
reduction conditions were applied, 1,4-addition resulting in product 3.24 was generated 
in 4%. When compound 3.21 was treated with the reducing reagent, 
diisobutylaluminium hydride (DIBAH), only starting material was recovered. Finally, 
reduction of the carbonyl was achieved using TES along with PdCl2 catalyst, however this 
was secondary to the initial 1,4-addition returning a mixture of 3.24 and the compound 
3.25 possessing a fully reduced sidechain. Based on these observations, this synthetic 
route was abandoned. 
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Scheme 3-2 Friedel-Crafts Acylation and Ketone Reduction Synthetic Attempt 
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3.2.1.3 Claisen Rearrangement and Wittig Reaction 
In order to avoid the problematic reduction of the carbonyl moiety encountered above 
the Claisen rearrangement was considered as a route to access the desired architecture. 
Theoretically two regioisomers can be generated after a Claisen rearrangement, which 
can be used to access both the neogrifolin and grifolin substitution patterns (3.28 and 
3.30 respectively, Scheme 3-3). The allyl resorcinol derivatives thus formed can then 
undergo ozonolysis to yield a phenylacetaldehyde, which is ready for Wittig olefination 
to furnish the required prenyl substituted compound. Execution of this pathway 
(Scheme 3-3) started from commercially available orcinol, which was monomethylated 
under Williamson conditions to return the desired monomethyether (3.26) in 31% yield. 
The isolated product 3.26 was subject to a second etherification with an allyl bromide, 
generating the 3-allyloxy-5-methoxy toluene (3.27) in excellent yield, which was 
submitted to the Claisen rearrangement under standard conditions.31 Upon workup and 
chromatography three products were obtained, two of them were the expected allyl 
resorcinol regioisomers (3.28, 19% and 3.30, 34%) in addition to a dihydrobenzofuran 
(3.29, 16%) the result of a 5-exo-trig ring closure from compound 3.28. Curiously the 
equivalent dihydrobenzofuran from cyclisation of the other regioisomer (3.30) was not 
observed. In order to gain a substrate for Wittig olefination, compound 3.28 was 
subjected to ozonolysis, working up with dimethyl sulfide to produce the 
phenylacetaldehyde 3.31, supported by the appearance of a characteristic aldehyde 
resonance in the 1H NMR spectrum at 9.77 ppm as a sticky yellow oil.32 However, this 
ozonolysis reaction was found difficult to control with the reaction not generating any 
product if ozone were streamed for less than 3 min while the product was completely 
decomposed if reacted with streaming ozone for more than 10 min. The maximum yield 
of the phenylacetaldehyde recovered was an unacceptable 21%. Compound 3.28 was 
then methylated to generate product 3.32 and ozonolysis carried out under the same 
reaction conditions, consistently affording the methanol hemiacetal 3.33 in in low yield 
(28%). The possible reason for the refractory reactivity was that electron donating 
groups such as methoxy and hydroxy enriched the electron density of the aromatic ring 
rendering it vulnerable to ozonolysis, resulting in decomposition. It was reasonable to 
believe that compound 3.31 with the same electron donating groups would present 
similar challenges during its ozonolysis, so this approach was discarded. 
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Scheme 3-3 Claisen Rearrangement and Wittig Reaction Synthetic Attempt 
3.2.2 General Synthetic Procedure 
As previously described, the Claisen rearrangement of the allyl ether derived from 
Williamson etherification of orcinol afforded two regioisomeric products representing 
the precursors for grifolin and neogrifolin type targets. We considered that cross 
metathesis with the terminal olefin would furnish the desired prenyl group, and upon 
implementing this strategy the designed targets were achieved (Scheme 3-4). 
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Scheme 3-4 Retrosynthetic Strategy 
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The synthetic pathway was instigated by protecting the phenol groups in the Claisen 
products of 3.34 as tert-butyldimethylsilyl (TBS) ethers and cross metathesis employing 
a second generation Grubbs catalyst,33,34 then TBS deprotection generated the required 
final products. However, the application of mild acid conditions during deprotection 
resulted in low yields and it was found that such protection and deprotection of phenols 
was entirely unnecessary allowing cross metathesis to be conducted directly, without 
protecting the phenol in advance. So the modified method shortened the number of 
synthetic steps, saved reagents and gave excellent yields of a stable product. 
What follows describes the general synthetic route.  It is divided into two categories, 
which start from two different commercially available materials orcinol and orsellinic 
acid in order to target grifolin/neogrifolin and grifolic/neogrifolic acid analogues, 
respectively. 
3.2.2.1 Grifolin and Neogrifolin Analogues 
The syntheses of targets 1 to 7 (3.1-3.7, Figure 3-2) were achieved following the 
chemistry described in Scheme 3-5. The commercial product orcinol was alkylated 
employing one equivalent of allylic bromide under Williamson conditions to generate a 
mono-ether 3.34. In previous synthetic attempts, the neat material was heated at 220 °C 
for prolonged periods (2 h) in order for them to undergo Claisen rearrangements, 
producing two regioisomers (3.28 and 3.30) in addition to a heterocyclic product (3.29) 
(Scheme 3-3) along with significant decomposed material. In contrast to this traditional 
method, a microwave mediated Claisen rearrangement in N,N-diethyl aniline was found 
to produce the same three products but with shortened reaction duration and without 
thermal decomposition improving yields. 
The neogrifolin type product (3.35) was the major product isolated, supported by the 
appearance of an AB spin system in the aromatic region of the 1H NMR spectrum (δ 6.22, 
1H, d, J= 2.3 Hz; δ 6.28, 1H, d, J= 2.3 Hz) representing a yield of 53%. In addition 5% of 
its 5-exo-trig ring closure product (3.36) was isolated. The yield of the grifolin type 
product (3.37) was 31%, as indicated by the symmetrical A2 spin system of the aromatic 
protons in the 1H NMR spectrum (δ 6.26, 2H, s). With a ratio of 58:31 (approx. 2:1) these 
data suggest that the Claisen rearrangement had no discernible regiochemical 
preference.  In order to form the target compound, the 2-allyl resorcinol (3.37) was 
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directly subjected to the olefin cross metathesis reaction with 2-methyl-2-butene using 
the second generation Grubbs catalyst, giving an excellent yield of the desired 
prenylated resorcinol 3.1. Product formation was supported by two singlet CH3 signals 
δ 1.64, 3H, s; δ 1.74, 3H, s and a triplet olefinic proton resonance, δ 5.21, 1H, t, J= 7.1 Hz. 
In order to diversify the library of compounds, thereby allowing us to explore the 
relationship between free hydroxy groups and antioxidant activity, the resorcinol (3.1) 
was alkylated using 1.3 equiv. of dimethyl sulfate to afford, after separation, 26% of 
monomethylated product 3.2 and 51% of dimethylated product 3.3. These compounds 
were easily recognised by the appearance of singlet methoxyl resonances at 3.74 ppm 
integrating for three hydrogens and 3.76 ppm integrating for six hydrogens for 
compounds 3.2 and 3.3 respectively. 
Following the same method, compound 3.4 was generated from compound 3.35 after 
the cross metathesis. The product was once again readily identified as possessing the 
1,3,4,5-tetrasubstituted pattern around the aromatic ring, consistent with neogrifolin 
type compounds, by the appearance of two aromatic hydrogen resonances in the 1H 
NMR spectrum (δ 6.11, 1H, d, J= 2.1 Hz; δ 6.13, 1H, d, J= 2.1 Hz). Due to the 
unsymmetrical nature of the starting resorcinol (3.4) the subsequent methylation 
reaction returned three compounds in the form of 2 monomethylated derivatives (3.5 
and 3.6) and the dimethylated derivative 3.7. These monomethylated derivatives (3.5 
and 3.6) were easily recognised by the correlations in HMBC spectrum. In compound 3.6, 
the singlet methoxyl signal at 3.73 ppm was associated with a carbon signal at 159.6 
ppm (C-1) which was also associated with an allylic methylene resonance at 3.22 ppm. 
Despite the stability of the longer chain farnesylated natural product, the synthetic 
targets (3.1-3.7) were found to be sensitive to acid, decomposing rapidly even in 
chloroform solution. 
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Scheme 3-5 Synthetic Route to Grifolin and Neogrifolin Analogues 
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3.2.2.2 Grifolic Acid and Neogrifolic Acid Analogues 
In order to achieve targets 3.8-3.15, the synthetic route needed to start from the 
commercially available compound orsellinic acid. The carboxylic acid was firstly 
esterified to form a methyl ester 3.38, followed by Williamson reaction with allyl 
bromide to generate the ether 3.39. Subjecting this material to our established 
microwave mediated conditions for Claisen rearrangement resulted in the formation of 
3.40 (86%) without its regioisomer (Scheme 3-6). Since the hydroxy group ortho to the 
carbonyl is able to form a 6-centred hydrogen bond, the electrons are unevenly 
distributed between A and B, which makes the electron density at A higher than B. The 
resulting Claisen rearrangement can occur in a concerted intramolecular process 
whereas the alternative Claisen rearrangement requires an intermolecular 
deprotonation event, which may explain the exclusive product 3.40 (Scheme 3-7). We 
reasoned that elimination of the hydrogen bonding capacity can redistribute the 
electron density enabling formation of the expected two regioisomers. The Claisen 
rearrangement was conducted again after the ortho hydroxy group in compound 3.39 
was protected as the t-butyldimethylsilyl ether 3.41, returning two regioisomers 3.42 
and 3.43 with yields of 63% and 29% respectively (Scheme 3-6). The compound 3.43, 
possessing the substitution pattern consistent with grifolic acid was subjected to the 
conditions for cross metathesis furnishing the desired prenylated material 3.44 as 
supported by two singlet CH3 signals δ 1.64, 3H, s; δ 1.70, 3H, s and a triplet olefinic 
proton resonance, δ 5.13, 1H, t, J= 6.3 Hz. Deprotection of the silyl ether with 
tetrabutylammonium fluoride proceeded as expected to afford the 2,4-
dihydroxybenzoate ester 3.45. We envisaged that the ester (3.45) would readily be 
hydrolysed to return the target acid 3.8, however all efforts to effect this transformation 
resulted in decomposition returning complex mixtures (Scheme 3-6). 
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Scheme 3-6 Synthetic Attempt to Grifolic Acid and Neogrifolic Acid Analogues 
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Scheme 3-7 the Effect of Hydrogen Bond in Electron Density between A and B 
Turning our attention to the compound 3.42 with the substitution pattern consistent 
with neogrifolic acid, which represented the major compound obtained from the Claisen 
rearrangement of the allyl ether (3.41), we implemented the cross metathesis and 
deprotection to return compounds 3.46 and 3.47 respectively (Scheme 3-6). As for 3.45 
the 2,4-dihydroxybenzoate (3.47) was also unstable under all conditions trialed and the 
desired acid 3.12 was not generated. However, whereas previous efforts resulted in 
complex mixtures the acid catalysed hydrolysis of 3.47 returned high yields of a cyclised 
dihydropyran product 3.48. The formation of this heterocycle was supported by two 
singlet CH3 signals δ 1.29, 6H, s and two triplet methylene proton resonances δ 1.82, 2H, 
t, J= 6.9 Hz; δ 2.61, 2H, t, J= 6.9 Hz (Scheme 3-6). A review of the relevant literature 
confirmed that a free hydroxy placed at the para position to the carboxyl group resulted 
in a decarboxylation product under basic conditions.35-39 The only reported solution to 
hydrolyse such esters was to stir it in concentrated sulfuric acid for 20 h.40,41 While we 
considered these conditions harsh, exploration of this pathway was considered using 
the 2,4-dihydroxybenzoates 3.40 and 3.49 which were much less acid sensitive than 
compounds 3.45 and 3.47. Unsurprisingly both compounds also underwent 
decomposition under these conditions returning small amounts of heterocyclic products, 
identified as the dihydrobenzofurans 3.50, 3.51 and 3.52, the structure of which were 
supported by analysis of the 2D NMR data (Scheme 3-8). Formation of a dihydrofuran 
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here as opposed to the previously observed formation of the dihydropyran above 
merely reflects the stability of the intermediate carbocation in the allyl versus prenyl 
precursors. 
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Scheme 3-8 Sulfuric Acid Catalysed Ester Hydrolysis 
So far there has not been a synthetic method reporting the synthesis of target para 
hydroxy benzoic acids, targets 8, 9, 12 and 13. Given the instability of esters 3.45 and 
3.47 to hydrolysis under either basic or acidic condition resulting in either 
decarboxylation or an increased propensity of the prenyl group toward cyclization to 
form a dihydropyran, these target para hydroxy benzoic acids were removed from 
consideration in the SAR profile. So synthetic targets 8, 9, 12 and 13 were abandoned. 
The simpler p-methoxy esters 3.53 and 3.55, which were the methylation products of 
allylated compounds 3.49 and 3.40 respectively, were successfully hydrolysed to their 
corresponding acids 3.54 and 3.56 under basic conditions (Scheme 3-9) supporting the 
hypothesis that a p-hydroxy group was necessary for decarboxylation. Nevertheless, 
while the allylated materials are moderately stable to acid the corresponding prenylated 
targets 10, 11, 14 and 15 would still be susceptible due to their prenyl structures, 
affording the stable tertiary carbocation upon protonation and resulting in 
decomposition (cyclisation). Thus targets 10, 11, 14 and 15 were abandoned. The 
alternative targets were the corresponding methyl esters conferring a greater stability 
by reducing the possibility of self acid catalysis. So compounds 3.57, 3.58 and 3.59 were 
formed from methylation of 3.45 and 3.47 (Scheme 3-10). 
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Scheme 3-9 Hydrolysis of the Methylated Esters under Basic Conditions 
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Scheme 3-10 Synthesis of Alternative Targets 
In addition, several side-products 3.60-3.63 (Figure 3-3) were isolated during the 
preparation of synthetic targets, they were added to the compound library to assess 
their antioxidant activities as well. 
OH OMe
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COOMe
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OMe O
OMe
OMe
COOMe
3.60 3.61 3.62 3.63  
Figure 3-3 Isolated Side Products during Synthetic Targets Preparation 
3.3 Conclusions 
Grifolin and neogrifolin analogues 3.1-3.7 were successfully prepared, while grifolic acid 
and neogrifolic acid analogues 3.8-3.15 were abandoned because of their instability. 
Synthesis of the alternatives targets, esters 3.45, 3.47, 3.57, 3.58 and 3.59 were 
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achieved. A general synthetic route to those designed targets was worked out. Based on 
this synthetic route, 28 other compounds possessing the similar associated structures 
to synthetic targets were prepared. All these structures built up a compound library, 
which are ready for bioassay to investigate SAR, they have two main regiochemistry 
patterns. Within the same regiochemistry pattern, these structures have different 
numbers of free phenol. The assessment of these structures’ antioxidant activities is 
useful to elucidate how the number of prenyl units and their regiochemistry affect 
antioxidant activity as well as the number of free phenol groups. 
The original designed targets belongs to two different chemical patterns, namely grifolin 
and neogrifolin pattern, which are two regioisomers. So the investigation of a versatile 
synthetic pathway to those targets is very important, a reaction generating relatively 
even different regioisomers at one step is a promising candidate to constitute the 
versatile synthetic pathway. The Claisen rearrangement generating two regioisomer 
products gives a considerable solution. Our methodology investigation discovered that 
compared with the traditional protocol, the microwave aid method offers a higher yield 
and less side products, is a perfect option. After that, synthesis derives from two main 
ways toward targets. The prenyl moiety is especially sensitive to acid in the presence of 
an ortho hydroxy group due to intramolecular cyclisation. The deprotection of a phenol 
ether or hydrolysis of an ester would both increase the acidity resulting in lower yields 
due to cyclisation. Prenyl was furnished by a cross metathesis reaction, which is 
generally considered to not proceed on a structure with free hydroxy groups, which 
means the protection of hydroxy is necessary for such structures prior to undergo cross 
metathesis. However, the protection and later deprotection were shown to be 
unnecessary by our research. The direct cross metathesis reaction gave a higher yield 
(99%) within one step. The reaction of methylating phenol not only generates 
regioisomers but also affords mono and di methylation products in one step, so it should 
be effected after prenylation. So the general synthetic route was taken in the described 
order. 
Compounds 3.1-3.7, esters 3.45, 3.47, 3.57, 3.58 and 3.59 are acid sensitive 
(decomposed in CHCl3) mainly due to their common prenyl structures, their self-cyclised 
products under acidic condition were also observed during the investigation. However, 
acid sensitivities of grifolin, neogrifolin, grifolic acid and other analogues possessing two 
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or three prenyl units’ side chains haven’t been mentioned by literatures so far, the 
greater steric hindrance of longer side chain may be the reason. 
3.4 Experimental 
3.4.1 Equipment and Chemical Reagents 
For General Experimental conditions see chapter two experimental section. 
3.4.2 Experimental Data 
1,3-dimethoxy-5-methylbenzene (3.16). A solution of orcinol (1.00 g, 
8.12 mmol) in acetone (20 mL) was added to a round bottom flask. Then 
potassium carbonate (4.3 eq., 4.86 g, 35.24 mmol) was added to the 
flask. After that methyl iodide (4.3 eq., 2.20 mL, 35.24 mmol) was added to the flask, 
and the reaction mixture was stirred and refluxed. The reaction was monitored by TLC 
and GC-MS, and was continued until the starting material was consumed. The reaction 
mixture was concentrated in vacuo and the residue was suspended in water and 
acidified by 1 M HCl, followed by extraction with EtOAc three times. The combined 
organic layer was washed with deionised water and dried over Na2SO4 and concentrated 
in vacuo. The residue was subjected to flash column chromatography on silica using 25% 
EtOAc in petroleum ether as eluent to return the title compound as a viscous yellow oil 
(95%, 1.17 g, 7.70 mmol).24 1H NMR (400 MHz, CDCl3): δ 2.32 (3H, s, 5-Me), 3.78 (6H, s, 
1,3-OMe), 6.30 (1H, brs, 2-H), 6.35 (2H, brs, 4,6-H). 13C NMR (100 MHz, CDCl3): δ 21.9 (5-
Me), 55.3 (1,3-OMe), 97.6 (2-C), 107.2 (4,6-C), 140.3 (5-C), 160.8 (1, 3-C). EIMS: m/z 152 
[M]·+ (100), 123 (33). 
2-bromo-1,5-dimethoxy-3-methylbenzene (3.17). A solution of 
compound 3.16 (1.07 g, 7.03 mmol) in dichloromethane (15 mL) was 
added to a round bottom flask. Then N-Bromosuccinimide (NBS) (1.4 
eq., 1.75 g, 9.83 mmol) was added to the flask, and the reaction mixture 
was stirred and refluxed for 4 h. Then the reaction mixture was filtered, the filtrate was 
concentrated in vacuo and the residue was subjected to flash column chromatography 
on silica using 5% EtOAc in petroleum ether as eluent to return the title compound as a 
low-melting solid (51%, 0.83 g, 3.58 mmol).24 1H NMR (400 MHz, CDCl3): δ 2.39 (3H, s, 3-
Me), 3.78 (3H, s, 5-OMe), 3.86 (3H, s, 1-OMe), 6.34 (1H, brs, 6-H), 6.43 (1H, brs, 4-H). 13C 
NMR (100 MHz, CDCl3): δ 23.7 (3-Me), 55.6 (5-OMe), 56.4 (1-OMe), 97.3 (6-C), 105.2 (2-
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C), 107.3 (4-C), 139.9 (3-C), 156.7 (5-C), 159.4 (1-C). EIMS: m/z 232 [M+2]·+ (97), 230 [M]·+ 
(100), 189 (19), 187 (23), 149 (41). 
(3’-methylbut-2’-en-1’-yl)benzene (3.19). A solution of 
phenylboronic acid (100 mg, 0.57 mmol) in anhydrous toluene (5 mL) 
was added to a oven-dried 2-neck round bottom flask. Then prenyl 
bromide (1.0 eq., 66 μl, 0.57 mmol) and potassium carbonate (1.0 eq., 79 mg, 0.57 mmol) 
were added to the flask, and the reaction mixture was stirred and refluxed for 6 h under 
an argon atmosphere. The reaction mixture was diluted with diethyl ether (5 mL) and 
washed with deionised water twice. The organic layer was dried over Na2SO4 and 
concentrated in vacuo and the residue was subjected to flash column chromatography 
on silica using 10% EtOAc in petroleum ether as eluent to return the title compound as 
a colourless oil (6%, 5 mg, 0.03 mmol).27 1H NMR (400 MHz, CDCl3): δ 1.73 (3H, s, 4’ or 
5’-H), 1.75 (3H, s, 4’ or 5’-H), 3.35 (2H, d, J= 6.9 Hz, 1’-H), 5.34 (1H, t, J= 6.9 Hz, 2’-H), 
7.17-7.45 (5H, m, 1, 3,4,5,6-H). EIMS: m/z 146 [M]·+ (17), 131 (100), 115 (16), 91 (83). 
1’-(2,4-dimethoxy-6-methylphenyl)-3’-methylbut-2’-en-1’-one 
(3.21). A solution of 3-methylcrotonic acid (1.00 g, 10.00 mmol) 
in anhydrous DCM (50 mL) was added to a oven-dried 2-neck 
round bottom flask. Then trifluoroacetic anhydride (TFAA) (2.0 
eq., 2.80 mL, 20.00 mmol) was added dropwise to the flask at 0 °C, and the reaction 
mixture was stirred at room temperature under an argon atmosphere. The reaction was 
monitored by GC-MS, and was continued until the starting material was consumed. The 
reaction mixture was concentrated in vacuo without further purification to return an 
anhydride 3.20 as a yellow oil (68%, 615 mg, 3.38 mmol). This product was used 
immediately for the next reaction. A solution of anhydride 3.20 (610 mg, 3.35 mmol) in 
anhydrous toluene (5 mL) was added to a oven-dried 2-neck round bottom flask. Then 
compound 3.16 (0.2 eq., 125 mg, 0.82 mmol) and anhydrous p-toluenesulfonic acid were 
added to the flask, and the reaction mixture was stirred at room temperature under an 
argon atmosphere. The reaction was monitored by TLC and GC-MS, and was continued 
until compound 3.16 was consumed. The reaction mixture was washed with potassium 
carbonate aqueous solution, the organic layer was dried over Na2SO4 and concentrated 
in vacuo. The residue was subjected to flash column chromatography on silica using 10% 
EtOAc in petroleum ether as eluent to return the title compound as a viscous yellow oil 
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(50%, 95 mg, 0.41 mmol). 1H NMR (400 MHz, CDCl3): δ 1.91 (3H, s, 4’-H), 2.14 (3H, s, 5’-
H), 2.22 (3H, s, 6-Me), 3.76 (3H, s, 2-OMe), 3.80 (3H, s, 4-OMe), 6.26 (1H, s, 2’-H), 6.31 
(2H, brs, 3,5-H). 13C NMR (100 MHz, CDCl3): δ 19.8 (6-Me), 20.8 (5’-C), 28.1 (4’-C), 55.5 
(2-OMe), 55.9 (4-OMe), 96.3 (3-C), 107.1 (5-C), 125.7 (1-C), 127.1 (2’-C), 137.6 (6-C), 
154.4 (3’-C), 157.9 (2-C), 160.9 (4-C), 196.4 (1’-C). EIMS: m/z 234 [M]·+ (36), 219 (100), 
203 (24), 191 (26), 179 (47), 83 (19). HREIMS: m/z 234.1257 (calculated for C14H18O3 
234.1256). 
1’-(2,6-dimethoxy-4-methylphenyl)-3’-methylbut-2’-en-1’-one 
(3.22). This compound was isolated from the same reaction mixture 
generating 3.21 as a viscous yellow oil (16%, 31 mg, 0.13 mmol). 1H 
NMR (400 MHz, CDCl3): δ 1.90 (3H, s, 4’-H), 2.17 (3H, s, 5’-H), 2.34 
(3H, s, 4-Me), 3.76 (6H, s, 2,6-OMe), 6.24 (1H, s, 2’-H), 6.36 (2H, s, 3,5-H). 13C NMR (100 
MHz, CDCl3): δ 20.9 (5’-C), 22.4 (4-Me), 28.0 (4’-C), 56.0 (2,6-OMe), 105.1 (3,5-C), 119.3 
(1-C), 126.9 (2’-C), 140.9 (4-C), 154.6 (3’-C), 157.1 (2,6-C), 194.0 (1’-C). EIMS: m/z 234 
[M]·+ (40), 219 (23), 203 (100), 179 (70), 83 (34). HREIMS: m/z 234.1256 (calculated for 
C14H18O3 234.1256). 
1’,1’’-(4,6-dimethoxy-2-methyl-1,3-phenylene)bis(3’-
methylbut-2’-en-1’-one) (3.23). This compound was isolated 
from the same reaction mixture generating 3.21 as a viscous 
yellow oil (39%, 101 mg, 0.32 mmol). 1H NMR (400 MHz, CDCl3): 
δ 1.90 (6H, s, 4’,4’’-H), 2.05 (3H, s, 2-Me), 2.14 (6H, s, 5’,5’’-H), 
3.79 (6H, s, 4,6-OMe), 6.20 (2H, s, 2’,2’’-H), 6.31 (1H, s, 5-H). 13C NMR (100 MHz, CDCl3): 
δ 16.1 (2-Me), 20.9 (5’,5’’-C), 28.0 (4’,4’’-C), 55.9 (4,6-OMe), 93.1 (5-C), 126.1 (1,3-C), 
126.8 (2’,2’’-C), 133.6 (2-C), 155.4 (3’,3’’-C), 157.5 (4,6-C), 196.2 (1’,1’’-C). EIMS: m/z 316 
[M]·+ (36), 301 (100), 273 (23), 261 (33), 245 (63), 219 (20), 83 (48). HREIMS: m/z 
316.1678 (calculated for C19H24O4 316.1675). 
1’-(2,4-dimethoxy-6-methylphenyl)-3’-methylbutan-1’-one 
(3.24). A solution of compound 3.21 (131 mg, 0.56 mmol) in 
anhydrous ethanol (8 mL) was added to a oven-dried 2-neck 
round bottom flask. Then triethylsilane (2.0 eq., 182 μl, 1.12 
mmol) and palladium (II) chloride (14%, 14 mg, 0.08 mmol) were added to the flask, and 
the reaction mixture was stirred overnight under an argon atmosphere. The reaction 
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was quenched by adding water, the reaction mixture was extracted with DCM twice. 
The combined organic layer was dried over Na2SO4 and concentrated in vacuo. The 
residue was subjected to flash column chromatography on silica using 30% EtOAc in 
petroleum ether as eluent to return the title compound as a colourless oil (45%, 59 mg, 
0.25 mmol). 1H NMR (400 MHz, CDCl3): δ 0.95 (3H, s, 4’ or 5’-H), 0.96 (3H, s, 4’ or 5’-H), 
2.19-2.29 (1H, m, 3’-H), 2.23 (3H, s, 6-Me), 2.65 (2H, d, J= 6.8 Hz, 2’-H), 3.78 (3H, s, 2-
OMe), 3.80 (3H, s, 4-OMe), 6.30 (1H, d, J= 2.2 Hz, 3-H), 6.31 (1H, d, J= 2.2 Hz, 5-H). 13C 
NMR (100 MHz, CDCl3): δ 19.9 (6-Me), 22.9 (4’,5’-C), 24.7 (3’-C), 54.0 (2’-C), 55.5 (4-OMe), 
55.6 (2-OMe), 96.2 (3-C), 107.3 (5-C), 124.7 (1-C), 137.7 (6-C), 158.3 (2-C), 161.1 (4-C), 
207.2 (1’-C). EIMS: m/z 236 [M]·+ (11), 221 (4), 193 (14), 179 (100), 136 (7). HREIMS: m/z 
236.1411 (calculated for C14H20O3 236.1412). 
2-isopentyl-1,5-dimethoxy-3-methylbenzene (3.25). This 
compound was isolated from the same reaction mixture 
generating 3.24 as a viscous yellow oil (46%, 57 mg, 0.25 mmol). 
1H NMR (400 MHz, CDCl3): δ 0.94 (3H, s, 4’ or 5’-H), 0.96 (3H, s, 4’ or 5’-H), 1.23-1.27 (2H, 
m, 2’-H), 1.57-1.65 (1H, m, 3’-H), 2.28 (3H, s, 3-Me), 2.52-2.56 (2H, m, 1’-H), 3.78 (6H, s, 
1,5-OMe), 6.32 (2H, brs, 4,6-H). 13C NMR (100 MHz, CDCl3): δ 19.9 (3-Me), 22.7 (4’,5’-C), 
23.8 (1’-C), 28.7 (3’-C), 38.9 (2’-C), 55.4 (1 or 5-OMe), 55.6 (1 or 5-OMe), 96.2 (6-C), 106.5 
(4-C), 122.7 (2-C), 137.7 (3-C), 158.1 (1 or 5-C), 158.5 (1 or 5-C). EIMS: m/z 222 [M]·+ (34), 
199 (9), 179 (8), 165 (100), 149 (26), 135 (30). HREIMS: m/z 222.1620 (calculated for 
C14H22O2 222.1620). 
3-methoxy-5-methylphenol (3.26). A solution of orcinol (5.00 g, 40.30 
mmol) in acetone (150 mL) was added to a round bottom flask. Then 
potassium carbonate (1.1 eq., 6.11 g, 44.30 mmol) was added to the 
flask. After that methyl iodide (1.1 eq., 2.80 mL, 44.30 mmol) was added to the flask, 
and the reaction mixture was stirred and refluxed for 2 h. The reaction mixture was 
concentrated in vacuo and the residue was suspended in water and acidified by 1 M HCl, 
then extracted with EtOAc three times. The combined organic layer was washed with 
deionised water and dried over Na2SO4 and concentrated in vacuo. The residue was 
subjected to flash column chromatography on silica using 30% EtOAc in petroleum ether 
as eluent to return the title compound as a viscous yellow oil (31%, 1.73 g, 12.58 
mmol).42 1H NMR (400 MHz, CDCl3): δ 2.27 (3H, s, 5-Me), 3.76 (3H, s, 3-OMe), 5.12 (1H, 
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brs, 1-OH), 6.24 (1H, dd, J= 2.3, 1.8 Hz, 2-H), 6.27 (1H, brs, 6-H), 6.33 (1H, brs, 4-H). 13C 
NMR (100 MHz, CDCl3): δ 21.7 (5-Me), 55.4 (3-OMe), 98.8 (2-C), 107.5 (4-C), 108.8 (6-C), 
140.8 (5-C), 156.6 (1-C), 160.9 (3-C). EIMS: m/z 138 [M]·+ (100), 121 (8), 109 (33). 
1-(allyloxy)-3-methoxy-5-methylbenzene (3.27). A solution of 
compound 3.26 (1.73 g, 12.58 mmol) in acetone (50 mL) was added 
to a round bottom flask. Then potassium carbonate (1.5 eq., 2.60 g, 
18.87 mmol) and that allyl bromide (1.5 eq., 1.60 mL, 18.87 mmol) 
were added to the flask, and the reaction mixture was stirred and refluxed for 6 h. The 
reaction mixture was concentrated in vacuo, the residue was suspended in water and 
extracted with EtOAc three times. The combined organic layer was washed with 
deionised water and dried over Na2SO4 and concentrated in vacuo. The residue was 
subjected to flash column chromatography on silica using 30% EtOAc in petroleum ether 
as eluent to return the title compound as a viscous yellow oil (92%, 2.06 g, 11.59 
mmol).31 1H NMR (400 MHz, CDCl3): δ 2.30 (3H, s, 5-Me), 3.77 (3H, s, 3-OMe), 4.50 (2H, 
d, J= 5.6 Hz, 1’-H), 5.28 (1H, d, J= 10.5 Hz, 3’-Ha), 5.40 (1H, d, J= 17.3 Hz, 3’-Hb), 6.00-
6.10 (1H, m, 2’-H), 6.31 (1H, dd, J= 2.3, 2.1 Hz, 2-H), 6.35 (2H, brs, 4,6-H). 13C NMR (100 
MHz, CDCl3): δ 22.0 (5-Me), 55.4 (3-OMe), 68.9 (1’-C), 98.4 (2-C), 107.5 (4 or 6-C), 108.0 
(4 or 6-C), 117.7 (3’-C), 133.5 (2’-C), 140.3 (5-C), 159.8 (1-C), 160.8 (3-C). EIMS: m/z 178 
[M]·+ (100), 163 (36), 135 (25), 123 (11), 109 (36). 
2-allyl-5-methoxy-3-methylphenol (3.28). The neat compound 
3.27 (2.06 g, 11.59 mmol) was rapidly heated up to 220 °C in a 
round bottom flask under an argon atmosphere. The reaction 
was monitored by TLC, and was continued until the starting material was consumed. The 
reaction mixture was recovered after it cooled down to room temperature, then was 
subjected to flash column chromatography on silica using 10% EtOAc in petroleum ether 
as eluent to return the title compound as a viscous yellow oil (19%, 401 mg, 2.25 
mmol).31 1H NMR (400 MHz, CDCl3): δ 2.26 (3H, s, 3-Me), 3.36 (2H, dt, J= 5.8, 1.8 Hz, 1’-
H), 3.75 (3H, s, 5-OMe), 4.93 (1H, brs, 1-OH), 5.00-5.09 (2H, m, 3’-H), 5.90-6.00 (1H, m, 
2’-H), 6.28 (1H, d, J= 2.5 Hz, 4 or 6-H), 6.37 (1H, d, J= 2.5 Hz, 4 or 6-H). 13C NMR (100 MHz, 
CDCl3): δ 20.1 (3-Me), 30.2 (1’-C), 55.5 (5-OMe), 99.6 (6-C), 108.7 (4-C), 115.4 (3’-C), 
116.1 (2-C), 136.1 (2’-C), 139.0 (3-C), 155.1 (1-C), 158.7 (5-C). EIMS: m/z 178 [M]·+ (100), 
163 (56), 151 (58), 135 (28), 117 (13), 91 (28). 
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6-methoxy-2,4-dimethyl-2,3-dihydrobenzofuran (3.29). This 
compound was isolated from the same reaction mixture generating 
3.28 as a viscous yellow oil (16%, 325 mg, 1.82 mmol). 1H NMR (400 
MHz, CDCl3): δ 1.46 (3H, d, J= 6.2 Hz, 2-Me), 2.19 (3H, s, 4-Me), 2.63-
2.68 (1H, m, 3-Ha), 3.15-3.21 (1H, m, 3-Hb), 3.75 (3H, s, 6-OMe), 4.90-4.98 (1H, m, 2-H), 
6.22 (1H, d, J= 2.3 Hz, 5 or 7-H), 6.23 (1H, d, J= 2.3 Hz, 5 or 7-H). 13C NMR (100 MHz, 
CDCl3): δ 19.4 (4-Me), 22.1 (2-Me), 35.6 (3-C), 55.6 (6-OMe), 80.3 (2-C), 93.6 (7-C), 106.8 
(5-C), 118.1 (4a-C), 135.1 (4-C), 160.4 (6,7a-C). EIMS: m/z 178 [M]·+ (100), 163 (45), 151 
(16), 135 (19), 119 (7), 91 (19). HREIMS: m/z 178.0994 (calculated for C11H14O2 178.0994). 
2-allyl-3-methoxy-5-methylphenol (3.30). This compound was 
isolated from the same reaction mixture generating 3.28 as a viscous 
yellow oil (34%, 701 mg, 3.94 mmol).31 1H NMR (400 MHz, CDCl3): δ 
2.29 (3H, s, 5-Me), 3.43 (2H, d, J= 6.1 Hz, 1’-H), 3.80 (3H, s, 3-OMe), 4.97 (1H, brs, 1-OH), 
5.05-5.13 (2H, m, 3’-H), 5.92-6.02 (1H, m, 2’-H), 6.33 (2H, brs, 4,6-H). 13C NMR (100 MHz, 
CDCl3): δ 21.7 (5-Me), 27.3 (1’-C), 55.9 (3-OMe), 104.5 (4 or 6-C), 109.6 (4 or 6-C), 110.6 
(2-C), 115.4 (3’-C), 136.7 (2’-C), 137.9 (5-C), 155.1 (1-C), 158.1 (3-C). EIMS: m/z 178 [M]·+ 
(100), 149 (42), 135 (36), 121 (44), 91 (33). 
2’-(2-hydroxy-4-methoxy-6-
methylphenyl)acetaldehyde (3.31). A solution 
of compound 3.28 (82 mg, 0.46 mmol) in 
DCM/MeOH (1:1) (15 mL) was added to a 
round bottom flask. Then O2/O3  (30:70) stream was bubbled into the solution for 10 
min with the flow rate 1 L/min at -78 °C, then N2 stream was bubbled for 10 min to 
remove O3 residue. After that, dimethyl sulfide (1.3 eq., 46 μl, 0.59 mmol) was added 
dropwise into the solution and the reaction mixture was stirred for 0.5 h at room 
temperature. The reaction mixture was concentrated in vacuo and the residue was 
subjected to flash column chromatography on silica using 30% EtOAc in petroleum ether 
as eluent to return the title compound as a viscous yellow oil (21%, 17.2 mg, 0.10 mmol). 
This compound is represented as a mixture of aldehyde and semi-acetal. 1H NMR (400 
MHz, CDCl3): δ 2.21 (3H, s, 6-Me), 2.89 (1H, dd, J= 16.2, 2.0 Hz, 2’’-Ha), 3.10 (2H, d, J= 
7.0 Hz, 2’-H), 3.23 (1H, dd, J= 16.2, 6.5 Hz, 2’’-Hb), 3.36 (1H, d, J= 5.4 Hz, 1’’-OH), 3.75 
(3H, s, 4-OMe), 6.07 (1H, m, 1’’-H), 6.29 (2H, brs, 3,5-H), 9.77 (1H, s, 1’-H). 13C NMR (100 
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MHz, CDCl3): δ 19.3 (6-Me), 36.4 (2’ and 2’’-C), 55.6 (4-OMe), 94.1 (1’’-C), 101.6 (3 or 5-
C), 107.9 (3 or 5-C), 115.8 (1-C), 135.3 (6-C), 158.5 (4-C), 160.5 (2-C), 198.2 (1’-C). EIMS: 
m/z 180 [M]·+ (30), 151 (100), 137 (3), 123 (6), 91 (11). 
2-allyl-1,5-dimethoxy-3-methylbenzene (3.32). A solution of 
compound 3.28 (500 mg, 2.81 mmol) in acetone (15 mL) was 
added to a round bottom flask. Then potassium carbonate (1.5 
eq., 582 mg, 4.22 mmol) and methyl iodide (3.0 eq., 525 μl, 8.43 mmol) were added to 
the flask, and the reaction mixture was stirred and refluxed overnight. The reaction 
mixture was concentrated in vacuo, then the residue was suspended in water and 
extracted with EtOAc three times. The combined organic layer was dried over Na2SO4 
and concentrated in vacuo, and the residue was subjected to flash column 
chromatography on silica using 15% EtOAc in petroleum ether as eluent to return the 
title compound as a viscous yellow oil (95%, 513 mg, 2.67 mmol).31 1H NMR (400 MHz, 
CDCl3): δ 2.28 (3H, s, 3-Me), 3.35 (2H, m, 1’-H), 3.80 (6H, s, 1,5-OMe), 4.88-4.96 (2H, m, 
3’-H), 5.84-5.95 (1H, m, 2’-H), 6.35 (2H, brs, 4,6-H). 13C NMR (100 MHz, CDCl3): δ 19.9 (3-
Me), 30.0 (1’-C), 55.4 (1 or 5-OMe), 55.8 (1 or 5-OMe), 96.3 (6-C), 106.7 (4-C), 114.1 (3’-
C), 119.0 (2-C), 136.8 (2’-C), 138.6 (3-C), 158.5 (1 or 5-C), 158.7 (1 or 5-C). EIMS: m/z 192 
[M]·+ (100), 177 (65), 165 (47), 135 (41), 115 (13), 91 (28). 
2’-(2,4-dimethoxy-6-methylphenyl)-1’-methoxyethan-1’-ol 
(3.33). A solution of compound 3.32 (135 mg, 0.70 mmol) in 
DCM/MeOH (1:1) (15 mL) was added to a round bottom flask. 
Then O2/O3  (30:70) stream was bubbled into the solution for 10 min with the flow rate 
1 L/min at -78 °C, then N2 stream was bubbled for 10 min to remove O3 residue. After 
that, dimethyl sulfide (1.3 eq., 72 μl, 0.91 mmol) was added dropwise into the solution 
and the reaction mixture was stirred for 0.5 h at room temperature. The reaction 
mixture was concentrated in vacuo, and the residue was subjected to flash column 
chromatography on silica using 30% EtOAc in petroleum ether as eluent to return the 
title compound as a viscous yellow oil (28%, 45 mg, 0.20 mmol). 1H NMR (400 MHz, 
CDCl3): δ 2.31 (3H, s, 6-Me), 2.86 (1H, dd, J= 14.5, 4.0 Hz, 2’-Ha), 3.18 (1H, dd, J= 14.5, 
7.8 Hz, 2’-Hb), 3.49 (3H, s, 1’-OMe), 3.79 (3H, s, 4-OMe), 3.85 (3H, s, 2-OMe), 4.75-4.79 
(1H, m, 1’-H), 6.37 (1H, d, J= 2.6 Hz, 3 or 5-H), 6.38 (1H, d, J= 2.6 Hz, 3 or 5-H), 8.90 (1H, 
s, 1’-OH). 13C NMR (100 MHz, CDCl3): δ 20.4 (6-Me), 28.5 (2’-C), 55.4 (4-OMe), 56.0 (1’-
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OMe), 56.1 (2-OMe), 96.6 (3-C), 107.5 (5-C), 107.7 (1’-C), 115.5 (1-C), 139.5 (6-C), 158.7 
(4-C), 159.2 (2-C). ESIMS: m/z 265 [M+K]+ (19), 247 (19), 233 (22), 209 (14), 193 (21), 165 
(100). 
3-(allyloxy)-5-methylphenol (3.34). A solution of orcinol (1.00 g, 
8.06 mmol) in acetone (30 mL) was added to a round bottom flask. 
Then potassium carbonate (1.3 eq., 1.45 g, 10.48 mmol) was 
added to the solution. After that allyl bromide (1.3 eq., 888 μl, 10.48 mmol) was added 
to a dropping funnel contaning 10 mL acetone, and added dropwise to the flask, and the 
reaction mixture was stirred and refluxed under an argon atmosphere. The reaction was 
monitored by TLC and GC-MS and was continued until the starting material was 
consumed. The reaction mixture was concentrated in vacuo, then the residue was 
suspended in water and acidified by 0.1 M HCl, then extracted with EtOAc three times. 
The combined organic layer was washed with deionised water and dried over Na2SO4 
and concentrated in vacuo, the residue was subjected to flash column chromatography 
on silica using 25% EtOAc in petroleum ether as eluent to return the title compound as 
a sticky yellow oil (67%, 595 mg, 3.62 mmol). 1H NMR (400 MHz, CDCl3): δ 2.26 (3H, s, 5-
Me), 4.48 (2H, dt, J= 5.3, 1.5 Hz, 1’-H), 5.29 (1H, dt, J= 10.5, 1.5 Hz, 3’-Ha), 5.41 (1H, dt, 
J= 17.3, 1.5 Hz, 3’-Hb), 5.99-6.09 (1H, m, 2’-H), 6.30 (2H, m, 2, 6-H), 6.37 (1H, brs, 4-H). 
13C NMR (100 MHz, CDCl3): δ 21.6 (5-Me), 69.0 (1’-C), 99.6 (2-C), 108.4 (4-C), 109.2 (6-
C), 117.9 (3’-C), 133.2 (2’-C), 140.7 (5-C), 156.4 (1-C), 159.7 (3-C). EIMS: m/z 164 [M]·+ 
(100), 149 (47), 121 (39), 109 (29), 95 (31), 77 (24). HREIMS: m/z 164.0837 (calculated 
for C10H12O2 164.0837). 
4-allyl-5-methylbenzene-1,3-diol (3.35). A solution of compound 
3.34 (595 mg, 3.62 mmol) in N,N-diethylaniline (1 mL) was added 
to a reaction vessel. Then the solution was heated up to 250 °C by 
microwave followed by the procedure (250 W, ramp 5 min) and kept 250 °C for 20 min. 
The reaction mixture was diluted by EtOAc (50 mL) after cooling down to the room 
temperature, then washed with 1 M HCl twice. The organic layer was washed with brine 
and dried over Na2SO4 before concentration in vacuo, the residue was subjected to flash 
column chromatography on silica using 30% EtOAc in petroleum ether as eluent to 
return the title compound as a viscous colourless oil (53%, 316 mg, 1.93 mmol). 1H NMR 
(400 MHz, CDCl3): δ 2.21 (3H, s, 5-Me), 3.33 (2H, d, J= 5.8 Hz, 1’-H), 4.98-5.06 (2H, m, 3’-
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H), 5.88-5.98 (1H, m, 2’-H), 6.22 (1H, d, J= 2.3 Hz, 2-H), 6.28 (1H, d, J= 2.3 Hz, 6-H). 13C 
NMR (100 MHz, CDCl3): δ 19.8 (5-Me), 30.1 (1’-C), 101.1 (2-C), 110.0 (6-C), 115.3 (3’-C), 
116.4 (4-C), 136.1 (2’-C), 139.3 (5-C), 154.4 (1-C), 155.0 (3-C). EIMS: m/z 164 [M]·+ (100), 
153 (19), 149 (49), 137 (50), 123 (34), 91 (13), 77 (16). HREIMS: m/z 164.0837 (calculated 
for C10H12O2 164.0837). 
2,4-dimethyl-2,3-dihydrobenzofuran-6-ol (3.36). This compound was 
isolated from the same reaction mixture generating 3.35 as a pale 
yellow solid (5%, 30 mg, 0.18 mmol). 1H NMR (400 MHz, CDCl3): δ 1.45 
(3H, d, J= 6.3 Hz, 2-Me), 2.16 (3H, s, 4-Me), 2.61-2.64 (1H, m, 3-Ha), 
3.12-3.18 (1H, m, 3-Hb), 4.89-4.97 (1H, m, 2-H), 6.13 (1H, d, J= 1.9 Hz, 7-H), 6.14 (1H, d, 
J= 1.9 Hz,  5-H). 13C NMR (100 MHz, CDCl3): δ 19.2 (4-Me), 22.1 (2-Me), 35.6 (3-C), 80.4 
(2-C), 95.0 (7-C), 108.0 (5-C), 118.3 (4a-C), 135.4 (4-C), 156.0 (6-C), 160.5 (7a-C). EIMS: 
m/z 164 [M]·+ (100), 149 (56), 137 (19), 121 (28), 91 (19). HREIMS: m/z 164.0836 
(calculated for C10H12O2 164.0837). 
2-allyl-5-methylbenzene-1,3-diol (3.37). This compound was isolated 
from the same reaction mixture generating 3.33 as a viscous yellow 
oil (31%, 185 mg, 1.13 mmol).43 1H NMR (400 MHz, CDCl3): δ 2.22 
(3H, s, 5-Me), 3.44 (2H, dt, J= 6.0, 1.8 Hz, 1’-H), 5.11-5.19 (2H, m, 3’-H), 5.95-5.05 (1H, 
m, 2’-H), 6.26 (2H, s, 4,6-H). 13C NMR (100 MHz, CDCl3): δ 21.3 (5-Me), 27.5 (1’-C), 108.9 
(2-C), 109.3 (4,6-C), 116.1 (3’-C), 116.4 (6-C), 136.3 (2’-C), 138.2 (5-C), 154.9 (1,3-C). EIMS: 
m/z 164 [M]·+ (100), 149 (39), 137 (36), 121 (30), 91 (20). HREIMS: m/z 164.0836 
(calculated for C10H12O2 164.0837). 
5-methyl-2-(3’-methylbut-2’-en-1’-yl)benzene-1,3-diol (3.1). A 
solution of compound 3.37 (51 mg, 0.31 mmol) in anhydrous 
trimethylethylene solution (2M in THF, 100 eq., 15.5 mL, 31 mmol) 
was added to a oven-dried and air-free 2-neck round bottom flask, the solution at 0 °C 
was then exposed to a stream of argon. After that, Grubb’s 2nd generation catalyst (5%, 
13 mg, 0.02 mmol) was added, and the reaction mixture was stirred at room 
temperature under an argon atmosphere. The reaction was monitored by TLC and GC-
MS, and was continued until the starting material was consumed. The reaction mixture 
was concentrated in vacuo and the residue was subjected to flash column 
chromatography on silica using 50% EtOAc in petroleum ether as eluent to return the 
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title compound as a viscous green oil (99%, 60 mg, 0.31 mmol).44 1H NMR (400 MHz, 
CD3OD): δ 1.64 (3H, s, 4’-H), 1.74 (3H, s, 5’-H), 2.13 (3H, s, 5-Me), 3.23 (2H, d, J= 7.1 Hz, 
1’-H), 5.21 (1H, t, J= 7.1 Hz, 2’-H), 6.12 (2H, s, 4,6-H). 13C NMR (100 MHz, CD3OD): δ 17.9 
(5’-C), 21.3 (5-Me), 23.0 (1’-C), 26.0 (4’-C), 108.5 (4,6-C), 113.3 (2-C), 125.0 (2’-C), 130.8 
(3’-C), 137.1 (5-C), 156.9 (1,3-C). EIMS: m/z 192 [M]·+ (61), 177 (31), 137 (100), 136 (31), 
121 (16), 108 (18). 
3-methoxy-5-methyl-2-(3’-methylbut-2’-en-1’-yl)phenol (3.2). A 
solution of compound 3.1 (54 mg, 0.28 mmol) in anhydrous 
acetone (8 mL) was added to a oven-dried 2-neck round bottom 
flask. Then potassium carbonate (1.3 eq., 52 mg, 0.37 mmol) was added to the flask. 
After that dimethylsulfate (1.3 eq., 35 μl, 0.37 mmol) was added to a dropping funnel 
contaning 5 mL anhydrous acetone, and added dropwise to the flask, and the reaction 
mixture was stirred and refluxed under an argon atmosphere. The reaction was 
monitored by TLC and GC-MS, and was continued until the starting material was 
consumed. The reaction mixture was concentrated in vacuo, the residue was suspended 
in water and acidified by 0.1 M HCl, then extracted with EtOAc three times. The 
combined organic layer was washed with deionised water, dried over Na2SO4 and 
concentrated in vacuo, the residue was subjected to flash column chromatography on 
silica using 20% EtOAc in petroleum ether as eluent to return the title compound as a 
viscous yellow oil (26%, 12 mg, 0.06 mmol). 1H NMR (400 MHz, CD3OD): δ 1.63 (3H, s, 4’-
H), 1.73 (3H, s, 5’-H), 2.21 (3H, s, 5-Me), 3.23 (2H, d, J= 7.1 Hz, 1’-H), 3.74 (3H, s, 3-OMe), 
5.16 (1H, t, J= 7.1 Hz, 2’-H), 6.24 (2H, brs, 4,6-H). 13C NMR (100 MHz, CD3OD): δ 17.8 (5’-
C), 21.7 (5-Me), 22.9 (1’-C), 26.0 (4’-C), 56.0 (3-OMe), 104.3 (4-C), 109.8 (6-C), 114.7 (2-
C), 124.9 (2’-C), 130.8 (3’-C), 137.4 (5-C), 156.5 (1-C), 159.7 (3-C). EIMS: m/z 206 [M]·+ 
(73), 191 (41), 151 (100), 150 (25), 138 (17), 121 (27). HREIMS: m/z 206.1307 (calculated 
for C13H18O2 206.1307). 
1,3-dimethoxy-5-methyl-2-(3’-methylbut-2’-en-1’-yl)benzene (3.3). 
This compound was isolated from the same reaction mixture 
generating 3.2 as a viscous yellow oil (51%, 26 mg, 0.12 mmol).18 1H 
NMR (400 MHz, CD3OD): δ 1.62 (3H, s, 4’-H), 1.72 (3H, s, 5’-H), 2.29 (3H, s, 5-Me), 3.23 
(2H, d, J= 7.1 Hz, 1’-H), 3.76 (6H, s, 1,3-OMe), 5.10 (1H, t, J= 7.1 Hz, 2’-H), 6.39 (2H, s, 
4,6-H). 13C NMR (100 MHz, CD3OD): δ 17.8 (5’-C), 22.0 (5-Me), 22.8 (1’-C), 25.9 (4’-C), 
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56.1 (1,3-OMe), 105.7 (4,6-C), 116.2 (2-C), 124.8 (2’-C), 130.9 (3’-C), 137.9 (5-C), 159.2 
(1,3-C). EIMS: m/z 220 [M]·+ (81), 205 (100), 189 (22), 165 (29), 152 (36), 135 (16). ESIMS: 
m/z 243 [M+Na]+ (66), 221 (35), 167 (41), 153 (100), 149 (60), 113 (45). HREIMS: m/z 
220.1465 (calculated for C14H20O2 220.1463). HRESIMS: m/z 243.1360 (calculated for 
C14H20O2Na 243.1361). 
5-methyl-4-(3’-methylbut-2’-en-1’-yl)benzene-1,3-diol (3.4). A 
solution of compound 3.35 (118 mg, 0.72 mmol) in anhydrous 
trimethylethylene solution (2M in THF, 100 eq., 36 mL, 72 mmol) 
was added to a oven-dried and air-free 2-neck round bottom flask, the solution at 0 °C 
was then exposed to a stream of argon. After that, Grubb’s 2nd generation catalyst (10%, 
61 mg, 0.07 mmol) was added, the reaction mixture was stirred at room temperature 
under an argon atmosphere. The reaction was monitored by TLC and GC-MS, and was 
continued until the starting material was consumed. The reaction mixture was 
concentrated in vacuo and the residue was subjected to flash column chromatography 
on silica using 40% EtOAc in petroleum ether as eluent to return the title compound as 
a viscous green oil (94%, 130 mg, 0.67 mmol).44 1H NMR (400 MHz, CD3OD): δ 1.66 (3H, 
s, 4’-H), 1.74 (3H, s, 5’-H), 2.14 (3H, s, 5-Me), 3.22 (2H, d, J= 6.5 Hz, 1’-H), 5.04 (1H, t, J= 
6.5 Hz, 2’-H), 6.11 (1H, d, J= 2.1 Hz, 6-H), 6.13 (1H, d, J= 2.1 Hz, 2-H). 13C NMR (100 MHz, 
CD3OD): δ 17.9 (5’-C), 20.0 (5-Me), 25.6 (1’-C), 25.9 (4’-C), 101.2 (2-C), 109.4 (6-C), 119.3 
(4-C), 125.1 (2’-C), 130.8 (3’-C), 139.2 (5-C), 156.4 (1-C), 156.8 (3-C). EIMS: m/z 192 [M]·+ 
(40), 177 (29), 138 (28), 137 (100), 124 (28). HREIMS: m/z 192.1152 (calculated for 
C12H16O2 192.1150). 
5-methoxy-3-methyl-2-(3’-methylbut-2’-en-1’-yl)phenol (3.5). A 
solution of compound 3.4 (146 mg, 0.76 mmol) in anhydrous 
acetone (25 mL) was added to a oven-dried 2-neck round 
bottom flask. Then potassium carbonate (1.3 eq., 137 mg, 0.99 mmol) was added to the 
flask. After that dimethylsulfate (1.3 eq., 94 μl, 0.99 mmol) was added to a dropping 
funnel contaning 10 mL anhydrous acetone, and added dropwise to the flask, and the 
reaction mixture was stirred and refluxed under an argon atmosphere. The reaction was 
monitored by TLC and GC-MS, and was continued until the starting material was 
consumed. The reaction mixture was concentrated in vacuo, the residue was suspended 
in water and acidified by 0.1 M HCl, then extracted with EtOAc three times. The 
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combined organic layer was washed with deionised water, dried over Na2SO4 and 
concentrated in vacuo, the residue was subjected to flash column chromatography on 
silica using 25% EtOAc in petroleum ether as eluent to return the title compound as a 
viscous yellow oil (7%, 11 mg, 0.06 mmol).45 1H NMR (400 MHz, CD3OD): δ 1.66 (3H, s, 
4’-H), 1.75 (3H, s, 5’-H), 2.18 (3H, s, 3-Me), 3.24 (2H, d, J= 6.7 Hz, 1’-H), 3.69 (3H, s, 5-
OMe), 5.04 (1H, t, J= 6.7 Hz, 2’-H), 6.22 (2H, brs, 4,6-H). 13C NMR (100 MHz, CD3OD): δ 
17.9 (5’-C), 20.1 (3-Me), 25.6 (1’-C), 25.9 (4’-C), 55.4 (5-OMe), 99.9 (6-C), 107.8 (4-C), 
120.4 (2-C), 124.8 (2’-C), 131.0 (3’-C), 139.3 (3-C), 156.8 (1-C), 159.4 (5-C). ESIMS: m/z 
245 [M+K]+ (8), 229 [M+Na]+ (14), 221 (23), 207 (100), 205 (12), 183 (47), 165 (13). 
HRESIMS: m/z 245.0945 (calculated for C13H18O2K 245.0944), 229.1205 (calculated for 
C13H18O2Na 229.1204). 
3-methoxy-5-methyl-4-(3’-methylbut-2’-en-1’-yl)phenol (3.6). 
This compound was isolated from the same reaction mixture 
generating 3.5 as a viscous yellow oil (22%, 34 mg, 0.17 mmol). 
1H NMR (400 MHz, CD3OD): δ 1.65 (3H, s, 4’-H), 1.74 (3H, s, 5’-H), 2.16 (3H, s, 5-Me), 3.22 
(2H, d, J= 6.9 Hz, 1’-H), 3.73 (3H, s, 3-OMe), 4.98 (1H, t, J= 6.9 Hz, 2’-H), 6.20 (1H, d, J= 
2.0 Hz, 6-H), 6.25 (1H, d, J= 2.0 Hz, 2-H). 13C NMR (100 MHz, CD3OD): δ 17.9 (5’-C), 19.9 
(5-Me), 25.5 (1’-C), 25.9 (4’-C), 55.9 (3-OMe), 97.6 (2-C), 109.9 (6-C), 120.6 (4-C), 124.9 
(2’-C), 130.9 (3’-C), 138.9 (5-C), 156.9 (1-C), 159.6 (3-C). EIMS: m/z 206 [M]·+ (84), 192 
(53), 191 (100), 177 (19), 151 (50), 138 (52), 121 (31). HREIMS: m/z 206.1309 (calculated 
for C13H18O2 206.1307). 
1,5-dimethoxy-3-methyl-2-(3’-methylbut-2’-en-1’-yl)benzene 
(3.7). This compound was isolated from the same reaction 
mixture generating 3.5 as a viscous yellow oil (34%, 57 mg, 0.26 
mmol). 1H NMR (400 MHz, CD3OD): δ 1.64 (3H, s, 4’-H), 1.74 (3H, s, 5’-H), 2.21 (3H, s, 3-
Me), 3.24 (2H, d, J= 6.7 Hz, 1’-H), 3.73 (3H, s, 5-OMe), 3.75 (3H, s, 1-OMe), 4.98 (1H, t, 
J= 6.7 Hz, 2’-H), 6.31 (1H, d, J= 2.2 Hz, 4-H), 6.33 (1H, d, J= 2.2 Hz, 6-H). 13C NMR (100 
MHz, CD3OD): δ 17.9 (5’-C), 20.1 (3-Me), 25.6 (1’-C), 25.9 (4’-C), 55.6 (5-OMe), 55.9 (1-
OMe), 97.0 (6-C), 107.9 (4-C), 121.9 (2-C), 124.6 (2’-C), 131.1 (3’-C), 138.9 (3-C), 159.5 
(1-C), 159.8 (5-C). ESIMS: m/z 259 [M+K]+ (5), 243 [M+Na]+ (13), 221 (11), 188 (44), 153 
(100), 108 (13). HRESIMS: m/z 259.1103 (calculated for C14H20O2K 259.1100), 243.1361 
(calculated for C14H20O2Na 243.1361). 
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methyl 2,4-dihydroxy-6-methylbenzoate (3.38). A solution of orsellinic 
acid (1.50 g, 8.92 mmol) in acetone (50 mL) was added to a round bottom 
flask. Then potassium carbonate (0.5 eq., 616 mg, 4.46 mmol) and methyl 
iodide (10.0 eq., 5.55 mL, 89.2 mmol) were added to the solution, the 
reaction mixture was stirred and refluxed overnight. The reaction mixture was 
concentrated in vacuo, the residue was suspended in a saturated NaHCO3 aqueous 
solution and extracted with EtOAc three times. The combined organic layer was washed 
with deionised water, dried over Na2SO4 and concentrated in vacuo without further 
purification to return the title compound as white crystals (99%, 1.62 g, 8.92 mmol).24 
1H NMR (400 MHz, CDCl3): δ 2.49 (3H, s, 6-Me), 3.93 (3H, s, 1-COOCH3), 5.27 (1H, s, 4-
OH), 6.23 (1H, s, 3-H), 6.27 (1H, s, 5-H), 11.73 (1H, s, 2-OH). 13C NMR (100 MHz, CDCl3): 
δ 24.4 (6-Me), 52.0 (1-COOCH3), 101.4 (3-C), 105.9 (1-C), 111.5 (5-C), 144.2 (6-C), 160.3 
(2-C), 165.5 (4-C), 172.3 (1-COOCH3). EIMS: m/z 182 [M]·+ (51), 151 (36), 150 (100), 122 
(59), 94 (17). HREIMS: m/z 182.0586 (calculated for C9H10O4 182.0579). 
methyl 4-(allyloxy)-2-hydroxy-6-methylbenzoate (3.39). A solution of 
compound 3.38 (392 mg, 2.15 mmol) in acetone (30 mL) was added to 
a round bottom flask. Then potassium carbonate (1.0 eq., 297 mg, 2.15 
mmol) and allyl bromide (1.0 eq., 182 μl, 2.15 mmol) were added to 
the solution, and the reaction mixture was stirred and refluxed overnight. The reaction 
mixture was diluted in 200 mL DCM, then filtered. The filtrate was concentrated in vacuo, 
and the residue was subjected to flash column chromatography on silica using 20% 
EtOAc in petroleum ether as eluent to return the title compound as a white solid (99%, 
472 mg, 2.13 mmol). 1H NMR (400 MHz, CDCl3): δ 2.49 (3H, s, 6-Me), 3.92 (3H, s, 1-
COOCH3), 4.53 (2H, d, J= 5.3 Hz, 1’-H), 5.29-5.43 (2H, m, 3’-H), 5.97-6.07 (1H, m, 2’-H), 
6.31 (1H, s, 5-H), 6.33 (1H, s, 3-H), 11.75 (1H, s, 2-OH). 13C NMR (100 MHz, CDCl3): δ 24.5 
(6-Me), 52.0 (1-COOCH3), 68.8 (1’-C), 99.6 (3-C), 105.5 (1-C), 111.8 (5-C), 118.2 (3’-C), 
132.6 (2’-C), 143.3 (6-C), 163.0 (4-C), 165.6 (2-C), 172.3 (1-COOCH3). EIMS: m/z 222 [M]·+ 
(37), 190 (100), 175 (28), 162 (75), 121 (26), 91 (24). HREIMS: m/z 222.0893 (calculated 
for C12H14O4 222.0892). 
methyl 3-allyl-4,6-dihydroxy-2-methylbenzoate (3.40). A solution 
of compound 3.39 (105 mg, 0.47 mmol) in N,N-diethylaniline (1 
mL) was added to a reaction vessel. Then the solution was heated 
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up to 250 °C by microwave followed by the procedure (250 W, ramp 5 min) and kept 
250 °C for 20 min. The reaction mixture was diluted by EtOAc (50 mL) after cooling down 
to the room temperature, then washed with 1 M HCl twice. The organic layer was 
washed with brine and dried over Na2SO4 before concentration in vacuo, the residue 
was subjected to flash column chromatography on silica using 30% EtOAc in petroleum 
ether as eluent to return the title compound as a viscous yellow oil (86%, 90 mg, 0.41 
mmol). 1H NMR (400 MHz, CDCl3): δ 2.44 (3H, s, 2-Me), 3.40 (2H, dt, J= 5.5, 2.0 Hz, 1’-H), 
3.93 (3H, s, 1-COOCH3), 4.91-5.05 (2H, m, 3’-H), 5.60 (1H, s, 4-OH), 5.88-5.97 (1H, m, 2’-
H), 6.31 (1H, s, 5-H), 11.31 (1H, s, 6-OH). 13C NMR (100 MHz, CDCl3): δ 18.7 (2-Me), 30.1 
(1’-C), 52.1 (1-COOCH3), 101.5 (5-C), 107.0 (1-C), 115.3 (3’-C), 117.8 (3-C), 135.8 (2’-C), 
141.9 (2-C), 159.1 (4-C), 162.5 (6-C), 172.3 (1-COOCH3). EIMS: m/z 222 [M]·+ (56), 190 
(100), 175 (15), 162 (25), 134 (19), 91 (21). HREIMS: m/z 222.0892 (calculated for 
C12H14O4 222.0892). 
methyl 4-(allyloxy)-2-((tert-butyldimethylsilyl)oxy)-6-methylbenzoate 
(3.41). A solution of compound 3.39 (1.06 g, 4.77 mmol) in anhydrous 
dimethylformamide (DMF) (20 mL) was added to a oven-dried 2-neck 
round bottom flask. Then tert-Butyldimethylsilyl chloride (2.0 eq., 1.44 
g, 9.53 mmol) was added to the solution, after that N,N-diisopropylethylamine (2.0 eq., 
1.66 mL, 9.53 mmol) was added dropwise to the flask at 0 °C, the reaction mixture was 
stirred for 4 h under an argon atmosphere. The reaction was quenched by adding brine, 
the reaction mixture was extracted with DCM three times. The combined organic layer 
was dried over Na2SO4 and concentrated in vacuo, and the residue was subjected to 
flash column chromatography on silica using 20% EtOAc in petroleum ether as eluent to 
return the title compound as a pale yellow oil (99%, 1.61 g, 4.77 mmol). 1H NMR (400 
MHz, CDCl3): δ 0.21 (6H, s, 2-OSi(CH3)2C(CH3)3), 0.96 (9H, s, 2-OSi(CH3)2C(CH3)3), 2.26 (3H, 
s, 6-Me), 3.84 (3H, s, 1-COOCH3), 4.49 (2H, dt, J= 5.3, 1.6 Hz, 1’-H), 5.27-5.41 (2H, m, 3’-
H), 5.97-6.07 (1H, m, 2’-H), 6.23 (1H, s, 3-H), 6.36 (1H, s, 5-H). 13C NMR (100 MHz, CDCl3): 
δ -4.2 (2-OSi(CH3)2C(CH3)3), 18.2 (2-OSi(CH3)2C(CH3)3), 20.2 (6-Me), 25.7 (2-
OSi(CH3)2C(CH3)3), 52.0 (1-COOCH3), 69.0 (1’-C), 103.8 (3-C), 109.3 (5-C), 118.0 (3’-C), 
119.5 (1-C), 133.1 (2’-C), 138.4 (6-C), 154.2 (2-C), 160.0 (4-C), 168.9 (1-COOCH3). EIMS: 
m/z 321 (7), 305 (14), 279 (100), 210 (23). ESIMS: m/z 359 [M+Na]+ (99), 337 (38), 305 
(100). HREIMS: m/z 321.1523 (calculated for C17H25O4Si 321.1522), 305.1575 (calculated 
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for C17H25O3Si 305.1573). HRESIMS: m/z 359.1661 (calculated for C18H28O4SiNa 
359.1655), 337.1838 (calculated for C18H29O4Si 337.1835). 
methyl 3-allyl-6-((tert-butyldimethylsilyl)oxy)-4-hydroxy-2-
methylbenzoate (3.42). A solution of compound 3.41 (860 mg, 
2.56 mmol) in N,N-diethylaniline (3 mL) was added to a reaction 
vessel. Then the solution was heated up to 250 °C by microwave 
followed by the procedure (250 W, ramp 5 min) and kept 250 °C for 20 min. The reaction 
mixture was diluted by EtOAc (50 mL) after cooling down to the room temperature, then 
washed with 1 M HCl twice. The organic layer was washed with brine and dried over 
Na2SO4 before concentration in vacuo, the residue was subjected to flash column 
chromatography on silica using 20% EtOAc in petroleum ether as eluent to return the 
title compound as a viscous pale yellow oil (63%, 542 mg, 1.61 mmol). 1H NMR (400 MHz, 
CDCl3): δ 0.20 (6H, s, 6-OSi(CH3)2C(CH3)3), 0.95 (9H, s, 6-OSi(CH3)2C(CH3)3), 2.16 (3H, s, 2-
Me), 3.34 (2H, dt, J= 5.6, 1.8 Hz, 1’-H), 3.84 (3H, s, 1-COOCH3), 4.96-5.06 (2H, m, 3’-H), 
5.26 (1H, s, 4-OH), 5.85-5.95 (1H, m, 2’-H), 6.23 (1H, s, 5-H). 13C NMR (100 MHz, CDCl3): 
δ -4.3 (6-OSi(CH3)2C(CH3)3), 16.7 (2-Me), 18.1 (6-OSi(CH3)2C(CH3)3), 25.6 (6-
OSi(CH3)2C(CH3)3), 30.1 (1’-C), 52.1 (1-COOCH3), 104.5 (5-C), 115.7 (3’-C), 117.1 (3-C), 
120.5 (1-C), 135.5 (2’-C), 136.1 (2-C), 151.8 (6-C), 155.5 (4-C), 169.8 (1-COOCH3). ESIMS: 
m/z 359 [M+Na]+ (18), 337 (5), 305 (100). HRESIMS: m/z 359.1659 (calculated for 
C18H28O4SiNa 359.1655), 337.1835 (calculated for C18H29O4Si 337.1835). 
methyl 3-allyl-2-((tert-butyldimethylsilyl)oxy)-4-hydroxy-6-
methylbenzoate (3.43). This compound was isolated from the same 
reaction mixture generating 3.42 as white crystals (29%, 253 mg, 
0.69 mmol). 1H NMR (400 MHz, CDCl3): δ 0.09 (6H, s, 2-
OSi(CH3)2C(CH3)3), 1.01 (9H, s, 2-OSi(CH3)2C(CH3)3), 2.24 (3H, s, 6-Me), 3.41 (2H, d, J= 6.0 
Hz, 1’-H), 3.83 (3H, s, 1-COOCH3), 5.16-5.23 (2H, m, 3’-H), 5.50 (1H, s, 4-OH), 5.88-5.98 
(1H, m, 2’-H), 6.38 (1H, s, 5-H). 13C NMR (100 MHz, CDCl3): δ -3.8 (2-OSi(CH3)2C(CH3)3), 
18.5 (2-OSi(CH3)2C(CH3)3), 20.5 (6-Me), 26.0 (2-OSi(CH3)2C(CH3)3), 28.9 (1’-C), 51.8 (1-
COOCH3), 112.1 (5-C), 114.4 (3-C), 117.1 (3’-C), 119.1 (1-C), 136.2 (2’-C), 137.1 (6-C), 
151.8 (2-C), 157.2 (4-C), 168.9 (1-COOCH3). EIMS: m/z 335 (1), 321 (10), 305 (13), 279 
(100), 249 (9), 239 (10), 205 (8). HREIMS: m/z 335.1668 (calculated for C18H27O4Si 
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335.1679), 321.1524 (calculated for C17H25O4Si 321.1522), 305.1569 (calculated for 
C17H25O3Si 305.1573), 279.1054 (calculated for C14H19O4Si 279.1053). 
methyl 2-((tert-butyldimethylsilyl)oxy)-4-hydroxy-6-methyl-3-(3’-
methylbut-2’-en-1’-yl)benzoate (3.44). A solution of compound 
3.43 (148 mg, 0.44 mmol) in anhydrous trimethylethylene solution 
(2M in THF, 100 eq., 22.0 mL, 44.00 mmol) was added to a oven-
dried and air-free 2-neck round bottom flask, the solution at 0 °C was then exposed to 
a stream of argon. After that, Grubb’s 2nd generation catalyst (5%, 19 mg, 0.02 mmol) 
was added, and the reaction mixture was stirred at room temperature under an argon 
atmosphere. The reaction was monitored by TLC and GC-MS, and was continued until 
the starting material was consumed. The reaction mixture was concentrated in vacuo 
and the residue was subjected to flash column chromatography on silica using 25% 
EtOAc in petroleum ether as eluent to return the title compound as a white solid (99%, 
214 mg, 0.59 mmol). 1H NMR (400 MHz, CD3OD): δ 0.08 (6H, s, 2-OSi(CH3)2C(CH3)3), 1.00 
(9H, s, 2-OSi(CH3)2C(CH3)3), 1.64 (3H, s, 4’-H), 1.70 (3H, s, 5’-H), 2.19 (3H, s, 6-Me), 3.25 
(2H, d, J= 6.3 Hz, 1’-H), 3.79 (3H, s, 1-COOCH3), 5.13 (1H, t, J= 6.3 Hz, 2’-H), 6.33 (1H, s, 
5-H). 13C NMR (100 MHz, CD3OD): δ -3.6 (2-OSi(CH3)2C(CH3)3), 18.2 (5’-C), 19.3 (2-
OSi(CH3)2C(CH3)3), 20.5 (6-Me), 24.2 (1’-C), 25.8 (4’-C), 26.5 (2-OSi(CH3)2C(CH3)3), 52.1 (1-
COOCH3), 111.9 (5-C), 118.8 (1-C), 119.1 (3-C), 124.6 (2’-C), 131.7 (3’-C), 136.7 (6-C), 
153.2 (2-C), 159.1 (4-C), 171.0 (1-COOCH3). EIMS: m/z 349 (5), 333 (6), 307 (100), 293 
(11), 251 (36). ESIMS: m/z 387 [M+Na]+ (44), 365 (36), 333 (100), 289 (14). HREIMS: m/z 
349.1835 (calculated for C19H29O4Si 349.1835), 307.1364 (calculated for C16H23O4Si 
307.1366). HRESIMS: m/z 387.1970 (calculated for C20H32O4SiNa 387.1968), 365.2148 
(calculated for C20H33O4Si 365.2148). 
methyl 2,4-dihydroxy-6-methyl-3-(3’-methylbut-2’-en-1’-
yl)benzoate (3.45). A solution of compound 3.44 (151 mg, 0.42 
mmol) in anhydrous THF (9 mL) was added to a oven-dried 2-neck 
round bottom flask. Then tetra-n-butylammonium fluoride solution 
(1M in THF, 1.5 eq., 0.68 mL, 0.68 mmol) was added dropwise to the flask, and the 
reaction mixture was stirred for 0.5 h under an argon atmosphere. The reaction was 
quenched by adding water, the reaction mixture was extracted with EtOAc three times. 
The combined organic layer was washed with saturated NH4Cl aqueous solution, dried 
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over Na2SO4 before concentration in vacuo, the residue was subjected to flash column 
chromatography on silica using 20% EtOAc in petroleum ether as eluent to return the 
title compound as a white solid (79%, 83 mg, 0.33 mmol).19 1H NMR (400 MHz, CD3OD): 
δ 1.64 (3H, s, 4’-H), 1.75 (3H, s, 5’-H), 2.41 (3H, s, 6-Me), 3.26 (2H, d, J= 7.1 Hz, 1’-H), 3.87 
(3H, s, 1-COOCH3), 5.19 (1H, t, J= 7.1 Hz, 2’-H), 6.20 (1H, s, 5-H). 13C NMR (100 MHz, 
CD3OD): δ 17.9 (5’-C), 22.8 (1’-C), 24.4 (6-Me), 25.9 (4’-C), 52.0 (1-COOCH3), 105.1 (1-C), 
111.7 (5-C), 114.1 (3-C), 124.0 (2’-C), 131.5 (3’-C), 141.2 (6-C), 161.2 (4-C), 164.0 (2-C), 
174.0 (1-COOCH3). EIMS: m/z 250 [M]·+ (76), 218 (76), 203 (52), 190 (90), 175 (100), 163 
(94), 147 (16). HREIMS: m/z 250.1205 (calculated for C14H18O4 250.1205). 
methyl 6-((tert-butyldimethylsilyl)oxy)-4-hydroxy-2-methyl-3-
(3’-methylbut-2’-en-1’-yl)benzoate (3.46). A solution of 
compound 3.42 (140 mg, 0.42 mmol) in anhydrous 
trimethylethylene solution (2M in THF, 100 eq., 21.0 mL, 42.00 
mmol) was added to a oven-dried and air-free 2-neck round bottom flask, the solution 
at 0 °C was then exposed to a stream of argon. After that, Grubb’s 2nd generation 
catalyst (5%, 18 mg, 0.02 mmol) was added, and the reaction mixture was stirred at 
room temperature under an argon atmosphere. The reaction was monitored by TLC and 
GC-MS, and was continued until the starting material was consumed. The reaction 
mixture was concentrated in vacuo and the residue was subjected to flash column 
chromatography on silica using 25% EtOAc in petroleum ether as eluent to return the 
title compound as a viscous yellow oil (99%, 153 mg, 0.42 mmol). 1H NMR (400 MHz, 
CD3OD): δ 0.21 (6H, s, 6-OSi(CH3)2C(CH3)3), 0.96 (9H, s, 6-OSi(CH3)2C(CH3)3), 1.67 (3H, s, 
4’-H), 1.75 (3H, s, 5’-H), 2.10 (3H, s, 2-Me), 3.27 (2H, d, J= 6.7 Hz, 1’-H), 3.80 (3H, s, 1-
COOCH3), 5.02 (1H, t, J= 6.7 Hz, 2’-H), 6.28 (1H, s, 5-H). 13C NMR (100 MHz, CD3OD): δ -
4.2 (6-OSi(CH3)2C(CH3)3), 16.7 (2-Me), 17.9 (5’-C), 18.9 (6-OSi(CH3)2C(CH3)3), 25.6 (1’-C), 
25.9 (4’-C), 26.1 (6-OSi(CH3)2C(CH3)3), 52.4 (1-COOCH3), 104.6 (5-C), 120.0 (1-C), 121.5 
(3-C), 124.2 (2’-C), 131.7 (3’-C), 136.5 (2-C), 152.2 (6-C), 157.7 (4-C), 171.9 (1-COOCH3). 
ESIMS: m/z 387 [M+Na]+ (66), 365 (23), 333 (100), 319 (13), 289 (5). HRESIMS: m/z 
387.1969 (calculated for C20H32O4SiNa 387.1968), 365.2145 (calculated for C20H33O4Si 
365.2148). 
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methyl 4,6-dihydroxy-2-methyl-3-(3’-methylbut-2’-en-1’-
yl)benzoate (3.47). A solution of compound 3.46 (148 mg, 0.41 
mmol) in anhydrous THF (8 mL) was added to a oven-dried 2-neck 
round bottom flask. Then tetra-n-butylammonium fluoride 
solution (1M in THF, 2.0 eq., 0.82 mL, 0.82 mmol) was added dropwise to the flask, and 
the reaction mixture was stirred for 0.5 h under an argon atmosphere. The reaction was 
quenched by adding water, the reaction mixture was extracted with EtOAc three times. 
The combined organic layer was washed with saturated NH4Cl aqueous solution, dried 
over Na2SO4 before concentration in vacuo, the residue was subjected to flash column 
chromatography on silica using 20% EtOAc in petroleum ether as eluent to return the 
title compound as a white solid (99%, 105 mg, 0.42 mmol). 1H NMR (400 MHz, CD3OD): 
δ 1.67 (3H, s, 4’-H), 1.75 (3H, s, 5’-H), 2.34 (3H, s, 2-Me), 3.29 (2H, d, J= 6.9 Hz, 1’-H), 3.88 
(3H, s, 1-COOCH3), 5.00 (1H, t, J= 6.9 Hz, 2’-H), 6.22 (1H, s, 5-H). 13C NMR (100 MHz, 
CD3OD): δ 17.9 (5’-C), 18.4 (2-Me), 25.7 (1’-C), 25.9 (4’-C), 52.1 (1-COOCH3), 101.2 (5-C), 
108.3 (1-C), 121.6 (3-C), 124.4 (2’-C), 131.6 (3’-C), 140.8 (2-C), 161.1 (4-C), 161.5 (6-C), 
173.3 (1-COOCH3). EIMS: m/z 250 [M]·+ (77), 218 (83), 203 (43), 175 (20), 163 (100), 150 
(14). ESIMS: m/z 251 [M+H]+ (42), 219 (100), 207 (20), 195 (15), 163 (11). HREIMS: m/z 
250.1212 (calculated for C14H18O4 250.1205). HRESIMS: m/z 251.1284 (calculated for 
C14H19O4 251.1283). 
methyl 7-hydroxy-2,2,5-trimethylchromane-6-carboxylate (3.48). A 
solution of compound 3.47 (22 mg, 0.09 mmol) in anhydrous THF (2 mL) 
was added to a round bottom flask. Then 1M HCl aqueous solution (2 
mL) was added to the flask, and the reaction mixture was stirred and 
refluxed overnight. The reaction mixture was diluted by water and extracted with EtOAc. 
The combined organic layer was washed with deionised water, dried over Na2SO4 before 
concentration in vacuo, the residue was subjected to flash column chromatography on 
silica using 15% EtOAc in petroleum ether as eluent to return the title compound as a 
white solid (92%, 20 mg, 0.08 mmol). 1H NMR (400 MHz, CD3OD): δ 1.29 (6H, s, 2-Me), 
1.82 (2H, t, J= 6.9 Hz, 3-H), 2.31 (3H, s, 5-Me), 2.61 (2H, t, J= 6.9 Hz, 4-H), 3.88 (3H, s, 1-
COOCH3), 6.12 (1H, s, 8-H). 13C NMR (100 MHz, CD3OD): δ 17.6 (5-Me), 21.4 (4-C), 26.8 
(2-Me), 34.0 (3-C), 52.3 (1-COOCH3), 75.4 (2-C), 103.2 (8-C), 110.4 (6-C), 113.8 (5a-C), 
140.3 (5-C), 159.3 (8a-C), 160.2 (7-C), 172.8 (1-COOCH3). EIMS: m/z 250 [M]·+ (53), 232 
3
5
1
OH
OH
COOMe
1'3'
5'
5a
8a
8
765 OH
COOMe
4
3 2 O
Chapter 3: Synthesis of Grifolin Analogues 89 
(8), 218 (90), 203 (21), 195 (26), 175 (10), 163 (100), 134 (16). HREIMS: m/z 250.1205 
(calculated for C14H18O4 250.1205). 
methyl 3-allyl-2,4-dihydroxy-6-methylbenzoate (3.49). A solution of 
compound 3.43 (220 mg, 0.65 mmol) in anhydrous THF (13 mL) was 
added to a oven-dried 2-neck round bottom flask. Then tetra-n-
butylammonium fluoride solution (1M in THF, 1.5 eq., 0.98 mL, 0.98 
mmol) was added dropwise to the flask, and the reaction mixture was stirred for 0.5 h 
under an argon atmosphere. The reaction was quenched by adding water, the reaction 
mixture was extracted with EtOAc three times. The combined organic layer was washed 
with saturated NH4Cl aqueous solution, dried over Na2SO4 before concentration in vacuo, 
the residue was subjected to flash column chromatography on silica using 40% EtOAc in 
petroleum ether as eluent to return the title compound as a white solid (98%, 141 mg, 
0.64 mmol). 1H NMR (400 MHz, CDCl3): δ 2.47 (3H, s, 6-Me), 3.46 (2H, d, J= 6.1 Hz, 1’-H), 
3.92 (3H, s, 1-COOCH3), 5.09-5.17 (2H, m, 3’-H), 5.48 (1H, s, 4-OH), 5.94-6.04 (1H, m, 2’-
H), 6.24 (1H, s, 5-H), 12.07 (1H, s, 2-OH). 13C NMR (100 MHz, CDCl3): δ 24.3 (6-Me), 27.3 
(1’-C), 52.0 (1-COOCH3), 105.6 (1-C), 110.1 (3-C), 111.3 (5-C), 115.9 (3’-C), 136.0 (2’-C), 
141.4 (6-C), 159.0 (4-C), 162.9 (2-C), 172.7 (1-COOCH3). EIMS: m/z 222 [M]·+ (75), 190 
(65), 175 (67), 162 (100), 147 (17), 91 (45). HREIMS: m/z 222.0893 (calculated for 
C12H14O4 222.0892). 
4-hydroxy-2,6-dimethyl-2,3-dihydrobenzofuran-7-carboxylic acid 
(3.50). Compound 3.49 (50 mg, 0.23 mmol) was dissolved in 
concentrated H2SO4 (5 mL) at 0 °C, this solution was stirred at the same 
temperature overnight. The reaction mixture was poured into ice-
water (20 mL) and rapidly extracted with DCM three times. The combined organic layer 
was washed with saturated NaCO3 aqueous solution. The aqueous layer was acidified by 
2 M HCl to pH=1, then extracted with DCM three times. The combined organic layer was 
washed with deionised water, dried over Na2SO4 before concentration in vacuo, the 
residue was subjected to flash column chromatography on silica using 55% EtOAc in 
petroleum ether containing 0.2% acetic acid as eluent to return the title compound as a 
pale yellow solid (trace amount, less than 2%). 1H NMR (800 MHz, CDCl3): δ 1.57 (3H, d, 
J= 6.3 Hz, 2-Me), 2.60 (3H, s, 6-Me), 2.80-2.82 (1H, m, 3-Ha), 3.32-3.35 (1H, m, 3-Hb), 
5.21-5.24 (1H, m, 2-H), 6.30 (1H, s, 5-H). 13C NMR (200 MHz, CDCl3): δ 22.0 (2-Me), 22.8 
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(6-Me), 33.5 (3-C), 83.7 (2-C), 105.1 (7-C), 110.2 (4a-C), 113.1 (5-C), 145.5 (6-C), 155.5 
(4-C), 161.4 (7a-C), 165.0 (1-COOH). ESIMS: m/z 231 [M+Na]+ (100), [M+H]+ 209 (17), 191 
(17). HREIMS: m/z 231.0633 (calculated for C11H12O4Na 231.0633). 
6-hydroxy-2,4-dimethyl-2,3-dihydrobenzofuran-5-carboxylic acid (3.51). 
Compound 3.40 (50 mg, 0.23 mmol) was dissolved in concentrated 
H2SO4 (5 mL) at 0 °C, this solution was stirred at the same temperature 
overnight. The reaction mixture was poured into ice-water (20 mL) and 
rapidly extracted with DCM three times. The combined organic layer was washed with 
saturated NaCO3 aqueous solution. The aqueous layer was acidified by 2 M HCl to pH=1, 
then extracted with DCM three times. The combined organic layer was washed with 
deionised water, dried over Na2SO4 before concentration in vacuo, the residue was 
subjected to flash column chromatography on silica using 55% EtOAc in petroleum ether 
containing 0.2% acetic acid as eluent to return the title compound as a pale yellow solid 
(trace amount, less than 2%). 1H NMR (800 MHz, CDCl3): δ 1.48 (3H, d, J= 6.3 Hz, 2-Me), 
2.47 (3H, s, 4-Me), 2.67-2.73 (1H, m, 3-Ha), 3.21-3.26 (1H, m, 3-Hb), 4.96-5.01 (1H, m, 2-
H), 6.26 (1H, s, 7-H), 11.56 (1H, s, 6-OH). 13C NMR (200 MHz, CDCl3): δ 20.5 (4-Me), 22.1 
(2-Me), 35.9 (3-C), 81.0 (2-C), 96.3 (7-C), 103.4 (5-C), 120.5 (4a-C), 139.1 (4-C), 165.2 (7a-
C), 167.0 (6-C), 176.2 (1-COOH). ESIMS: m/z 231 [M+Na]+ (79), [M+H]+ 209 (55), 191 
(100). HREIMS: m/z 231.0633 (calculated for C11H12O4Na 231.0633). 
4-hydroxy-2,6-dimethyl-2,3-dihydrobenzofuran-5-carboxylic acid (3.52). 
This compound was isolated from the same reaction mixture generating 
3.51 as a pale yellow solid (tiny amount, less than 2%). 1H NMR (800 MHz, 
CDCl3): δ 1.48 (3H, d, J= 6.3 Hz, 2-Me), 2.57 (3H, s, 6-Me), 2.73-2.78 (1H, 
m, 3-Ha), 3.27-3.33 (1H, m, 3-Hb), 5.02-5.08 (1H, m, 2-H), 6.26 (1H, s, 7-H), 11.52 (1H, s, 
4-OH). 13C NMR (200 MHz, CDCl3): δ 22.1 (2-Me), 24.9 (6-Me), 33.8 (3-C), 82.1 (2-C), 
104.1 (5-C), 106.3 (7-C), 111.1 (4a-C), 145.8 (6-C), 161.4 (4-C), 165.8 (7a-C), 175.6 (1-
COOH). ESIMS: m/z 231 [M+Na]+ (78), [M+H]+ 209 (60), 191 (100). HREIMS: m/z 
209.0814 (calculated for C11H13O4 209.0814). 
methyl 3-allyl-2-hydroxy-4-methoxy-6-methylbenzoate (3.53). A 
solution of compound 3.49 (107 mg, 0.48 mmol) in anhydrous 
acetone (25 mL) was added to a oven-dried 2-neck round bottom 
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flask. Then potassium carbonate (1.3 eq., 97 mg, 0.70 mmol) was added to the flask. 
After that dimethylsulfate (1.3 eq., 67 μl, 0.70 mmol) was added to a dropping funnel 
contaning 10 mL anhydrous acetone, and added dropwise to the flask, and the reaction 
mixture was stirred and refluxed under an argon atmosphere. The reaction was 
monitored by TLC and GC-MS, and was continued until the starting material was 
consumed. The reaction mixture was concentrated in vacuo, the residue was suspended 
in water and acidified by 1 M HCl, then extracted with EtOAc three times. The combined 
organic layer was washed with deionised water and dried over Na2SO4 before 
concentration in vacuo, the residue was subjected to flash column chromatography on 
silica using 25% EtOAc in petroleum ether as eluent to return the title compound as 
white crystals (76%, 86 mg, 0.36 mmol). 1H NMR (400 MHz, CDCl3): δ 2.53 (3H, s, 6-Me), 
3.39 (2H, dt, J= 6.1, 1.6 Hz, 1’-H), 3.85 (3H, s, 4-OMe), 3.92 (3H, s, 1-COOCH3), 4.93-5.01 
(2H, m, 3’-H), 5.91-6.01 (1H, m, 2’-H), 6.29 (1H, s, 5-H), 11.81 (1H,s, 2-OH). 13C NMR (100 
MHz, CDCl3): δ 24.8 (6-Me), 27.1 (1’-C), 52.0 (1-COOCH3), 55.7 (4-OMe), 105.9 (1-C), 
106.3 (5-C), 113.0 (3-C), 114.3 (3’-C), 136.5 (2’-C), 141.2 (6-C), 161.4 (4-C), 162.1 (2-C), 
172.6 (1-COOCH3). EIMS: m/z 236 [M]·+ (91), 221 (5), 204 (100), 189 (84), 176 (98), 161 
(75). HREIMS: m/z 236.1048 (calculated for C13H16O4 236.1049). 
3-allyl-2-hydroxy-4-methoxy-6-methylbenzoic acid (3.54). A solution 
of compound 3.53 (29 mg, 0.12 mmol) in H2O/MeOH/THF (1:1:4) (6 
mL) was added to a round bottom flask. Then potassium hydroxide 
(20 eq., 134 mg, 2.4 mmol) was added to the flask, and the reaction 
mixture was stirred and refluxed for 4 h. The reaction mixture was diluted by water and 
acidified by 1 M HCl, then extracted with DCM three times. The combined organic layer 
was washed with saturated NaCO3 aqueous soluton three times. The combined aqueous 
layer was acidified by 2 M HCl to pH=1 then extracted with DCM three times. The 
combined organic layer was dried over Na2SO4 and concentrated in vacuo, the residue 
was subjected to flash column chromatography on silica using 60% EtOAc in petroleum 
ether containing 0.2% acetic acid as eluent to return the title compound as a white solid 
(99%, 28 mg, 0.12 mmol). 1H NMR (400 MHz, CDCl3): δ 2.60 (3H, s, 6-Me), 3.40 (2H, d, J= 
6.1 Hz, 1’-H), 3.87 (3H, s, 4-OMe), 4.94-5.02 (2H, m, 3’-H), 5.90-6.00 (1H, m, 2’-H), 6.34 
(1H, s, 5-H), 11.61 (1H,s, 2-OH). 13C NMR (100 MHz, CDCl3): δ 24.9 (6-Me), 27.0 (1’-C), 
55.8 (4-OMe), 104.4 (1-C), 106.7 (5-C), 113.2 (3-C), 114.4 (3’-C), 136.3 (2’-C), 142.9 (6-C), 
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162.4 (4-C), 163.1 (2-C), 175.6 (1-COOH). ESIMS: m/z 245 [M+Na]+ (47), 227 (25), 205 
(100), 130 (31). HREIMS: m/z 245.0790 (calculated for C12H14O4Na 245.0790). 
methyl 3-allyl-6-hydroxy-4-methoxy-2-methylbenzoate (3.55). A 
solution of compound 3.40 (10 mg, 0.05 mmol) in anhydrous 
acetone (10 mL) was added to a oven-dried 2-neck round bottom 
flask. Then potassium carbonate (1.3 eq., 9 mg, 0.07 mmol) was 
added to the flask. After that dimethylsulfate (1.3 eq., 7 μl, 0.07 mmol) was added to a 
dropping funnel contaning 5 mL anhydrous acetone, and added dropwise to the flask, 
and the reaction mixture was stirred and refluxed under an argon atmosphere. The 
reaction was monitored by TLC and GC-MS, and was continued until the starting material 
was consumed. The reaction mixture was concentrated in vacuo, the residue was 
suspended in water and acidified by 1 M HCl, then extracted with EtOAc three times. 
The combined organic layer was washed with deionised water and dried over Na2SO4 
before concentration in vacuo, the residue was subjected to flash column 
chromatography on silica using 25% EtOAc in petroleum ether as eluent to return the 
title compound as a pale yellow oil (99%, 11 mg, 0.05 mmol). 1H NMR (400 MHz, CDCl3): 
δ 2.43 (3H, s, 2-Me), 3.38 (2H, dt, J= 5.7, 1.6 Hz, 1’-H), 3.81 (3H, s, 4-OMe), 3.92 (3H, s, 
1-COOCH3), 4.83-4.96 (2H, m, 3’-H), 5.81-5.91 (1H, m, 2’-H), 6.36 (1H, s, 5-H), 11.43 (1H,s, 
6-OH). 13C NMR (100 MHz, CDCl3): δ 18.5 (2-Me), 29.8 (1’-C), 52.0 (1-COOCH3), 55.7 (4-
OMe), 97.2 (5-C), 106.0 (1-C), 114.4 (3’-C), 119.6 (3-C), 136.3 (2’-C), 140.6 (2-C), 162.4 
(4-C), 163.2 (6-C), 172.5 (1-COOCH3). EIMS: m/z 236 [M]·+ (56), 204 (100), 189 (24), 177 
(18), 161 (15). HREIMS: m/z 236.1050 (calculated for C13H16O4 236.1049). 
3-allyl-6-hydroxy-4-methoxy-2-methylbenzoic acid (3.56). A 
solution of compound 3.55 (32 mg, 0.14 mmol) in H2O/MeOH/THF 
(1:1:4) (6 mL) was added to a round bottom flask. Then potassium 
hydroxide (20 eq., 157 mg, 2.8 mmol) was added to the flask, and 
the reaction mixture was stirred and refluxed for 4 h. The reaction mixture was diluted 
by water and acidified by 1 M HCl, then extracted with DCM three times. The combined 
organic layer was washed with saturated NaCO3 aqueous soluton three times. The 
combined aqueous layer was acidified by 2 M HCl to pH=1 then extracted with DCM 
three times. The combined organic layer was dried over Na2SO4 and concentrated in 
vacuo, the residue was subjected to flash column chromatography on silica using 60% 
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EtOAc in petroleum ether containing 0.2% acetic acid as eluent gives the title compound 
as a white solid (99%, 31 mg, 0.14 mmol). 1H NMR (400 MHz, CDCl3): δ 2.53 (3H, s, 2-
Me), 3.40 (2H, d, J= 5.5 Hz, 1’-H), 3.84 (3H, s, 4-OMe), 4.85-4.98 (2H, m, 3’-H), 5.83-5.92 
(1H, m, 2’-H), 6.39 (1H, s, 5-H), 11.35 (1H,s, 6-OH). 13C NMR (100 MHz, CDCl3): δ 18.6 (2-
Me), 29.8 (1’-C), 55.9 (4-OMe), 97.4 (5-C), 104.5 (1-C), 114.6 (3’-C), 120.3 (3-C), 136.2 
(2’-C), 142.3 (2-C), 163.5 (4-C), 164.6 (6-C), 176.4 (1-COOH). ESIMS: m/z 245 [M+Na]+ 
(53), 227 (66), 205 (100). HRESIMS: m/z 245.0793 (calculated for C12H14O4Na 245.0790). 
methyl 2-hydroxy-4-methoxy-6-methyl-3-(3’-methylbut-2’-en-1’-
yl)benzoate (3.57). A solution of compound 3.45 (83 mg, 0.33 mmol) 
in anhydrous acetone (10 mL) was added to a oven-dried 2-neck 
round bottom flask. Then potassium carbonate (1.0 eq., 46 mg, 
0.33 mmol) was added to the flask. After that dimethylsulfate (1.0 eq., 31 μl, 0.33 mmol) 
was added to a dropping funnel contaning 5 mL anhydrous acetone, and added dropwise 
to the flask, the reaction mixture was stirred and refluxed under an argon atmosphere. 
The reaction was monitored by TLC and GC-MS, and was continued until the starting 
material was consumed. The reaction mixture was concentrated in vacuo, the residue 
was suspended in water and acidified by 1 M HCl, then extracted with EtOAc three times. 
The combined organic layer was washed with deionised water and dried over Na2SO4 
before concentration in vacuo, the residue was subjected to flash column 
chromatography on silica using 20% EtOAc in petroleum ether as eluent to return the 
title compound as a white solid (70%, 61 mg, 0.23 mmol).46 1H NMR (400 MHz, CD3OD): 
δ 1.63 (3H, s, 4’-H), 1.74 (3H, s, 5’-H), 2.50 (3H, s, 6-Me), 3.26 (2H, d, J= 7.2 Hz, 1’-H), 3.83 
(3H, s, 4-OMe), 3.90 (3H, s, 1-COOCH3), 5.14 (1H, t, J= 7.2 Hz, 2’-H), 6.38 (1H, s, 5-H). 13C 
NMR (100 MHz, CD3OD): δ 17.8 (5’-C), 22.7 (1’-C), 24.7 (6-Me), 25.9 (4’-C), 52.2 (1-
COOCH3), 56.0 (4-OMe), 106.7 (1-C), 107.2 (5-C), 115.6 (3-C), 123.8 (2’-C), 131.7 (3’-C), 
141.9 (6-C), 162.6 (4-C), 162.7 (2-C), 173.8 (1-COOCH3). EIMS: m/z 264 [M]·+ (59), 250 
(19), 232 (57), 217 (57), 204 (79), 189 (100), 177 (74), 91 (16). HREIMS: m/z 264.1362 
(calculated for C15H20O4 264.1362). 
methyl 6-hydroxy-4-methoxy-2-methyl-3-(3’-methylbut-2’-en-1’-
yl)benzoate (3.58). A solution of compound 3.47 (102 mg, 0.41 
mmol) in anhydrous acetone (10 mL) was added to a oven-dried 
2-neck round bottom flask. Then potassium carbonate (1.0 eq., 
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57 mg, 0.41 mmol) was added to the flask. After that dimethylsulfate (1.0 eq., 39 μl, 0.41 
mmol) was added to a dropping funnel contaning 5 mL anhydrous acetone, and added 
dropwise to the flask, the reaction mixture was stirred and refluxed under an argon 
atmosphere. The reaction was monitored by TLC and GC-MS, and was continued until 
the starting material was consumed. The reaction mixture was concentrated in vacuo, 
the residue was suspended in water and acidified by 1 M HCl, then extracted with EtOAc 
three times. The combined organic layer was washed with deionised water and dried 
over Na2SO4 before concentration in vacuo, the residue was subjected to flash column 
chromatography on silica using 20% EtOAc in petroleum ether as eluent gives the title 
compound as a transparent oil (57%, 62 mg, 0.23 mmol). 1H NMR (400 MHz, CD3OD): δ 
1.64 (3H, s, 4’-H), 1.73 (3H, s, 5’-H), 2.31 (3H, s, 2-Me), 3.26 (2H, d, J= 6.5 Hz, 1’-H), 3.78 
(3H, s, 4-OMe), 3.87 (3H, s, 1-COOCH3), 4.93 (1H, t, J= 6.5 Hz, 2’-H), 6.33 (1H, s, 5-H). 13C 
NMR (100 MHz, CD3OD): δ 17.9 (5’-C), 18.3 (2-Me), 25.6 (1’-C), 25.9 (4’-C), 52.3 (1-
COOCH3), 56.0 (4-OMe), 97.8 (5-C), 109.2 (1-C), 122.5 (3-C), 124.1 (2’-C), 131.8 (3’-C), 
139.8 (2-C), 161.6 (6-C), 162.6 (4-C), 173.1 (1-COOCH3). EIMS: m/z 264 [M]·+ (83), 249 
(17), 232 (100), 217 (99), 196 (13), 189 (34), 177 (22), 164 (37), 149 (37). HREIMS: m/z 
264.1363 (calculated for C15H20O4 264.1362). 
methyl 4,6-dimethoxy-2-methyl-3-(3’-methylbut-2’-en-1’-
yl)benzoate (3.59). This compound was isolated from the same 
reaction mixture generating 3.58 as a transparent oil (4%, 5 mg, 
0.02 mmol). 1H NMR (400 MHz, CD3OD): δ 1.66 (3H, s, 4’-H), 1.75 
(3H, s, 5’-H), 2.12 (3H, s, 2-Me), 3.28 (2H, d, J= 6.7 Hz, 1’-H), 3.80 (3H, s, 6-OMe), 3.83 
(3H, s, 1-COOCH3), 3.84 (3H, s, 4-OMe), 4.96 (1H, t, J= 6.5 Hz, 2’-H), 6.50 (1H, s, 5-H). 13C 
NMR (100 MHz, CD3OD): δ 16.6 (2-Me), 17.9 (5’-C), 25.5 (1’-C), 25.9 (4’-C), 52.5 (1-
COOCH3), 56.2 (4-OMe), 56.4 (6-OMe), 94.4 (5-C), 118.1 (1-C), 122.2 (3-C), 123.9 (2’-C), 
131.9 (3’-C), 136.1 (2-C), 157.1 (6-C), 160.3 (4-C), 171.6 (1-COOCH3). EIMS: m/z 278 [M]·+ 
(100), 263 (91), 247 (50), 231 (33), 210 (33), 189 (26), 179 (26), 149 (6). HREIMS: m/z 
278.1519 (calculated for C16H22O4 278.1518). 
3-methoxy-2,5-dimethylphenol (3.60). This compound was isolated 
from the same reaction mixture generating 3.16 as a transparent oil 
(trace amount, less than 2%).47 1H NMR (400 MHz, CDCl3): δ 2.07 (3H, s, 
2-Me), 2.27 (3H, s, 5-Me), 3.80 (3H, s, 3-OMe), 6.29 (2H, s, 4,6-H). 13C NMR (100 MHz, 
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CDCl3): δ 7.9 (2-Me), 21.6 (5-Me), 55.8 (3-OMe), 104.2 (4-C), 108.8 (6-C), 109.0 (2-C), 
136.7 (5-C), 154.4 (1-C), 158.6 (3-C). EIMS: m/z 152 [M]·+ (100), 137 (41), 121 (31). 
2,6-dimethyl-2,3-dihydrobenzofuran-4-ol (3.61). This compound was 
isolated from the same reaction mixture generating 3.36 as a pale 
yellow solid (trace amount, less than 1%).48 1H NMR (800 MHz, CDCl3): 
δ 1.46 (3H, d, J= 6.3 Hz, 2-Me), 2.24 (3H, s, 6-Me), 2.69-2.71 (1H, m, 3-Ha), 3.21-3.24 (1H, 
m, 3-Hb), 4.93-4.96 (1H, m, 2-H), 6.13 (1H, s, 6-H), 6.22 (1H, s, 7-H). 13C NMR (200 MHz, 
CDCl3): δ 21.7 (6-Me), 22.0 (2-Me), 34.0 (3-C), 80.3 (2-C), 103.4 (7-C), 108.3 (5-C), 109.6 
(4a-C), 139.8 (6-C), 152.2 (4-C), 161.5 (7a-C). EIMS: m/z 164 [M]·+ (36), 147 (100), 103 
(86). HREIMS: m/z 164.0839 (calculated for C10H12O2 164.0837). 
methyl 2-hydroxy-4-methoxy-6-methylbenzoate (3.62). This compound 
was isolated from the same reaction mixture generating 3.38 as a white 
solid (trace amount, less than 1%).49 1H NMR (400 MHz, CDCl3): δ 2.49 
(3H, s, 6-Me), 3.79 (3H, s, 4-OMe), 3.92 (3H, s, 1-COOCH3), 6.28 (1H, s, 3-
H), 6.32 (1H, s, 5-H). 13C NMR (100 MHz, CDCl3): δ 24.5 (6-Me), 51.9 (1-COOCH3), 55.4 (4-
OMe), 98.8 (3-C), 105.4 (1-C), 111.5 (5-C), 143.2 (6-C), 164.1 (2-C), 165.7 (4-C), 172.3 (1-
COOCH3). EIMS: m/z 196 [M]·+ (50), 164 (100), 136 (46), 121 (24), 93 (25). HREIMS: m/z 
196.0737 (calculated for C10H12O4 196.0736). 
methyl 2,4-dimethoxy-6-methylbenzoate (3.63). This compound was 
isolated from the same reaction mixture generating 3.38 as a viscous 
pale yellow oil (trace amount, less than 1%).24 1H NMR (400 MHz, CDCl3): 
δ 2.28 (3H, s, 6-Me), 3.79 (6H, s, 2,4-OMe), 3.88 (3H, s, 1-COOCH3), 6.31 
(2H, s, 3,5-H). 13C NMR (100 MHz, CDCl3): δ 20.1 (6-Me), 52.1 (1-COOCH3), 55.5 (2 or 4-
OMe), 56.0 (2 or 4-OMe), 96.3 (3-C), 106.8 (1-C), 116.5 (5-C), 138.4 (6-C), 158.3 (2 or 4-
C), 161.5 (2 or 4-C), 168.8 (1-COOCH3). EIMS: m/z 210 [M]·+ (43), 179 (100). HREIMS: m/z 
210.0892 (calculated for C11H14O4 210.0892). 
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3.6 Appendix NMR Spectra of Novel Compounds 
Figure 3-4 1H NMR Spectrum of Compound 3.21 (400 MHz, CDCl3) 
Figure 3-5 13C NMR Spectrum of Compound 3.21 (100 MHz, CDCl3) 
Figure 3-6 1H NMR Spectrum of Compound 3.22 (400 MHz, CDCl3) 
Figure 3-7 13C NMR Spectrum of Compound 3.22 (100 MHz, CDCl3) 
Figure 3-8 1H NMR Spectrum of Compound 3.23 (400 MHz, CDCl3) 
Figure 3-9 13C NMR Spectrum of Compound 3.23 (100 MHz, CDCl3) 
Figure 3-10 1H NMR Spectrum of Compound 3.24 (400 MHz, CDCl3) 
Figure 3-11 13C NMR Spectrum of Compound 3.24 (100 MHz, CDCl3) 
Figure 3-12 1H NMR Spectrum of Compound 3.25 (400 MHz, CDCl3) 
Figure 3-13 13C NMR Spectrum of Compound 3.25 (100 MHz, CDCl3) 
Figure 3-14 1H NMR Spectrum of Compound 3.29 (400 MHz, CDCl3) 
Figure 3-15 13C NMR Spectrum of Compound 3.29 (100 MHz, CDCl3) 
Figure 3-16 1H NMR Spectrum of Compound 3.31 (400 MHz, CDCl3) 
Figure 3-17 13C NMR Spectrum of Compound 3.31 (100 MHz, CDCl3) 
Figure 3-18 1H NMR Spectrum of Compound 3.33 (400 MHz, CDCl3) 
Figure 3-19 13C NMR Spectrum of Compound 3.33 (100 MHz, CDCl3) 
Figure 3-20 1H NMR Spectrum of Compound 3.35 (400 MHz, CDCl3) 
Figure 3-21 13C NMR Spectrum of Compound 3.35 (100 MHz, CDCl3) 
Figure 3-22 1H NMR Spectrum of Compound 3.36 (400 MHz, CDCl3) 
Figure 3-23 13C NMR Spectrum of Compound 3.36 (100 MHz, CDCl3) 
Figure 3-24 1H NMR Spectrum of Compound 3.2 (400 MHz, CD3OD) 
Figure 3-25 13C NMR Spectrum of Compound 3.2 (100 MHz, CD3OD) 
Figure 3-26 1H NMR Spectrum of Compound 3.6 (400 MHz, CD3OD) 
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Figure 3-27 13C NMR Spectrum of Compound 3.6 (100 MHz, CD3OD) 
Figure 3-28 1H NMR Spectrum of Compound 3.7 (400 MHz, CD3OD) 
Figure 3-29 13C NMR Spectrum of Compound 3.7 (100 MHz, CD3OD) 
Figure 3-30 1H NMR Spectrum of Compound 3.40 (400 MHz, CDCl3) 
Figure 3-31 13C NMR Spectrum of Compound 3.40 (100 MHz, CDCl3) 
Figure 3-32 1H NMR Spectrum of Compound 3.41 (400 MHz, CDCl3) 
Figure 3-33 13C NMR Spectrum of Compound 3.41 (100 MHz, CDCl3) 
Figure 3-34 1H NMR Spectrum of Compound 3.42 (400 MHz, CDCl3) 
Figure 3-35 13C NMR Spectrum of Compound 3.42 (100 MHz, CDCl3) 
Figure 3-36 1H NMR Spectrum of Compound 3.43 (400 MHz, CDCl3) 
Figure 3-37 13C NMR Spectrum of Compound 3.43 (100 MHz, CDCl3) 
Figure 3-38 1H NMR Spectrum of Compound 3.44 (400 MHz, CD3OD) 
Figure 3-39 13C NMR Spectrum of Compound 3.44 (100 MHz, CD3OD) 
Figure 3-40 1H NMR Spectrum of Compound 3.46 (400 MHz, CD3OD) 
Figure 3-41 13C NMR Spectrum of Compound 3.46 (100 MHz, CD3OD) 
Figure 3-42 1H NMR Spectrum of Compound 3.47 (400 MHz, CD3OD) 
Figure 3-43 13C NMR Spectrum of Compound 3.47 (100 MHz, CD3OD) 
Figure 3-44 1H NMR Spectrum of Compound 3.48 (400 MHz, CD3OD) 
Figure 3-45 13C NMR Spectrum of Compound 3.48 (100 MHz, CD3OD) 
Figure 3-46 1H NMR Spectrum of Compound 3.49 (400 MHz, CDCl3) 
Figure 3-47 13C NMR Spectrum of Compound 3.49 (100 MHz, CDCl3) 
Figure 3-48 1H NMR Spectrum of Compound 3.50 (800 MHz, CDCl3) 
Figure 3-49 13C NMR Spectrum of Compound 3.50 (200 MHz, CDCl3) 
Figure 3-50 1H NMR Spectrum of Compound 3.51 (800 MHz, CDCl3) 
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Figure 3-51 13C NMR Spectrum of Compound 3.51 (200 MHz, CDCl3) 
Figure 3-52 1H NMR Spectrum of Compound 3.52 (800 MHz, CDCl3) 
Figure 3-53 13C NMR Spectrum of Compound 3.52 (200 MHz, CDCl3) 
Figure 3-54 1H NMR Spectrum of Compound 3.53 (400 MHz, CDCl3) 
Figure 3-55 13C NMR Spectrum of Compound 3.53 (100 MHz, CDCl3) 
Figure 3-56 1H NMR Spectrum of Compound 3.54 (400 MHz, CDCl3)  
Figure 3-57 13C NMR Spectrum of Compound 3.54 (100 MHz, CDCl3)  
Figure 3-58 1H NMR Spectrum of Compound 3.55 (400 MHz, CDCl3) 
Figure 3-59 13C NMR Spectrum of Compound 3.55 (100 MHz, CDCl3) 
Figure 3-60 1H NMR Spectrum of Compound 3.56 (400 MHz, CDCl3) 
Figure 3-61 13C NMR Spectrum of Compound 3.56 (100 MHz, CDCl3) 
Figure 3-62 1H NMR Spectrum of Compound 3.58 (400 MHz, CD3OD) 
Figure 3-63 13C NMR Spectrum of Compound 3.58 (100 MHz, CD3OD) 
Figure 3-64 1H NMR Spectrum of Compound 3.59 (400 MHz, CD3OD) 
Figure 3-65 13C NMR Spectrum of Compound 3.59 (100 MHz, CD3OD) 
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Figure 3-4 1H NMR Spectrum of Compound 3.21 (400 MHz, CDCl3) 
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Figure 3-5 13C NMR Spectrum of Compound 3.21 (100 MHz, CDCl3) 
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Figure 3-6 1H NMR Spectrum of Compound 3.22 (400 MHz, CDCl3) 
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Figure 3-7 13C NMR Spectrum of Compound 3.22 (100 MHz, CDCl3) 
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Figure 3-8 1H NMR Spectrum of Compound 3.23 (400 MHz, CDCl3) 
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Figure 3-9 13C NMR Spectrum of Compound 3.23 (100 MHz, CDCl3) 
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Figure 3-10 1H NMR Spectrum of Compound 3.24 (400 MHz, CDCl3) 
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Figure 3-11 13C NMR Spectrum of Compound 3.24 (100 MHz, CDCl3) 
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Figure 3-12 1H NMR Spectrum of Compound 3.25 (400 MHz, CDCl3) 
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Figure 3-13 13C NMR Spectrum of Compound 3.25 (100 MHz, CDCl3) 
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Figure 3-14 1H NMR Spectrum of Compound 3.29 (400 MHz, CDCl3) 
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Figure 3-15 13C NMR Spectrum of Compound 3.29 (100 MHz, CDCl3) 
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Figure 3-16 1H NMR Spectrum of Compound 3.31 (400 MHz, CDCl3) 
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Figure 3-17 13C NMR Spectrum of Compound 3.31 (100 MHz, CDCl3) 
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Figure 3-18 1H NMR Spectrum of Compound 3.33 (400 MHz, CDCl3) 
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Figure 3-19 13C NMR Spectrum of Compound 3.33 (100 MHz, CDCl3) 
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
f1 (ppm
)
20.4447
28.4811
55.3980
55.9976
56.0933
77.1600
96.5824
107.5435
107.7318
115.5200
139.5001
158.6915
159.1797
OMe
OMe
HO
MeO
3.33
Chapter 3: Synthesis of Grifolin Analogues 117 
 
Figure 3-20 1H NMR Spectrum of Compound 3.35 (400 MHz, CDCl3) 
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Figure 3-21 13C NMR Spectrum of Compound 3.35 (100 MHz, CDCl3) 
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Figure 3-22 1H NMR Spectrum of Compound 3.36 (400 MHz, CDCl3) 
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Figure 3-23 13C NMR Spectrum of Compound 3.36 (100 MHz, CDCl3) 
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Figure 3-24 1H NMR Spectrum of Compound 3.2 (400 MHz, CD3OD) 
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Figure 3-25 13C NMR Spectrum of Compound 3.2 (100 MHz, CD3OD) 
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Figure 3-26 1H NMR Spectrum of Compound 3.6 (400 MHz, CD3OD) 
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Figure 3-27 13C NMR Spectrum of Compound 3.6 (100 MHz, CD3OD) 
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Figure 3-28 1H NMR Spectrum of Compound 3.7 (400 MHz, CD3OD) 
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Figure 3-29 13C NMR Spectrum of Compound 3.7 (100 MHz, CD3OD) 
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Figure 3-30 1H NMR Spectrum of Compound 3.40 (400 MHz, CDCl3) 
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Figure 3-31 13C NMR Spectrum of Compound 3.40 (100 MHz, CDCl3) 
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Figure 3-32 1H NMR Spectrum of Compound 3.41 (400 MHz, CDCl3) 
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Figure 3-33 13C NMR Spectrum of Compound 3.41 (100 MHz, CDCl3) 
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Figure 3-34 1H NMR Spectrum of Compound 3.42 (400 MHz, CDCl3) 
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Figure 3-35 13C NMR Spectrum of Compound 3.42 (100 MHz, CDCl3) 
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Figure 3-36 1H NMR Spectrum of Compound 3.43 (400 MHz, CDCl3) 
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Figure 3-37 13C NMR Spectrum of Compound 3.43 (100 MHz, CDCl3) 
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Figure 3-38 1H NMR Spectrum of Compound 3.44 (400 MHz, CD3OD) 
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Figure 3-39 13C NMR Spectrum of Compound 3.44 (100 MHz, CD3OD) 
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Figure 3-40 1H NMR Spectrum of Compound 3.46 (400 MHz, CD3OD) 
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Figure 3-41 13C NMR Spectrum of Compound 3.46 (100 MHz, CD3OD) 
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Figure 3-42 1H NMR Spectrum of Compound 3.47 (400 MHz, CD3OD) 
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Figure 3-43 13C NMR Spectrum of Compound 3.47 (100 MHz, CD3OD) 
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Figure 3-44 1H NMR Spectrum of Compound 3.48 (400 MHz, CD3OD) 
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Figure 3-45 13C NMR Spectrum of Compound 3.48 (100 MHz, CD3OD) 
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Figure 3-46 1H NMR Spectrum of Compound 3.49 (400 MHz, CDCl3) 
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Figure 3-47 13C NMR Spectrum of Compound 3.49 (100 MHz, CDCl3) 
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Figure 3-48 1H NMR Spectrum of Compound 3.50 (800 MHz, CDCl3) 
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Figure 3-49 13C NMR Spectrum of Compound 3.50 (200 MHz, CDCl3) 
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Figure 3-50 1H NMR Spectrum of Compound 3.51 (800 MHz, CDCl3) 
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Figure 3-51 13C NMR Spectrum of Compound 3.51 (200 MHz, CDCl3) 
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Figure 3-52 1H NMR Spectrum of Compound 3.52 (800 MHz, CDCl3) 
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Figure 3-53 13C NMR Spectrum of Compound 3.52 (200 MHz, CDCl3) 
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Figure 3-54 1H NMR Spectrum of Compound 3.53 (400 MHz, CDCl3) 
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Figure 3-55 13C NMR Spectrum of Compound 3.53 (100 MHz, CDCl3) 
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Figure 3-56 1H NMR Spectrum of Compound 3.54 (400 MHz, CDCl3) 
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Figure 3-57 13C NMR Spectrum of Compound 3.54 (100 MHz, CDCl3) 
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Figure 3-58 1H NMR Spectrum of Compound 3.55 (400 MHz, CDCl3) 
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Figure 3-59 13C NMR Spectrum of Compound 3.55 (100 MHz, CDCl3) 
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Figure 3-60 1H NMR Spectrum of Compound 3.56 (400 MHz, CDCl3) 
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Figure 3-61 13C NMR Spectrum of Compound 3.56 (100 MHz, CDCl3) 
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Figure 3-62 1H NMR Spectrum of Compound 3.58 (400 MHz, CD3OD) 
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Figure 3-63 13C NMR Spectrum of Compound 3.58 (100 MHz, CD3OD) 
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Figure 3-64 1H NMR Spectrum of Compound 3.59 (400 MHz, CD3OD) 
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Figure 3-65 13C NMR Spectrum of Compound 3.59 (100 MHz, CD3OD) 
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Chapter 4: Antioxidant Assay of Grifolin Analogues 
4.1 Introduction 
4.1.1 Antioxidant Assay Mechanisms and Classifications 
With the increasing interest in antioxidant research, numerous methods have been 
established and developed to assess antioxidant activity, so far a large number of 
reviews and monographs regarding antioxidant assays are available.1-32 The brief 
description of various antioxidant assays as well as their advantages and disadvantages 
is given in this section, for more details the reader is referred to aforementioned 
references, in particular those cited here.9,10,12,17,19,24,26,27 Reagents, instruments and 
procedures vary a lot in antioxidant assays, however, all of them are based on two major 
reaction mechanisms, namely hydrogen atom transfer (HAT) and electron transfer (ET). 
As discussed in chapter one, an antioxidant has the property to inhibit formation of free 
radicals or interrupt propagation of the free radical.33 So the radical can be neutralised 
either by directly receiving a hydrogen from the antioxidant, which is the HAT 
mechanism, or by receiving an electron from the antioxidant, which is the ET mechanism. 
In general, X· is symbolised as a radical, AH is symbolised as a hydrogen donor, M is 
symbolised as a transition metal. The reaction in a HAT based antioxidant assay can be 
described as below (Scheme 4-1), in which the working radical X· is directly quenched to 
XH by the antioxidant.10,12,24,27 
AH XH AX  
Scheme 4-1 HAT Based Antioxidant Reaction 
The reaction in a ET based antioxidant assay is shown in Scheme 4-2, where the working 
radical X· is eventually quenched to XH, however, the progress is different from that in 
HAT mechanism and a molecule of water is involved in this reaction. In some ET based 
antioxidant assays, a transition metal ion rather than a radical is reduced by the 
antioxidant.10,12,24,27 
AH X AHX
H2O A H3O XH H2O
M AH MAH 3+
2+
Or
X
 
Scheme 4-2 ET Based Antioxidant Reactions 
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Therefore, antioxidant assays are divided into two major classifications based on their 
reaction mechanisms. The HAT based methods including oxygen radical absorbance 
capacity (ORAC), total radical-trapping antioxidant parameter (TRAP), inhibition of 
induced low density lipoprotein (LDL) oxidation, total oxyradical scavenging capacity 
assay (TOSCA), crocin-bleaching assays, chemiluminescent assay, lipid peroxidation 
inhibition capacity (LPIC) assay and inhibited oxygen uptake (IOC); the ET based method 
including total phenolics assay by Folin-Ciocalteu reagent assay, trolox equivalence 
antioxidant capacity (TEAC) assay, ferric ion reducing antioxidant power (FRAP) assay, 
total antioxidant potential assay (using a Cu2+-complex as an oxidant), 2,2-diphenyl-1-
picrylhydrazyl (DPPH) radical scavenging, 2,2-azinobis 3-ethylbenzthiazoline-6-sulphonic 
acid radical (ABTS) scavenging assay, N,N-dimethyl-p-phenylenediamine radical (DMPD) 
scavenging assay, cupric (Cu2+) reducing antioxidant capacity (CUPRAC) assay.10,12,19,24,27 
It is worth noting that TEAC, DPPH and ABTS assays are argued as mixed HAT and ET 
based assays.10,24,27 In addition, in terms of samples’ sources, antioxidant assays can also 
be classified as in vitro and in vivo. Essentially many methods are applicable to both 
physiological and nonphysiological testing samples, so this classification isn’t well-
defined, however, the results of in vivo antioxidant methods are generally regarded as 
more accurate than their in vitro counterparts because in vivo assays are conducted 
under conditions with more biological relevance, which approximate interactions 
between antioxidants in the body.10,24,27 Since the first assay evaluating a compound 
antioxidant potential, by mean of the stable radical DPPH in 1958, a great number of 
approaches have been established to measure antioxidant capacity.1,3,4,7-10,12,14-20,22-28,30 
In the last few decades, the application of combining various chromatography technique 
including thin-layer chromatography (TLC), gas-chromatography (GC), liquid-
chromatography (LC) with traditional determination methods has enabled researchers 
to eliminate interference and achieve higher accuracy.17,19,23,27 In this chapter, the 
classification of antioxidant assay follows the standard demonstrated in the 
International Union of Pure and Applied Chemistry (IUPAC) technical report.27 Several 
common methods with their advantages and drawbacks are briefly introduced in the 
following section. 
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4.1.2 Antioxidant Assays 
4.1.2.1 ORAC Assay 
The oxygen radical absorbance capacity (ORAC) assay is to measure the antioxidant 
capacity of inhibiting peroxyl radical produced by thermal decomposition of 2,2’-
azobis(2-amidino-propane) dihydrochloride (AAPH) (Scheme 4-3) in aqueous buffer in 
the presence of sufficient oxygen. The generated peroxyl radical reacts with a 
fluorescent probe such as the protein β-phycoerythrin or fluorescein which quenches 
the fluorescence. The antioxidant can scavenge the peroxyl radical and delay the decay 
of fluorescence. The mechanism is outlined below (Scheme 4-3).10,24,26,27 
N N RR
O2 N2 + 2ROO
ROO + Probe(fluorescent) ROOH + Probe(non-fluorescent)
ROO + AH ROOH + A
ROO + A ROO A
H2N
NH
N
N
NH2
NH
2HCl
.
AAPH
 
Scheme 4-3 AAPH Structure and the ORAC Assay Mechanism 
The net integrated areas under fluorescence decay curves indicate test samples 
antioxidant capacity which can be used to make the comparison and assessment. Values 
of net area under curve (AUC) from different samples are normally converted to Trolox 
(an aqueous congener of tocopherol) equivalents (TE) by comparing a standard curve of 
Trolox following linear or quadratic relationships. This standard curve is formed by using 
a series of Trolox concentrations with their corresponding net AUC.10,24,26,27 
ORAC assay supplies a controllable source of various peroxyl radicals, which are 
biological relevant. This assay can be adapted to measure both hydrophilic and 
hydrophobic antioxidants by varying the radical source and solvent, and it can be easily 
developed to an automated and high–throughput assay coupling with other 
instruments.10,19,24 This assay is recommended by IUPAC as a standardised method for 
antioxidant evaluation.27 However, like other assays, the ORAC assay is sensitive to 
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temperature, and the equipment requirement of this assay is relatively high, since a 
fluorometer may not be routinely accessed in analytical laboratories.10,19,24,27 
4.1.2.2 TRAP Assay 
Total radical-trapping antioxidant parameter (TRAP) assay also measures an antioxidant 
ability against peroxyl radicals. Essentially, TRAP assays are variants of ORAC assays in 
principle with a broader range of initiator, probes and endpoint measurements.27 
Likewise, the peroxyl radical is initiated by different initiators such as AAPH, enzymes 
like horseradish peroxidase, H2O2-hemin, nitric oxide radical ·NO or singlet oxygen 1O2. 
Then the generated peroxyl radical reacts with a target probe. The method has different 
variations to verify the target probe, so oxygen uptake, fluorescence of R-phycoerythrin 
or absorbance of 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) can be 
measured to evaluate a test sample’s antioxidant capacities.10,24,27 TRAP assay is mostly 
applied to measure in vivo antioxidant capacity of serum or plasma samples. Among 
them, measuring the oxygen uptake during a controlled lipid peroxidation reaction is 
the most widely used method.24 Generally, rather than net AUC in the ORAC assay, the 
lag-phase duration of oxidant inhibition is measured in the TRAP assay to quantify 
antioxidant capacity. This is based on the assumption that all antioxidant reactions show 
a lag phase and the length of the lag phase is proportional to samples’ antioxidant 
capacities. As in the ORAC assay, this value is also usually converted to a TE.10,24 
The TRAP assay utilises the biologically relevant testing radical and is conducted in 
systems similar to physiological conditions, the antioxidant capacity measured by this 
method may more closely reflect in vivo action.10 This assay is usually recommended as 
a standardised measurement of antioxidant evaluation.10,27 Nevertheless, this assay 
requires sophisticated instruments and a time consuming preparation is needed to 
achieve the measurement. Additionally, because too many different endpoints have 
been used, comparisons between laboratories are challenging. The most significant 
disadvantage is that the measured value is often underestimated since not every 
antioxidant has an obvious lag phase, and the antioxidant profile before or after the lag 
phase is totally ignored in the TRAP assay.10,19,27 
4.1.2.3 TEAC Assay and ABTS Assay 
Trolox equivalent antioxidant capacity (TEAC) assay uses the long-life 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) radical anion ABTS·+ initiated by the 
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oxidation of ABTS  (Scheme 4-4) with peroxyl radicals or other oxidants. The generation 
of anion ABTS·+ includes chemical reactions with oxidised reagents such as hydrogen 
peroxide, manganese dioxide, AAPH and potassium persulfate (K2S2O8), enzyme 
reactions with enzymes  like metmyoglobin, hemoglobin and horseradish 
peroxidase.10,27 The produced ABTS·+ possessing intense colour can be subsequently 
quenched to ABTS by the post added testing antioxidant with loss of colour intensity. 
The mechanism of TEAC assay initiated by K2S2O8 is shown below (Scheme 4-4). 
ABTS
N
N
N
S
N
S
S
S
HO
O
O
OHO
O
ABTS
ABTS + K2S2O8
ABTSABTS + ArOH + ArO + H
+ K2SO4
 
Scheme 4-4 ABTS Structure and the TEAC Assay Mechanism 
The ABTS·+ radical possesses maximum absorptions at wavelengths of 415, 645, 734 and 
815 nm while ABTS has nearly no absorption at these wavelengths. Therefore the 
absorptions of a test sample after a fixed time at these wavelengths (in particular 734 
nm) because both interference from sample can be minimised and the extinction 
coefficient of ABTS·+ is higher at this wavelength, is proportional to the ABTS·+ radical 
concentration, which is used to quantify samples’ antioxidant capacities after a fixed 
reaction time. The final value of the TEAC assay is expressed as a TE, representing the 
concentration of Trolox that can eliminate the same portion of ABTS.+ at the same 
temperature after the same fixed reaction time.10,24,26,27 The ABTS assay and TEAC assay 
are similar, the only difference is the value of ABTS assay isn’t necessary to process TE 
conversion. 
TEAC and ABTS assays are simple, rapid assays and run over a wide range of pH, are 
compatible for both hydrophilic and hydrophobic antioxidants without being affected 
by ionic strength. They can be easily developed to high–throughput assays. The results 
of TEAC and ABTS assays are comparable between different laboratories.4,10,24,26,27 They 
are recommended for antioxidant capacity measurement by IUPAC.27 However, the 
testing radical ABTS·+ is a nitrogen radical without biological relevance. The results of 
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these assays are dependent on time of analysis, so the values may be underestimated 
for the slow processed antioxidant reactions.24 Moreover, the high extinction coefficient 
of ABTS·+ at working wavelength limits the evaluated antioxidant concentration range. 
In order to get accurate results based on spectrophotometer reading, the concentration 
of generated ABTS·+ should be within 1.5 to 70 μM, which means the concentration of 
test sample should also be within the same range.27 
4.1.2.4 FRAP Assay 
Ferric reducing antioxidant power (FRAP) assay is to measure the ability of an 
antioxidant to reduce the ferric 2,4,6-tripyridyl-s-triazine complex [Fe(TPTZ)2]3+ (Scheme 
4-5) to the corresponding ferrous complex in acidic medium, the mechanism of which is 
described in Scheme 4-5. Because the redox potential of the reaction [Fe(TPTZ)2]3+ is 0.7 
V, the FRAP assay can react with compounds with smaller redox potentials, these 
compound are regarded as antioxidants which may also maintain their reducing 
potentials and function as real antioxidants in cells or tissues.10 
[Fe(TPTZ)2]3+ + ArOH + ArO
N
N
N
N
N
N
NN
N
N
N
N
Fe3+
[Fe(TPTZ)2]3+
[Fe(TPTZ)2]2+ + H  
Scheme 4-5 [Fe(TPTZ)2]3+ Structure and the TRAP Assay Mechanism 
The generated ferrous complex is an intense blue colour with a maximum absorption at 
595 nm wavelength. The increased absorbance at 595 nm is proportional to the 
concentration of generated ferrous ion after calibration with that of a standard ferrous 
ion solution so it can be used to quantify samples’ antioxidant abilities after a fixed 
reaction time.10,24,27 The values of samples’ antioxidant activities are generally processed 
to IC50 (concentration of an antioxidant where the testing radical or ion is reduced by 
half) for evaluation. The FRAP assay was originally designed to measure reducing power 
in plasma, but it was later adapted and used for botanical samples’ testing.10,24 The acidic 
pH is essential for this method to maintain iron solubility. 
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The FRAP assay is simply, speedy, economic, robust and does not require specialised 
instruments, it can be easily developed to automated and high-throughput operation. 
However, one drawback of the assay is that the required acidic operational condition 
limits its application. Also, the TRAP assay only detects the compounds with reducing 
capacity while the compounds that act as antioxidants, like thiols and proteins, by 
quenching radicals cannot be measured. Therefore the results of antioxidant capacity 
determined by this method are always underestimated. In addition, this assay relies on 
the hypothesis that all antioxidant reactions finish within a fixed testing time, however, 
that is not true for many cases because many compounds, especially polyphenols such 
as caffeic acid, tannic acid, ferulic acid, ascorbic acid and quercetin react very slowly with 
ferric ion. The reduction reactions between those polyphenols and ferric ion usually take 
several hours to complete while the practical operation time is normally within half an 
hour, which results in the underestimation as well.10,19,24,26 
4.1.2.5 DPPH Assay 
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical assay measure the abilities of 
antioxidants to scavenge a stable nitrogen radical DPPH· (Scheme 4-6). The DPPH· radical 
is commercially available compound with a deep purple colour, its neutral form becomes 
pale yellow after reacting with an antioxidant (Scheme 4-6).10,19,24,26 
+ ArOH + ArO + H
N N
NO2
NO2
O2N
DPPH
DPPH DPPH
(purple) (yellow)  
Scheme 4-6 DPPH Radical Structure and the DPPH Assay Mechanism 
The DPPH· radical has a maximum absorption at 515 nm wavelength while its neutral 
form possesses almost no absorption at this wavelength (details in chapter two section 
2.2.2). So the absorbance at this wavelength is proportional to DPPH· radical 
concentration, which can be used to quantify the antioxidant effect of a test sample 
after a fixed reaction time.10,19,24,26 As in the FRAP assay, the results of the DPPH assay 
are always processed to return an IC50 value for evaluation and comparison. 
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The DPPH assay is the oldest method to directly measure antioxidant activity, it was first 
reported in 1958.1 Since DPPH radical is commercially available, it can be directly applied 
for assessment, it is the simplest, most rapid and inexpensive antioxidant assay, that is 
the reason why it is the most widely used assay in antioxidant screening. The DPPH assay 
is recommended as a standard method by IUPAC, it can be easily developed to various 
automated and high-throughput assays. The DPPH assay is compatible for hydrophilic 
and hydrophobic antioxidants.3,4,6-8,10,19,24,26,27 However, the DPPH radical is not 
biologically relevant, as it cannot be found in any cell or tissue. Compared with highly 
active radicals in organism, this stable radical reacts much slower with antioxidants, so 
the results achieved within the fixed time (normally no more than 0.5 h) may be 
underestimated. Also, the steric accessibility is another cause to generate 
underestimation of results in this assay, only antioxidants with small molecular 
structures can easily get close to reaction site and rapidly complete the reaction while 
the big molecules undergo very slow reaction.10,19,24,26,27 
4.1.2.6 CUPRAC Assay 
Cupric ion reducing antioxidant capacity (CUPRAC) assay is to measure an antioxidant’s 
ability of reducing Cu2+ to Cu+ in aqueous-ethanolic medium. The light blue CUPRAC 
reagent (Scheme 4-7), bis(neocuproine)copper (II) cation [Cu(Nc)2]2+ is able to be 
reduced to the yellow-orange CUPRAC chromophore bis(neocuproine)copper (I) cation 
[Cu(Nc)2]+ by receiving an electron from the antioxidants. For example phenols are 
commonly oxidised to the corresponding quinones (Scheme 4-7).10,19,24,26,27 The 
efficiency of the CUPRAC reduction depends on the number and position of hydroxyl 
groups on the aromatic ring. It is also affected by the overall conjugation level of the 
polyphenolic molecule.27 
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Scheme 4-7 CUPRAC Reagent Structure and the CUPRAC Assay Mechanism 
The reduction product bis(neocuproine)copper (I) [Cu(Nc)2]+ chelate possesses the 
maximum absorption at 450 nm. So this can be used to measure the antioxidant capacity 
after a fixed reaction time (normally within 30 min). The absorbance at 450 nm 
wavelength is proportional to the concentration of this generated CUPRAC 
chromophore cation. Sometimes a curve generated by uric acid or Trolox standards is 
used to convert sample antioxidant value to uric acid equivalents.10,26 
The CUPRAC assay is simultaneously cost-effective, rapid, stable, selective and 
compatible for both hydrophilic and hydrophobic antioxidants. It is recommended by 
IUPAC as a standard method for evaluation of antioxidant capacity.27 Compared with the 
FRAP assay, copper ions have a lower redox potential than iron ions, so the CUPRAC 
assay can detect some antioxidants including thiols which cannot be measured in the 
FRAP assay. Also, the copper reaction kinetics are faster than iron. Moreover, many 
interfering compounds like simple sugars and citric acid in the FRAP assay can be 
oxidised by the CUPRAC reagent. The operational pH in CUPRAC assay is 7.0 which is 
close to the physiological pH. However, the preparation of CUPRAC reagent is time 
intensive, the operational procedure is not simple and the instrument requirement is 
high. As with any method using a fixed time as the endpoint, the low reaction rates with 
less active antioxidants may induce the underestimation of antioxidants values in the 
CUPRAC assay.10,19,24,26,27 
4.1.2.7 Overview 
Numerous variations of antioxidant evaluation methods and abundant new 
measurements applying completely new mechanisms, and technology, have arisen in 
the last few decades. Therefore it was pointless to list all antioxidant assays and only the 
most common and representative methods were discussed above. It is worth noting that 
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there is no single method that can offer comprehensive results for the variety of 
antioxidants that exist. It is recommended to combine the results of at least two 
different methods to give reliable and accurate values for antioxidant assessment. 
However, from these a best method can be selected based on testing sample structure, 
properties and reaction mechanisms.4,10,17  
In order to evaluate the number of free hydroxy groups on the effect of antioxidant 
capacity in grifolin (2.3) and its analogues, TEAC, ATBS and DPPH assays are the best 
choices since they are mixed HAT and ET based assays, with the DPPH being the first 
option among these three candidates. As the oldest, simplest and the most economical 
method, the DPPH assay is the most frequently and widely used in vitro antioxidant 
assessment.1,23,26 Various developments to the DPPH assays have overcome its 
limitations and give reliable and high throughput results. The adjustments in the 
previous DPPH assay have resulted in a method suitable for grifolin and its analogues. 
All the test samples are small molecules not anticipated to present steric obstruction to 
the reactive site on the DPPH radical and consequently samples are expected to react 
rapidly with the DPPH radical. Therefore, a modified DPPH assay was chosen to evaluate 
grifolin and its analogues’ antioxidant capacities. 
4.2 Development of the DPPH Assay 
The DPPH assay described here has been developed from published methods.34-36 The 
DPPH assay and the accuracy of the results have been reported to be sensitive to some 
Lewis bases, light, oxygen, pH and solvent types.1,4,23,37-41 In addition the selection of a 
positive standard reference compound, which is used to calculate the test samples’ 
antioxidant activities, also plays an important role in the assay. In order to gain a rapid, 
high-throughput and accurate antioxidant assay to evaluate grifolin and its analogues, a 
plate reader assisted DPPH assay was developed after investigation of the following 
assay factors.  
4.2.1 Solvent 
DPPH is only soluble in organic solvent.1,37 Generally alcoholic media like methanol and 
ethanol are first considered, with many reported antioxidant assays using these 
alcoholic solvents.34-36 The solvent tert-butyl alcohol is reported to increase the 
reactivity of the DPPH radical with antioxidants.38,40 However, the application of an 
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alcoholic solvent has two significant limitations. First is the solubility, where some of the 
test samples, grifolin and its analogues, possessing low polarities have difficulty 
dissolving in the alcoholic solvents while they are quite soluble in solvents such as CH2Cl2 
or EtOAc. Unsurprisingly precipitation in the wells of the 96-well plate deleteriously 
interferes with absorption readings. Previously antioxidant screening of mushroom 
crude extracts within the group encountered solubility issues when methanol was used 
as solvent. Loss of volume in wells is another critical problem due to the volatility of the 
alcoholic solvents, but the loss of volume is inevitable during the operation, which 
involves 30 minutes incubation at 37 °C. Even a small loss of volume will significantly 
impact the results when only 200 μL of solution is added to each well. Because of the 
solubility to most structural classes and the very low volatility, DMSO represents a 
perfect alternative solvent. Figure 4-1 shows the volumes of DMSO versus methanol 
solutions in wells kept at room temperature overnight. The volume change in the DMSO 
wells was not noticeable while at the same time methanol solutions had become dry. As 
such all the testing of compounds in our DPPH assay were conducted in DMSO. 
 
Figure 4-1 Volume Changes of DMSO and Methanol Solvent in a 96-Well Plate 
4.2.2 DPPH Solution Concentration 
DPPH solution is intensely coloured and has an absorption maximum at 515 nm 
wavelength. As such the concentration of DPPH solution should be set in a range in order 
to obtain a reliable and accurate value, within which the Beer-Lambert law is obeyed.42 
A 500 μM alcoholic solution of DPPH is regarded as the maximum concentration for 
quantitative analysis, while a range of 50-100 μM is a normal working concentration. 
The absorbance value of DPPH solution is recommended to be no more than 1.0.1,23,34-
37,43 As such DPPH DMSO solutions with two different concentrations, 100 μM and 137 
μM respectively were used, the total volume of each well was set as 200 μL following 
reference suggestions.34-36 The absorbance values of wells with various volumes DPPH 
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DMSO solution (using DMSO to make up to 200 μL in each well) were measured, the test 
wells were duplicated in each measurement. The results are shown in Table 4-1. 
Table 4-1 Absorbance Values of Wells with Various Volumes DPPH Solutions 
Concentration Absorbance (mean + SD) 
 190 μL DPPH 180 μL DPPH 160 μL DPPH 120 μL DPPH 40 μL DPPH 
100 μM 0.553 ± 0.004 0.525 ± 0.001 0.468 ± 0.002 0.354 ± 0.001 0.124 ± 0.002 
137 μM 0.654 ± 0.001 0.627 ± 0.001 0.555 ± 0.001 0.417 ± 0.002 0.140 ± 0.003 
By using DPPH DMSO solution with these two concentrations, the absorbance values of 
all the wells are within the spectrometer’s working range, reliable and reproducible. 
Further linear analysis of the relationship between absorbance value and concentration 
offers the values of R2 with 1 and 0.9998 at 100 μM and 137 μM respectively. The 
repeated measurements using different sources of DPPH at the two specified 
concentrations also confirmed the linear relationship between absorbance and 
concentration. 
4.2.3 Volume Composition 
According to the manufacture’s description, the working volume of 96-well plates is 50-
200 μL and the recommendation of working volume is at least 100 μL.44,45 200 μL is set 
as the working volume for optimum performance, this working volume was also applied 
in the reported assays.34-36 As shown in Figure 2-6 and as discussed in the introduction 
of this chapter, the DPPH radical has a maximum absorption at 515 nm while its neutral 
form possesses very weak (nearly zero absorption) at this wavelength. The positive 
control group using excess reference compound, ascorbic acid, should achieve nearly 
100% scavenging activity but the actual result is in conflict with this assumption. The 
highest scavenging activity achieved in experiments was below 90% while absorbance 
values of various ascorbic acid DMSO solutions with different concentrations have been 
confirmed to be almost zero at 515 nm. Figure 4-2 shows that the measured absorbance 
value of the positive control, which is comprised of 190 μL of a 100 μM DPPH DMSO 
solution and 10 μL of a 10 mM ascorbic acid DMSO solution, is always higher than the 
blank, which is comprised of 200 μL pure DMSO solvent and used for absorption 
calibration. According to theoretical calculation and experimental data, the 
stoichiometry between DPPH and ascorbic acid is 2:1, therein ascorbic acid is in excess.23 
As such the absorption difference between the blank and positive control cannot be 
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attributed to unreacted DPPH radical. Therefore interactions between the DPPH radical 
and ascorbic acid solutions must cause interference which induces a background 
absorption. 
 
Figure 4-2 Spectra of DPPH + Ascorbic Acid and Blank Solutions 
In order to understand how these interactions impact results and minimise background 
absorption, different volumes of DPPH solution were added to wells, with volumes 
topped up to the working volume, 200 μL in each well, with ascorbic acid solution. DPPH 
solutions were at concentrations of 100 μM and 137 μM, the concentration of ascorbic 
acid solution was set as 10 mM following reference suggestions,34,35 the testing wells 
were duplicated and their mean absorbance values were used to process scavenging 
activities as shown in Table 4-2.  
Table 4-2 Scavenging Activities of Various Volumes DPPH Solutions 
Concentration Scavenging Activity (%) 
 190 μL 180 μL 160 μL 120 μL 40 μL 
100 μM 85.1 84.8 84.1 81.7 74.1 
137 μM 87.9 87.6 86.9 85.4 79.6 
These results show the scavenging activity reduces with the decrease of added DPPH. 
This suggests the background absorption from interactions between DPPH and ascorbic 
acid solutions is not from DPPH-ascorbic acid reaction products and therefore isn’t able 
to be eliminated by normalization. This interference increases its significance in a 
solution with a small absorbance value. The larger the volume of added DPPH solution 
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is, the higher the absorbance value of the solution, and consequently the less the system 
error is. So the maximum volume of DPPH solution should be used in an assay in order 
to acquire an accurate result and this is possibly the reason why a volume of 195 μL of 
DPPH solution was applied in the reported method.34,35 However, our results show the 
difference of scavenging activity between experiments using 190 μL and 160 μL of added 
DPPH solution was only 1% (Table 4-2). In practice, the manipulation of adding the 40 
μL of solution has been confirmed to be easier, faster, more accurate and stable than 
that of adding 10 or 20 μL, especially when the absorption of DPPH decreases markedly 
with time, which will be discussed later.41 In preliminary studies the scavenging activity 
of adding 195 μL DPPH solution was very close to that of adding 160 μL while air bubbles 
were always trapped during 5 μL liquid transfer,45 which makes the manipulation of 
adding 195 μL DPPH solution impractical. Therefore, the working volume in each well is 
set as 200 μL, which is comprised of 160 μL DPPH solution, for acquiring an accurate, 
stable and reproducible result. 
4.2.4 Ascorbic Acid Concentration 
As mentioned in section 4.2.3, interactions between DPPH and ascorbic acid solutions 
cause background absorption and interfere with the accuracy of measurements. 
Undoubtedly, not only volume composition but also the concentration of ascorbic acid 
solution will affect such interactions. 10 mM ascorbic acid solution was applied in 
reported methods,34,35 it is used to assess the concentration effect as well as its tenfold 
dilution. While recognising the optimised working volume of 200 μL, different volumes 
of ascorbic acid solutions with concentrations of 10 mM or 1 mM and compensating 
volumes of 100 μM DPPH solutions, were added into wells. The ascorbic acid in each 
well was in excess based on the aforementioned stoichiometry. The testing wells were 
duplicated and their mean absorbance values were used to process scavenging activities, 
the results are shown in Table 4-3. 
Table 4-3 Scavenging Activities of Ascorbic Acid Solutions 
Concentration Scavenging Activity (%) 
 10 μL 20 μL 40 μL 80 μL 160 μL 
10 mM 85.1 84.8 84.1 81.7 74.1 
1 mM 87.8 87.5 86.9 85.2 75.4 
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The result shows the diluted ascorbic acid solution (1 mM) always gives a higher 
scavenging activity than the concentrated solution (10 mM), which suggests the high 
concentration ascorbic acid solution increases the interactions with DPPH solution and 
consequently causes a high background absorption. In order to acquire an accurate 
result, the concentration of ascorbic acid solution is set as 1 mM. It is worth noting that 
the differences of scavenging activity between 10 μL and 40 μL ascorbic acid solutions, 
at the two concentrations of 10 mM and 1 mM, are very small (less than 1%), affirming 
previously optimised volume composition employed by us. Subsequently, 80 μL of 1 mM 
ascorbic acid solution was added into a well, followed by 7-level series dilution, then 160 
μL of 100 μM DPPH solution was added into each well. The negative control comprised 
of 160 μL of 100 μM DPPH DMSO solution and 40 μL DMSO solvent was used as a 
reference for spectra comparison. The testing wells were duplicated and their mean 
absorbance values were used to process scavenging activities, the results are shown in 
Table 4-4, their spectra are displayed in Figure 4-3. 
Table 4-4 Scavenging Activities of Ascorbic Acid Series Diluted Solutions 
Concentration (μM) Scavenging Activity (%) 
1000.0 87.5 
500.0 87.0 
250.0 87.1 
125.0 58.6 
62.5 28.7 
31.3 14.9 
15.6 7.9 
7.8 4.9 
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Figure 4-3 Spectra of Ascorbic Acid Series Diluted Solutions and DPPH Solution 
 According to the stoichiometry between DPPH and ascorbic acid, ascorbic acid is still in 
excess after 2nd level dilution. Based on Table 4-4 and Figure 4-3, after 2nd level dilution, 
the scavenging activities of ascorbic acid solutions are almost the same, and their 
spectra are almost completely overlapped (the lowest absorbance at 515 nm). Herein 
the 100% radical scavenging can be triple checked and the concentration of ascorbic 
acid solution has a negligible effect on background absorption. The DPPH radical is 
partially scavenged from 3rd level dilution onwards, the relationship between 
concentration of ascorbic acid and its scavenging activity afterward is perfectly linear, 
the R2 value is 0.9994. The spectra (Figure 4-3) clearly show solution absorption at 515 
nm continuously increases with the ongoing dilution of ascorbic acid and finalises the 
value lower than absorption of reference DPPH solution. The scavenging activities and 
spectra (Table 4-4 and Figure 4-3) confirm the usage of 1mM ascorbic acid solution used 
as the positive control is able to offer an accurate, constant and reliable result. 
4.2.5 DPPH Stability 
DPPH radical is a stable radical which is commercially available and ready for use. For 
convenience, the working DPPH solution is generally prepared at high concentration and 
stored in an amber container covered with foil and placed in a refrigerator. It is further 
diluted to the required concentration before usage. However, the solvated DPPH is less 
stable than non-solvated material, in addition to its sensitivity to light, oxygen and 
temperature,23,38,40,41,43 resulting in irreversible degradation during the storage of the 
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stock solution which reduces the absorbance value and consequently affects the final 
result. Moreover, the melting point of DMSO is only 19 °C, so the stock DPPH solution is 
frozen in the refrigerator, and the thawing procedure is likely to increase the possibility 
of DPPH degredation.23,37,41,43 Hence, it is necessary to check the stability of DPPH 
solution in order to guarantee the accuracy of result. First, two 100 μM DPPH DMSO 
solutions were compared. One of them was diluted from 50 mM stock solution stored 
in a refrigerator for four days, another one was freshly prepared. 40 μL of a 1 mM 
ascorbic acid was 7-level series diluted in a 96-well plate and after making up to 200 μL 
their absorbance values were measured. An image and absorbance values are displayed 
in Figure 4-4 and Table 4-5. 
 
Figure 4-4 Four-day Stocked and Fresh DPPH Solutions Antioxidant Assay 
Table 4-5 Four-day Stocked and Fresh DPPH Solutions Antioxidant Assay 
Dilution Level 
Scavenging Activity (%) 
Diluted Stocked DPPH Fresh DPPH 
0 78.2 87.7 
1 77.9 87.2 
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2 78.7 86.8 
3 70.1 61.7 
4 34.7 31.2 
5 17.3 16.1 
6 8.3 8.1 
7 4.2 5.0 
The 3rd level diluted ascorbic acid didn’t show any purple colour after mixing with stock 
DPPH solution while the same level of ascorbic acid was light purple after mixing with 
fresh DPPH solution (Figure 4-4). The scavenging activities of ascorbic acid (dilution level 
0-2) against fresh DPPH solution is higher than against the stock DPPH solution with the 
same concentration where ascorbic acid is in excess. However, we observed that the 
scavenging activities of ascorbic acid at lower dilutions, where it is stoichiometrically 
inadequate (dilution level 3-6), against fresh DPPH solution is lower than the stock DPPH 
solution (Table 4-5). These observations confirm that DPPH solution degrades over time 
in the refrigerator. In addition, Figure 4-5 shows spectra of two 100 μM DPPH in DMSO 
solutions, diluted from 50 mM two-day stock and freshly prepared respectively. 
Apparently, DPPH solution shows significant degradation after two days. Therefore, we 
advise that DPPH solution to be used for testing should be prepared immediately before 
use. 
 
Figure 4-5 Spectra of Two-day Stock and Fresh DPPH Solutions 
The DPPH assay is generally incubated at 37 °C for around 30 min before measuring 
absorbance value.34-36 This manipulation is to imitate physiologic condition and allow 
sufficient reaction time. As mentioned in the introduction section of this chapter, the 
short reaction time may result in an underestimation, while the longer incubation time 
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will increase DPPH degradation. In order to optimise the reaction time, 200 μL freshly 
prepared 100 μM DPPH in DMSO solution was added to three rows of a 96-well plate, it 
was then covered and placed under dark conditions at 25 °C. Absorbance values of each 
well were recorded every 15 min for 14 h. The data shows the absorbance mean reduced 
by 7%, 12% and 35% after 30 min, 1 h and 14 h respectively. Therefore, incubation time 
significantly affects result accuracy. Since all testing structures are small molecules, 
repeated experiments have confirmed their reactions with DPPH were complete within 
30 min, thus 30 min is determined as the incubation time. The absorbance value tracking 
also suggests the operation of whole test should finish as soon as possible to avoid 
interference from DPPH self-degradation. 
4.2.6 Ascorbic Acid Stability 
Ascorbic acid is unstable with the most common method of degradation being oxidation 
to dehydroascorbic acid. Many references have investigated the stability of ascorbic acid 
confirming that storage temperature and its exposure to air significantly affect its 
stability. However, the literature gives different suggestions on storage duration ranging 
from 24 h or 4 days.46-50 For convenience, ascorbic acid is generally prepared and stored 
under sealed and dark conditions before usage. In order to explore the activity of 
degradation, two 1 mM ascorbic acid in DMSO solutions, prepared either four days 
earlier or freshly prepared, were compared for their antioxidant abilities. Following the 
aforementioned method, 40 μL of 1 mM ascorbic acid solution was subjected to a 7-
level series dilution in a 96-well plate and their absorbance values were measured to 
process the corresponding scavenging activities. All wells were duplicated and the 
results are displayed in Table 4-6. 
Table 4-6 Four-day Stock and Fresh Ascorbic Acid Solutions Antioxidant Assay 
Dilution Level 
Scavenging Activity (%) 
Stocked Ascorbic Acid Fresh Ascorbic Acid 
0 87.5 87.4 
1 86.9 86.6 
2 86.7 86.4 
3 52.0 63.0 
4 25.6 31.3 
5 12.6 15.2 
6 6.9 8.3 
7 4.6 5.1 
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From Table 4-6, the scavenging activities of four-day stock ascorbic acid solution 
(dilution level 0-2) differ marginally from the fresh ascorbic acid solution. As such it is 
acceptable to prepare the ascorbic acid solution up to four days in advance. 
4.2.7 Interactions between Samples and DPPH 
As already mentioned, because of the interaction between ascorbic acid and DPPH, the 
resulting background absorption reduces the maximum achievable scavenging activity 
of ascorbic acid to around 88%. A similar phenomenon can also be observed in the DPPH 
assay of some test samples (such as orcinol, compounds 3.5, 3.23, 3.47 and 3.59). We 
observed that in such cases (Figure 4-6), a high concentration sample solution returned 
a low or even negative scavenging activity while low concentrations of the same sample 
solution could show a higher activity (DPPH solution used as a negative control). Figure 
4-6 shows that after compound 3.47 with the highest concentration (dilution level 0) 
reacted with DPPH, the absorption of the reaction mixture at 515 nm was even higher 
than DPPH solution, the negative control, returning a negative scavenging activity. After 
the 1st and 2nd level dilution of compound 3.47, the absorptions of the reaction mixture 
at 515 nm significantly reduced, returning stronger scavenging activities. However, from 
the 3rd level dilution onwards, the absorptions of the reaction mixture increased at 515 
nm, returning weaker scavenging activities, and their spectrum was increasingly close to 
DPPH’s. The absorptions of test samples such as compound 3.47 have been confirmed 
to be very weak at 515 nm in the preliminary study. As such from the 3rd level dilution 
onwards, the increased absorptions observed (Figure 4-6) of the reaction mixture must 
be from the increasing residual DPPH. In dilution level 0-2, the decreased absorptions of 
the mixture were from the decreased sample-DPPH complex as a consequence of less 
test compound being present. Herein DPPH could interact with a test sample or ascorbic 
acid to generate a complex with strong absorption, inducing the interference, this 
explains why the maximum achieved scavenging rate of ascorbic acid is less than 90% 
without illumination. The preliminary study found that continuous illumination from an 
incandescent lamp (30 W) was able to reduce absorption of residual DPPH while 
absorption of the generated complex wasn’t changed. Absorption of residual DPPH was 
found to be completely eliminated after 168 h continuous illumination (Figure 4-7). 
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Figure 4-6 Spectra of Compound 3.47 DPPH Assay before Illumination 
 
Figure 4-7 Spectra of Compound 3.47 DPPH Assay after 168 h Illumination 
As a result, the absorption difference induced by illumination only comes from the 
residual DPPH, which can be used to calculate the sample’s genuine antioxidant activity. 
Therefore, the absorption difference before and after illumination is directly 
proportional to residual DPPH, and it should be used to calculate actual scavenging 
activity. As a developed method, the absorbance value of each sample’s well is 
measured after incubation at 37 °C under dark conditions for 30 min, then the 96-well 
plate was illuminated by the lamp for 168 h, the absorbance value of each sample’s well 
was measured again. The absorbance difference between the two readings (∆A Sample) 
was from residual DPPH in each well, the mean absorbance of wells (A DPPH) in the first 
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reading is regarded as pure DPPH which is the equal to the absorption of initially adding 
DPPH, so the scavenging activity is processed as below (Equation 4-1). 
Equation 4-1 Scavenging Activity Equation 
% scavenging
 =
100 ×
∆A Sample
A DPPH
1 -
 
Following the developed method, interference from background absorption of a 
generated complex can be so eliminated, the scavenging activity of ascorbic acid is able 
to achieve 100%, which is higher than the counterparts acquired from the same testing 
material based on published methods (Table 4-7). This confirms the validity and accuracy 
of the method developed in the work presented here, and confirms ascorbic acid in the 
first three dilution levels is in excess. In the developed method (Table 4-7), some errors 
can be seen, these are attributable to variation of solvent volume during the illumination, 
and the error will become more significant when higher levels of residual DPPH exists. It 
also confirms the importance of choosing a less volatile solvent like DMSO. 
Table 4-7 Scavenging Activities of Ascorbic Acid between Two Methods 
Dilution Level 
Scavenging Activity (%) 
Published Method34,35* Developed Method 
0 86.2 102.9 
1 86.2 100.8 
2 85.8 98.2 
3 61.1 69.2 
4 30.2 31.3 
5 13 14.9 
6 6.9 8.3 
7 3.9 7.7 
*The working Volume is comprised of a 160 μL DPPH solution and a 40 μL ascorbic acid solution 
 
4.3 Antioxidant Result of Synthetic Grifolin’s Analogues 
A selection of commercially available and synthetic analogues of grifolin prepared in 
chapter three (Figure 4-8 to Figure 4-11) were subjected to antioxidant assessment 
following the DPPH assay developed in this study. 
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Figure 4-8 EC50 Values (mM) of Neogrifolin and Its Analogues 
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Figure 4-9 EC50 Values (mM) of Grifolin and Its Analogues 
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Figure 4-10 EC50 Values (mM) of Neogrifolic Acid’s Analogues 
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Figure 4-11 EC50 Values (mM) of Grifolic Acid’s Analogues  
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Based on a test sample’s concentration and its corresponding radical scavenging activity, 
OriginPro (2015) software was applied for calculating the EC50 value of DPPH radical 
scavenging. The results are listed in Figure 4-8 to Figure 4-11. 
In this work an EC50 value of 10 mM, which is two orders of magnitude greater than the 
EC50 value of grifolin, is regarded as the threshold value for antioxidant activity. Thus 
among analogues of neogrifolin and grifolin (Figure 4-8 and Figure 4-9), orcinol, 
compounds 3.26, 3.16 are inactive, no matter how many free phenols are present. 
However, the antioxidant activity is extraordinarily enhanced after a carbon chain is 
appended to the structures (for example compounds 3.35 and 3.4 in Figure 4-8, and 
compounds 3.37 and 3.1 in Figure 4-9). After being furnished with a carbon chain 
(propenyl or prenyl), the position of the carbon chain (for example compounds 3.4 and 
3.1), and the number of free phenols (for example compounds 3.4, 3.5, 3.6 and 3.7) does 
not significantly affect the antioxidant activity. It is worth noting that among the carbon 
chains, those possessing a prenyl group generally possess more activity than their 
propenyl counterparts (3.5 and 3.28, or 3.2 and 3.30), but clearly oxidation of the 
aromatic ring plays a role as the structure containing only an aromatic ring and a prenyl 
substituent (3.19),  does not indicate an antioxidant activity. Manipulation of the prenyl 
sidechain of 3.7 through reduction of the double bond to return 3.25, or oxidation to 
deliver 3.21, or both to give 3.24, resulted in loss of activity. The increased length of 
carbon chain (for example 3.4 and neogrifolin, or 3. 1 and grifolin) significantly enhances 
the activity. The increased activity can be attributable to the increased stability of a 
structure with the longer carbon chain, discussed in section 3.2.2.1 and section 3.3. 
The comparison of antioxidant activity of analogues of neogrifolic acid and grifolic acid 
(Figure 4-10 and Figure 4-11), also indicates that the presence of free phenols 
(compounds 3.38, 3.62 and 3.63) is not correlated to antioxidant activity, contrary to 
popularly held beliefs.51,52 However, as observed previously the addition of a carbon 
chain (propenyl or prenyl) is sufficient to introduce appreciable levels of antioxidant 
activity to the previously inactive structures (for example compounds 3.40 and 3.47 
compared to 3.38). The position of the carbon chain (for example compounds 3.47 and 
3.45), and the number of free phenols (for example compounds 3.47, 3.58 and 3.59) 
have an irregular effect on activity. 
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Among analogues prepared and tested here compound 3.6 (EC50 0.81 ± 0.03 mM) is the 
most active compound, however, it is around 20 times less active than neogrifolin (EC50 
0.034 ± 0.005 mM) containing three prenyl units.  Curiously among the side products 
isolated and tested in this study (3.36, 3.29, 3.31, 3.33, 3.48, 3.60 and 3.61), the 
hemiacetal derivative (3.33) possessed the highest activity of any compound being 
slightly more active (EC50 0.68 ± 0.05 mM) than 3.6. 
4.4 Conclusions 
4.4.1.1 A Developed DPPH Assay 
The DPPH assay developed here is a simple, fast, economic and efficient method to offer 
a reproducible antioxidant evaluation. Several factors have been considered and carried 
out in the investigation to optimise the DPPH antioxidant assay. As a result, DMSO was 
chosen as the solvent, the concentration of testing DPPH solution was set as 100 μM, 
the concentration of the positive control, ascorbic acid solution, was set as 1 mM, the 
total volume of testing solution in each well was set as 200 μL, comprised of 160 μL 
DPPH solution and 40 μL test sample solution (at various dilutions). The DPPH solution 
should be prepared fresh while ascorbic acid solution can be prepared in advance and 
stored for up to four days. After incubation and shaking thoroughly at 37 °C in the dark 
for 30 min, the absorbance of each well of the 96-well plate is determined. The formula 
(Equation 2-1) can be used to calculate a test sample’s DPPH scavenging activity. 
% scavenging
 =
100 ×
A negative control
 − A 
testing sample
A negative control
 − A 
positive control  
However, it was found that sometimes a test sample interacted with DPPH to generate 
a complex inducing a strong background absorption at 515 nm.  In such cases the 
continuous illumination provided by an incandescent lamp (30 W) represented a 
solution. Subtraction of the absorbance value after 168 h illumination from the first 
measured absorbance value returned the absorbance value difference (∆A Sample), which 
is the absorption of residual DPPH in each well. Then the exact DPPH scavenging activity 
of a test sample can be calculated using Equation 4-1 where the absorption of DPPH (A 
DPPH) in the reading obtained prior to illumination. 
% scavenging
 =
100 ×
∆A Sample
A DPPH
1 - (Equation 4-1)
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4.4.1.2 Result of SAR Research 
Based on testing results, the SAR of grifolin and its analogues can be elucidated as below. 
The essential components for a molecule to show an antioxidant activity requires the 
aromatic ring to be allylated with a carbon chain in addition to the presence of phenols, 
no matter if the phenols are alkylated or not. The position of the carbon chain, grifolin 
versus neogrifolin type substitution does not significantly impact on the antioxidant 
activity. The enhanced activity of a carbon chain substituted with a propenyl or a prenyl, 
group can be attributed, in part, to the double bond present (Figure 4-12), which can 
delocalise a radical produced by a HAT mechanism in the DPPH radical scavenging 
reaction. Clearly the oxygenation of the ring plays a role as the prenylated aromatic (3.19) 
is inactive. The increased activity generally observed in going from a propenyl to a prenyl 
can be attributed to the increased stability of a radical with a prenyl structure (Figure 
4-12). The increased activity observed with the increased length of a carbon chain, that 
is more prenyl units, is attributed to the increased stability of the structure itself. 
OR
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Figure 4-12 Stabilities of the Generated Radicals 
4.4.1.3 Exploitation of Fungal Biosynthesis 
As discussed in chapter three section 3.1, based on the biosynthesis of antioxidant 
metabolites such as grifolin and neogrifolin, it is practicable to add components, such as 
an aromatic core like orcinol and/or an aliphatic side chain like farnesyl pyrophosphate 
(FOPP), to a mushroom culture medium to increase the metabolites yields. In practice, 
even though FOPP is a commercially available reagent, the application of FOPP isn’t 
industrially valuable due to its high price. However, the analogue of FOPP with a shorter 
carbon chain, prenyl pyrophosphate (POPP), is around 10 time cheaper. As discussed in 
the section 4.4.1.2 a structure containing a prenylated orcinol shows antioxidant activity, 
thus the addition of POPP instead of FOPP into the mushroom culture medium, could 
also enhance the mushroom antioxidant activity while decreasing the cost of production. 
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However, the results determined by our DPPH assay show that the antioxidant activity 
of the alternative product, compound 3.1 (EC50 1.03 ± 0.09 mM), is about 10 time less 
than the activity of grifolin (EC50 0.13 ± 0.02 mM). As such, the usage of POPP in an 
aberrant biosynthesis approach does not appear to represent a solution to 
commercialise the production of antioxidants in mushrooms. 
4.5 Experimental 
4.5.1 General Procedure of the Developed DPPH Assay 
4.5.1.1 Preparation of the DPPH in DMSO solution 
3.9 mg DPPH (MW= 394.32 g/mol) was dissolved in 100 mL freshly distilled DMSO in a 
volumetric flask, wrapped with aluminium foil (solution concentration c= 0.1 mM). 
4.5.1.2 Preparation of Ascorbic acid (positive control) 
8.81 mg L-ascorbic acid (MW= 176.12 g/mol) was dissolved in 50 mL freshly distilled 
DMSO in a volumetric flask, wrapped with aluminium foil. This solution (concentration 
c= 1 mM) could be stored for up to four days. The volumetric flask is covered with an 
atmosphere of nitrogen and sealed after each use. 
4.5.1.3 Preparation of Sample 
Add 200 μL DMSO in a vial to dissolve sample (W mg) and mix on the vortex mixer. 
4.5.1.4 Preparation of Sample Control (Optional) 
This is applicable when a sample is highly coloured, most often in a crude extract sample. 
Preparation of sample control is the same as the procedure conducted in the 
preparation of sample (4.5.1.3). In order to execute an accurate assay a sample’s 
background absorption should be eliminated during the absorbance measurement.  This 
can be done by subtracting the absorption of a sample from the absorption of a sample 
control. 
4.5.1.5 Absorbance Measurement 
Add 200 μL DMSO solvent to wells labelled as “DMSO Solvent” (Figure 4-13 or Figure 
4-14). 
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Figure 4-13 96 Well Plate Layout without Sample Controls 
(numbers in column A1-H1 represent relative concentrations) 
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Figure 4-14 96 Well Plate Layout with Sample Controls 
(numbers in column A1-H1 represent relative concentrations) 
Add 40 μL DMSO solvent to wells labelled as “DPPH”. 
Add 40 μL DMSO solvent to the wells of rows (B-H) labelled as “Sample”, “Sample 
Control” (optional) and “Ascorbic Acid”. 
Add 80 μL of sample, sample control (optional) and ascorbic acid to the corresponding 
wells in row A of the plate (Figure 4-13 or Figure 4-14). 
Take 40 μL from wells in row A of “Sample”, “Sample Control” (optional) and “Ascorbic 
Acid”, then add to wells in the next row (B) of the same column, then mix thoroughly. 
Repeat the previous step until the last row (H) and discard the 40 μL of solution. 
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Add 160 μL DPPH in DMSO solution to wells labelled as “Sample”, “Sample Control” 
(optional), “Ascorbic Acid” and “DPPH” (Figure 4-13 or Figure 4-14).  
Cover the plate with aluminium foil and place it in an incubator at 37 °C for 30 min. 
Place the plate in the plate reader and start absorbance measurement. The wells 
labelled as “DMSO Solvent” are used as a blank, their mean absorbance values are 
applied for a calibration of autozero. The wells labelled as “DPPH” are used as the 
negative control. 
For a sample without an intense colour, its scavenging activity is processed by the 
formula below (Equation 2-1). 
% scavenging
 =
100 ×
A negative control
 − A 
test sample
A negative control
 − A 
positive control
(Equation 2-1)
 
For a highly coloured sample, the scavenging activity is processed followed by the 
formula below (Equation 4-2). 
Equation 4-2 Scavenging Activity Equation of Coloured Sample 
% scavenging
 =
100 ×
A negative control
 − (A 
test sample - A sample control)
A negative control
 − A 
positive control  
4.5.1.6 Epoch Plate Reader Protocol 
Open Gen 5, “Create a new protocol” or open an existing protocol. 
Select plate type from the pull-down menu from the top right window with proper 
ticking “Use lid”. Then set up “Read” for single quick reading or “Kinetic” for multiple 
readings under “Procedure”. 
In the middle right window under “Description”, choose a step to add by dragging the 
step from the list of left window, change the order of steps by dragging up and down. 
Choose the step and either press “delete” or right click then click “Remove” to delete 
the chosen step. The chosen step can be edited by either double click or right click then 
click “Edit”. 
Edit “Read” step to set up wavelength and read speed. 
Double click “Plate Layout” to lay out blank (BLK), assay control including positive control 
(PC) and agent control (AC), sample (SPL) and sample control (SPLC) groups.  
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Double click each group (for instance “Sample”) on the list of left window to set up labels 
and parameters of each group. 
Choose type of dilution or concentration in the coming window. On the right bottom 
“Auto” menu, click “Increment” with typing a number in its right (which means 
automatically adds the typed number for the next dilution/ concentration) or “Factor” 
with typing a number in its right (which means automatically multiples the typed 
number for the next dilution/concentration), then set up the first dilution/concentration 
on the left window, followed by sequent double click to add the dilution/concentration 
for the rest. 
Choose a group (for instance “SPL1”) and choose a “Replicates” model under “Serial 
Assignment”, then drag in the corresponding wells in the chosen plate, sequent drags 
enable to assign the rest sample groups. This function is applicable for all the groups. 
Double click “Data Reduction” to run automatic result analysis. 
Double click analysis steps to add under “Description” and change the order of them by 
dragging them up and down. 
For instance, “Blank” (only available when blank group is laid out) is to run a background 
subtraction for all the data by simply choose the data being subtracted. 
For instance, “Custom” can run the complicated calculation to achieve the final result. 
4.5.1.7 EC50 Calculation 
A sample’s concentration at the dilution level 0 (row A) is determined by (Equation 4-3);  
Equation 4-3 a Sample’s Concentration at the Dilution Level 0 
c =
MW (g
⋅mol-1) × 200 (µL) × 10
−6 × 200 (µL)
W (mg) × 10-3
 × 40 (µL) × 103 mM
c =
MW
1000 ×
 W
mM, W is a sample's mass, MW is the sample molecular weight
 
A sample’s concentrations in different dilution levels along with their corresponding 
scavenging activities are analysed by OriginPro (2015) software, followed by sigmoidal 
fit using category “growth/sigmoidal”, function “dose/response”. EC50 value of this 
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sample will be directly given by the conducted simulation, it is reported as mean ± 
standard error. 
4.5.2 General Procedure of the Developed DPPH Assay with Illumination 
This first part of the procedure, prior to illumination, is exactly the same as the 
developed DPPH assay described above. The first reading is measured after incubation 
under dark conditions for 30 min at 37 °C. Subsequently the 96-well plate was sealed 
with Scotch tape to prevent evaporation then placed approximately 15 cm from an 
incandescent lamp (30 W) and subjected to continuous illumination for 168 h after 
which the absorbance was measured. 
The absorption of the DPPH (A DPPH) is measured prior to illumination, ∆A Sample is 
sample’s mean absorbance value difference before and after illumination. The 
scavenging activity is determined by Equation 4-1. 
% scavenging
 =
100 ×
∆A Sample
A DPPH
1 - (Equation 4-1)
 
Subsequently, the calculation of each sample’s EC50 value is directly output by OriginPro 
(2015) software as described in previous section. 
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Chapter 5: Halogenated Natural Products 
5.1 Introduction 
The natural halogens are comprised of fluorine (F), chlorine (Cl), bromine (Br), iodine (I) 
and astatine (At), a halogen is normally symbolised as X. However, due to the instability 
of astatine with the half-lives of all its isotopes being less than one minute,1 generally 
halogens are regarded to include only the stable elements fluorine, chlorine, bromine 
and iodine, and this conception of halogen is applied in this chapter. In 1968 the world 
renowned organic chemist and Nobel laureate, Sir Robert Robinson stated “… present 
information suggests that organic compounds containing covalently bound halogens are 
found only infrequently in living organisms although the species known to elaborate 
these compounds span the Orders of the animal and plant kingdoms.”2 Scientific 
community used to deny the existence of halogenated natural products, considering 
them as artefacts formed during the isolation, fifty years later the discovery of 
thousands of halogenated natural products with various structures negates the previous 
conclusion while there still remains a persistent controversy about the existence of 
naturally occurring organohalogens.3-5 The number of natural organohalogen 
compounds, such as Tyrian purple,6 structurally solved in 1909 and 3,5-dibromotyrosine 
which had its two dimensional structure solved in in 1913 (Figure 5-1),7 were two of only 
a dozen compounds known by 1954,8 and were regarded as chemical freaks and largely 
ignored by the scientific community.9 However, this number has increased significantly, 
multiplying hundreds of times in the past decades,8,10-12 with more than 5000 naturally 
occurring organohalogen compounds existing today.13-16 Gribble, in his frequent 
commentary on the subject,13,14,16,17 suggests this enormous increase in organohalogen 
discovery results from; 
(1) a worldwide revitalisation of natural products research in the search for new 
medicinal compounds from all aspects of our environment, 
(2) improved isolation, separation and identification techniques, 
(3) selective bioassays to identify biologically active extracts, and 
(4) an awareness of folk medicine and ethnobotany for guidance to potentially 
important organisms. 
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Tyrian purple 3,5-dibromotyrosine  
Figure 5-1 Early Discovered Natural Organohalogen Compounds 
The continual discovery of natural organohalogen compounds described in the primary 
literature and through a number of relevant reviews affords abundant evidence to end 
the debate.18-38 Contrary to early held scientific opinions, organohalogens are not 
chemical freaks and without doubt occur often in nature. 
Naturally occurring organohalogen compounds have both biotic and abiotic origins.17 
This chapter will discuss biotic organohalogen “natural products”,39-41 that is those 
which are produced by a living organism. The abiotic organohalogens, which are 
generated by biomass combustion, sediments and soil production, volcanic and other 
geophysical phenomena, mining operations and in interstellar space, are beyond the 
scope of this chapter, and the reader is referred to the literature.12,17,42-45 
Halogenated natural products often express powerful biological effects and in many 
cases the halogen atoms play the key role in influencing these biological 
activities.12,15,17,18,29,46-49 For instance, the antibiotic vancomycin, which is produced by 
the soil bacterium, Amycolatopsis orientalis, is the last choice of treatment against 
multiple-drug resistant Staphylococcus aureus infection.  In this molecule two chlorine 
atoms are essential with the antibacterial effect of the drug diminishing 30% after one 
chlorine atom (Cl*) was substituted by hydrogen and diminishing 50% after both 
chlorine atoms were substituted by hydrogens.50  
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7-Hydroxylaurene, isolated from the red alga Laurencia okamurai, shows stronger lethal 
toxicity against brine shrimp than its natural bromide analogues,51 while the synthetic 
non-halogenated anticancer drug tamoxifen expresses strongly hepatocarcinogenic 
activity in contrast to its chlorinated analogue toremifene.52,53 These examples serve to 
negate “halogenophobia”,11,17 the perception that halogenated compounds tend to be 
more toxic than their non-halogen substituted counterparts.54,55 
Cl
O
N
toremifene
O
N
tamoxifen  
The structural diversity of halogenated natural products and their various biological 
activities are attracting increasing attention from chemists and biologists. So far, a large 
number of literature examples regarding the structures of halogenated natural products 
are available, Gribble in particular has contributed a lot to this field,3,5,8-17 including two 
comprehensive monographs.12,17 To be specific, 2448 naturally occurring organohalogen 
compounds were listed in his review in 1996,12 while an additional 2266 compounds 
were identified based in his update review in 2009.17 As Gribble wrote, intensive 
research has been ongoing resulting in halogenated compounds amounting to 15-20% 
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of newly discovered natural products, representing 100-200 compounds per year.17 
With so many halogenated natural products reported every year, updating all newly 
discovered halogenated natural products since Gribble’s monograph (2009) is beyond 
the scope of this PhD thesis. It is worth noting that natural functions and bioactivities of 
biotic organohalogen compounds were only discussed quite briefly in Gribble’s two 
monographs before 2010, and after 2010 the bioactive halogenated natural products 
described in his other reviews were basically classified by bioactivities rather than 
structures. As such, instead of a comprehensive description, selected examples 
discovered from 2010 onwards will be given in this chapter following a structural 
classification, in addition to their bioactivities, in order to showcase the structural 
diversity and the bioactive variety of halogenated natural products. The biosynthetic 
mechanisms of halogenated natural products will be detailed in the end of this chapter. 
5.2 Structures 
Halogenated natural products possess a broad range of structures, distributed across 
many chemical classes.17 As mentioned in the previous section, Gribble has given 
comprehensive structural information of halogenated natural products in his two 
monographs,12,17 in which he has applied a specific and consistent structural 
classification system. In order to keep the consistency, the updated structures presented 
herein are based on the format used in Gribble’s two monographs. It is worth noting 
that Gribble’s category system may induce arguments since the classified structures are 
easily overlapped, resulting in confusion, such as in the categories of alkaloids, 
heterocycles, aromatics and phenols. In addition, this structural classification system 
produces confusion in some of the naming, therefore some amendments have been 
applied. The category of ‘polyacetylenes’ in Gribble’s original format is replaced by the 
term polyynes in the following format to avoid confusion with the classification of 
polymers of acetylene possessing the general molecular formula (C2H2)n. The category 
of ‘simple alkanes’ used by Gribble’s is replaced by the term simple hydrocarbons to 
properly refer to the halogenated alkanes, alkenes and alkynes. The categories of 
‘simple phenols’ and ‘complex phenols’ in Gribble’s monograph are merged into the 
term phenols described below to avoid unnecessary and undemanding subdivision. 
As such, categories of the updated structures include simple hydrocarbons, simple 
functionalised acyclic organohalogens and simple functionalised cyclic organohalogens, 
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terpenes, steroids, marine nonterpenes: acetogenins, iridoids, lipids and fatty acids, 
furanones, amino acids and peptides, alkaloids, heterocycles, polyynes, enediynes, 
macrolides and polyethers, naphthoquinones, higher quinones and related compounds, 
aromatics, phenols, glycopeptides, dioxins and dibenzofurans. 
5.2.1 Simple Hydrocarbons 
It is estimated that around 23,000 tonnes of chloroform (CHCl3) is produced every year 
from microalgae, while industry contributes approximately 66,000 tonnes.56,57 Indeed, 
marine algae and salt marsh organisms, and some terrestrial organisms are capable of 
generating enormous amounts of simple haloalkanes. For instance, the essential oil of 
marine red alga Asparagopsis taxiformis, which is the favourite Hawaiian edible 
seaweed ‘limu kohu’, is comprised of 80% CHBr3 by weight.11,58 Numerous other simple 
halohydrocarbons have been confirmed to be of biotic origins, some representative 
examples are shown in Figure 5-2.17,26 
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CCl3CHCl2 CCl3CCl3 CF3CF2CF2H
n-C12H25Cl n-C18H37Cl n-C29H59Cln-C24H49Cl
 
Figure 5-2 Representative Examples of Biotic Halohydrocarbons 
 The simple hydrocarbons discovered from marine organisms are mainly substituted by 
chlorine, rather than fluorine, bromine or iodine with the exception that the 
predominant volatile metabolites of brown and green algae are bromoform.59 
5.2.2 Simple Functionalised Acyclic Organohalogens 
The cyanobacterium Leptolyngbya crosbyana‡ which is found on Hawaiian coral was 
reported to produce three new simple functionalised acyclic organohalogens, the 
                                                     
‡ Leptolyngbya crossbyana is used in this reference, it is the misspelling of Leptolyngbya crosbyana. 
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honaucin A-C (5.1-5.3).§ 60 Two novel biologically active lipids, pitinoic acid B and C (5.4-
5.5), were isolated from an unidentified Guamanian cyanobacterium.61 Four novel 
iodinated acetylenic acid metabolites (5.6-5.9) were isolated from the South Korean 
marine sponges, the former two metabolites (5.6-5.7) were produced by Suberites 
mammilaris and the latter two metabolites (5.8-5.9) were produced by Suberites 
japonicus.62 
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§ Despite honaucin A (5.1) incorporating a lactone, it is classified as acyclic based on Gribble’s 
classification due to its skeleton. 
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5.2.3 Simple Functionalised Cyclic Organohalogens 
The aforementioned red alga ‘limu kohu’ (Asparagopsis taxiformis) was reported to 
generate the first examples of natural 2,3-dibromocyclopentenone derivatives, two new 
highly brominated cyclopentenones, mahorone and 5-bromomahorone (5.10-5.11).63 
O O
Br
HO
Br
Br
Br
Br HO
Br
Br
Br
Br
mahorone (5.10) 5-bromomahorone (5.11)  
Polyporapyranone D (5.12) has been isolated from a seagrass (Thalassia hemprichii)-
derived fungi of the order Polyporales PSU-ES44,64 a new azaphilone, chaetomugilin S 
(5.13) has been isolated from a marine fish (Mugil cephalus) derived fungi Chaetomium 
globosum.65 
O
O
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Cl
polyporapyranone D (5.12)
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A chloroazaphilone, (+)-isochromophilone X (5.14), was isolated together with (+)-
isochromophilone XI and (+)-isochromophilone XII from fungus Diaporthe sp. in 2012, 
which was itself isolated from the Chinese mangrove Rhizophora stylosa.66 In 2013 the 
fungus Bartalinia robillardoides strain LF550, which was isolated from the 
Mediterranean sponge Tethya aurantium, was reported to produce two novel 
chloroazaphilones which the authors also named isochromophilone X and 
isochromophilone XI (5.15).67 Given these numbers were already assigned, a renaming 
of the second occurrence of isochromophilone X and isochromophilone XI to 
isochromophilone XIII and isochromophilone XIV (5.15) is required. 
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5.2.4 Terpenes 
Two new polyhalogenated monoterpenes, (-)-plocamenone and a reportedly unstable 
isoplocamenone (5.16-5.17) were isolated from marine alga Plocamium angustum.68 
Curiously the enantiomer of the reported structure of (-)-plocamenone was synthesised 
in 2015 and also reported to possess a negative specific rotation,69 raising doubt as to 
the stereochemistry reported. The synthesis paper also noted a light mediated 
interconversion between (-)-plocamenone and (-)-isoplocamenone. A polychlorinated 
monoterpene (5.18) was isolated from a red alga Plocamium cartilagineum collected 
from eastern coast of South Africa.70 
Cl Cl
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Cl Cl
Br
(-)-plocamenone (5.16) isoplocamenone (5.17) 5.18
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Three monobrominated sesquiterpenes (5.19-5.21) have been isolated from the red 
alga Laurencia okamurai Yamada collected from the coast of Nanji Island, China.71 A 
tribrominated sesquiterpene tristichol A (5.22) was isolated from a red alga Laurencia 
tristicha collected from the coast of Hsiao Liuchiu Island on Taiwan southwestern 
coast.72 
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A new briarane type diterpenoid fragilisinin J (5.23) was isolated from the South China 
Sea gorgonian Junceella fragilis.73 A new briarane type diterpenoid gemmacolide O (5.24) 
was isolated from the South China Sea gorgonian Dichotella gemmacea,74 while in the 
later studies further new briarane type diterpenoid dichotellide H (5.25),75 as well as 
gemmacolide T-Y (5.26-5.31) were revealed.76 It is worth noting that the name of 
gemmacolide U refers to the structure of 5.27,76,77 while it also refers to a different 
diterpenoid, 12-epi-fragilide G.78,79 Here gemmacolide U only refers to the structure of 
5.27. 
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Eight new diterpenoids, kalihinol M-T (5.32-5.39) were isolated from the South China 
Sea sponge Acanthella cavernosa.80 
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5.2.5 Steroids 
A new chlorinated steroid, 4-chloro-β-sitosterone (5.40) was obtained from the tuber of 
Bletilla striata used in Traditional Chinese Medicine.81 
O
Cl
4-chloro-β-sitosterone (5.40)  
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5.2.6 Marine Nonterpenes: Acetogenins 
The red alga Laurencia sp., collected in Omaezaki, Japan, was reported to yield three 
brominated C15-acetogenins, omaezallene and two unnamed analogues (5.41-5.43).82 
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5.2.7 Iridoids 
Two chlorinated iridoid glucosides, longifolioside A and B (5.44-5.45) were isolated from 
the plant Veronica longifolia.83 
O
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longifolioside A (5.44)  R= 3,4-di-OH-benzoyl
longifolioside B (5.45)  R=caffeoyl
HO
 
5.2.8 Lipids and Fatty Acids 
The marine sponge Melophlus sp., collected along the coast of Cicia Island, Fiji, was 
reported to produce a new chlorinated tetramic acid glycoside aurantoside K (5.46).84 
N
OHCl O
O
H2N
O
O OHO
O
OH
OH
O O
HO OH
OH
aurantoside K (5.46)  
210 Chapter 5: Halogenated Natural Products 
 
 
Two novel polyketide lactones coibacin C-D (5.47-5.48) were isolated from a 
Panamanian marine cyanobacterium, Oscillatoria sp.,85 another new chlorinated 
polyketide lactone PM050489 (5.49) was isolated from the Madagascan sponge 
Lithoplocamia lithistoides.86  
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A Papua New Guinea collection of the marine cyanobacterium Lyngbya sordida yielded 
a new compound malyngamide 2 (5.50),87 the marine cyanobacterium Lyngbya 
majuscula collected from Cocos Lagoon, Guam yielded another new compound 
malyngamide 3 (5.51).88  
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5.2.9 Furanones 
Two new brominated furanones, 3'-bromorubrolide E and 3',3''-dibromorubrolide E 
(5.52-5.53) were isolated from a South African tunicate Synoicum globosum Parker-
Nance sp. nov. (Ascidiacea, Aplousobranchia).89 Six new brominated furanones, 
cadiolide C-F, and rubrolide P-Q (5.54-5.59), were isolated from the Korean ascidian 
Pseudodistoma antinboja,90 another three new brominated furanones, cadiolide G-I 
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(5.60-5.62) were reported to be generated by the ascidian Synoicum sp. collected off 
the Korean coast of Chuja-do.91 
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5.2.10 Amino Acids and Peptides 
A new brominated amino acid herdmanine D (5.63) was isolated from the Korean marine 
ascidian Herdmania momus.92 
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The cyanobacterium Anabaena cylindrica strain Bio33 was isolated from a water sample 
collected from the Rugen Island in the Baltic Sea, its laboratory cultivation yielded two 
chlorinated lipopeptides, balticidin A and B (5.64-5.65) with partial stereochemistry 
being assigned.93,94  
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5.2.11 Alkaloids 
A new bisindole derived alkaloid indimicin B (5.66) was isolated from a deep-sea derived 
Streptomyces sp. SCSIO 03032.95 
N N
H
N
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Cl Cl
indimicin B (5.66)  
A new brominated pyrrole alkaloid aspidostomide E (5.67) was isolated from the 
Patagonian bryozoan Aspidostoma giganteum.96 A new chlorinated alkaloid 
chloromangiferamide (5.68) was isolated from the Sri Lanka endemic plant Mangifera 
zeylanica Hook.f. (Anacardiaceae), which is traditionally used in Ayurvedic medicine for 
the treatment of various diseases.97  
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Two new dibrominated alkaloids pulmonarin A and B (5.69-5.70) were isolated from the 
sub-Arctic ascidian Synoicum pulmonaria collected off the Norwegian coast.98 
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 Two structurally unique dimeric brominated pyrrole alkaloids, agelamadin A and B 
(5.71-5.72) were isolated from a marine sponge Agelas sp.,99 another three brominated 
pyrrole alkaloids, agelamadin C-E (5.73-5.75), were isolated from the same sponge.100 
214 Chapter 5: Halogenated Natural Products 
 
 
agelamadin C (5.73)
HOOC
O
HN N
H
NHHN
NH
O
Br
Br
NH2
ONH3
agelamadin A (5.71) R=OMe
agelamadin B (5.72) R=OH
agelamadin D (5.74)
HOOC
O
HN N
H
NHHN
NH
O
Br
Br
NH2
ONH3
agelamadin E (5.75)
HOOC
O
HN N
H
NHHN
NH
O
Br
Br
NH2
ONH3
NH
HN
HN
N
H NH
N
O
H
H2N
NH2
R
H H
O
NH
Br
Br
H
N
Br
Br
 
5.2.12 Heterocycles 
The Mediterranean gorgonian Paramuricea clavata was reported to produce a new 
monobrominated indole (5.76),101 the marine bryozoan cheilostomatous species 
Chartella (Terminoflustra) membranaceatruncata (Smitt, 1868) was reported to yield a 
new tribrominated indole (5.77).102 
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A Fijian red alga Callophycus sp. produced five new brominated diterpene-benzoates 
bromophycoic acid A-E (5.78-5.82).103 
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5.2.13 Polyynes 
The Korean marine sponge Placospongia sp. generated an iodinated diacetylene 
placotylene A (5.83).104  
I
HO
placotylene A (5.83)  
The Red Sea sponge, Haliclona sp. yielded two new brominated acetylenes, a 
diacetylenic acid and its methyl ester (5.84-5.85),105 while the Japanese marine sponge 
Theonella swinhoei, collected off the coast of Tanegashima, Kagoshima Prefecture, 
produced a new brominated C17-diacetylenic acid, bromotheoynic acid (5.86).106 
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5.2.14 Enediynes 
A nitrogenous halogenated long-chain enediyne, mollenyne A (5.87) was isolated from 
the sponge Spirastrella mollis collected off the coast of Bahamas.107 
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5.2.15 Macrolides and Polyethers 
The marine-derived fungus Humicola fuscoatra (UCSC strain no. 108111A) produced a 
new resorcylic acid lactone radicicol B (5.88),108 a marine sponge of the Petrosiidae 
family collected off the coast of Pemba (Tanzania) furnished two new polyketide 
macrolides phormidolide B and C (5.89-5.90), with partial stereochemistry being 
assigned.109  
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Three new brominated polyethers, 15-dehydroxythyrsenol A, prethyrsenol A and 13-
hydroxyprethyrsenol A (5.91-5.93) have been isolated from the red alga Laurencia 
viridis,110 another two brominated polyethers, iubol and 22-hydroxy-15(28)-
dehydrovenustatriol (5.94-5.95) were isolated from the same red alga,111 as well as two 
new brominated oxasqualenoids, saiyacenol A and B (5.96-5.97).112 
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5.2.16 Naphthoquinones, Higher Quinones and Related Compounds 
Four new dihalogenated napyradiomycins (5.98-5.101) were isolated from the marine-
derived actinomycete strain CNQ525, which was collected from California.113 Three new 
napyradiomycins (5.102-5.104) were isolated from a marine-derived actinomycete 
Streptomyces strain SCSIO 10428.114 A new chlorinated metabolite guignardin E (5.105) 
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was isolated from the endophytic fungus Guignardia sp. KcF8 derived from a mangrove 
Kandelia candel.115 
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A cultured marine-derived actinomycete Streptomyces strain CNQ-329, isolated from 
marine sediments collected in California, was reported to produce the novel chlorinated 
compound napyradiomycin A (5.106).116 
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5.2.17 Aromatics 
Two new paracyclophanes carbamidocyclophane F and G (5.107-5.108) were isolated 
from a cultured freshwater cyanobacterium Nostoc sp. (UIC 10274), collected near Des 
Plaines, Illinois.117 
Cl
OCONH2Cl
Cl HO OH
HO
ClOHHO
Cl
OCONH2Cl
Cl HO OH
H3COCO
ClOHHO
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5.2.18 Phenols 
Three new brominated polyphenols (5.109-5.111) were isolated from a marine red alga 
Symphyocladia latiuscula, which was collected from the coast of Qingdao, China.118 
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The southern Australian sponge Pseudoceratina sp. yielded two new bromotyrosine-
derived metabolites, (-)-purealin B and purealin C (5.112-5.113).119 
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Fourteen new chlorinated depsidone-based compounds spiromastixone B-O (5.114-
5.127) were isolated from the a deep-sea fungus Spiromastix sp..120 
O
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R4
R5
spiromastixone B (5.114) R1=R3=R5=H, R2=Cl, R4=OH
spiromastixone C (5.115) R1=Cl, R2=R3=R5=H, R4=OH
spiromastixone D (5.116) R1=R5=Cl, R2=R3=H, R4=OH
spiromastixone E (5.117) R1=R2=Cl, R3=R5=H, R4=OH
spiromastixone F (5.118) R1=R2=R5=Cl, R3=H, R4=OH
spiromastixone G (5.119) R1=R2=R5=Cl, R3=H, R4=OMe
spiromastixone H (5.120) R1=R2=R3=Cl, R4=OH, R5=H
spiromastixone I (5.121)  R1=R2=R3=R5=Cl, R4=OH
spiromastixone J (5.122) R1=R2=R3=R5=Cl, R4=OMe  
O
O
O
R1
HO
R2
R5
R4R3
spiromastixone K (5.123) R1=R2=R5=Cl, R3=H, R4=OMe
spiromastixone L (5.124) R1=R2=R3=R5=Cl, R4=OMe
spiromastixone M (5.125) R1=R2=Cl, R3=R5=H, R4=OH
spiromastixone N (5.126) R1=R2=R5=Cl, R3=H, R4=OH
spiromastixone O (5.127) R1=R2=R3=R5=Cl, R4=OH  
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5.2.19 Glycopeptides 
A new bicyclic glycopeptide theonellamide G (5.128) was isolated from the Red Sea 
sponge Theonella swinhoei, with partial stereochemistry being assigned.121 
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5.2.20 Dioxins and Dibenzofurans 
No bioactive halogenated dioxins with a biotic source have been discovered since 2010 
based on the literature search. A new chlorinated dibenzofuran Pf-1 (5.129) was isolated 
from fruiting bodies of the cellular slime mould Polysphondylium filamentosum.122 
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Two polybrominated dibenzofurans, boletopsin 13 and 14 (5.130-5.131) were isolated 
from a terrestrial macrofungi Boletopsis sp., a traditionally used mushroom as a food 
source and as a treatment for gastrointestinal disorders by the Kiovi Tribe of the Lufa 
district in the Eastern Highlands province of Papua New Guinea.123 
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5.3 Bioactivities 
The large variety and complexity of structures of natural halogenated products has 
resulted in them displaying a variety of bioactivities. Halogenated natural products have 
demonstrated antibacterial activity, antifouling activity, antifungal activity, antiparasitic 
activity, antiviral activity, antitumour activity, antioxidant activity, anti-inflammatory 
activity, enzymatic and molecular regulation activity.13-18,23,26,29,124 
5.3.1 Antibacterial Activity 
The simple functionalised acyclic organohalogens the honaucin A-C (5.1-5.3) show 
activity against Gram-negative Escherichia coli (JB525) and the marine derived 
bioluminescent bacterium Vibrio harveyi (BB120).60 Pitinoic acid B (5.4) and C (5.5) are 
active against the Gram-negative Pseudomonas aeruginosa.61 
The simple functionalised cyclic organohalogens, mahorone (5.10) and 5-
bromomahorone (5.11) exhibit broad spectrum activity being active against the Gram-
positive Staphylococcus aureus and the Gram-negative V. fisheri, and the Gram-negative 
Acinetobacter baumannii and E. coli.63 Isochromophilone XIV (5.15) also shows broad 
spectrum activity being inhibitory toward B. subtilis and S. lentus.67 
The monoterpene (-)-plocamenone (5.16) displays activity against the Gram-positive 
Bacillus subtilis.68 The sesquiterpene tristichol A (5.22) display activity against the Gram-
negative Enterobacter aerogenes, Serratia marcescens, and Yersinia enterocolitica.72  
The diterpene gemmacolide O (5.24) shows activity against E. coli and is the most 
antibacterial active compound among the gemmacolides.74 The diterpene gemmacolide 
T-Y (5.26-5.31) show activity against E. coli. 
The furanones 3'-bromorubrolide E and 3',3''-dibromorubrolide E (5.52-5.53) show 
activity against methicillin-resistant S. aureus (MRSA) and S. epidermidis.89 The 
furanones cadiolide C-I and rubrolide P-Q (5.54-5.62) show broad spectrum antibacterial 
activity, with 5.54-5.59 possessing activity against S. aureus, B. subtilis, S. epidermidis 
and Kocuria rhizophilia while 5.60-5.62 have activity against B. subtilis, K. rhizophilia and 
Salmonella enterica.90,91 
The alkaloids agelamadin A-E (5.71-5.75) are active against B. subtilis and the Gram-
positive to Gram-variable Micrococcus luteus.99,100 
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The heterocyclic compound 5.76 shows strong antibacterial activity against 
Pseudoalteromonas sp. D41 and TC8, and Paracoccus sp. 4M6.101 The heterocyclic 
compounds bromophycoic acid A-E (5.78-5.82) all exhibit activity against MRSA, with 
bromophycoic acid A (5.78) being more active than vancomycin. In addition, 
bromophycoic acid A (5.78) and E (5.82) are active against vancomycin-resistant 
Enterococcus faecium (VRE).103 
The naphthoquinones 5.102-5.103 are active against S. aureus (ATCC 29213), B. 
thuringiensis (SCS10 BT01) and B. subtilis (SCS10 BS01) while 5.104 is only active against 
the latter two bacteria.114 Napyradiomycin A (5.106) is strongly active against MRSA.116 
The phenol purealin C (5.113) shows significant activity against S.aureus and B. subtilis, 
while (-)-purealin B (5.112) only shows activity against B. subtilis.119 Spiromastixone B-O 
(5.114-5.127) display activity against S. aureus (ATCC 29213), B. thuringiensis (SCS10 
BT01) and B. subtilis (SCS10 BT01).120 
The dibenzofurans boletopsin 13 and 14 (5.130-5.131) show broad spectrum activity 
being active against the Gram-positive S. epidermidis and the Gram-negative E. coli.123  
5.3.2 Antifouling Activity 
The diterpenoids fragilisinin J (5.23) and dichotellide H (5.25) exhibit antifouling activity 
inhibiting larval settlement of the barnacle Balanus amphitrite.73,75 Kalihinol O-T (5.34-
5.39) also display antifouling activity against the same barnacle larvae.80 
The acetogenin omaezallene (5.41) shows the strongest antifouling activity against the 
barnacle Balanus amphitrite while the analogues 5.42-5.43 exhibit weak antifouling 
activity.82 
5.3.3 Antifungal Activity 
The simple functionalised cyclic organohalogen isochromophilone XIV (5.15) shows 
activity against Trichophyton rubrum.67 
The monoterpene (-)-plocamenone (5.16) shows activity against Candida albicans and 
Cladosporium resinae.68 The sesquiterpenes laurepoxyene (5.19) and 3β-
hydroperoxyaplysin (5.20) show activity against C. glabrata, while 3β-
hydroperoxyaplysin (5.20) and 3α-hydroperoxy-3-epiaplysin (5.21) display activity 
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against Cryptococcus neoformans.71 The diterpenes gemmacolide T-Y (5.26-5.31) display 
activity against Microbotryum violaceum and Septoria tritici.76 
The lipid and fatty acid classified aurantoside K (5.46) shows broad antifungal activity 
against wild type C. albicans, amphotericin-resistant C. albicans, C. neoformans, 
Aspergillus niger, Penicillium sp., Rhizopus sporangia and Sordaria sp.84  
The peptides balticidin A-B (5.64-5.65) show antifungal activity against C. maltosa, C. 
albicans, C. krusei, A. fumigatus, Microsporum gypseum, M. canis, and Mucor sp.93,94 
The alkaloids agelamadin A-E (5.71-5.75) are active against C. neoformans.99,100 
The heterocyclic compound 5.77 displays activity against C. albicans and Saccharomyces 
cerevisiae.102 
The phenols 5.109-5.111 exhibit activity against C. albicans.118 
The glycopeptide theonellamide G (5.128) possesses activity against both wild type and 
amphotericin B-resistant strains of C. albicans.121 
5.3.4 Antiparasitic Activity 
The lipid and fatty acid classified compounds coibacin C (5.47) and D (5.48) are active 
against the parasite Leishmania donovani responsible for the debilitating disease 
leishmaniansis.85 
5.3.5 Antiviral Activity 
The macrolide radicicol B (5.88) shows activity against human immunodeficiency virus 
type-1 (HIV-1).108 
5.3.6 Antitumour Activity 
The simple functionalised cyclic organohalogens polyporapyranone D (5.12), 
chaetomugilin S (5.13) and (+)-isochromophilone X (5.14) demonstrate antitumor 
activity. Compound 5.12 exhibits cytotoxic activity against African green monkey kidney 
fibroblasts (Vero) cell line,64 5.13 inhibits P388, HL-60, L1210  and KB cell lines,65 while 
5.14 shows activity against MCF-7 (breast), SGC-7901 (gastric), SW1116 (colorectal), 
A549 (lung) and A375 (melanoma) human cancer cell lines.66  
The monoterpenes (-)-plocamenone and isoplocamenone (5.16-5.17) exhibit 
cytotoxicity against P388 mouse leukemia cells.68 The monoterpene 5.18 exhibits 
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activity against the human lung cancer (NCI-H460) and the mouse neuro-2a 
neuroblastoma cell lines.70 The sesquiterpene 3β-hydroperoxyaplysin (5.20) shows 
cytotoxicity against the A-549 (lung) cell line.71 The diterpenoids gemmacolide T-Y (5.26-
5.31) show activity against A549 and MG63 human cancer cell lines, with 5.28 and 5.31 
possessing stronger cytotoxicity than other analogues.76 The diterpenoids kalihinol O-R 
(5.34-5.37) show activity against HCT-116 human colon cancer cell.80 
The steroid 4-chloro-β-sitosterone (5.40) shows weak toxicity to 293A cells of human.81 
The lipid and fatty acid classified compound PM050489 (5.49) is a tubulin-binder and 
inhibits HT-29 (colon), A-549 (lung) and MDA-MB-231 (breast) human tumor cells.86 
Malyngamide 2 (5.50) is active against H-460 (lung) cells,87 malyngamide 3 (5.51) is 
weakly inhibitory to MCF-7 (breast) and HT-29 (colon) cells.88,125 
The alkaloid Indimicin B (5.66) displays cytotoxic activity against human breast cancer 
MCF-7 cells,95 aspidostomide E (5.67) is active against the human renal cancer 786-O 
cells,96 while chloromangiferamide (5.68) shows cytotoxicity against the human breast 
cancer MDA-MB-231 cell line.97 
The polyynes 5.84-5.85 show activity against MCF-7 human breast cancer cells.105 
Bromotheoynic acid (5.86) inhibits the proliferation of U937, HL60, A549, H1299, 
HEK293 human cell lines.106 
The enediyne mollenyne A (5.87) is highly active against HCT-116 human colon cancer 
cells.107 
The macrolides phormidolide B and C (5.89-5.90) show significant inhibition to the 
growth of A-549(lung), HT-29 (colon) and MDA-MB-231 (breast) cell lines.109 Polyether 
compounds 5.91-5.97 all exhibit antitumor activity against MM144, HeLa, CAD-ES-1 
human cancer cell lines with the exception that compound 5.95 only inhibits HeLa 
cells.110-112 
The naphthoquinone compounds napyradiomycins CNQ525.510B (5.98), CNQ525.538 
(5.99), CNQ525.554 (5.100) and CNQ525.600 (5.101) can  induce apoptosis in the human 
colon cancer cell line HCT-116.113 Guignardin E (5.105) shows cytotoxicity towards K562, 
A549, Huh-7, H1975, MCF-7, U937, BGC823, HL60, HeLa, MOLT-4 human cancer cells.115 
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The aromatic compounds carbamidocyclophane F (5.107) and G (5.108) show inhibition 
of the growth of MDA-MB-435 (breast) and HT-29 (colon) human cancer cell lines.117 
The dibenzofuran Pf-1 (5.129) exhibits cytotoxicity against human K562 and HeLa cell 
lines, and the mouse embryo fibroblast 3T3-L1 cell line.122 
5.3.7 Antioxidant Activity 
The iridoids longifolioside A and B (5.44-5.45) show antioxidant activity against nitric 
oxide, superoxide and 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals.83 
5.3.8 Anti-inflammatory Activity 
The simple functionalised acyclic organohalogens 5.6 and 5.7 display strong inhibition 
of nitric oxide production from RAW 264.7 cells, while 5.8 and 5.9 show stronger 
inhibition of nitric oxide production from BV2 cells than the former compounds. All four 
compounds attenuate PGE2 (prostaglandin E2) production from RAW 264.7 and BV2 
cells.62 
The sesquiterpene tristichol A (5.22) inhibits N-formylmethionyl-leucyl-
phenylalanine/cytochalasin B (fMLP/CB)-induced superoxide anion generation.72 
The amino acid herdmanine D (5.63) is able to suppress the nitric oxide production of 
RAW 264.7 cells induced by lipopolysaccharide (LPS), resulting from inhibiting the mRNA 
expression of the inducible nitric oxide synthase (i-NOS).92 
5.3.9 Enzymatic and Molecular Regulation Activity 
The simple functionalised cyclic organohalogen isochromophilone XIV (5.15) shows 
phosphodiesterase 4 (PDE4) inhibition activity.67 
The alkaloids pulmonarin A and B (5.69-5.70) both show reversible, non-competitive 
acetylcholinesterase inhibition activity.98 
The polyyne placotylene A (5.83) suppresses receptor activator of nuclear factor κB 
ligand (RANKL) induced TRAP-positive osteoclast differentiation.104 Compounds 5.84-
5.85 are able to stimulate differentiation of the ST-13 preadipocytes to adipocytes.126 
Bromotheoynic acid (5.86) inhibits the maturation of starfish (Asterina pectinifera) 
oocytes.106 
The dibenzofuran Pf-1 (5.129) suppresses the activity of β-galactosidase.122 
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5.4 Biosynthetic Mechanisms 
Since the reality of halogenated natural products is undoubted, their remarkable 
chemistry and bioactivities in addition to their biosynthetic origins have attracted the 
attention of scientists. Biotic halogenation can be divided into enzymatic and 
nonenzymatic pathways, although enzymatic halogenation is believed to be the most 
common route. Enzymatic halogenation can be grouped into three classes: (1) 
hypohalite (XO-) origin, which is chemically equivalent to a halonium cation (X+), (2) 
halogen radical (X·) origin and (3) halide anion (X-) origin. 
The abundances of halogens vary enormously in nature, for instance, the composition 
of fluorine (F) : chlorine (Cl) : bromine (Br) : iodine (I) in Earth’s primitive mantle is 
estimated to be 18:1.4:0.0036:0.001.127 F and Cl are by far the most abundant halogens 
in nature, and are generally regarded as proxies for the other halogens,1,127-131 Despite 
fluorine’s high natural abundance, the naturally occurring organofluorides are not 
common. Since fluoride (F-) readily forms hydrogen bonds in water it is difficult to 
desolvate and generate active F- ion in aqueous solution. Fluorine radical (F·) is also rare 
due to its electronegativity. In addition, because of the extremely high redox potential 
of fluoride (Eo[F2/F-]: 2.87 V), which is much higher than that of peroxide (Eo[H2O2/H2O]: 
1.78 V), fluoride ion (F-) is impossible to be oxidised to the fluoride cation (F+) for 
electrophilic fluorination in nature. These reasons may explain the scarcity of fluorinated 
natural products with around 30 compounds, even though fluoride is widespread in 
nature.32 
Due to the high relative natural abundance of chloride and bromide and low natural 
abundance of iodide, molar ratios of Cl- : Br- : I- is around 500,000 : 1,000 : 1 in ocean 
water and 100:5:1 in terrestrial soil respectively,34 naturally occurring organochlorine 
and organobromine compounds represent more than 95% of all organohalogens.32 
However, since the redox potentials of Br- and I- are lower than that of Cl- (Eo[HOCl/Cl-]: 
1.48 V versus Eo[HOBr/Br-]: 1.33 V and Eo[HOI/I-]: 0.99 V), indicating they are more 
readily oxidised to Br+ and I+ than Cl- is to Cl+, goes some way to explain why 
organobromides and organoiodides are statistically overrepresented. In the enzymatic 
oxidative halogenation pathway, an enzyme capable of oxidising chloride can also 
oxidise bromide and iodide and catalyse the corresponding bromination and iodination 
reactions. Similarly, an enzyme that can oxidise bromide can also catalyse an iodination 
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reaction however, an enzyme capable of oxidising iodide is selective and can only 
catalyse an iodination reaction. In the following discussion of biosynthetic halogenation 
mechanisms, only chlorination will be described if bromination and iodination follow on 
the same principle. 
5.4.1 Enzymatic Pathways 
Enzymatic halogenation is the most common route for halogen incorporation occurring 
in living organisms and has been being extensively investigated, though a lot of details 
remain unknown.17,18,20,21,29,32,34,37,38 Structurally and functionally versatile enzymes 
afford a complex and sophisticated approach to modify metabolites by halogenation, 
playing a significant role in establishing unique bioactivity.19,36 As mentioned above 
enzymatic pathways are classified into these three groups according to the origins of the 
halogen and each of these is described below. 
5.4.1.1 Halogenation by Halonium Cation, X+ 
The most common instances of enzymatic halogenation occur by the oxidation of 
abundant X- to generate the reactive X+ species, followed by reaction with electron-rich 
substrates. Depending on the different oxidants available, this kind of halogenation can 
be catalysed by two broad classes of enzymes: (i) haloperoxidases (HPO) which are 
promiscuous utilising peroxide (H2O2) and (ii) halogenases which are highly substrate-
specific and regioselective utilising molecular oxygen.18,20,21,132 
 
HPOs are widely distributed among terrestrial and marine organisms, especially among 
fungi of the class hyphomycetes which are common as saprophytes and plant pathogens 
and marine algae.18,19,32,36 HPOs are classified as either haem- or vanadate-dependent 
HPOs in terms of the enzyme metal centres. 
For a haem-dependent HPO, the enzyme has an iron (Fe) metal centre. The Fe atom is 
redox active and changes its oxidation state during the catalytic cycle. Chloroperoxidase 
(CPO) isolated from fungus Caldariomyces fumago, which produces the chlorinated 
natural product caldariomycin, is a representative example of a haem-dependent HPO. 
This enzyme binds an Fe(III) haem-water (H2O) complex where the catalytic cycle starts 
and is considered the resting state. Firstly, hydrogen peroxide displaces water and is 
subsequently deprotonated with assistance from a glutamic acid residue (Glu 183) to 
5.4.1.1.1 Haloperoxidases (HPOs) 
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give compound 0 (Scheme 5-1). After that the coordinated and negative charged oxygen 
of the peroxide is bound to Fe(III), then the peroxide is protonated by Glu 183, then 
leaves as water after an Fe(IV)-oxo complex, compound I, is formed (Scheme 5-1). The 
generated Fe(IV)-oxo complex subsequently reacts with chloride (Cl-) by oxidising Cl- to 
generate Fe(III)-hypohalite (ClO-) complex. Controversially, the generated ClO- is either 
a ligand coordinated to this Fe(III) haem complex or released to form a free 
hypochlorous acid (HOCl) which diffuses out of the enzyme through channels. Both of 
these two hypothesises are supported by corresponding experimental observations, 
indicating more studies need to be done to address the controversy.19,32,36 Finally, either 
coordinated ClO- or free HOCl reacts with electron-rich organic substrate to yield biotic 
organochlorine compounds. At the same time the catalytic cycle ends up with Fe(III) 
haem complex coordinating with H2O (Scheme 5-1). 
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Scheme 5-1 Proposed Catalytic Cycle for Haem-dependent CPO19,36 
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Another well studied HPO is the vanadate-dependent HPO. Analogous to its haem-
dependent counterpart, a vanadate-dependent HPO has a vanadium metal centre while 
the vanadium atom does not appear to be redox active and maintains its oxidation state 
during the catalytic cycle. Vanadate-dependent HPOs are responsible for the vast 
majority of biotic marine organohalogen compounds.18 Vanadate-dependent 
bromoperoxidases are widespread among marine seaweeds while chloroperoxidases 
predominate in terrestrial fungi. The chloroperoxidase from the plant pathogenic fungus 
Curvularia inaequalis is an intensively studied vanadate-dependent HPO, however, the 
exact mechanism involving oxygen-bound intermediates is still under debate because of 
insufficient experimental evidence.19,22,35,36,133 Generally, the catalytic cycle is 
considered to start from the resting state of the enzyme, V(V) with three equatorial 
vanadate oxygen (O) atoms coordinated with a single axial His 496 ligand and an apical 
water hydrogen-bonded to a His 404 in a trigonal bipyramidal coordination geometry. 
The cycle is initiated with hydrogen peroxide displacing water and coordinating with 
V(V). The His 404 deprotonates hydrogen peroxide and enables H2O2 to bind V(V), then 
a Lys deprotonates the H2O2 again and subsequently forms a hydrogen bond with one 
of the oxygen atoms from the bound peroxide (Scheme 5-2). In the generated peroxo-
V(V) complex, the peroxide is equatorially bound in a side-on manner and distorts the 
geometry to a tetragonal bipyramid (Scheme 5-2), coordinated ligand His 496 and the 
covalent oxygen atom is equatorial and the oxo group is apical, His 404 is no longer 
hydrogen-bonded to any oxygen atoms of the cofactor. Then akin to the haem-
dependent counterpart, Cl- is oxidised by the bound peroxide and subsequently dioxo-
V(V) complex is generated with either coordinated ClO- or free HOCl being formed, which 
can react with electron-rich organic substrate to yield biotic organochlorine compounds, 
at the same time the dioxo-V(V) complex coordinates with another water to return the 
resting state (Scheme 5-2). 
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Scheme 5-2 Proposed Catalytic Cycle for Vanadate-dependent CPO19,22,35,36,133 
 
In contrast to HPOs using hydrogen peroxide, halogenases utilise dioxygen (O2) as the 
oxidant during their catalytic halogenation. Flavin-dependent halogenases are the best 
known halogenases referring to the oxidation of X- to X+ and exist in numerous 
organisms, nevertheless, much less is known about their catalytic mechanism compared 
to the HPOs.18-21,29,32,33,36 The tryptophan 7-halogenase (PrnA) isolated from 
Pseudomonas fluorescens BL915 was the first described flavin-dependent halogenase. 
The mechanism is believed to involve an enzyme bound reduced flavin, FADH2, that 
reacts with O2 to form the oxidised flavin, FADH-OOH, which subsequently reacts with 
Cl- to generate HOCl and FADH-OH. The HOCl produced reacts with a lysine residue to 
generate a less reactive but chiral chloramine rather than being released to act as a more 
reactive but unselective chlorinating agent. This can explain why halogenases possess 
highly substrate-specific and regioselective activities. The chloramine reacts with 
electron-rich organic substrates to yield biotic organochlorine compounds and returning 
the amine to re-enter the cycle (Scheme 5-3). The FADH-OH is dehydrated to FAD which 
is reduced by NADPH with a flavin reductase in order to produce a FADH2. The 
mechanism is shown in Scheme 5-3. 
5.4.1.1.2 Halogenases 
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5.4.1.2 Halogenation by Halogen Radical, X· 
The structures of many halogenated natural products, such as barbamide, dysidenin and 
hapalindole A, show halogenation occurs at non-activated (not electron-rich) carbon 
centres, which suggests such halogenations occur via a different mechanism from 
halonium, X+, mediated halogenations. 
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Investigations led to the isolation of a class of enzymes which are responsible for 
halogenations at inactivated carbon centres. Alpha-Ketoglutarate (αKG), O2 and the 
halide, X-, were found to be essential in this highly substrate-specific and regioselective 
reaction. An Fe(II) metal centre is involved and changes its oxidation state during the 
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catalytic cycle. This class of enzymes are called non-haem Fe(II)/αKG-dependent 
halogenases which utilise anionic halide, X-, to form X· for the generation of halogenated 
natural products.18,19,21,31,36,37 Syringomycin halogenase (SyrB2) from the bacterium 
Pseudomonas syringae is a well-studied Fe(II)/αKG-dependent chlorogenase. The 
catalytic cycle starts from the enzyme binding αKG and Cl-, a proton from the bonded 
αKG is transferred to OH resulting in forming H2O which coordinates with Fe(II) (Scheme 
5-4). Molecular oxygen then displaces H2O and coordinates with Fe(II), an Fe(IV)-
superoxo complex is subsequently generated. After that, the dioxygen bond is 
weakened and broken to form an Fe(IV)-oxo complex with αKG decarboxylation, the 
generated Fe(IV)-oxo complex then reacts with an organic substrate via hydrogen (H) 
atom abstraction, leading to a Fe(III)-hydroxy complex and a substrate radical R·. The 
produced radical R· subsequently reacts with the bound chlorine Cl in Fe(III)-hydroxy 
complex to furnish a halogenated natural product and an Fe(II)-hydroxy complex is 
produced, which subsequently binds αKG and Cl- to start another catalytic cycle. The 
mechanism is described in Scheme 5-4. 
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Scheme 5-4 Proposed Catalytic Cycle for Fe(II)/αKG-dependent Chlorogenase18,19,21,36 
5.4.1.3 Halogenation by Halide Anion X- 
Some fluorinated natural products are produced by F- directly reacting with the 
electrophilic organic substrate. Some enzymes have been discovered to catalyse this 
kind of direct fluorination, for example 5’-fluoro-5’-deoxyadenosine synthetase (5’-FDAS) 
isolated from the bacterium Streptomyces cattleya. The mechanism is thought to involve 
solvated F- bound to a hydrophobic pocket provided by the enzyme and F- is desolvated 
when the protein residues coordinate to H2O. The free F- generated then attacks the 
electrophilic 5’ carbon of the co-substrate, S-adenosyl-L-methionine (SAM), via a 
bimolecular nucleophilic substitution (SN2 substitution), and the intermediate 5’-fluoro-
5’-deoxyadenosine produced is converted to fluoroacetate and 4-
fluorothreonine.18,19,21,29,36,134 The description of this mechanism is shown in Scheme 5-5. 
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Scheme 5-5 Proposed Mechanism of 5’-FDAS Induced Fluorination18,19,21,29,36,134 
A 5’-FDAS analogue enzyme, identified as chlorinase SalL, isolated from the marine 
actinomycete Salinispora tropica is regarded as incorporating Cl- into salinosporamide A, 
the mechanism is similar with 5’-FDAS and displayed in Scheme 5-6.18,19,21,29 
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Scheme 5-6 Proposed Mechanism of SalL Induced Chlorination18,19,21,29 
SAM is also a substrate for a methyltransferase, which transfers the methyl group 
bonded with sulphur (S) to a halide, a monohalomethane is generated as a result. Methyl 
chloride transferase was discovered in seaweeds and also in many plants, the 
mechanism is shown in Scheme 5-7.19,21 
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Scheme 5-7 Proposed Mechanism of Methyl Chloride Transferase19,21 
5.4.2 Nonenzymatic Pathways 
Remarkably, a few nonenzymatic pathways of biotic halogenations have been 
discovered as the supplement of enzymatic pathways. Polycyclic chlorinated 
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metabolites cyanosporaside A and B in addition to sporolide A and B, isolated from a 
marine actinomycete genus Salinispora, are such examples. They are regarded as 
originating from nine-membered enediyne precursors, adducting with Cl- is 
hypothesised to occur after a Bergman cyclization and this is supported by experimental 
evidence.18,29,134 Therefore, the produced natural products only halogenated at one but 
never both of two positions of an aromatic ring followed by this pathway. Details are 
shown in Scheme 5-8. 
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Scheme 5-8 Proposed Mechanism of Nonenzymatic Chlorination18,29,134 
5.5 Conclusion 
Naturally occurring organohalogen compounds are predominantly processed by 
chlorine and bromine via halonium cation or halogen radical pathways under the 
catalysis of various enzymes. The biosynthetic pathway via halide anion, nonenzymatic 
pathway in particular, is very rare. To date, knowledge about halogenated natural 
products, especially their biosynthetic mechanisms, is limited even though intensive 
investigations have been ongoing during the last few decades. Inspiringly, this field has 
become a research hotspot and the increasing effort may solve numerous “unknowns” 
about halogenated natural products. As new equipment and technology is applied, 
discoveries of new species and bioactivities screening become much more efficient, 
molecular investigations will become much easier, which will lead a more productive 
trend in this area. Importantly, to dispel public “halogenophobia”, the entire knowledge 
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of halogenated natural products, especially their beneficial uses, should be exploited 
and communicated back to our community. 
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Chapter 6: Discovery of a Novel Halogenation Reaction 
6.1 Introduction 
6.1.1 Azaphilones 
The word azaphilone signifies the affinity of a compound for nitrogen. The nomenclature 
is used to describe “a structurally variable family of fungal polyketide metabolites 
possessing a highly oxygenated pyranoquinone bicyclic core, usually known as 
isochromene, and a quaternary carbon center.”1 The azaphilone scaffolds and a 
representative example citrinin are shown in Figure 6-1. 
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Figure 6-1 Azaphilone Scaffold and Citrinin Structure 
An azaphilone readily reacts with a primary amine to exchange the pyran oxygen with a 
nitrogen. Many of the azaphilones are orange coloured pigments and in this process a 
characteristic colour change to a bright red, as a result of generating a vinylogous 4-
pyridone, is observed. Some azaphilones are traditionally used as food colorants in East 
Asian countries, namely pigments produced by fungi in the genus Monascus.2,3 In 
addition, azaphilones are very useful taxonomical markers because of the occurrence of 
specific and unique azaphilones in some fungal species.1,4 Importantly, azaphilones 
show promising bioactivities, such as enzymatic and molecular inhibitors and regulators, 
anti-HIV, anticancer, anti-inflammatory, antimicrobial, antiplasmodial, antioxidant, 
cytotoxic, hypolipidemic and antihypertensive activities. These effects are generally 
attributed to the reactions of azaphilones with cellular amino groups such as amino acids, 
proteins and nucleic acids to form nitrogenised azaphilones as shown in Scheme 6-1.1,3-
7 
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Scheme 6-1 Proposed Mechanism for Nitrogenised Azaphilone Formation 
However, these reactions are always nonselective, indiscriminately reacting with amines 
leading to the main impediment for their development as drug candidates.4 To date, 
some reviews of azaphilones are available, in particular two monographs, offering 
detailed structural commentary and detailing bioactivities.1,4 A review published in early 
2013 described 373 azaphilones generated by 23 genera from 13 fungal families, with 
overrepresentation from members of the families Trichocomaceae and Xylariaceae. 
These azaphilones are classified into 18 different structural categories,1,4 and of 373 
azaphilones, 90 of them are halogenated, predominantly through chlorination. 
6.1.2 Discovery of an Abiotic Halogenation Reaction among Azaphilones 
The chemical investigation of fungus Penicillium sp. MINAP 9902 isolated from the 
fruiting body of the myxomycete Lycogala epidendrum led to discovery of some 
azaphilone compounds, which were isolated from the ethanol/dichloromethane 
extraction of fungal mycelia. These included the known compound (+)-sclerotiorin (6.1) 
and a novel non-halogenated compound (+)-deschlorosclerotiorin (6.2).8 These two 
compounds were also isolated from a PNG mushroom with the local name Kula avara 
(Figure 6-2), which belongs to an unidentified Clavarioid species of fungi.9 
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246 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
 
Figure 6-2 the PNG Mushroom Kula avara (Unidentified Clavarioid Species) 
It is noteworthy that (+)-sclerotiorin is the C-5 chlorinated analogue of (+)-
deschlorosclerotiorin and surprising that (+)-deschlorosclerotiorin was cleanly 
converted to (+)-sclerotiorin after being placed in deuterated chloroform (CDCl3) 
overnight (Scheme 6-2). We have also observed a similar transformation converting (+)-
ochrephilone into (+)-isochromophilone I (Scheme 6-2) in CDCl3.10 The mechanism which 
has not been investigated before could conceivably involve a chlorine radical from 
homolysis of a carbon chlorine bond or a chloride anion from chloroform degradation 
that results in production of small amounts of hydrochloric acid. 
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Scheme 6-2 the Abiotic Halogenation Reaction among Isolated Azaphilones 
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It is now interesting to speculate how many of the 90 halogenated azaphilones, 79 of 
which are halogenated at the same C-5 position are the results of extracellular 
modifications. Halogenation reactions observed to be occurring between (+)-
deschlorosclerotiorin and ochrephilone may not be occasional but in fact be the norm 
for such compounds. Hence, it is quite necessary to investigate such a nonenzymatic 
halogenation reaction. 
In order to determine how readily the C-5 position undergoes halogenation, a series of 
model compounds were proposed. The azaphilone scaffold possessing the 
pyranoquinone bicyclic core, or more specifically a 6H-isochromene-6,8(7H)-dione 
(Figure 6-3) was chosen, varying the nature of the substituent at C-3 in order to 
investigate the role of the sidechain. As such this sidechain was varied from TMS (6.3), 
H (6.4), Me (6.5) to 1-propenyl (6.6). In addition azaphilones that possess the analogous 
isoquinoline-6,8(2H,7H)-dione bicyclic core (6.7-6.10), resulting from reaction of a 6H-
isochromene-6,8(7H)-dione with a primary amine have been considered in this study. 
(+)-Isochromophilone VI for example,11,12 could represent the reaction product of (+)-
deschlorosclerotiorin (6.2) with 2-aminoethanol with subsequent chlorination or the 
reaction of (+)-sclerotiorin (6.1) with 2-aminoethanol, presumably formed intracellularly. 
This study will address the capacity of compounds 6.7 and 6.8 to undergo halogenation. 
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Figure 6-3 Structures of Model Compounds 
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In the absence of strongly alkaline conditions chloroform is generally regarded as an 
inert solvent, however a stoichiometric amount of chlorine radical (Cl·) or chloride (Cl-) 
reasonably exist in the solvent,13-17 which might be the origin of chlorine atom in 
sclerotiorin and isochromophilone I. The model compounds (6.3-6.8) will be exposed to 
different halogenation conditions in order to ascertain the probable source of the 
halogen in the halogenated azaphilones. 
6.2 Synthesis 
6.2.1 Synthetic Strategy 
The challenging structures and biological activities associated with the azaphilones have 
resulted in numerous synthetic efforts being directed toward their synthesis.1 The first 
synthesis of sclerotiorin was carried out by Whalley and colleagues in 1969,18 detailed 
in 1971,19 it commenced with 3,5-dihydroxy-4-methylbenzoic acid (6.11) transforming it 
into racemic sclerotiorin over 12 steps (Scheme 6-3). Notably the chlorine was 
incorporated relatively early in the synthetic strategy and involved the use of sulfuryl 
chloride, a source of molecular chlorine, and presumably proceeded by an electrophilic 
aromatic substitution. Creation of the pyranoquinone heterocycle was achieved through 
a phosphorous pentoxide mediated cyclisation of a keto-benzaldehyde (6.12) with a 
subsequent Pb(OAc)4 oxidation. The yield of the final transformation to afford (±)-
sclerotiorin (6.13) was a disappointing 12%. 
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Scheme 6-3 the First Synthesis of Racemic Sclerotiorin by Whalley and Colleagues18,19  
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More recently, in 2011, Porco and colleagues reported an enantioselective synthesis of 
(+)-sclerotiorin (6.1).20 The ring forming reaction proceeded through a 
cycloisomerisation of an aryl acetylene (6.14) utilising a (+)-sparteine surrogate-Cu2O2 
complex to produce the pyranoquinone core (6.15) in 76% isolated yield (dr = 12:1). In 
this approach the chlorination was achieved after the esterification of the tertiary 
alcohol, using the electrophilic source of chlorine, N-chlorosuccinimide to transform (+)-
deschlorosclerotiorin (6.16) into (+)-sclerotiorin (6.1), the overall yield of the two steps 
was 65% (Scheme 6-4). 
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Scheme 6-4 the Synthesis of (+)-Sclerotiorin by Porco and Colleagues20 
Other groups have utilised a cycloisomerisation strategy, that utilises a pyrylium salt as 
a key intermediate, in their efforts to produce the pyranoquinone core.1 In general a 
dihydroxy-halobenzaldehyde (6.17) is transformed via a Sonogashira coupling with an 
appropriate alkyne to provide what will become the side chain at the C-6 position. The 
o-alkynylbenzaldehyde (6.18) is cycloisomerised to a 2-benzopyrylium salt (6.19) 
catalysed by transition metal as a Lewis acid, such as Pd (II), Cu (II), Ag (I) or Au (III).1,21 
Subsequently, oxidation using a reagent such as o-iodoxybenzoic acid (IBX) or lead 
tetraacetate are applied to form the final azaphilone core (6.20) (Scheme 6-5).1 
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Scheme 6-5 the General Synthetic Route to the Azaphilone Core1 
6.2.2 Synthetic Route to the General Precursor (6.27) 
Recognising the utility of the chemistry described we devised a synthetic route to 
achieve 2,4-dihydroxy-6-iodo-3-methylbenzaldehyde (6.27) as a general precursor for 
Sonogashira couplings (Scheme 6-6).20-26 In this direction commercially available 2-
methylresorcinol (6.21) was methylated using dimethyl sulfate to furnish 2,6-
dimethoxytoluene (6.22) in excellent yield. 
Initial attempts to formylate 6.22 using modified Rieche conditions where titanium 
tetrachloride was replaced with the more easily handled Lewis acidic aluminium 
trichloride were disappointing returning starting material in addition to low yields of the 
formylated product, 2-hydroxy-4-methoxy-3-methylbenzaldehyde (6.23), that had been 
deprotected ortho to the site of formylation. Fortunately regioselective installation of 
the aldehyde was achieved using dichloromethyl methyl ether under standard Rieche 
conditions to generate 2,4-dimethoxy-3-methylbenzaldehyde (6.24) in excellent (99%) 
yield.26 Its formation was supported by the appearance of a downfield resonance in the 
1H NMR spectrum at 10.22 ppm and a downfield resonance in the 13C NMR spectrum at 
189.3 ppm. Protection of the aldehyde by reaction with N,N'-dimethylethylenediamine 
returned the dimethylimidazolidine (6.25) as a colourless oil. Whereas an analogous 
reaction reported by Ryan and colleagues employed a Dean-Stark trap to remove the 
water generated,24 we found this was unnecessary with the reaction proceeding in 
refluxing toluene to return the desired product in an excellent (99%) yield. Directed 
ortho metalation (DoM) utilising the influence of the amine nitrogens ensured 
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deprotonation  at -55 °C by t-butyllithium occurred at the C-6 position.  The anion 
generated, upon reaction with 1,2-diiodoethane resulted in clean conversion to an 
iodinated dimethylimidazolidine which was immediately deprotected by treatment with 
2M aqueous hydrochloric acid to afford 6-iodo-2,4-dimethoxy-3-methylbenzaldehyde 
(6.26). The regioselectivity of the iodination was easily recognised by the correlations in 
HMBC spectrum. Finally deprotection of the methyl ethers under standard conditions 
using boron tribromide resulted in the efficient formation of 2,4-dihydroxy-6-iodo-3-
methylbenzaldehyde (6.27), the compound to be used as a general precursor for 
Sonogashira couplings. 
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Scheme 6-6 the Synthetic Route to Our General Precursor (6.27) 
6.2.3 Synthetic Route to 7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-
isochromene-6,8(7H)-dione (6.3) 
Long provided a convenient approach of Sonogashira coupling by using triethylamine 
(NEt3) as both the required base and solvent.25 However, when applying these 
conditions in our system repeated reactions consistently gave a mixture of the desired 
alkyne 6.28 along with the desilylated alkyne 6.29 (Scheme 6-7). Since the TMS 
acetylene is not stable under basic conditions it was apparent that the excessive NEt3 
employed here was causing C-Si bond cleavage resulting in the terminal alkyne 6.29. 
Jianglong offered another method of Sonogashira coupling by using tetrahydrofuran as 
solvent while employing only a slight excess of base.27 Ultimately we devised a modified 
approach combining elements of both Long and Jianglong’s methods, that involved 
252 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
reacting the general precursor 6.27 with ethynyltrimethylsilane and NEt3 in dry THF 
employing bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2) and copper(I) 
iodide (CuI) as catalysts, to deliver an excellent yield of 2,4-dihydroxy-3-methyl-6-
((trimethylsilyl)ethynyl)benzaldehyde (6.28) (Scheme 6-7). Cycloisomerisation of 6.28 by 
gold(III) acetate (Au(OAc)3) catalysis proceeded through the presumed benzopyrylium 
cation (6.30) present as the trfluoroacetate salt. Both silver and gold catalysts were 
trialed at this stage with the literature supporting their use,25,27,28 in what is formally a 
6-endo-dig cyclisation. We found that Au(OAc)3 at a catalyst loading of 5 mol% returned 
reproducibly good results. No efforts were made to isolate the benzopyrylium salt, 
instead in-situ oxidation using IBX efficiently gave the racemic pyranoquinone 6.3 in 99% 
yield over the one pot, two step process (Scheme 6-7). A broad singlet resonance at 4.30 
ppm (7-OH), and three diagnostic singlet resonances at 5.48, 6.78 and 8.04 ppm in the 
1H NMR spectrum in association with two diagnostic ketone resonances at 196.9 and 
197.3 ppm in the 13C NMR spectrum supported the formation of the product 6.3. 
Curiously and preempting results to be revealed, tiny amounts of a chlorinated product 
(m/z 300 and 298), as detected through monitoring of the reaction by GC-MS could 
always be observed during this cyclisation reaction when a mixture of 1,2-
dichloroethane (DCE) and trifluoroacetic acid (TFA) (10:1) was used. To avoid this a 
mixture of toluene and TFA (10:1) is employed for the cyclisation in the synthesis of 6.3 
and all analogous targets in order to eliminate the generation of chlorinated products. 
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Scheme 6-7 Synthetic Route to Compound 6.3 
6.2.4 Synthetic Route to 7-hydroxy-7-methyl-6H-isochromene-6,8(7H)-
dione (6.4) 
Initial efforts for the preparation of 7-hydroxy-7-methyl-6H-isochromene-6,8(7H)-dione 
(6.4) focussed on deprotection of the silyl protected precursor 6.28.  Not surprisingly, 
the silyl alkyne 6.28 could be deprotected by adding anhydrous K2CO3 in dry methanol 
to return the terminal alkyne 6.29 (Scheme 6-8) with a yield of 93%.25,27 The appearance 
of a diagnostic alkyne proton resonance at 2.07 ppm in the 1H NMR spectrum which was 
coupled to a resonance at 85.4 ppm in the 13C NMR spectrum supported the assigned 
structure. Attempts at the cyclisation of the alkyne 6.29 using the Au(OAc)3 conditions 
outlined above for the conversion of 6.28 to 6.3 (Scheme 6-7) returned a complex 
mixture from which the hydrated alkyne, 6-acetyl-2,4-dihydroxy-3-methylbenzaldehyde 
(6.31) was isolated. Repeated efforts employing a variety of conditions involving both 
silver(I) nitrate (AgNO3) and Au(OAc)3 were to no avail.25,28 Having the pyranoquinone 
(6.3) in hand our attention turned to efforts to deprotect it as a means to afford the 
desired compound 6.4. Upon treatment of 6.3 with tetra-n-butylammonium fluoride 
(TBAF) in ethyl acetate (EtOAc) at -78 °C, 6.4 was achieved, albeit in a yield of just 29% 
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(Scheme 6-8). After adding TBAF the orange reaction mixture immediately turns purple 
and forms an insoluble purple material as the temperature warms up from -78 °C to 0 °C. 
The isolated compound 6.4 presents as a pale yellow solid that degrades to an insoluble 
purple complex over time and immediately degrades upon exposure to acidic conditions. 
These observations indicate 6.4 is very unstable and explain why synthetic efforts 
employing reactions in an acidic medium (TFA) produced only trace quantities of 6.4. 
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Scheme 6-8 Synthetic Route to Compound 6.4 
6.2.5 Synthetic Route to 7-hydroxy-3,7-dimethyl-6H-isochromene-
6,8(7H)-dione (6.5) 
Following the same method, the general precursor 6.27 was reacted with propyne and 
NEt3 in dry THF using PdCl2(PPh3)2 and CuI as catalysts to give 2,4-dihydroxy-3-methyl-6-
(prop-1-yn-1-yl)benzaldehyde (6.32), which was subsequently subjected to cyclisation 
by Au(OAc)3 catalysis and the intermediate benzopyrylium salt was oxidised by IBX to 
generate the target compound 6.5 in excellent yield (99%) over two steps (Scheme 6-9). 
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Scheme 6-9 Synthetic Route to Compound 6.5 
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6.2.6 Synthetic Route to (E)-7-hydroxy-7-methyl-3-(prop-1-en-1-yl)-6H-
isochromene-6,8(7H)-dione (6.6) 
The synthetic route to (E)-7-hydroxy-7-methyl-3-(prop-1-en-1-yl)-6H-isochromene-
6,8(7H)-dione (6.6), proceeds through a Sonogashira coupling between 6-ethynyl-2,4-
dihydroxy-3-methylbenzaldehyde (6.29) and  (E)-1-bromo-1-propene (Scheme 6-10).27 
The reaction returned the desired (E)-2,4-dihydroxy-3-methyl-6-(pent-3-en-1-yn-1-
yl)benzaldehyde (6.33) as supported by the vicinal coupling constant (J= 15.8 Hz) 
between the olefinic hydrogen resonances, with a modest yield (53%). Cyclisation 
(Au(OAc)3) and oxidation (IBX) as described previously generated the desired 
isochromene dione 6.6 in a good yield (62%) with retention of the trans disposed double 
bond as evidenced by the 1H NMR data, 6.22 (1H, dq, J= 15.7 Hz, 1.6 Hz, 9-H), 6.59 (1H, 
dq, J= 15.7 Hz, 7.0 Hz, 10-H). 
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Scheme 6-10 Synthetic Route to Compound 6.6 
6.2.7 Synthetic Route to 7-hydroxy-2-(2-hydroxyethyl)-7-methyl-3-
(trimethylsilyl)isoquinoline-6,8(2H,7H)-dione (6.7) 
With the isochromene dione 6.3 on hand we utilised it to ascertain the conditions 
required to transform it in to the isoquinoline dione (6.7) desired in our study.  
Treatment of 6.3 with 2-aminoethanol in dry acetone was observed to result in 
consumption of the starting material, as assessed by LC-MS analysis after five minutes 
of reaction. However, at this stage of the reaction the predominant product was 
observed to be the hemiaminal 6.34 (Scheme 6-11), as assessed by the observation of a 
protonated molecule ([M+H]+) in the mass spectrum with a m/z of 326. Also evident in 
the mass spectrum was a trace amount of a compound with m/z of 308 ([M+H]+) 
presumably corresponding to the desired compound 6.7 (Scheme 6-11). The reaction 
mechanism (Scheme 6-1) explains these observations. Since the protonation of a 
hydroxy in the intermediate hemiaminal (6.34 herein) is the slow step in the overall 
reaction procedure, the immediately generated hemiaminal requires a relative long 
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reaction time to be finally dehydrated to the nitrogenised azaphilone (compound 6.7 
herein). 
After the reaction was allowed to proceed for 48 hours, not surprisingly the major 
product was observed to be the isoquinoline dione 6.7 with minor amounts of the 
hemiaminal 6.34 still present (Scheme 6-11). During ESIMS analysis compound 6.7 was 
found to be unstable in MeOH solutions, converting to the desilylated analogue 6.8. 
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Scheme 6-11 Synthetic Route to Compound 6.7 
6.2.8 Synthetic Route to 7-hydroxy-2-(2-hydroxyethyl)-7-
methylisoquinoline-6,8(2H,7H)-dione (6.8) 
Capitalising on the observed instability of 7-hydroxy-2-(2-hydroxyethyl)-7-methyl-3-
(trimethylsilyl)isoquinoline-6,8(2H,7H)-dione (6.7), it was exposed to 2-aminoethanol in 
methanol which effected a rapid conversion to the desired desilylated product 6.8 in 60% 
yield after chromatography (Scheme 6-12). 
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Scheme 6-12 Synthetic Route to Compound 6.8 
With two of the target isoquinolines in hand and with time limitations of the PhD 
program, the remaining isoquinoline dione targets (6.9 and 6.10) were not further 
investigated. 
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6.3 Halogenation Investigation 
6.3.1 Halogenation of 7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-
isochromene-6,8(7H)-dione (6.3) 
6.3.1.1 Chlorination 
With pyranoquinone starting materials (6.3-6.6) to investigate the halogenation 
reaction of azaphilones in hand, we embarked upon a strategy to produce authentic 
material. Porco, in his synthesis of (+)-sclerotiorin (6.1) utilised an electrophilic 
chlorination at C-5, employing N-chlorosuccinimide (NCS) as the source of chloronium 
ion.20 Mechanistically this is a standard electrophilic chlorination with the 
regiochemistry explained through the generation of a stabilised pyrylium intermediate 
(Scheme 6-13). 
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Scheme 6-13 Mechanism of NCS Promoted Electrophilic Chlorination at C-5 for (+)-
Deschlorosclerotiorin 
When 7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-isochromene-6,8(7H)-dione (6.3) was 
treated with NCS in acetone in the dark, clean C-5 chlorination was observed to produce 
5-chloro-7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-isochromene-6,8(7H)-dione (6.35) as 
a stable orange oil in good (80%) yield (reaction 1, Scheme 6-14). While NCS is 
sometimes used as a source for chlorine radical in reactions, given the reaction was 
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performed under dark conditions in the absence of added initiator, this reactivity was 
discounted. 
In contrast to electrophilic chlorination at C-5 of compound 6.3 by NCS, in reaction 2 in 
Scheme 6-14 we observed a nucleophilic chlorination at C-5 of compound 6.3, resulting 
in the same product 6.35. In the previously described reaction generating compound 6.3 
from 6.28 (Scheme 6-7), we found compound 6.35 was the only product if brine 
(saturated aqueous NaCl solution) instead of deionised water was used to wash the 
reaction mixture or if solid NaCl was added to the reaction mixture during the work-up 
procedure. This nucleophilic chlorination was complete within 0.5 h when a 
stoichiometric amount of NaCl was present in the reaction mixture. 
For further investigation of this unusual electrophilic chlorination, a solution of 
compound 6.3 in EtOAc was treated with NaCl overnight, no matter the presence of TFA 
or not and no matter under dark conditions or not, no C-5 chlorinated product 6.35 was 
observed as assessed by LC-MS (reaction 3, Scheme 6-14). Curiously, the chlorinated 
product 6.35 was produced if the EtOAc solution of 6.3 was treated with NaCl in addition 
to Au(OAc)3, no matter the presence of TFA or not (reaction 4 and 5, Scheme 6-14). It is 
worth noting that if TFA was present in the reaction mixture, the reaction to produce 
the chlorinated product 6.35 was more rapid. 
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Scheme 6-14 Chlorination of Compound 6.3 
6.3.1.2 Bromination 
Unsurprisingly, the exclusive product 5-bromo-7-hydroxy-7-methyl-3-(trimethylsilyl)-
6H-isochromene-6,8(7H)-dione (6.36) was generated with an excellent yield (99%) 
resulting from a nucleophilic bromination, after aqueous sodium bromide (NaBr) 
solution was used to wash the reaction mixture or if solid NaBr was added to the 
reaction mixture in the aforementioned reaction designed to generate compound 6.3 
from 6.28 (reaction 1, Scheme 6-15). This C-5 nucleophilic bromination occurred even if 
only a trace amount of TFA was present in the reaction mixture. 
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In contrast to the chlorination result (reaction 3, Scheme 6-14), the EtOAc solution of 
6.3 was treated with NaBr overnight, under dark conditions or not, produced the 
brominated product 6.36 when TFA was present as assessed by LC-MS (reaction 2, 
Scheme 6-15). However, 6.36 was not observed in the absence of TFA under the same 
reaction conditions (reaction 3, Scheme 6-15). In the presence of Au(OAc)3, 6.3 was 
readily brominated at C-5 by NaBr, TFA was not required to present (reaction 4 and 5, 
Scheme 6-15), nevertheless the presence of TFA contributed to a higher yield of the 
brominated product 6.36. 
In an experiment designed to assess the competitiveness of chlorination versus 
bromination a reaction (reaction 6, Scheme 6-15) was performed and at the workup 
phase a mixture of excess solid NaCl and NaBr (1:1 by weight) was added generating 
compound 6.36 from 6.28 as the exclusive product, as observed by LC-MS.  This is all the 
more noteworthy given the molar excess of NaCl exceeded that of NaBr. 
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Scheme 6-15 Bromination of Compound 6.3 
6.3.1.3 Iodination 
We observed through LC-MS that a small amount of a suspicious iodinated product 7-
hydroxy-5-iodo-7-methyl-3-(trimethylsilyl)-6H-isochromene-6,8(7H)-dione (6.37) was 
always present in the reaction mixture when generating compound 6.3 from 6.28. 
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Without adding exogenous iodine, we attributed the iodination to the reagent IBX or its 
degradation products containing iodine. When an aqueous solution of sodium iodide 
(NaI) was used to wash the reaction mixture or if solid NaI was added to the reaction 
mixture, an increasing, but still small amount of the aforementioned iodinated product 
(6.37) was observed (reaction 1, Scheme 6-16). In contrast to the chlorination and 
bromination, the iodinated product wasn’t able to be isolated due to its low yield. 
Repeated efforts employing a variety of conditions involving different concentrations of 
aqueous NaI solution, under an argon atmosphere and dark conditions were to no avail. 
In order to acquire the authentic material of the C-5 iodinated product 6.37, compound 
6.3 was treated with N-iodosuccinimide (NIS) in acetone in the dark, whereon clean C-5 
electrophilic iodination was observed to produce 6.37 in good (85%) yield (reaction 2, 
Scheme 6-16). As assessed by LC-MS, the suspected iodinated product generated in 
reaction 1 was confirmed to be 6.37 through co-elution and identical mass spectra. 
In order to investigate the nucleophilic iodination of compound 6.3, the EtOAc solution 
of it was treated with NaI under an argon atmosphere and dark conditions. Regardless 
of the presence or absence of TFA, 10 min later only trace amounts of C-5 nucleophilic 
iodination product 6.37 was observed as assessed by LC-MS (reaction 3, Scheme 6-16). 
It is worth noting that when TFA was present, the reaction mixture immediately turned 
dark brown colour after NaI was added. While the reaction mixture changed to pale 
brown colour after NaI was added without the presence of TFA. Unfortunately, no 
increase in the amount of 6.37 was observed with the reaction going overnight. The 
iodinated product 6.37 was also generated in a trace amount if an EtOAc solution of 6.3 
was treated with NaI in addition to Au(OAc)3, no matter the presence of TFA or not 
(reaction 4, Scheme 6-16). 
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Scheme 6-16 Iodination of Compound 6.3 
6.3.1.4 Fluorination 
As discussed in the introduction of chapter five (Section 5.4), fluoride readily forms 
hydrogen bond to water, resulting in fluoride being extremely difficult to be desolvated 
making a nucleophilic fluorination is challenging. Unsurprisingly, no fluorinated products 
such as 5-fluoro-7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-isochromene-6,8(7H)-dione 
(6.38) were observed as assessed by LC-MS after an aqueous solution of sodium fluoride 
(NaF) was used to wash the reaction mixture or if solid NaF was added to the mixture in 
the reaction designed to generate compound 6.3 from 6.28 (reaction 1, Scheme 6-17). 
Repeated efforts employing a variety of conditions were to no avail (reactions 1-4, 
Scheme 6-17). 
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Scheme 6-17 Fluorination of Compound 6.3 
Based on the halogenation investigation of compound 6.3, the exclusive C-5 chlorination, 
bromination and iodination were observed by both electrophilic and nucleophilic 
substitution mechanisms, while no fluorination was observed. As mentioned in the 
chapter five section 5.4.1.3, a nucleophilic halogenation is uncommon in nature, 
especially via a nonenzymatic pathway, where so far only one example of nucleophilic 
addition to an 4,7-indane diradical by chloride was discovered (chapter five section 
5.4.2). In this work we have discovered the first nonenzymatic nucleophilic halogen 
substitution reaction to occur in nature. Inspired by advantages of the nucleophilic 
halogenation reaction over its electrophilic counterpart, such as an excellent yield (up 
to 99%), an ultra-high reaction ratio (only one shake in the separating funnel), clean (no 
side product succinimide was generated which can be challenging for purification) and 
an ultra-simple work-up, the utility of this nucleophilic halogenation reaction was 
further investigated on the other synthetic analogues 6.4-6.6. 
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Among three feasible nucleophilic halogenations, chlorination and bromination were 
much more facile than iodination. Therefore, the following halogenation investigations 
of substrates 6.4-6.6 focused on chlorination and bromination. 
6.3.2 Halogenation of 7-hydroxy-7-methyl-6H-isochromene-6,8(7H)-
dione (6.4) 
6.3.2.1 Chlorination 
As mentioned in section 6.2.4, the molecule bearing a hydrogen at C-3, compound 6.4, 
is very unstable and its C-5 chlorinated analogue 6.39 can only be obtained in quantity 
from the deprotection of 6.35 rather than direct chlorination from 6.4 (reaction 1, 
Scheme 6-18). Despite compound 6.4 being unstable in aqueous or acidic conditions, 
pure 6.4 was treated with solid NaCl in EtOAc and small amounts of 6.39 were observed 
after 0.5 h, as assessed by LC-MS (reaction 2, Scheme 6-18). The chlorinated product 
6.39 was significantly more stable than its non-chlorinated precursor 6.4. 
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Scheme 6-18 Synthesis of Compound 6.39 
6.3.2.2 Bromination 
Similarly, compound 6.4 C-5 brominated product 6.40 was obtained from deprotection 
of 6.36 (reaction 1, Scheme 6-19). However, small quantities of 6.40 were observed after 
0.5 h when pure 6.4 was treated with solid NaBr in EtOAc (reaction 2, Scheme 6-19). 
Once again the halogenated, in this case brominated, product 6.40 was more stable than 
the deshalogenated compound 6.4. 
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Scheme 6-19 Synthesis of Compound 6.40 
6.3.3 Halogenation of 7-hydroxy-3,7-dimethyl-6H-isochromene-6,8(7H)-
dione (6.5) 
6.3.3.1 Chlorination 
7-hydroxy-3,7-dimethyl-6H-isochromene-6,8(7H)-dione (6.5) was treated with NCS in 
acetone overnight, with the resultant C-5 chlorination product 6.41 being generated 
with a modest yield 55% (reaction 1, Scheme 6-20). As we would predict, when reaction 
mixture designed to produce 6.5 from 6.32 was washed with a brine solution or if solid 
NaCl was added during the normal workup procedure compound 6.41 instead of 
compound 6.5 was exclusively observed as assessed by LC-MS (reaction 2, Scheme 6-20). 
It is worth noting that a mixture of the chlorinated product 6.41 and compound 6.5 was 
observed if TFA concentration in the reaction mixture was low. When pure compound 
6.5 dissolved in EtOAc and treated with NaCl overnight, regardless of the presence of 
TFA or not, a small amount of 6.41 was observed as assessed by LC-MS (reaction 3, 
Scheme 6-20). Compound 6.5 was also found unstable in aqueous or acidic conditions 
while, like its hydrogen analogue 6.39, the C-5 chlorinated product 6.41 was more stable. 
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Scheme 6-20 Chlorination of Compound 6.5 
6.3.3.2 Bromination 
When compound 6.5 was treated with NBS in acetone for 10 min, C-5 brominated 
product 6.42 was generated with an excellent yield 89% (reaction 1, Scheme 6-21). 
Compound 6.42 was also generated, with a yield 67%, after a saturated aqueous NaBr 
solution was used to wash the reaction mixture in the workup phase of the reaction 
designed to generate compound 6.5 from 6.32 (reaction 2, Scheme 6-21). As assessed 
by LC-MS, compound 6.42 was the only product identified even if TFA was absent in the 
reaction mixture. When pure 6.5 was dissolved in EtOAc and treated with NaBr 
overnight, regardless of the presence of TFA or not, a small amount of 6.42 was observed 
as assessed by LC-MS (reaction 3, Scheme 6-21). Curiously, much more 6.42 was 
generated with the presence of TFA than without TFA. The C-5 brominated product 6.42 
was found to be significantly more stable than the deshalogenated compound 6.5. 
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Scheme 6-21 Bromination of Compound 6.5 
6.3.4 Halogenation of (E)-7-hydroxy-7-methyl-3-(prop-1-en-1-yl)-6H-
isochromene-6,8(7H)-dione (6.6) 
6.3.4.1 Chlorination 
The chlorinated product 6.43 was generated with a 68% yield after NaCl brine was used 
to wash the reaction mixture in the reaction designed to generate compound 6.6 from 
6.33 (reaction 1, Scheme 6-22). When pure compound 6.6 was dissolved in EtOAc and 
treated with NaCl overnight, regardless of the presence of TFA or not, a small amount 
of 6.43 was observed as assessed by LC-MS (reaction 2, Scheme 6-22). Similarly, much 
more 6.43 was generated with the presence of TFA than without TFA. In the presence 
of Au(OAc)3, a higher yield of product 6.43 was observed (reaction 3, Scheme 6-22). 
Compound 6.6 was found to decompose in aqueous or acidic conditions while the 
chlorinated product 6.43 was found to be more stable than the deshalogenated 
counterpart, 6.6. 
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Scheme 6-22 Chlorination of Compound 6.6 
6.3.4.2 Bromination 
The brominated product 6.44 was generated with a modest yield of 46% after saturated 
aqueous NaBr solution was used to wash the reaction mixture in the reaction designed 
to generate compound 6.6 from 6.33 (reaction 1, Scheme 6-23). When a pure solution 
of compound 6.6 in EtOAc was washed in a separating funnel with aqueous saturated 
NaBr solution, a small amount of 6.44 was observed as assessed by LC-MS (reaction 2, 
Scheme 6-23). The C-5 brominated product 6.44 was found to be more stable than 
compound 6.6. 
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Scheme 6-23 Bromination of Compound 6.6 
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6.3.5 Halogenation of 7-hydroxy-2-(2-hydroxyethyl)-7-methyl-3-
(trimethylsilyl)isoquinoline-6,8(2H,7H)-dione (6.7) 
6.3.5.1 Chlorination 
Having unambiguously established the capacity of the isochromene-6,8(7H)-diones (6.3-
6.6) to undergo nucleophilic halogenation under mild conditions, the question now 
arose as to whether the isoquinoline-6,8(2H,7H)-diones underwent a similar 
transformation. An authentic sample of the chlorinated product of the isoquinoline-
6,8(2H,7H)-dione (6.7) was prepared by treating the chlorinated isochromene 6.35 with 
2-aminoethanol in anhydrous acetone (reaction 1, Scheme 6-24). Within 10 min a colour 
change from orange to red had occurred and TLC indicated the presence of a more polar 
compound. Upon workup a red oil was obtained in excellent yield (93%) with spectral 
data, including the downfield resonance in the 1H NMR spectrum at 8.15 (1H, s, 1-H), 
supporting the formation of the isoquinoline 6.45. With authentic material in hand a 
pure sample of compound 6.7 was dissolved in MeOH and treated with solid NaCl 
overnight (reaction 2, Scheme 6-24). A chlorinated product with identical retention time 
and mass spectrum to the authentic material 6.45 was observed as assessed by LC-MS. 
As mentioned in section 6.2.7, compound 6.7 was found unstable in MeOH solution 
readily undergoing TMS deprotection. Compound 6.45 was also found to decompose 
slowly in MeOH solution although it was more stable than compound 6.7. 
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Scheme 6-24 Synthesis of Compound 6.45 
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6.3.5.2 Bromination 
In an analogue manner to the method employed for the production of the authentic 
chlorinated material (6.45), an authentic sample of the brominated product 6.46 was 
obtained after compound 6.36 was treated with 2-aminoethanol in anhydrous acetone 
(reaction 1, Scheme 6-25). Compound 6.46 was isolated as a bright red oil in excellent 
yield (99%) following chromatography. The compound now possessed poor solubility in 
acetone while good solubility in MeOH and displayed resonances in the 1H NMR 
consistent with an isoquinoline, specifically two singlet resonances at 7.29 and 8.13 ppm 
assigned to the 4-H and 1-H hydrogens respectively. The mass spectrum also displayed 
the characteristic ions associated with a brominated product, in this case ions at m/z 
387 (19) and 385 (18). When a sample of the pure compound 6.7 was dissolved in MeOH 
and stirred in the presence of solid NaBr overnight (reaction 2, Scheme 6-25), 6.46 was 
readily observed as assessed by LC-MS. Similarly to previous observations, 6.46 was 
found to be significantly more stable than 6.7. 
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Scheme 6-25 Synthesis of Compound 6.46 
6.3.6 Halogenation of 7-hydroxy-2-(2-hydroxyethyl)-7-
methylisoquinoline-6,8(2H,7H)-dione (6.8) 
6.3.6.1 Chlorination 
While the anticipated halogenation reactions proceeded smoothly with the isoquinoline 
6.7, we chose to demonstrate it was also a general reaction by exposing 7-hydroxy-2-(2-
hydroxyethyl)-7-methylisoquinoline-6,8(2H,7H)-dione (6.8) to the same reaction 
conditions. 
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Authentic material was obtained by recognising the TMS group of compound 6.45 is 
deprotected in MeOH, thus compound 6.45 was dissolved in MeOH and subjected to 2-
aminoethanol to return compound 6.47 with an excellent isolated yield (90%) (reaction 
1, Scheme 6-26). Compound 6.47 presents as an extremely polar red solid, is sparingly 
solubile in most organic solvents but has a good solubility in DMSO. When a sample of 
pure compound 6.8 was dissolved in MeOH and stirred with the addition of solid NaCl, 
compound 6.47 was observed after 0.5 h as assessed by LC-MS (reaction 2, Scheme 6-26). 
In the presence of Au(OAc)3, after 0.5 h compound 6.47 was observed to be generated 
much more rapidly as assessed by LC-MS (reaction 3, Scheme 6-26). 
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Scheme 6-26 Chlorination of Compound 6.8 
6.3.6.2 Bromination 
In a manner analogous to previous reactions the authentic C-5 brominated product 6.48 
was achieved by placing the solution of compound 6.46 in MeOH and exposing it to 2-
aminoethanol (reaction 1, Scheme 6-27) which returned the desired compound in 
excellent yield (99%) as a red solid. Compound 6.48 only has a good solubility in DMSO 
but is poorly soluble in other solvents. When a sample of pure compound 6.8 was 
dissolved in MeOH and treated with solid NaBr, compound 6.48 was observed after 0.5 
h as assessed by LC-MS (reaction 2, Scheme 6-27). In the presence of Au(OAc)3, after 0.5 
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h the brominated compound 6.48 was observed much more rapidly as assessed by LC-
MS (reaction 3, Scheme 6-27). 
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Scheme 6-27 Synthesis of Compound 6.48 
6.3.7 Attempted Conversions between Chlorination and Bromination 
Products 
All the synthetic chlorinated products produced in this study were treated with NaBr 
solution in EtOAc and solid NaBr in order to ascertain if a dynamic equilibrium allowed 
for the exchange of a halogen. Not unexpectedly brominated products were not 
observed for any of the reactions as assessed by LC-MS, regardless of the presence of 
Au(OAc)3 and/or TFA or not. 
Conversely all the synthetic brominated products were treated with NaCl solution in 
EtOAc and solid NaCl. Once again no chlorinated products were observed as assessed by 
LC-MS, regardless of the presence of Au(OAc)3 and/or TFA or not. 
6.4 Discussion and Conclusion 
6.4.1 Discovery of Nonenzymatic Nucleophilic Halogenation Reaction 
Our initial observation recognised an unprecedented chlorination reaction taking place 
in the azaphilones when dissolved in deuterated chloroform. (+)-Deschlorosclerotiorin 
(6.2) and (+)-ochrephilone were transformed into (+)-sclerotiorin (6.1) and (+)-
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isochromophilone I respectively (Scheme 6-2), prompting us to investigate the reaction 
in detail. We have observed that isochromene-6,8(7H)-diones (6.3-6.6) and 
isoquinoline-6,8(2H,7H)-diones (6.7-6.8) (Figure 6-3) in the presence of nucleophilic 
sources of halide readily undergo substitution at C-5. All the more remarkable is that 
this site is also halogenated under electrophilic conditions using the reagents NCS, NBS 
or NIS. The fact that identical products are yielded when electrophilic reagents are 
replaced by the corresponding sodium halides confirms our discovery of a nonenzymatic 
halogenation through a nucleophilic substitution reaction. These enzyme-free 
halogenation reactions among the azaphilones and their analogues represent a 
completely novel discovery. 
The fact that 79 of the 90 known halogen containing azaphilones are halogenated at C-
5 raises the question as to whether these compounds are actually natural products.1  
Indeed it raises the issue of what constitutes a natural product? Is a natural product a 
compound produced inside a cell by metabolic processes or do they also include 
compounds produced extracellularly? Is (+)-5-bromoochrephilone (Figure 6-4), isolated 
from a Penicillium species fermented in a medium containing potassium bromide ,29 a 
natural product or an artefact of the process used to generate the precursor compound? 
We take the position that a natural product includes all compounds produced in nature 
regardless of whether they are generated inside or outside the cell.  We accept that 
what some researchers call artefacts we call natural but see these compounds as 
expressions of the diversity of nature. 
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Figure 6-4 Structures of Brominated and Chlorinated Ochrephilones 
Among the halides, as mentioned in chapter five (Section 5.4), chloride is predominant 
in nature explaining why the halogenated azaphilones are almost exclusively chlorinated. 
It is reasonable to consider this novel halogenation reaction exists widely in nature. That 
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means our discovery of a mild, rapid, nucleophilic, non-enzymatic halogenation will 
expand the knowledge of biosynthetic pathways of natural products.  
6.4.2 Features of the Novel Halogenation Reaction 
6.4.2.1 Reactive Site 
Our investigation using the model compounds (6.3-6.8) confirms the nucleophilic 
halogenations occur exclusively at the C-5 position among three available positions in 
the bicyclic core C-1, C-4 and C-5 (Scheme 6-28). It is noteworthy that C-5 is the most 
electron rich of the three available sites for substitution with the highest electron 
density, as indicated by the 13C NMR chemical shifts ranging from a low of 97.4 ppm (6.7) 
through to 107.1 ppm (6.4). This observation can explain why only C-5 substituted 
products are produced when NCS, NBS and NIS, regarded as the sources of electrophilic 
halonium cations are used but seems contrary to a mechanism supporting nucleophilic 
substitution. As such it suggests the novel halogenation reaction does not proceed by a 
direct reaction of a halide anion at the C-5 position, but instead progresses through a 
complex transformation of the bicyclic core involving a pyrylium or pyridinium cation. 
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Scheme 6-28 the Nucleophilic Halogenations of Model Compounds 
Once the C-5 position has been substituted by one halogen atom, experimental results 
show the product is not able to be substituted by further halogen atoms. 
6.4.2.2 Product Stability 
The stability of the isochromene/isoquinoline dione products with various C-3 side 
chains were observed to increase in the following order; H< methyl< propenyl< TMS. 
That is the stability increased along with the increasing steric bulk of the C-3 side chain. 
This might be explained by the decreasing ability of the molecule to act as a Michael 
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acceptor. Products were also observed to be much more stable after C-5 halogen 
substitution, with brominated products being more stable than the corresponding 
chlorinated products, following this order (at C-5) H< Cl< Br. For instance, model 
compound 6.4, with H in C-3 position, is vulnerable to acid and very mild base and 
degrades rapidly when exposed in air, however, its halogenated products are readily 
handled under these conditions. 
6.4.2.3 Reaction Rates 
Among halogen anions, rates of substitution in the novel halogenation reaction follow 
the order I- > Br- > Cl-, which matches their order of nucleophilicity. This order can be 
observed from the reactions of the model compound 6.3 with NaI, NaBr and NaCl. 
Iodination can occur rapidly (10 min) without any catalysts (see Section 6.4.2.4), 
bromination proceeds with TFA as catalyst while chlorination requires both TFA and gold 
catalysts. In addition, during the cyclization and oxidation step to generate the model 
compounds 6.3-6.6, the occurrence of small amounts of C-5 iodinated products 
indicates the facile nature and rapid rate of the iodination reaction. However, contrary 
to expectation, only trace amounts of iodinated products were observed among 
reactions conducted with NaI. Since I- is sensitive to oxygen and light, oxidising to I2, the 
generated product of a reaction between Au(OAc)3 and NaI would be AuI3, which would 
immediately degrade to AuI and I2.30 The active catalyst Au(III) (detailed in the following 
section 6.4.2.4) becomes the inactive Au(I), and the I2 produced readily reacts with 
unsaturated bonds in substrate molecules. 
As a very weak nucleophile, not surprisingly, F- was not observed to react at C-5 either 
in direct fluorination reaction attempts with azaphilones and their synthetic analogues 
or in TMS group deprotection reactions.  
6.4.2.4 Catalysts 
Acids including both the Lewis acid, Au(OAc)3, and the Brønsted acid, TFA, are catalysts 
used in this novel halogenation reaction. Take the example of model compound 6.3, 
here the chlorination only occurs at an appreciable rate with the presence of both 
Au(OAc)3 and TFA while bromination is able to occur with only the presence of TFA. 
Essentially, Au(III) is the active oxidation state of the catalyst, and the gold will maintain 
the same active, Au(III), oxidation state after generating AuBr3 or AuCl3, resulting from 
a reaction between Au(OAc)3 and NaBr or NaCl respectively. However, as discussed in 
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the previous section, gold changes from the active oxidation state Au(III) to inactive Au(I) 
after a reaction with NaI. Au(III) is regarded as a Lewis acid coordinating to the C=C 
double bonds which enables the nucleophilic attack at C-5 by a halide anion. In a similar 
manner if the Brønsted acid (TFA) is regarded as coordinating to the electron rich double 
bond an analogous mechanism can proceed. This does not discount the complex 
equilibria which would also be in motion surrounding protonating the two carbonyl 
oxygen atoms in the pyranoquinone bicyclic core. 
6.4.2.5 Structural Requirements 
Based on our previous and current observation, the halogenation occurs regardless of 
the substitution at C-7 with free hydroxy (6.3-6.8) or ester groups (ochrephilone or 
deschlorosclerotiorin, see Scheme 6-2) readily transforming. It was also observed that 
the nature of the C-3 side chain was inconsequential to the progress of the reaction but 
did impact the stability of the molecule, with the more sterically demanding C-3 
substituents rendering substrates more stable. Finally the nature of the bicyclic ring 
tolerates both isochromene-6,8(7H)-diones (e.g. 6.3-6.6) and isoquinoline-6,8(2H,7H)-
diones (e.g. 6.7-6.8). 
6.4.3 Proposed Reaction Mechanism 
Based on these observations, we have proposed a mechanism for the nucleophilic 
halogenation reaction as described below (Scheme 6-29). We suggest that when 
Au(OAc)3 is present (pathway a), the Lewis acidic Au(III) coordinates the electron rich 
carbon-carbon double bond between C-5 and C-4a, resulting in the increased 
electrophilicity of this carbon-carbon double bond. Halide (X-) then attacks at the less 
hindered C-5 position and H+ is taken at the C-4a position, consistent with the observed 
reaction outcome. After this the oxygen (or nitrogen in isoquinoline examples) donates 
a lone pair of electrons expelling hydride as a leaving group and generating an aromatic 
pyrylium (or pyridinium) cation in the process. Loss of a proton, perhaps concomitantly 
with the hydride loss effectively producing dihydrogen (H2) generates the C-5 and C-4a 
carbon-carbon double bond quenching the cation and thus a halogenated substrate is 
returned. If Lewis acid Au(OAc)3 is not present, the Brønsted acid (H+) coordinates with 
the carbon-carbon double bond between C-5 and C-4a, effectively following the same 
procedure. 
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Scheme 6-29 Proposed Mechanism of Nucleophilic Halogenation Reaction 
This proposed mechanism explains why the similar halogenation reactions occur in 
solvents like chloroform (which may contain acid HCl) and why acids are catalysts. 
Additionally, it can explain the exclusive halogenation at position C-5. If halide reacted 
at the more sterically congested C-4a, subsequent aromatisation to generate the 
pyrylium cation would expel halide and subsequent loss of a proton (effective loss of HX) 
would regenerate the starting material. The increased stability of the halogenated 
products observed over their non-halogenated counterparts suggests thermodynamic 
stability selects for these compounds in the complex equilibria. During the reaction, the 
generation of hydride seems rare, but not unknown with the example of generation 
being observed in the Cannizzaro Reaction.31 
6.4.4 Essential Structure 
Based on the proposed mechanism, the key intermediate of this halogenation reaction 
is the capacity to form a pyrylium (or pyridinium) ion. Thus the bicyclic core 7,8-dihydro-
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6H-isochromene or 2,6,7,8-tetrahydroisoquinoline (Figure 6-5) represents the essential 
structural elements which enable this halogenation reaction. It is worth noting that the 
78 azaphilones halogenated at C-5 position possess one of these essential structures 
(Figure 6-5). 
O
7,8-dihydro-6H-isochromene
NR
2,6,7,8-tetrahydroisoquinoline  
Figure 6-5 Essential Structure for the Halogenation Reaction 
6.4.5 Heat Induced Transformation 
 
Figure 6-6 1H NMR Spectrum of Compound 6.5 (400 MHz, (CD3)2CO) 
An interesting rearrangement/degradation was observed for molecules possessing the 
a 2,2-disubstututed cyclohex-4-ene-1,3-dione such as are present in the azaphilones 
studied here. While compound purity was readily ascertained from analysis of the 1H 
NMR spectrum (Figure 6-6), upon injection (inlet temperature 250 °C) to the gas 
chromatogram two peaks in the TIC displaying near identical mass spectra were always 
observed (Figure 6-7). 
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Figure 6-7 Gas Chromatogram (TIC) and EI-MS of Compound 6.5 (Inlet 250 °C) 
The ratio between the two peaks observed in the TIC varied as a function of the inlet 
temperature indicating the changes were thermally induced. For instance, pure 
compound 6.5 generates two significant peaks (retention times of 14.21 min and 15.60 
min) when the inlet temperature was set to 250 °C (Figure 6-7), however, a single peak 
(retention time 15.60 min) was observed when the inlet temperature was set to 125 °C. 
In the mass spectra fragments of [M-42]·+ and [M-43]+ can be observed for each peak 
but with different ratios (Figure 6-7). It is reasonable that an isomer is generated upon 
heating to high temperatures, however, all efforts to generate such an isomer and 
elucidate its structure by heating pure sclerotiorin or its analogues in NMR tubes under 
argon protection failed. A proposed mechanism of the thermally induced 
transformation is described below (Scheme 6-30) which can conceivably follow one of 
two pathways, given a single additional peak is observed at elevated inlet temperatures. 
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Scheme 6-30 Proposal Mechanism of Thermo Transformation 
Either pathway produces a molecule that can be rationalised as generating fragments 
ions of [M-42]·+ and [M-43]+. The HREIMS results confirm that fragments of [M-42]·+ and 
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[M-43]+ are [M-C2H2O]·+ and [M-C2H3O]+ with a plausible mechanism shown in (Scheme 
6-31). 
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Scheme 6-31 Probable Fragmentations Leading to [M-42]·+ and [M-43]+ 
6.5 Experimental 
6.5.1 General Procedure of Halogenation Reaction via Sodium Halides 
A EtOAc solution (5 mL) of pure compound (6.3-6.8, 10 mg) was added to either solid 
sodium halide (50 mg, excess) or a saturated aqueous solution of the sodium halide (5 
mL) at room temperature, then the reaction mixture was stirred for 12 h. 
The reaction mixture was ready for GC-MS and/or LC-MS analysis. The production of 
halogenated product was confirmed by the comparison of its retention time and mass 
spectrum with that of the reference halogenated product which was previously 
synthesised. 
6.5.2 Equipment and Chemical Reagents 
For General Experimental conditions see chapter two experimental section. 
6.5.3 Experimental Data 
(+)-sclerotiorin (6.1). A bright orange solid, [α]20D  = 
+ 565 (c = 0.034, EtOH). 1H NMR (500 MHz, CDCl3): 
δ 0.85 (3H, dd, J= 7.4, 7.4 Hz, 15-H), 1.00 (3H, d, J= 
6.7 Hz, 16-H), 1.32 (1H, ddq, J= 13.2, 7.4, 5.8 Hz, 14-
Hb), 1.43 (1H, ddq, J= 13.2, 7.4, 5.8 Hz, 14-Ha), 1.56 (3H, s, 7-Me), 1.83 (3H, d, J= 1.1 Hz, 
17-H), 2.16 (3H, s, 7-COOCH3), 2.48 (1H, m, 13-H), 5.70 (1H, brd, J= 9.7 Hz, 12-H), 6.07 
(1H, d, J= 15.7 Hz, 9-H), 6.63 (1H, s, 4-H), 7.05 (1H, d, J= 15.7 Hz, 10-H), 7.93 (1H, s, 1-H). 
13C NMR (125 MHz, CDCl3): δ 12.1 (15-C), 12.5 (17-C), 20.2 (7-COOCH3), 20.3 (16-C), 22.6 
6
7 88a
4a
5
1
O
3
4 9
10
11
12
13
14
15
17 16
O
O
AcO
Cl
282 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
(7-Me), 30.2 (14-C), 35.2 (13-C), 84.7 (7-C), 106.5 (4-C), 110.8 (5-C), 114.6 (8a-C), 115.8 
(9-C), 132.1 (11-C), 138.9 (4a-C), 143.0 (10-C), 149.0 (12-C), 152.8 (1-C), 158.2 (3-C), 
170.2 (7-COOCH3), 186.1 (6-C), 191.9 (8-C). ESIMS: m/z [M+2+H]+ 393 (35), [M+H]+ 391 
(100), 351 (15), 349 (46), 305 (17), 303 (48). HREIMS: m/z 390.1242 (calculated for 
C21H23O535Cl 390.1234), 392.1217 (calculated for C21H23O537Cl 392.1205). 
(+)-deschlorosclerotiorin (6.2). A bright orange solid, 
[α]10D  = + 136 (c = 0.014, EtOH). 1H NMR (500 MHz, 
C6D6): δ 0.77 (3H, dd, J= 7.5, 7.5 Hz, 15-H), 0.88 (3H, 
d, J= 6.7 Hz, 16-H), 1.16 (1H, m, 14-Hb), 1.25 (1H, m, 
14-Ha), 1.50 (3H, s, 7-Me), 1.57 (3H, s, 17-H), 1.82 (3H, s, 7-COOCH3), 2.24 (1H, m, 13-H), 
5.18 (1H, s, 4-H), 5.37 (1H, d, J= 9.8 Hz, 12-H), 5.45 (1H, d, J= 15.8 Hz, 9-H), 5.60 (1H, s, 
5-H), 6.68 (1H, d, J= 15.8 Hz, 10-H), 7.36 (1H, s, 1-H). 13C NMR (125 MHz, C6D6): δ 12.1 
(15-C), 12.3 (17-C), 20.4 (7-COOCH3), 26.1 (16-C), 29.8 (7-Me), 30.4 (14-C), 35.2 (13-C), 
87.5 (7-C), 106.5 (5-C), 108.5 (4-C), 110.8 (8a-C), 116.2 (9-C), 123.4 (11-C), 132.2 (4a-C), 
141.2 (10-C), 147.2 (12-C), 152.7 (1-C), 165.3 (3-C), 168.4 (7-COOCH3), 189.3 (6-C), 194.2 
(8-C). ESIMS: m/z [M+Na]+ 379 (100), [M+H]+ 357 (70), 315 (37), 273 (18). HREIMS: m/z 
356.1627 (calculated for C21H24O5 356.1624). Note: these compounds were acquired in 
deuterated benzene to prevent chlorination at C -5. 
1,3-dimethoxy-2-methylbenzene (6.22). A solution of compound 6.21 
(5.0 g, 40.3 mmol) in anhydrous acetone (240 mL) was added to a oven-
dried round bottom flask. Then anhydrous K2CO3 (2.0 eq., 11.1 g, 80.6 
mmol) and Me2SO4 (2.0 eq., 7.64 mL, 80.6 mmol) were added and the reaction mixture 
was stirred at refluxed overnight under an argon atmosphere. The reaction mixture was 
filtered by Buchner funnel, the filtrate was concentrated in vacuo, the residue was 
subjected to flash column chromatography on silica using 25% EtOAc in petroleum ether 
as eluent to return the title compound as a colourless oil (99%, 6.1 g, 40.2 mmol). 1H 
NMR (400 MHz, CDCl3): δ 2.12 (3H, s, 2-Me), 3.84 (6H, s, 1,3-OMe), 6.56 (2H, d, J= 8.4 
Hz, 4, 6-H), 7.13 (1H, t, J= 8.4 Hz, 5-H). 13C NMR (100 MHz, CDCl3): δ 8.3 (2-Me), 55.9 
(1,3-OMe), 103.7 (4,6-C), 114.7 (2-C), 126.3 (5-C), 158.5 (1,3-C). EIMS: m/z [M]·+ 152 
(100), 137 (27), 121 (30). HREIMS: m/z 152.0837 (calculated for C9H12O2 152.0837). 
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2-hydroxy-4-methoxy-3-methylbenzaldehyde (6.23). A solution of 
compound 6.22 (0.1 g, 0.7 mmol) in anhydrous DCM (10 mL) was 
added in a oven-dried 2-neck round bottom flask. Then Cl2CHOCH3 
(1.25 eq., 75 μL, 0.8 mmol) and AlCl3 (2.5 eq., 220 mg, 1.7 mmol) were added dropwise 
to the flask 0 °C under an argon atmosphere, and the mixture was warmed up to room 
temperature and stirred for 3 h. The reaction mixture was poured onto crushed ice and 
stirred for 0.5 h, then extracted with DCM three times. The combined organic layer was 
washed with 1M HCl, then washed with brine and dried over Na2SO4 before 
concentration in vacuo. Then the residue was subjected to flash column 
chromatography on silica using 25% EtOAc in petroleum ether as eluent to return the 
title compound as colourless crystals (68%, 74 mg, 0.5 mmol). 1H NMR (400 MHz, CDCl3): 
δ 2.09 (3H, s, 3-Me), 3.91 (3H, s, 4-OMe), 6.55 (1H, d, J= 8.7 Hz, 5-H), 7.36 (1H, d, J= 8.7 
Hz, 6-H), 9.71 (1H, s, 1-CHO), 11.44 (1H, s, 2-OH). 13C NMR (100 MHz, CDCl3): δ 7.4 (3-
Me), 56.0 (4-OMe), 102.9 (5-C), 113.5 (3-C), 115.6 (1-C), 133.4 (6-C), 161.2 (2-C), 164.5 
(4-C), 194.9 (1-CHO). EIMS: m/z [M]·+ 166 (100), 148 (26), 136 (21), 77 (19). HREIMS: m/z 
166.0631 (calculated for C9H10O3 166.0630). 
2,4-dimethoxy-3-methylbenzaldehyde (6.24). A solution of 
compound 6.22 (0.4 g, 2.7 mmol) in anhydrous DCM (30 mL) was 
added in a oven-dried 2-neck round bottom flask. Then Cl2CHOCH3 
(1.25 eq., 310 μL, 3.4 mmol) and TiCl4 (2.5 eq., 754 μL, 6.8 mmol) were added dropwise 
to the flask at 0 °C under an argon atmosphere, and the mixture stirred for 1 h. The 
reaction mixture was poured onto crushed ice and stirred for 0.5 h, then extracted with 
DCM three times. The combined organic layer was washed with 1M HCl, then washed 
with brine and dried over Na2SO4 before concentration in vacuo. Then the residue was 
subjected to flash column chromatography on silica using 25% EtOAc in petroleum ether 
as eluent to return the title compound as colourless crystals (99%, 486 mg, 2.7 mmol). 
1H NMR (400 MHz, CDCl3): δ 2.15 (3H, s, 3-Me), 3.85 (3H, s, 4-OMe), 3.89 (3H, s, 2-OMe), 
6.73 (1H, d, J= 8.8 Hz, 5-H), 7.73 (1H, d, J= 8.8 Hz, 6-H), 10.22 (1H, s, 1-CHO). 13C NMR 
(100 MHz, CDCl3): δ 8.6 (3-Me), 56.0 (4-OMe), 63.3 (2-OMe), 106.7 (5-C), 120.2 (3-C), 
122.9 (1-C), 128.1 (6-C), 162.7 (2-C), 164.1 (4-C), 189.3 (1-CHO). EIMS: m/z [M]·+ 180 
(100), 163 (88), 135 (55), 77 (47). HREIMS: m/z 180.0786 (calculated for C10H12O3 
180.0786). 
3
1
5
CHO
OMe
MeO
3
1
5
CHO
OH
MeO
284 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
2-(2,4-dimethoxy-3-methylphenyl)-1,3-dimethylimidazolidine 
(6.25). A solution of compound 6.23 (2.0 g, 10.9 mmol) in 
anhydrous toluene (20 mL) was added to a oven-dried round 
bottom flask. Then N,N'-dimethylethylendiamine (1.2 eq., 1.40 mL, 
13.0 mmol) was added to the flask and the reaction mixture refluxed under an argon 
atmosphere until TLC indicated the starting material was consumed. The reaction 
mixture was dried over Na2SO4 and concentrated in vacuo to return the title compound 
as a colourless oil (99%, 2.7 g, 10.9 mmol). 1H NMR (400 MHz, CDCl3): δ 2.16 (3H, s, 3-
Me), 2.19 (6H, s, 1’,3’-Me), 2.55-2.597 (2H, m, 4’,5’-Ha), 3.35-3.39 (2H, m, 4’,5’-Hb), 3.71 
(3H, s, 2 or 4-OMe), 3.76 (1H, s, 2’-H), 3.82 (3H, s, 2 or 4-OMe), 6.71 (1H, d, J= 8.7 Hz, 5-
H), 7.46 (1H, d, J= 8.7 Hz, 6-H). 13C NMR (100 MHz, CDCl3): δ 9.2 (3-Me), 39.7 (1’,3’-Me), 
53.4 (2,4-OMe), 55.6 (4’ or 5’-C), 61.4 (4’ or 5’-C), 107.0 (5-C), 118.5 (1 or 3-C), 124.2 (1 
or 3-C), 127.1 (6-C), 158.5 (2 or 4-C), 159.1 (2 or 4-C). EIMS: m/z [M]·+ 249 (27), 206 (29), 
163 (21), 99 (100). HREIMS: m/z 249.1603 (calculated for C14H21N2O2 249.1603). 
6-iodo-2,4-dimethoxy-3-methylbenzaldehyde (6.26). A solution of 
compound 6.25 (2.7 g, 10.9 mmol) in anhydrous diethyl ether (50 
mL) was added to a oven-dried 2-neck round bottom flask. Then t-
BuLi solution (1.3 M in hexane, 1.1 eq., 9.22 mL, 12.0 mmol) was added dropwised to 
the flask at -55 °C, the mixture was allowed to warm to 0 °C and stirred under an argon 
atmosphere for 1 h. After that the reaction mixture was cooled down to -78 °C, a solution 
of 1,2-diiodoethane (1.2 eq., 3.7 g, 13.1 mmol) in anhydrous diethyl ether (28 mL) was 
added and the reaction mixture warmed to room temperature and stirred for 0.5 h. The 
reaction mixture was quenched with 2 N HCl (50 mL) and stirred for 0.5 h, then extracted 
with DCM three times. The combined organic layer was washed with saturated aqueous 
NH4Cl and dried over Na2SO4 before concentration in vacuo. The residue was subjected 
to flash column chromatography on silica using 30% EtOAc in petroleum ether as eluent 
to return the title compound as a colourless solid (87%, 2.9 g, 9.5 mmol). 1H NMR (400 
MHz, CDCl3): δ 2.09 (3H, s, 3-Me), 3.80 (3H, s, 2-OMe), 3.88 (3H, s, 4-OMe), 7.24 (1H, s, 
5-H), 10.05 (1H, s, 1-CHO). 13C NMR (100 MHz, CDCl3): δ 8.7 (3-Me), 56.3 (4-OMe), 62.9 
(2-OMe), 95.2 (6-C), 119.9 (5-C), 121.9 (3-C), 122.5 (1-C), 162.1 (2-C), 162.9 (4-C), 191.6 
(1-CHO). EIMS: m/z [M]·+ 306 (100), 289 (68), 260 (22), 162 (57), 117 (60), 75 (64). 
HREIMS: m/z 305.9745 (calculated for C10H11O3I 305.9753). 
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2,4-dihydroxy-6-iodo-3-methylbenzaldehyde (6.27). A solution of 
compound 6.26 (0.4 g, 1.3 mmol) in anhydrous DCM (10 mL) was 
added to a oven-dried 2-neck round bottom flask. Then BBr3 solution 
(1 M in DCM, 4.0 eq., 5.24 mL, 5.2 mmol) was added dropwise to the flask at -78 °C, the 
reaction mixture was warmed to room temperature and stirred under an argon 
atmosphere overnight. The reaction mixture was then cooled to 0 °C, quenched with 
water and stirred for 0.5 h, then extracted with DCM three times. The combined organic 
layer was washed with brine and dried over Na2SO4 before concentration in vacuo. The 
residue was subjected to flash column chromatography on silica using 30% EtOAc in 
petroleum ether as eluent to return the title compound as a colourless amorphous solid 
(86%, 375 mg, 1.4 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 2.02 (3H, s, 3-Me), 7.14 (1H, 
s, 5-H), 9.81 (1H, s, 1-CHO), 12.80 (1H, s, 2-OH). 13C NMR (100 MHz, (CD3)2CO): δ 7.4 (3-
Me), 100.4 (6-C), 113.1 (1-C), 113.9 (3-C), 121.0 (5-C), 163.8 (4-C), 164.4 (2-C), 201.0 (1-
CHO). EIMS: m/z [M]·+ 278 (100), 150 (23), 122 (17), 83 (21). HREIMS: m/z 277.9442 
(calculated for C8H7O3I 277.9440). 
2,4-dihydroxy-3-methyl-6-((trimethylsilyl)ethynyl)benzaldehyde 
(6.28). A solution of compound 6.27 (35 mg, 0.12 mmol) in 
anhydrous THF (3 mL) was added to an oven-dried and air-free 
2-neck round bottom flask. Then PdCl2(PPh3)2 (5 mol%, 4 mg, 
0.006 mmol), CuI (5 mol%, 1 mg, 0.006 mmol), trimethylsilylacetylene (2.0 eq., 36 μL, 
0.24 mmol) and triethlyamine (1.3 eq., 22 μL, 0.24 mmol) was added to the flask and the 
reaction mixture was allowed to stirr at room temperature under an argon atmosphere 
for 4 h. The reaction mixture was diluted by 40 mL water , then immediately neutralised 
by 0.1 M HCl and extracted with EtOAc three times. The combined organic layer was 
washed with brine and dried over Na2SO4 before concentration in vacuo. The residue 
was subjected to flash column chromatography on silica using 15% EtOAc in petroleum 
ether as eluent to return the title compound as a yellow solid (99%, 31 mg, 0.12 mmol). 
1H NMR (400 MHz, (CD3)2CO): δ 0.26 (9H, s, 2’-TMS), 2.06 (3H, s, 3-Me), 6.69 (1H, s, 5-
H), 10.18 (1H, s, 1-CHO), 12.36 (1H, s, 2-OH). 13C NMR (100 MHz, (CD3)2CO): δ -0.2 (2’-
TMS), 7.6 (3-Me), 100.7 (1’-C), 101.4 (2’-C), 113.5 (5-C), 113.8 (3-C), 114.4 (1-C), 126.5 
(6-C), 163.5 (4-C), 163.8 (2-C), 195.2 (1-CHO). EIMS: m/z [M]·+ 248 (14), 233 (100). 
3
1
5
CHO
I
OH
HO
3
1
5
CHO
1'
OH
HO 2'
TMS
286 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
6-ethynyl-2,4-dihydroxy-3-methylbenzaldehyde (6.29). A solution of 
compound 6.28 (31 mg, 0.12 mmol) in anhydrous MeOH (3 mL) was 
added to a oven-dried round bottom flask. Then anhydrous K2CO3 
(1.5 eq., 26 mg, 0.18 mmol) was added to the flask and the mixture was stirred at room 
temperature under an argon atmosphere for 1 h. The reaction mixture was diluted by 
30 mL water, then neutralised by 0.5 M HCl and immediately extracted with EtOAc three 
times. The combined organic layer was washed with brine and dried over Na2SO4 before 
concentration in vacuo. The residue was subjected to flash column chromatography on 
silica using 35% EtOAc in petroleum ether as eluent to return the title compound as a 
yellow solid (93%, 21 mg, 0.1 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 2.07 (3H, s, 3-Me), 
4.06 (1H, s, 2’-H), 6.73 (1H, s, 5-H), 10.19 (1H, s, 1-CHO), 12.39 (1H, s, 2-OH). 13C NMR 
(100 MHz, (CD3)2CO): δ 7.5 (3-Me), 79.4 (1’-C), 85.4 (2’-C), 113.9 (5-C), 113.9 (3-C), 114.7 
(1-C), 125.8 (6-C), 163.2 (4-C), 163.9 (2-C), 195.2 (1-CHO). EIMS: m/z M]·+ 176 (100), 148 
(30), 91 (30). HREIMS: m/z 176.0473 (calculated for C10H8O3 176.0473). 
7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-isochromene-6,8(7H)-
dione (6.3). A solution of compound 6.28 (20 mg, 0.08 mmol) in 
anhydrous toluene (2 mL) was added to a oven-dried 2-neck 
round bottom flask. Then Au(OAc)3 (5 mol%, 1 mg, 0.004 mmol) and TFA (200 μL) were 
added to the flask and the mixture was stirred at room temperature under an argon 
atmosphere for 2 h. After that IBX (1.5 eq., 34 mg, 0.12 mmol) was added to the flask 
and the reaction mixture was stirred for 0.5 h. The reaction mixture was diluted by 20 
mL EtOAc and washed with deionised water three times, the organic layer was dried 
over Na2SO4 and concentrated in vacuo. The residue was subjected to flash column 
chromatography on silica using 70% EtOAc in petroleum ether as eluent to  return the 
title compound as a viscous bright yellow oil (99%, 22 mg, 0.08 mmol). 1H NMR (400 
MHz, (CD3)2CO): δ 0.30 (9H, s, 3-TMS), 1.43 (3H, s, 7-Me), 4.30 (1H, brs, 7-OH), 5.48 (1H, 
s, 5-H), 6.78 (1H, s, 4-H), 8.04 (1H, s, 1-H). 13C NMR (100 MHz, (CD3)2CO): δ -3.0 (3-TMS), 
28.2 (7-Me), 84.3 (7-C), 106.2 (5-C), 116.7 (8a-C), 120.8 (4-C), 142.1 (4a-C), 154.8 (1-C), 
170.2 (3-C), 196.9 (8-C), 197.3 (6-C). EIMS: m/z [M]·+ 264 (32), 222 (100), 193 (44), 73 
(84). HREIMS: m/z 264.0818 (calculated for C13H16O4Si 264.0818). 
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6-acetyl-2,4-dihydroxy-3-methylbenzaldehyde (6.31). A solution of 
compound 6.29 (10 mg, 0.06 mmol) in anhydrous toluene (2 mL) was 
added to a oven-dried 2-neck round bottom flask. Then Au(OAc)3 (5 
mol%, 1 mg, 0.003 mmol) and TFA (200 μL) were added to the flask 
and reaction mixture was stirred at room temperature under an argon atmosphere until 
the starting material was consumed as indicated by TLC. The reaction mixture was 
concentrated in vacuo and the residue was subjected to flash column chromatography 
on silica using 40% EtOAc in petroleum ether as eluent to return the title compound as 
a pale yellow solid (30%, 3 mg, 0.02 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 2.10 (3H, s, 
3-Me), 2.59 (3H, s, 2’-H), 7.02 (1H, s, 5-H), 10.03 (1H, s, 1-CHO), 12.86 (1H, s, 2-OH). 13C 
NMR (100 MHz, (CD3)2CO): δ 7.8 (3-Me), 29.4 (2’-C), 110.4 (5-C), 111.8 (1-C), 115.4 (3-C), 
142.7 (6-C), 162.2 (4-C), 164.8 (2-C), 196.6 (1-CHO). EIMS: m/z [M]·+ 194 (94), 151 (100), 
123 (26). HREIMS: m/z 194.0580 (calculated for C10H10O4 194.0579). 
7-hydroxy-7-methyl-6H-isochromene-6,8(7H)-dione (6.4). A solution 
of compound 6.3 (13 mg, 0.05 mmol) in EtOAc (6 mL) was added to 
a round bottom flask. Then TBAF solution (1M in THF, 1.1 eq., 52 μL, 
0.05 mmol) was added dropwise to the flask at -78 °C before the mixture was warmed 
to 0 °C and stirred for 0.5 h. The reaction mixture was concentrated in vacuo and the 
residue was subjected to flash column chromatography on silica using 70% EtOAc in 
acetone as eluent to return the title compound as a pale yellow solid (29%, 3 mg, 0.01 
mmol). 1H NMR (400 MHz, (CD3)2CO): δ 1.44 (3H, s, 7-Me), 4.34 (1H, brs, 7-OH), 5.53 (1H, 
s, 5-H), 6.58 (1H, d, J= 5.8 Hz, 4-H), 7.41 (1H, d, J= 5.8 Hz, 3-H), 7.96 (1H, s, 1-H). 13C NMR 
(100 MHz, (CD3)2CO): δ 28.1 (7-Me), 84.4 (7-C), 107.1 (5-C), 113.0 (4-C), 117.6 (8a-C), 
143.0 (4a-C), 149.9 (3-C), 153.5 (1-C), 196.6 (8-C), 196.9 (6-C). EIMS: m/z [M]·+ 192 (29), 
150 (100), 121 (43), 92 (37), 63 (36). HREIMS: m/z 192.0428 (calculated for C10H8O4 
192.0423). HRESIMS: m/z 193.0499 (calculated for C10H9O4 192.0423), 215.0320 
(calculated for C10H8O4Na 215.0320). 
2,4-dihydroxy-3-methyl-6-(prop-1’-yn-1’-yl)benzaldehyde (6.32). A 
solution of compound 6.27 (50 mg, 0.2 mmol) in anhydrous THF 
(3 mL) was added to a oven-dried and air-free 2-neck round 
bottom flask, PdCl2(PPh3)2 (5 mol%, 6 mg, 0.009 mmol) and CuI (5 
mol%, 2 mg, 0.009 mmol) were added to the flask. Then propyne (5.0 eq., 68 μL, 0.9 
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mmol) and triethlyamine (1.5 eq., 38 μL, 0.3 mmol) were added to the flask at -78 °C, 
after that the reaction mixture was warmed to room temperature and stirred under an 
argon atmosphere for 2.5 h. The reaction mixture was diluted by 30 mL water, then 
neutralised by 0.1 M HCl and extracted with EtOAc three times. The combined organic 
layer was washed with brine and dried over Na2SO4 before concentration in vacuo. The 
residue was subjected to flash column chromatography on silica using 40% EtOAc in 
petroleum ether as eluent to return the title compound as a yellow solid (99%, 37 mg, 
0.2 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 2.04 (3H, s, 3-Me), 2.10 (3H, s, 3’-H), 6.60 
(1H, s, 5-H), 10.16 (1H, s, 1-CHO), 12.40 (1H, s, 2-OH). 13C NMR (100 MHz, (CD3)2CO): δ 
4.1 (3’-C), 7.4 (3-Me), 75.6 (1’-C), 93.5 (2’-C), 112.5 (3-C), 112.9 (5-C), 114.7 (1-C), 128.0 
(6-C), 163.3 (4-C), 163.8 (2-C), 195.7 (1-CHO). EIMS: m/z [M]·+ 190 (100), 161 (20), 147 
(30), 115 (20). HREIMS: m/z 190.0630 (calculated for C11H10O3 190.0630). 
7-hydroxy-3,7-dimethyl-6H-isochromene-6,8(7H)-dione (6.5). A 
solution of compound 6.32 (30 mg, 0.16 mmol) in anhydrous toluene 
(2 mL) was added to a oven-dried 2-neck round bottom flask. Then 
Au(OAc)3 (5 mol%, 3 mg, 0.008 mmol) and TFA (200 μL) were added to the flask and the 
reaction mixture was stirred at room temperature under an argon atmosphere until the 
starting material was consumed. After that IBX (1.1 eq., 50 mg, 0.18 mmol) was added 
to the flask, the reaction mixture was stirred for 0.5 h before it was diluted by 20mL 
EtOAc and washed with deionised water three times, the organic layer was dried over 
Na2SO4 and concentrated in vacuo. The residue was subjected to flash column 
chromatography on Sephadex-LH20 using acetone as eluent to return the title 
compound as a viscous bright orange oil (99%, 33 mg, 0.16 mmol). 1H NMR (400 MHz, 
(CD3)2CO): δ 1.42 (3H, s, 7-Me), 2.20 (3H, s, 3-Me), 5.44 (1H, s, 5-H), 6.37 (1H, s, 4-H), 
7.96 (1H, s, 1-H). 13C NMR (100 MHz, (CD3)2CO): δ 19.2 (3-Me), 28.3 (7-Me), 84.1 (7-C), 
105.7 (5-C), 109.3 (4-C), 116.8 (8a-C), 144.7 (4a-C), 153.7 (1-C), 160.2 (3-C), 196.6 (8-C), 
196.8 (6-C). EIMS: m/z [M]·+ 206 (27), 164 (100), 135 (39). HREIMS: m/z 206.0581 
(calculated for C11H10O4 206.0579). HRESIMS: m/z 207.0661 (calculated for C11H11O4 
207.0657), 229.0478 (calculated for C11H10O4Na 229.0477). 
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(E)-2,4-dihydroxy-3-methyl-6-(pent-3’-en-1’-yn-1’-
yl)benzaldehyde (6.33). A solution of compound 6.29 (33 mg, 
0.2 mmol) in anhydrous THF (3 mL) was added to a oven-
dried and air-free 2-neck round bottom flask. Then 
PdCl2(PPh3)2 (5 mol%, 7 mg, 0.009 mmol), CuI (5 mol%, 2 mg, 0.009 mmol) and (E)-1-
bromo-1-propene (2.0 eq., 32 μL, 0.4 mmol) and triethlyamine (1.3 eq., 32 μL, 0.2 mmol) 
were added to the flask and the reaction mixture was stirred at room temperature under 
an argon atmosphere for 1 h. After this it was diluted by 30 mL water, then neutralised 
by 0.1 M HCl and extracted with EtOAc three times. The combined organic layer was 
washed with brine and dried over Na2SO4 before concentration in vacuo. The residue 
was subjected to flash column chromatography on silica using 40% EtOAc in petroleum 
ether as eluent to return the title compound as a yellow solid (53%, 21 mg, 0.1 mmol). 
1H NMR (400 MHz, (CD3)2CO): δ 1.85 (3H, dd, J= 6.9, 1.8 Hz, 5’-H), 2.05 (3H, s, 3-Me), 
5.82 (1H, dq, J= 15.8, 1.8 Hz, 3’-H), 6.37 (1H, dq, J= 15.8, 6.9 Hz, 4’-H), 6.63 (1H, s, 5-H), 
10.16 (1H, s, 1-CHO), 12.40 (1H, s, 2-OH). 13C NMR (100 MHz, (CD3)2CO): δ 7.5 (3-Me), 
18.9 (5’-Me), 83.4 (1’-C), 95.1 (2’-C), 110.9 (3’-C), 112.7 (5-C), 113.0 (3-C), 114.3 (1-C), 
127.4 (6-C), 142.8 (4’-C), 163.2 (4-C), 163.9 (2-C), 195.4 (1-CHO). 
(E)-7-hydroxy-7-methyl-3-(prop-1-en-1-yl)-6H-isochromene-
6,8(7H)-dione (6.6). A solution of compound 6.33 (12 mg, 0.06 
mmol) in anhydrous toluene (2 mL) was added to an oven-
dried 2-neck round bottom flask. Then Au(OAc)3 (5 mol%, 1 mg, 0.003 mmol) and TFA 
(200 μL) were added to the flask and the reaction mixture was stirred at room 
temperature under an argon atmosphere until the starting material was consumed. 
After that IBX (1.5 eq., 24 mg, 0.08 mmol) was added to the flask and the reaction 
mixture was stirred for 0.5 h before it was diluted by 20 mL EtOAc and washed with 
deionised water three times, the organic layer was dried over Na2SO4 and concentrated 
in vacuo. The residue was subjected to flash column chromatography on silica using 80% 
EtOAc in acetone as eluent to return the title compound as a viscous bright yellow oil 
(62%, 8 mg, 0.03 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 1.44 (3H, s, 7-Me), 1.92 (3H, 
dd, J= 7.0, 1.6 Hz, 11-H), 4.30 (1H, brs, 7-OH), 5.52 (1H, s, 5-H), 6.22 (1H, dq, J= 15.7, 1.6 
Hz, 9-H), 6.42 (1H, s, 4-H), 6.59 (1H, dq, J= 15.7, 7.0 Hz, 10-H), 7.98 (1H, s, 1-H). 13C NMR 
(100 MHz, (CD3)2CO): δ 18.5 (11-C), 28.3 (7-Me), 84.1 (7-C), 107.0 (5-C), 109.0 (4-C), 
116.6 (8a-C), 123.6 (9-C), 135.6 (10-C), 144.4 (4a-C), 153.2 (1-C), 156.3 (3-C), 196.4 (8-C), 
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196.7 (6-C). EIMS: m/z [M]·+ 232 (33), 190 (100), 161 (40), 149 (14). HREIMS: m/z 
232.0736 (calculated for C13H12O4 232.0736). HRESIMS: m/z 255.0628 (calculated for 
C13H12O4Na 255.0633). 
7-hydroxy-2-(2-hydroxyethyl)-7-methyl-3-(trimethylsilyl)iso-
quinoline-6,8(2H,7H)-dione (6.7). A solution of compound 6.3 
(10 mg, 0.04 mmol) in anhydrous acetone (3 mL) was added 
to a oven-dried 2-neck round bottom flask. Then 2-aminoethanol (1.0 eq., 2 μL, 0.04 
mmol) was added to the flask and the mixture was stirred at room temperature under 
an argon atmosphere for 48 h before it was concentrated in vacuo. The residue was 
subjected to flash column chromatography on silica using acetone as eluent to return 
the title compound as a bright red oil (82%, 10 mg, 0.03 mmol). 1H NMR (400 MHz, 
CD3OD): δ 0.43 (9H, s, 3-TMS), 1.46 (3H, s, 7-Me), 3.82 (2H, m, 2’-H), 4.08 (2H, m, 1’-H), 
5.21 (1H, s, 5-H), 6.81 (1H, s, 4-H), 8.08 (1H, s, 1-H). 13C NMR (100 MHz, CD3OD): δ -0.21 
(3-TMS), 29.1 (7-Me), 59.6 (1’-C), 62.0 (2’-C), 83.8 (7-C), 97.4 (5-C), 116.7 (8a-C), 127.6 
(4-C), 144.2 (1-C), 151.4 (4a-C), 156.1 (3-C), 197.3 (6-C), 201.4 (8-C). EIMS: m/z [M]·+ 307 
(32), 264 (60), 236 (18), 73 (100). HREIMS: m/z 307.1241 (calculated for C15H21NO4Si 
307.1240). HRESIMS: m/z 308.1317 (calculated for C15H22NO4Si 308.1318). 
7-hydroxy-2-(2-hydroxyethyl)-7-methylisoquinoline-
6,8(2H,7H)-dione (6.8). A solution of compound 6.7 (12 mg, 
0.04 mmol) in MeOH (3 mL) was added to a round bottom 
flask. Then 2-aminoethanol (1.0 eq., 2 μL, 0.04 mmol) was added to the flask and the 
mixture was stirred at room temperature until the starting material was consumed. The 
reaction mixture was concentrated in vacuo and the residue was subjected to flash 
column chromatography on silica using 25% MeOH in acetone as eluent to return the 
title compound as a bright red oil (60%, 6 mg, 0.02 mmol). 1H NMR (400 MHz, CD3OD): 
δ 1.47 (3H, s, 7-Me), 3.82 (2H, t, J= 4.8 Hz, 2’-H), 3.98 (2H, t, J= 4.8 Hz, 1’-H), 5.22 (1H, s, 
5-H), 6.62 (1H, d, J= 7.3 Hz, 4-H), 7.33 (1H, d, J= 7.3 Hz, 3-H), 8.02 (1H, s, 1-H). 13C NMR 
(100 MHz, CD3OD): δ 29.1 (7-Me), 60.3 (1’-C), 61.6 (2’-C), 83.8 (7-C), 97.5 (5-C), 117.4 
(8a-C), 118.2 (4-C), 140.2 (3-C), 142.7 (1-C), 153.1 (4a-C), 196.8 (6-C), 201.2 (8-C). EIMS: 
m/z [M]·+ 235 (72), 192 (100), 164 (32), 148 (86), 87 (58). HREIMS: m/z 235.0847 
(calculated for C12H13NO4 235.0845). HRESIMS: m/z 236.0921 (calculated for C12H14NO4 
236.0923), 258.0741 (calculated for C12H13NO4Na 258.0742). 
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5-chloro-7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-isochromene-
6,8(7H)-dione (6.35).  
Method One (electrophilic substitution): A solution of compound 
6.3 (15 mg, 0.06 mmol) in acetone (3 mL) was added to a round bottom flask wrapped 
with aluminium foil to keep the contents protected from light. Then NCS (1.1 eq., 9 mg, 
0.07 mmol) was added to the flask and the reaction mixture was stirred at room 
temperature under dark conditions overnight. The reaction mixture was concentrated 
in vacuo, the residue was subjected to flash column chromatography on silica using 55% 
EtOAc in petroleum ether as eluent to return the title compound as a viscous bright 
yellow oil (80%, 14 mg, 0.05 mmol). 
Method Two (nucleophilic substitution): A solution of compound 6.28 (109 mg, 0.44 
mmol) in toluene (2 mL) was added to a round bottom flask. Then Au(OAc)3 (5 mol%, 8 
mg, 0.022 mmol) and TFA (200 μL) were added to the flask and the mixture was stirred 
at room temperature until the starting material was consumed. Then IBX (1.5 eq., 185 
mg, 0.66 mmol) was added to the flask and the reaction mixture was stirred for 0.5 h 
before it was diluted by 20 mL EtOAc and washed with brine three times, the organic 
layer was dried over Na2SO4 and concentrated in vacuo. The residue was subjected to 
flash column chromatography on silica using 55% EtOAc in petroleum ether as eluent to 
return the title compound as a viscous bright yellow oil (80%, 93 mg, 0.3 mmol). 
The data sets for both compounds were identical. 1H NMR (400 MHz, (CD3)2CO): δ 0.35 
(9H, s, 3-TMS), 1.47 (3H, s, 7-Me), 6.95 (1H, s, 4-H), 8.12 (1H, s, 1-H). 13C NMR (100 MHz, 
(CD3)2CO): δ -3.0 (3-TMS), 27.6 (7-Me), 84.8 (7-C), 109.6 (5-C), 116.4 (8a-C), 116.8 (4-C), 
137.3 (4a-C), 154.1 (1-C), 172.9 (3-C), 190.8 (6-C), 195.5 (8-C). EIMS: m/z [M+2]·+ 300 (6), 
[M]·+ 298 (16), 258 (40), 256 (100), 73 (43). HREIMS: m/z 300.0400 (calculated for 
C13H15O4Si37Cl 300.0399), 298.0420 (calculated for C13H15O4Si35Cl 298.0428). 
5-bromo-7-hydroxy-7-methyl-3-(trimethylsilyl)-6H-isochromene-
6,8(7H)-dione (6.36). A solution of compound 6.28 (20 mg, 0.08 
mmol) in toluene (2 mL) was added to a round bottom flask. Then 
Au(OAc)3 (5 mol%, 2 mg, 0.004 mmol) and TFA (200 μL) was 
added to the flask, reaction mixture was stirred at room temperature until the starting 
material was consumed. Then IBX (1.5 eq., 34 mg, 0.12 mmol) was added to the flask 
and the mixture was stirred for 0.5 h before it was diluted by 20 mL EtOAc and washed 
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with saturated aqueous NaBr solution three times, the organic layer was dried over 
Na2SO4 and concentrated in vacuo. The residue was subjected to flash column 
chromatography on silica using 85% EtOAc in petroleum ether as eluent to return the 
title compound as a viscous bright yellow oil (99%, 28 mg, 0.08 mmol). 1H NMR (400 
MHz, (CD3)2CO): δ 0.35 (9H, s, 3-TMS), 1.47 (3H, s, 7-Me), 6.97 (1H, s, 4-H), 8.10 (1H, s, 
1-H). 13C NMR (100 MHz, (CD3)2CO): δ -3.0 (3-TMS), 27.8 (7-Me), 84.9 (7-C), 101.8 (5-C), 
117.2 (8a-C), 119.4 (4-C), 139.7 (4a-C), 154.2 (1-C), 173.2 (3-C), 191.1 (6-C), 195.6 (8-C). 
EIMS: m/z [M+2]·+ 344 (6), [M]·+ 342 (6), 302 (38), 300 (38), 248 (100), 231 (68), 203 (19), 
73 (39). HREIMS: m/z 343.9904 (calculated for C13H15O4Si81Br 343.9903), 341.9921 
(calculated for C13H15O4Si79Br 341.9923). 
7-hydroxy-5-iodo-7-methyl-3-(trimethylsilyl)-6H-isochromene-
6,8(7H)-dione (6.37). A solution of compound 6.3 (12 mg, 0.05 
mmol) in acetone (3 mL) was added to a round bottom flask 
wrapped with aluminium foil. Then NIS (1.2 eq., 12 mg, 0.054 
mmol) was added to the flask and the mixture was stirred at room temperature under 
dark conditions for 0.5 h. The reaction mixture was then concentrated in vacuo, the 
residue was subjected to flash column chromatography on silica using 90% EtOAc in 
petroleum ether as eluent to return the title compound as a viscous bright yellow oil 
(85%, 15 mg, 0.04 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 0.36 (9H, s, 3-TMS), 1.46 (3H, 
s, 7-Me), 4.61 (1H, s, 7-OH), 6.97 (1H, s, 4-H), 7.98 (1H, s, 1-H). 13C NMR (100 MHz, 
(CD3)2CO): δ -3.0 (3-TMS), 28.0 (7-Me), 81.5 (5-C), 84.2 (7-C), 118.1 (8a-C), 124.5 (4-C), 
143.8 (4a-C), 154.1 (1-C), 173.5 (3-C), 192.8 (6-C), 196.0 (8-C). EIMS: m/z [M]·+ 390 (24), 
348 (100), 263 (34), 73 (54). HREIMS: m/z 389.9782 (calculated for C13H15O4Si127I 
389.9784). HRESIMS: m/z 390.9857 (calculated for C13H16O4Si127I 390.9863). 
5-chloro-7-hydroxy-7-methyl-6H-isochromene-6,8(7H)-dione (6.39). 
A solution of compound 6.35 (9 mg, 0.03 mmol) in EtOAc (2 mL) was 
added to a round bottom flask, TBAF solution (1.0 M in THF, 1.2 eq., 
34 μL, 0.03 mmol) was added dropwise and the mixture was stirred 
at room temperature for 10 min. The reaction mixture was concentrated in vacuo and 
the residue was subjected to flash column chromatography on silica using EtOAc as 
eluent to return the title compound as a viscous bright yellow oil (99%, 8 mg, 0.03 mmol). 
1H NMR (400 MHz, (CD3)2CO): δ 1.49 (3H, s, 7-Me), 4.69 (1H, s, 7-OH), 6.84 (1H, d, J= 5.8 
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Hz, 4-H), 7.65 (1H, d, J= 5.8 Hz, 3-H), 8.05 (1H, s, 1-H). 13C NMR (100 MHz, (CD3)2CO): δ 
27.5 (7-Me), 84.9 (7-C), 109.7 (4-C), 110.5 (5-C), 117.3 (8a-C), 138.6 (4a-C), 151.9 (3-C), 
152.8 (1-C), 190.5 (6-C), 195.3 (8-C). EIMS: m/z [M+2]·+ 228 (11), [M]·+ 226 (20), 186 (33), 
184 (100), 149 (34). HREIMS: m/z 228.0014 (calculated for C10H7O437Cl 228.0003), 
226.0038 (calculated for C10H7O435Cl 226.0033). HRESIMS: m/z 250.9904 (calculated for 
C10H7O4Na37Cl 250.9901), 248.9932 (calculated for C10H7O4Na35Cl 248.9931). 
5-bromo-7-hydroxy-7-methyl-6H-isochromene-6,8(7H)-dione (6.40). 
A solution of compound 6.35 (10 mg, 0.03 mmol) in EtOAc (2 mL) 
was added to a round bottom flask, TBAF solution (1.0 M in THF, 1.2 
eq., 36 μL, 0.04 mmol) was added dropwise and the mixture was 
stirred at room temperature for 10 min. The reaction mixture was concentrated in vacuo 
and the residue was subjected to flash column chromatography on silica using EtOAc as 
eluent to return the title compound as a viscous bright yellow oil (99%, 8 mg, 0.03 mmol). 
1H NMR (400 MHz, (CD3)2CO): δ 1.49 (3H, s, 7-Me), 4.69 (1H, s, 7-OH), 6.87 (1H, d, J= 5.8 
Hz, 4-H), 7.67 (1H, d, J= 5.8 Hz, 3-H), 8.04 (1H, s, 1-H). 13C NMR (100 MHz, (CD3)2CO): δ 
27.6 (7-Me), 84.9 (7-C), 102.5 (5-C), 112.3 (4-C), 118.0 (8a-C), 141.0 (4a-C), 152.2 (3-C), 
152.9 (1-C), 190.8 (6-C), 195.4 (8-C). EIMS: m/z [M+2]·+ 272 (9), [M]·+ 270 (9), 248 (100), 
230 (36), 228 (38), 203 (14), 149 (19). HREIMS: m/z 271.9508 (calculated for C10H7O481Br 
271.9507), 269.9529 (calculated for C10H7O479Br 269.9528). HRESIMS: m/z 294.9406 
(calculated for C10H7O4Na81Br 294.9405), 292.9423 (calculated for C10H7O4Na79Br 
292.9425). 
5-chloro-7-hydroxy-3,7-dimethyl-6H-isochromene-6,8(7H)-dione 
(6.41). A solution of compound 6.5 (11 mg, 0.06 mmol) in acetone (3 
mL) was added to a round bottom flask wrapped with aluminium foil. 
NCS (1.5 eq., 11 mg, 0.08 mmol) was added to the flask and the 
mixture was stirred at room temperature under dark conditions overnight  before it was 
concentrated in vacuo and the residue was subjected to flash column chromatography 
on silica using EtOAc as eluent to return the title compound as a viscous bright yellow 
oil (55%, 7 mg, 0.03 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 1.47 (3H, s, 7-Me), 2.33 (3H, 
s, 3-Me), 4.65 (1H, s, 7-OH), 6.67 (1H, s, 4-H), 8.04 (1H, s, 1-H). 13C NMR (100 MHz, 
(CD3)2CO): δ 19.5 (3-Me), 27.7 (7-Me), 84.6 (7-C), 106.2 (4-C), 109.2 (5-C), 116.4 (8a-C), 
140.2 (4a-C), 153.1 (1-C), 162.6 (3-C), 190.3 (6-C), 195.3 (8-C). EIMS: m/z [M+2]·+ 242 (6), 
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[M]·+ 240 (16), 200 (33), 198 (100). HREIMS: m/z 242.0159 (calculated for C11H9O437Cl 
242.0160), 240.0187 (calculated for C11H9O435Cl 240.0189). HRESIMS: m/z 265.0058 
(calculated for C11H9O4Na37Cl 265.0058), 263.0087 (calculated for C11H9O4Na35Cl 
263.0087). 
5-bromo-7-hydroxy-3,7-dimethyl-6H-isochromene-6,8(7H)-dione 
(6.42). 
Method One: A solution of compound 6.5 (12 mg, 0.06 mmol) in 
acetone (3 mL) was added to a round bottom flask, NBS (1.2 eq., 12 mg, 0.07 mmol) was 
added and the mixture was stirred at room temperature for 10 min before it was 
concentrated in vacuo and the residue was subjected to flash column chromatography 
on silica using EtOAc as eluent to return the title compound as a viscous bright yellow 
oil (89%, 15 mg, 0.05 mmol). 
Method Two: A solution of compound 6.32 (9 mg, 0.05 mmol) in toluene (2 mL) was 
added to a round bottom flask, then Au(OAc)3 (5 mol%, 1 mg, 0.002 mmol) and TFA (200 
μL) was added to the flask and the mixture was stirred at room temperature until the 
starting material was consumed. IBX (1.5 eq., 29 mg, 0.11 mmol) was added and the 
reaction mixture was stirred for 0.5 h before it was diluted by 20 mL EtOAc and washed 
with saturated aqueous NaBr solution three times, the organic layer was dried over 
Na2SO4 and concentrated in vacuo. The residue was subjected to flash column 
chromatography on silica using EtOAc as eluent to return the title compound as a viscous 
bright yellow oil (67%, 9 mg, 0.03 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 1.47 (3H, s, 7-
Me), 2.33 (3H, s, 3-Me), 6.69 (1H, s, 4-H), 8.02 (1H, s, 1-H). 13C NMR (100 MHz, (CD3)2CO): 
δ 19.6 (3-Me), 27.8 (7-Me), 84.7 (7-C), 101.1 (5-C), 108.8 (4-C), 117.1 (8a-C), 142.5 (4a-
C), 153.1 (1-C), 163.0 (3-C), 190.6 (6-C), 195.4 (8-C). EIMS: m/z [M+2]·+ 286 (16), [M]·+ 
284 (16), 244 (98), 242 (100), 99 (40). HREIMS: m/z 285.9665 (calculated for C11H9O481Br 
285.9664), 283.9685 (calculated for C11H9O479Br 283.9684). HRESIMS: m/z 308.9565 
(calculated for C11H9O4Na81Br 308.9561), 306.9583 (calculated for C11H9O4Na79Br 
306.9582). 
(E)-5-chloro-7-hydroxy-7-methyl-3-(prop-1-en-1-yl)-6H-
isochromene-6,8(7H)-dione (6.43). A solution of compound 
6.33 (10 mg, 0.05 mmol) in toluene (2 mL) was added to a 
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round bottom flask, Au(OAc)3 (5 mol%, 1 mg, 0.002 mmol) and TFA (200 μL) was added 
and the mixture was stirred at room temperature until the starting material was 
consumed. IBX (1.5 eq., 19 mg, 0.07 mmol) was added and the mixture was stirred for 
0.5 h before it was diluted by 20 mL EtOAc and washed with brine three times. The 
organic layer was dried over Na2SO4 then concentrated in vacuo and the residue was 
subjected to flash column chromatography on silica using EtOAc as eluent to return the 
title compound as a viscous bright yellow oil (68%, 8 mg, 0.03 mmol). 1H NMR (400 MHz, 
(CD3)2CO): δ 1.48 (3H, s, 7-Me), 1.95 (3H, dd, J= 7.0, 1.5 Hz, 11-H), 4.65 (1H, brs, 7-OH), 
6.39-6.43 (1H, m, 9-H), 6.68 (1H, s, 4-H), 6.69-6.75 (1H, m, 10-H), 8.06 (1H, s, 1-H). 13C 
NMR (100 MHz, (CD3)2CO): δ 18.7 (11-C), 27.7 (7-Me), 84.6 (7-C), 105.8 (4-C), 110.4 (5-
C), 116.2 (8a-C), 123.8 (9-C), 137.2 (10-C), 140.0 (4a-C), 152.6 (1-C), 158.1 (3-C), 190.2 
(6-C), 195.1 (8-C). EIMS: m/z [M+2]·+ 268 (13), [M]·+ 266 (19), 226 (34), 224 (100). HREIMS: 
m/z 268.0308 (calculated for C13H11O437Cl 268.0316), 266.0333 (calculated for 
C13H11O435Cl 266.0346). HRESIMS: m/z 291.0227 (calculated for C13H11O4Na37Cl 
291.0214), 289.0243 (calculated for C13H11O4Na35Cl 289.0244). 
(E)-5-bromo-7-hydroxy-7-methyl-3-(prop-1-en-1-yl)-6H-
isochromene-6,8(7H)-dione (6.44). A solution of compound 
6.33 (10 mg, 0.05 mmol) in toluene (2 mL) was added to a 
round bottom flask, Au(OAc)3 (5 mol%, 1 mg, 0.002 mmol) and 
TFA (200 μL) were added and the mixture was stirred at room temperature until the 
starting material was consumed. Then IBX (1.5 eq., 19 mg, 0.07 mmol) was added and 
the mixture was stirred for 0.5 h before it was diluted by 20 mL EtOAc and washed with 
saturated aqueous NaBr solution three times. The organic layer was collected, dried over 
Na2SO4 and concentrated in vacuo and the residue was subjected to flash column 
chromatography on silica using EtOAc as eluent to return the title compound as a viscous 
bright yellow oil (46%, 7 mg, 0.02 mmol). 1H NMR (400 MHz, (CD3)2CO): δ 1.48 (3H, s, 7-
Me), 1.95 (3H, dd, J= 7.0, 1.6 Hz, 11-H), 4.64 (1H, brs, 7-OH), 6.43 (1H, dq, J= 15.6, 1.6 
Hz, 9-H), 6.70 (1H, s, 4-H), 6.71 (1H, dq, J= 15.6, 7.0 Hz, 10-H), 8.04 (1H, s, 1-H). 13C NMR 
(100 MHz, (CD3)2CO): δ 18.7 (11-C), 27.9 (7-Me), 84.7 (7-C), 102.5 (5-C), 108.4 (4-C), 
117.0 (8a-C), 123.7 (9-C), 137.3 (10-C), 142.4 (4a-C), 152.6 (1-C), 158.4 (3-C), 190.5 (6-C), 
195.2 (8-C). EIMS: m/z [M+2]·+ 312 (20), [M]·+ 310 (20), 270 (96), 268 (100). HREIMS: m/z 
311.9831 (calculated for C13H11O481Br 311.9820), 309.9846 (calculated for C13H11O479Br 
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309.9841). HRESIMS: m/z 334.9718 (calculated for C13H11O4Na81Br 334.9718), 332.9732 
(calculated for C13H11O4Na79Br 332.9738). 
5-chloro-7-hydroxy-2-(2-hydroxyethyl)-7-methyl-3-(trimethyl-
silyl)isoquinoline-6,8(2H,7H)-dione (6.45). A solution of 
compound 6.35 (20 mg, 0.08 mmol) in anhydrous acetone (3 
mL) was added to a oven-dried 2-neck round bottom flask. 2-
Aminoethanol (1.0 eq., 5 μL, 0.08 mmol) was added and the mixture was stirred at room 
temperature under an argon atmosphere for 10 min. The reaction mixture was 
concentrated in vacuo and the residue was subjected to flash column chromatography 
on silica using acetone as eluent to return the title compound as a bright red oil (93%, 
22 mg, 0.06 mmol). 1H NMR (400 MHz, CD3OD): δ 0.47 (9H, s, 3-TMS), 1.47 (3H, s, 7-Me), 
3.85 (2H, m, 2’-H), 4.16 (2H, t, J= 5.2 Hz, 1’-H), 7.22 (1H, s, 4-H), 8.15 (1H, s, 1-H). 13C 
NMR (100 MHz, CD3OD): δ -0.23 (3-TMS), 28.8 (7-Me), 59.7 (1’-C), 62.0 (2’-C), 84.6 (7-C), 
100.6 (5-C), 116.9 (8a-C), 123.6 (4-C), 143.3 (1-C), 146.2 (4a-C), 158.3 (3-C), 189.9 (6-C), 
199.7 (8-C). EIMS: m/z [M+2]·+ 343 (14), [M]·+ 341 (35), 301 (27), 299 (75), 271 (13), 269 
(32), 75 (30), 73 (100). HREIMS: m/z 343.0823 (calculated for C15H20NO4Si37Cl 343.0821), 
341.0849 (calculated for C15H20NO4Si35Cl 341.0850). HRESIMS: m/z 344.0895 (calculated 
for C15H21NO4Si37Cl 344.0899), 342.0926 (calculated for C15H21NO4Si35Cl 342.0928). 
5-bromo-7-hydroxy-2-(2-hydroxyethyl)-7-methyl-3-
(trimethylsilyl)isoquinoline-6,8(2H,7H)-dione (6.46). A 
solution of compound 6.36 (14 mg, 0.04 mmol) in anhydrous 
acetone (3 mL) was added to a oven-dried 2-neck round 
bottom flask. 2-aminoethanol (1.0 eq., 3 μL, 0.04 mmol) was added and the mixture was 
stirred at room temperature under an argon atmosphere for 10 min. The reaction 
mixture was concentrated in vacuo and the residue was subjected to flash column 
chromatography on silica using acetone as eluent to return the title compound as a 
bright red oil (99%, 17 mg, 0.04 mmol). 1H NMR (400 MHz, CD3OD): δ 0.48 (9H, s, 3-TMS), 
1.47 (3H, s, 7-Me), 3.85 (2H, t, J= 5.0 Hz, 2’-H), 4.16 (2H, t, J= 5.0 Hz, 1’-H), 7.29 (1H, s, 4-
H), 8.13 (1H, s, 1-H). 13C NMR (100 MHz, CD3OD): δ -0.23 (3-TMS), 28.9 (7-Me), 59.7 (1’-
C), 62.0 (2’-C), 84.7 (7-C), 91.6 (5-C), 117.6 (8a-C), 126.3 (4-C), 143.2 (1-C), 147.8 (4a-C), 
158.3 (3-C), 190.3 (6-C), 199.9 (8-C). EIMS: m/z [M+2]·+ 387 (19), [M]·+ 385 (18), 345 (31), 
343 (35), 306 (48), 75 (31), 73 (100). HREIMS: m/z 387.0326 (calculated for 
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C15H20NO4Si81Br 387.0325), 385.0335 (calculated for C15H20NO4Si79Br 385.0345). 
HRESIMS: m/z 388.0408 (calculated for C15H21NO4Si81Br 388.0403), 386.0427 (calculated 
for C15H21NO4Si79Br 386.0423). 
5-chloro-7-hydroxy-2-(2-hydroxyethyl)-7-methylisoquinoline-
6,8(2H,7H)-dione (6.47). A solution of compound 6.45 (22 mg, 
0.06 mmol) in MeOH (3 mL) was added to a round bottom 
flask. 2-aminoethanol (1.0 eq., 4 μL, 0.06 mmol) was added to 
the flask and the mixture was stirred at room temperature for 10 min. The reaction 
mixture was concentrated in vacuo and the residue was washed with petroleum ether 
twice, followed by EtOAc twice and finally by MeOH three times to return the title 
compound as a bright red solid (90%, 16 mg, 0.06 mmol). 1H NMR (400 MHz, (CD3)2SO): 
δ 1.30 (3H, s, 7-Me), 3.65-3.68 (2H, m, 2’-H), 4.00 (2H, t, J= 5.0 Hz, 1’-H), 5.39 (1H, s, 7-
OH), 6.79 (1H, d, J= 7.4 Hz, 4-H), 7.60 (1H, d, J= 7.4 Hz, 3-H), 8.04 (1H, s, 1-H). 13C NMR 
(100 MHz, (CD3)2SO): δ 27.6 (7-Me), 58.4 (1’-C), 59.9 (2’-C), 82.7 (7-C), 98.9 (5-C), 112.2 
(4-C), 115.2 (8a-C), 140.5 (1-C), 140.8 (3-C), 144.9 (4a-C), 186.9 (6-C), 197.8 (8-C). EIMS: 
m/z [M+2]·+ 271 (24), [M]·+ 269 (74), 229 (34), 227 (100), 184 (24), 182 (55). HREIMS: m/z 
271.0430 (calculated for C12H12NO437Cl 271.0425), 269.0445 (calculated for 
C12H12NO435Cl 269.0455). HRESIMS: m/z 272.0511 (calculated for C12H13NO437Cl 
272.0504), 270.0537 (calculated for C12H13NO435Cl 270.0533). 
5-bromo-7-hydroxy-2-(2-hydroxyethyl)-7-methylisoquinoline-
6,8(2H,7H)-dione (6.48). A solution of compound 6.46 (15 mg, 
0.04 mmol) in MeOH (3 mL) was added to a round bottom 
flask. 2-aminoethanol (1.0 eq., 3 μL, 0.20 mmol) was added 
and the mixture was stirred at room temperature for 10 min. The reaction mixture was 
concentrated in vacuo and the residue was washed with petroleum ether twice, 
followed by EtOAc twice and finally by MeOH three times to return the title compound 
as a bright red solid (99%, 13 mg, 0.04 mmol). 1H NMR (400 MHz, (CD3)2SO): δ 1.30 (3H, 
s, 7-Me), 3.65-3.68 (2H, m, 2’-H), 4.00 (2H, t, J= 4.8 Hz, 1’-H), 5.39 (1H, s, 7-OH), 6.83 (1H, 
d, J= 7.4 Hz, 4-H), 7.60 (1H, d, J= 7.4 Hz, 3-H), 8.02 (1H, s, 1-H). 13C NMR (100 MHz, 
(CD3)2SO): δ 27.7 (7-Me), 58.4 (1’-C), 59.9 (2’-C), 82.8 (7-C), 90.6 (5-C), 114.8 (4-C), 116.0 
(8a-C), 140.5 (1-C), 141.0 (3-C), 146.6 (4a-C), 187.3 (6-C), 197.9 (8-C). EIMS: m/z [M+2]·+ 
315 (24), [M]·+ 313 (19), 273 (23), 271 (24), 69 (100). HREIMS: m/z 314.9938 (calculated 
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for C12H12NO481Br 314.9929), 312.9950 (calculated for C12H12NO479Br 312.9950). 
HRESIMS: m/z 337.9836 (calculated for C12H12NO4Na81Br 337.9827), 335.9842 
(calculated for C12H12NO4Na79Br 335.9847). 
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6.7 Appendix NMR Spectra of Novel Compounds 
Figure 6-8 1H NMR Spectrum of Compound 6.1 (500 MHz, CDCl3) 
Figure 6-9 13C NMR Spectrum of Compound 6.1 (125 MHz, CDCl3) 
Figure 6-10 1H NMR Spectrum of Compound 6.2 (500 MHz, C6D6) 
Figure 6-11 13C NMR Spectrum of Compound 6.2 (125 MHz, C6D6) 
Figure 6-12 1H NMR Spectrum of Compound 6.27 (400 MHz, (CD3)2CO) 
Figure 6-13 13C NMR Spectrum of Compound 6.27 (100 MHz, (CD3)2CO) 
Figure 6-14 1H NMR Spectrum of Compound 6.3 (400 MHz, (CD3)2CO) 
Figure 6-15 13C NMR Spectrum of Compound 6.3 (100 MHz, (CD3)2CO) 
Figure 6-16 1H NMR Spectrum of Compound 6.31 (400 MHz, (CD3)2CO) 
Figure 6-17 13C NMR Spectrum of Compound 6.31 (100 MHz, (CD3)2CO) 
Figure 6-18 1H NMR Spectrum of Compound 6.4 (400 MHz, (CD3)2CO) 
Figure 6-19 13C NMR Spectrum of Compound 6.4 (100 MHz, (CD3)2CO) 
Figure 6-20 1H NMR Spectrum of Compound 6.32 (400 MHz, (CD3)2CO) 
Figure 6-21 13C NMR Spectrum of Compound 6.32 (100 MHz, (CD3)2CO) 
Figure 6-22 1H NMR Spectrum of Compound 6.5 (400 MHz, (CD3)2CO) 
Figure 6-23 13C NMR Spectrum of Compound 6.5 (100 MHz, (CD3)2CO) 
Figure 6-24 1H NMR Spectrum of Compound 6.6 (400 MHz, (CD3)2CO) 
Figure 6-25 13C NMR Spectrum of Compound 6.6 (100 MHz, (CD3)2CO) 
Figure 6-26 1H NMR Spectrum of Compound 6.7 (400 MHz, CD3OD) 
Figure 6-27 13C NMR Spectrum of Compound 6.7 (100 MHz, CD3OD) 
Figure 6-28 1H NMR Spectrum of Compound 6.8 (400 MHz, CD3OD) 
Figure 6-29 13C NMR Spectrum of Compound 6.8 (100 MHz, CD3OD) 
Figure 6-30 1H NMR Spectrum of Compound 6.35 (400 MHz, (CD3)2CO) 
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Figure 6-31 13C NMR Spectrum of Compound 6.35 (100 MHz, (CD3)2CO) 
Figure 6-32 1H NMR Spectrum of Compound 6.36 (400 MHz, (CD3)2CO) 
Figure 6-33 13C NMR Spectrum of Compound 6.36 (100 MHz, (CD3)2CO) 
Figure 6-34 1H NMR Spectrum of Compound 6.37 (400 MHz, (CD3)2CO) 
Figure 6-35 13C NMR Spectrum of Compound 6.37 (100 MHz, (CD3)2CO) 
Figure 6-36 1H NMR Spectrum of Compound 6.39 (400 MHz, (CD3)2CO) 
Figure 6-37 13C NMR Spectrum of Compound 6.39 (100 MHz, (CD3)2CO) 
Figure 6-38 1H NMR Spectrum of Compound 6.40 (400 MHz, (CD3)2CO) 
Figure 6-39 13C NMR Spectrum of Compound 6.40 (100 MHz, (CD3)2CO) 
Figure 6-40 1H NMR Spectrum of Compound 6.41 (400 MHz, (CD3)2CO) 
Figure 6-41 13C NMR Spectrum of Compound 6.41 (100 MHz, (CD3)2CO) 
Figure 6-42 1H NMR Spectrum of Compound 6.42 (400 MHz, (CD3)2CO) 
Figure 6-43 13C NMR Spectrum of Compound 6.42 (100 MHz, (CD3)2CO) 
Figure 6-44 1H NMR Spectrum of Compound 6.43 (400 MHz, (CD3)2CO) 
Figure 6-45 13C NMR Spectrum of Compound 6.43 (100 MHz, (CD3)2CO) 
Figure 6-46 1H NMR Spectrum of Compound 6.44 (400 MHz, (CD3)2CO) 
Figure 6-47 13C NMR Spectrum of Compound 6.44 (100 MHz, (CD3)2CO) 
Figure 6-48 1H NMR Spectrum of Compound 6.45 (400 MHz, CD3OD) 
Figure 6-49 13C NMR Spectrum of Compound 6.45 (100 MHz, CD3OD) 
Figure 6-50 1H NMR Spectrum of Compound 6.46 (400 MHz, CD3OD) 
Figure 6-51 13C NMR Spectrum of Compound 6.46 (100 MHz, CD3OD) 
Figure 6-52 1H NMR Spectrum of Compound 6.47 (400 MHz, (CD3)2SO) 
Figure 6-53 13C NMR Spectrum of Compound 6.47 (100 MHz, (CD3)2SO) 
Figure 6-54 1H NMR Spectrum of Compound 6.48 (400 MHz, (CD3)2SO) 
Figure 6-55 13C NMR Spectrum of Compound 6.48 (100 MHz, (CD3)2SO) 
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Figure 6-8 1H NMR Spectrum of Compound 6.1 (500 MHz, CDCl3) 
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Figure 6-9 13C NMR Spectrum of Compound 6.1 (125 MHz, CDCl3) 
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Figure 6-10 1H NMR Spectrum of Compound 6.2 (500 MHz, C6D6) 
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Figure 6-11 13C NMR Spectrum of Compound 6.2 (125 MHz, C6D6) 
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
00
f1 (ppm
)
12.0989
12.3067
20.4019
26.1480
29.8322
30.3517
35.1581
87.5252
106.5308
108.5475
110.8207
116.2104
123.4072
128.0596
132.1532
141.2039
147.2296
152.6617
165.3374
168.3821
189.2886
194.1583
O
O
O
AcO
6.2
306 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
 
 
Figure 6-12 1H NMR Spectrum of Compound 6.27 (400 MHz, (CD3)2CO) 
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Figure 6-13 13C NMR Spectrum of Compound 6.27 (100 MHz, (CD3)2CO) 
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Figure 6-14 1H NMR Spectrum of Compound 6.3 (400 MHz, (CD3)2CO) 
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Figure 6-15 13C NMR Spectrum of Compound 6.3 (100 MHz, (CD3)2CO) 
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Figure 6-16 1H NMR Spectrum of Compound 6.31 (400 MHz, (CD3)2CO) 
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Figure 6-17 13C NMR Spectrum of Compound 6.31 (100 MHz, (CD3)2CO) 
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
20
f1 (ppm
)
7.8367
29.3570
29.8404
110.3506
111.8289
115.4059
142.7217
162.2020
164.7663
196.6133
200.5694
OH
HO
CHO
O
6.31
312 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
 
Figure 6-18 1H NMR Spectrum of Compound 6.4 (400 MHz, (CD3)2CO) 
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Figure 6-19 13C NMR Spectrum of Compound 6.4 (100 MHz, (CD3)2CO) 
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Figure 6-20 1H NMR Spectrum of Compound 6.32 (400 MHz, (CD3)2CO) 
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Figure 6-21 13C NMR Spectrum of Compound 6.32 (100 MHz, (CD3)2CO) 
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Figure 6-22 1H NMR Spectrum of Compound 6.5 (400 MHz, (CD3)2CO) 
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Figure 6-23 13C NMR Spectrum of Compound 6.5 (100 MHz, (CD3)2CO) 
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Figure 6-24 1H NMR Spectrum of Compound 6.6 (400 MHz, (CD3)2CO) 
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Figure 6-25 13C NMR Spectrum of Compound 6.6 (100 MHz, (CD3)2CO) 
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Figure 6-26 1H NMR Spectrum of Compound 6.7 (400 MHz, CD3OD) 
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Figure 6-27 13C NMR Spectrum of Compound 6.7 (100 MHz, CD3OD) 
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Figure 6-28 1H NMR Spectrum of Compound 6.8 (400 MHz, CD3OD) 
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Figure 6-29 13C NMR Spectrum of Compound 6.8 (100 MHz, CD3OD) 
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Figure 6-30 1H NMR Spectrum of Compound 6.35 (400 MHz, (CD3)2CO) 
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Figure 6-31 13C NMR Spectrum of Compound 6.35 (100 MHz, (CD3)2CO) 
-10
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
20
f1 (ppm
)
-2.9948
27.6320
29.8399
84.8254
109.5745
116.3987
116.7765
137.3214
154.0841
172.9082
190.7745
195.5341
O
O
O
HO
TMS
Cl
6.35
326 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
 
Figure 6-32 1H NMR Spectrum of Compound 6.36 (400 MHz, (CD3)2CO) 
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Figure 6-33 13C NMR Spectrum of Compound 6.36 (100 MHz, (CD3)2CO) 
-1
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
20
f1 (ppm
)
-3.0129
27.7685
29.8400
84.9111
101.7474
117.1810
119.3561
139.6575
154.1609
173.2248
191.0623
195.6431
O
O
O
HO
TMS
Br
6.36
328 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
 
Figure 6-34 1H NMR Spectrum of Compound 6.37 (400 MHz, (CD3)2CO) 
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Figure 6-35 13C NMR Spectrum of Compound 6.37 (100 MHz, (CD3)2CO) 
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Figure 6-36 1H NMR Spectrum of Compound 6.39 (400 MHz, (CD3)2CO) 
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Figure 6-37 13C NMR Spectrum of Compound 6.39 (100 MHz, (CD3)2CO) 
-1
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
20
f1 (ppm
)
27.4863
29.8403
84.8584
109.7042
110.4964
117.2612
138.5882
151.8459
152.8182
190.4992
195.2567
O
O
O
HO
H
Cl
6.39
332 Chapter 6: Discovery of a Novel Halogenation Reaction 
 
 
 
Figure 6-38 1H NMR Spectrum of Compound 6.40 (400 MHz, (CD3)2CO) 
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Figure 6-39 13C NMR Spectrum of Compound 6.40 (100 MHz, (CD3)2CO) 
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Figure 6-40 1H NMR Spectrum of Compound 6.41 (400 MHz, (CD3)2CO) 
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Figure 6-41 13C NMR Spectrum of Compound 6.41 (100 MHz, (CD3)2CO) 
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Figure 6-42 1H NMR Spectrum of Compound 6.42 (400 MHz, (CD3)2CO) 
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Figure 6-43 13C NMR Spectrum of Compound 6.42 (100 MHz, (CD3)2CO) 
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Figure 6-44 1H NMR Spectrum of Compound 6.43 (400 MHz, (CD3)2CO) 
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Figure 6-45 13C NMR Spectrum of Compound 6.43 (100 MHz, (CD3)2CO) 
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Figure 6-46 1H NMR Spectrum of Compound 6.44 (400 MHz, (CD3)2CO) 
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Figure 6-47 13C NMR Spectrum of Compound 6.44 (100 MHz, (CD3)2CO) 
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Figure 6-48 1H NMR Spectrum of Compound 6.45 (400 MHz, CD3OD) 
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Figure 6-49 13C NMR Spectrum of Compound 6.45 (100 MHz, CD3OD) 
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Figure 6-50 1H NMR Spectrum of Compound 6.46 (400 MHz, CD3OD) 
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Figure 6-51 13C NMR Spectrum of Compound 6.46 (100 MHz, CD3OD) 
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Figure 6-52 1H NMR Spectrum of Compound 6.47 (400 MHz, (CD3)2SO) 
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Figure 6-53 13C NMR Spectrum of Compound 6.47 (100 MHz, (CD3)2SO) 
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Figure 6-54 1H NMR Spectrum of Compound 6.48 (400 MHz, (CD3)2SO) 
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
f1 (ppm
)
1.3031
2.5002
3.3228
3.6489
3.6626
3.6713
3.6844
3.9927
4.0166
5.0867
5.3929
6.8249
6.8434
7.5930
7.5968
7.6115
7.6153
8.0239
8.0265
O
O
N
HO
H
Br
OH
6.48
Chapter 6: Discovery of a Novel Halogenation Reaction 349 
 
Figure 6-55 13C NMR Spectrum of Compound 6.48 (100 MHz, (CD3)2SO) 
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